
<html lang="en"     class="pb-page"  data-request-id="1cf54860-e152-4189-83e1-494aa465a19f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-11;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b01351"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research" /></meta><meta name="dc.Creator" content="Dorian M.  Cheff" /></meta><meta name="dc.Creator" content="Matthew D.  Hall" /></meta><meta name="dc.Description" content="The platinum-based anticancer agents cisplatin, carboplatin, and oxaliplatin represent a spectacular translational science achievement. The basic research observations that led to the discovery of ..." /></meta><meta name="Description" content="The platinum-based anticancer agents cisplatin, carboplatin, and oxaliplatin represent a spectacular translational science achievement. The basic research observations that led to the discovery of ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 28, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01351" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="This article not subject to U.S. Copyright.  Published 2017 by the American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01351" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01351" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01351" /></link>
        
    
    

<title>A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01351" /></meta><meta property="og:title" content="A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0006.jpeg" /></meta><meta property="og:description" content="The platinum-based anticancer agents cisplatin, carboplatin, and oxaliplatin represent a spectacular translational science achievement. The basic research observations that led to the discovery of Pt complexes as DNA-binding agents that elicit cell arrest, the preclinical tumor regression studies, and the inorganic medicinal chemistry that led to clinical implementation of effective platinum complexes in the clinic have fueled multidisciplinary research into platinum-based drugs. While the successes are clear and the research activity continues, a significant window of time has passed since a new Pt drug has been approved for clinical use. Here we assess the current Pt drug landscape and challenges for future Pt development and discuss opportunities for improving our understanding of Pt drugs that utilize contemporary translational science tools such as chemical biology and real-time imaging. The underexplored spaces may reveal new opportunities for Pt drug development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01351"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01351">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01351&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01351&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01351&amp;href=/doi/10.1021/acs.jmedchem.6b01351" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4517-4532</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.6b01761" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.8b01420"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dorian+M.++Cheff">Dorian M. Cheff</a></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+D.++Hall">Matthew D. Hall</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-5073-442X" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">NCATS Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</span></div><div class="corresp-info"><strong>*</strong>Telephone: (301) 217-5727. Fax: (301) 217-5736. E-mail: <a href="/cdn-cgi/l/email-protection#1d757c7171707c5d707c747133737475337a726b"><span class="__cf_email__" data-cfemail="b9d1d8d5d5d4d8f9d4d8d0d597d7d0d197ded6cf">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01351&amp;href=/doi/10.1021%2Facs.jmedchem.6b01351" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4517–4532</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 14, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 September 2016</li><li><span class="item_label"><b>Published</b> online</span>28 February 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 June 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01351" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01351</a></div><div class="article_header-article-copyright"><strong>Copyright © This article not subject to U.S. Copyright.  Published 2017 by the American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4517%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDorian%2BM.%2BCheff%252C%2BMatthew%2BD.%2BHall%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D11%26contentID%3Dacs.jmedchem.6b01351%26title%3DA%2BDrug%2Bof%2BSuch%2BDamned%2BNature.1%2BChallenges%2Band%2BOpportunities%2Bin%2BTranslational%2BPlatinum%2BDrug%2BResearch%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4532%26publicationDate%3DJune%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01351"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2726</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">51</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01351" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dorian&quot;,&quot;last_name&quot;:&quot;M. Cheff&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;D. Hall&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;4517-4532&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01351&quot;},&quot;abstract&quot;:&quot;The platinum-based anticancer agents cisplatin, carboplatin, and oxaliplatin represent a spectacular translational science achievement. The basic research observations that led to the discovery of Pt complexes as DNA-binding agents that elicit cell arrest, the preclinical tumor regression studies, and the inorganic medicinal chemistry that led to clinical implementation of effective platinum complexes in the clinic have fueled multidisciplinary research into platinum-based drugs. While the successes are clear and the research activity continues, a significant window of time has passed since a new Pt drug has been approved for clinical use. Here we assess the current Pt drug landscape and challenges for future Pt development and discuss opportunities for improving our understanding of Pt drugs that utilize contemporary translational science tools such as chemical biology and real-time imaging. The underexplored spaces may reveal new opportunities for Pt drug development.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01351&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01351" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01351&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01351" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01351&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01351" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01351&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01351&amp;href=/doi/10.1021/acs.jmedchem.6b01351" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01351" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01351" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01351%26sid%3Dliteratum%253Aachs%26pmid%3D28195724%26genre%3Darticle%26aulast%3DCheff%26date%3D2017%26atitle%3DA%2BDrug%2Bof%2BSuch%2BDamned%2BNature.1%2BChallenges%2Band%2BOpportunities%2Bin%2BTranslational%2BPlatinum%2BDrug%2BResearch%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D11%26spage%3D4517%26epage%3D4532%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290768" title="Antineoplastic agents">Antineoplastic agents</a>,</li><li><a href="/action/doSearch?ConceptID=292098" title="Platinum">Platinum</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/jmcmar.2017.60.issue-11/20170608/jmcmar.2017.60.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The platinum-based anticancer agents cisplatin, carboplatin, and oxaliplatin represent a spectacular translational science achievement. The basic research observations that led to the discovery of Pt complexes as DNA-binding agents that elicit cell arrest, the preclinical tumor regression studies, and the inorganic medicinal chemistry that led to clinical implementation of effective platinum complexes in the clinic have fueled multidisciplinary research into platinum-based drugs. While the successes are clear and the research activity continues, a significant window of time has passed since a new Pt drug has been approved for clinical use. Here we assess the current Pt drug landscape and challenges for future Pt development and discuss opportunities for improving our understanding of Pt drugs that utilize contemporary translational science tools such as chemical biology and real-time imaging. The underexplored spaces may reveal new opportunities for Pt drug development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48227" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48227" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Platinum stands out among chemotherapeutic classes for its spectacular successes and utility in combination therapy, but also for its inconvenience to the patient and the resistance that can arise. The first report related to the discovery of cisplatin was published over 50 years ago (1965) (see Hoeschele<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> for a detailed description of the early experiments). However, as is well reported, it was likely first synthesized by Michele Peyrone around 1840<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and was critical to Nobel prize-winner Alfred Werner’s work on inorganic isomerism.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Cisplatin became the first of three platinum-based anticancer agents registered for use with the FDA (1978), followed by carboplatin (1989) and oxaliplatin (2002) (structures shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Other Pt-based drugs have entered clinical trials, and some are approved for use in specific countries (discussed below). In parallel with this clinical effort, significant basic research has been conducted on Pt-based complexes with a number of aims, including to understand their mechanism(s) of action, to synthesize and test new Pt complexes as anticancer drug candidates, to characterize the ways in which cells become resistant to Pt drugs, to explore whether other (non-Pt) metal complexes can offer useful biological activity, to study the (bio)chemistry of Pt complexes in the context of reactions with biomolecules, and to characterize the cellular pharmacology and fate of Pt drugs.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of cisplatin, carboplatin, and oxaliplatin. In each case the <i>cis</i> nonleaving amines are at the left and the leaving groups (chloride, bidentate dicarboxylate, or oxalate) are at the right.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This review aims to serve as a reflection on the ghosts of platinum research past, present, and future. It is written to focus attention and inspire discussion on the strengths of the field and the future of Pt research. It was inspired partly by Richard Callaghan’s honest reflections on the relevance of drug transporters in cancer drug resistance<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> entitled “Providing a molecular mechanism for P-glycoprotein; Why would I bother?”.</div><div class="NLM_p">The corresponding author has spent 15 years studying Pt complexes, over that time transitioning from inorganic medicinal chemistry and biological spectroscopy to cell biology and mechanisms of resistance to Pt drugs.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6-9)</a> The discussion is written from the perspective of one who has been immersed in the field of Pt drugs but who, through the natural peregrinations of research, has evolved a view of the field from afar that might offer an external perspective on the strengths and weaknesses of the field. It is also an attempt to be candid. The difference is vast between the honest (and colloquial) poster-side conversation at conferences on the state and direction of a field, and the sober sanitized nature of published perspectives that are written to ensure no future reviewer will be offended. In that context, this review aims to be a useful conversation piece.</div><div class="NLM_p">Like other “microfields” of study, the topic of “metals-in-medicine” (or inorganic medicinal chemistry) has been subject to the vicissitudes of biomedical fashions and fads. With each new technology that emerges to improve cancer treatment, the hand-wringing over the relevance of “shotgun” therapeutics begins.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> It seems, anecdotally, that the typical expectation is that the need for Pt drugs will decline as a result of the new (“better”) technology, followed by the realization that the technology is not the complete solution that everyone anticipated, and finally the clinical demonstration that the new technology works very well in combination with a Pt drug!</div><div class="NLM_p">The health impact and economic benefit of Pt drugs has been tremendous.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> While we do not believe Pt drugs will leave the clinic for many generations to come, the expectation seems to be that “shotgun” therapeutics should be phased out, and this is understandable given the side effects experienced by patients and the superiority of targeted drugs against some malignancies in the genomic age.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> From a basic and translational research point of view, new biomedical discoveries with therapeutic implications should be welcomed as a way to empower Pt research and effectiveness in the clinic. A colleague once said that the major referee critique against their rejected grant application was that with the arrival of gene therapy, there would no longer be a need for chemotherapy!</div><div class="NLM_p">Despite the time that has passed since the discovery of cisplatin, the number of publications per year continues to increase for all three clinical Pt complexes. There are more than 60 000 publications indexed in Pubmed for “cisplatin” and more in 2015 than any other year (>3200). The same is true for carboplatin (more than 14 000 total, >790 in 2015) and oxaliplatin (over 8000 total, >850 in 2015) (depicted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). It is notable that oxaliplatin surpassed carboplatin in publications in 2015 for the first time. Comparison with other DNA-targeting chemotherapeutic agents developed in the same period (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B, chlorambucil, mitomycin, mitoxantrone, bleomycin) emphasizes the scientific and medical impact of the “platins”. In each case, an initial surge in publications per year occurred, followed by a plateau. In fact, the only “shotgun” chemotherapeutics that appear to come close are doxorubicin (Adriamycin) and the “blockbuster” drug paclitaxel (Taxol), which show similar research attention (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C). Even a modern “blockbuster” targeted drug such as the Bcr-Abl inhibitor imatinib (Glivec) shows static research output, while the antibody therapeutic trastuzumab (Herceptin), which targets HER2/neu receptor, does display continued growth in research output. The comparisons in publications made here are reflective only of scientific interest; they are not a measure of clinical impact, but among the >80 000 indexed papers on platinum drugs (and likely many thousands more on other Pt experimental therapeutics and compounds) there are a core of innovative papers that set the tone for topics of interest. This includes topics such as structure–activity relationships,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Pt-DNA structures,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> structure-rule-breakers<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> such as active <i>trans</i> complexes,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and highly active non-Pt complexes such as osmium,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> to name a few examples. While citation tracking of published papers that pre-exist the Internet are not complete, the 10 most highly cited research reports (excluding literature reviews, using Google Scholar<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>) describing the three clinical Pt drugs all appear to be clinical reports (not shown).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Publications indexed in PubMed referring to the drugs, cisplatin, carboplatin, or oxaliplatin in the title or abstract, displayed by year. (B) As a comparison, publications describing the FDA-registered DNA-damaging agents chlorambucil, mitomycin, mitaxantrone, and bleomycin. (C) Publications describing “blockbuster” oncology therapeutics paclitaxel, doxorubicin, imatinib, and trastuzumab.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the remarkable clinical importance of Pt drugs, it is critical to keep in mind the contrasting negative perception of them. Certainly the lay-person’s view of the drug being a toxic “heavy metal” is technically accurate, perhaps the worst press being Lance Armstrong’s inaccurate statement that “for testicular cancer, they treat you with plutonium, one of the harshest chemicals there is”<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (though the cure itself is testament to the drug’s effectiveness). Armstrong also stated in his autobiography that they gave him “... a cocktail of three different drugs, bleomycin, etoposide, and cisplatin, and they were so toxic that the nurses <i>wore radioactive protection when handling them</i>”<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (emphasis added), either confusing the radiotherapy arm of treatment or the personal protective equipment (PPE) worn by nurses to minimize chronic workplace exposure to cytotoxic (and possibly mutagenic) drugs.</div><div class="NLM_p">The historical clinical literature is peppered with the perspective that cisplatin would not be approved by the FDA if it were discovered today. Cisplatin’s clinical usefulness was ultimately rescued by prehydration to offset nephrotoxicity and antiemetics to manage nausea,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> after much experimentation. The challenge of irreversible ototoxicity in patients, which is not a dose-limiting toxicity but results life-changing effects such as deafness and tinnitus, remains unresolved.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> It is interesting to consider just how close cisplatin came to not being registered in spite of its activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The engrossing and lengthy transcript of the Witness Seminar held by the Wellcome Trust Center for the History of Medicine in 2006<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> contains multiple references by participants reflecting on the promising efficacy of cisplatin against malignancies such as ovarian cancer in early trials in England (ca. 1971/2) but also the clinical challenges associated with toxicity. These challenges were a significant topic of discussion at the 1973 Oxford meeting,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> perhaps best captured by Hill who summarized pessimistically that “New and better analogs are awaited with great interest”,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and this consensus led to the desire for less toxic analogs. The Johnson Matthey work on analogs led to the development of carboplatin (initially coded JM-8<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>), but other options were pursued. While not mentioned in the official proceedings publication that followed the 1973 meeting, nor in the Witness Seminar, the popular science writer June Goodfield attended the 1973 meeting and described the in-progress Pt story in a chapter of her book “Cancer Under Siege”<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> based on interviews she conducted with researchers at the meeting. The Pt chapter title “I want the platinum blues!” is a direct reference to Barnett Rosenberg’s stated belief during the 1973 meeting that the platinum blue complexes,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> with their lesser nephrotoxicity than cisplatin, would be the ultimate clinical Pt drug!</div><div class="NLM_p">Nevertheless, cisplatin and carboplatin prevailed. Any reader who has not observed a patient suffering from the specific effects of platinum chemotherapy need to look no further than a social media platform such as Twitter<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> to read posts by patients. Alongside the aforementioned cisplatin side effects, oxaliplatin produces peripheral neuropathy that results in cold hypersensitivity, such as shooting pains if a patient’s skin comes into contact with a metal surface,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> as well as peripheral neurotoxicity, often causing paresthesias and numbness. The drugs certainly stay with patients; it has been shown that platinum is detectable in the urine of subjects 8 years following their last Pt chemotherapy round.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">In the veterinary setting, cisplatin also presents benefits and challenges. While cisplatin is a single-agent curative for equine sarcoids (administered directly into the tumor site via needle as an oil suspension),<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> all veterinary trainees also learn that “cisplatin splats cats”, a reference to the species-specific pulmonary edema and death that precludes its use in felines.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">Intrinsic and acquired resistance to Pt drugs also occurs in patients. Drug resistance is normally studied by culturing a cell line in increasing concentrations of a given drug to force the acquisition of a resistance phenotype. It is nowrecognized that two-dimensional tissue culture is not the ideal cell model, but it is certainly the easiest model to study. Another weakness in this strategy is that single-agent resistance in cell lines is very different from the combination chemotherapies a tumor is normally exposed to and therefore develops resistance to. For example, patients diagnosed with ovarian cancer usually undergo surgical resection (debulking), followed by chemotherapy composed of a platinum (cisplatin or carboplatin) and a taxane (paclitaxel or docetaxel) drug, repeated every 21 or 28 days.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> A recent <i>Nature</i> supplement on tackling drug resistance in ovarian cancer singled out platinum as the cause of the resistance problem.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Despite the fact that the front-line treatment for high-grade serous ovarian carcinoma is a taxane and a platinum, the article’s accompanying video narration states “most die because their cancer develops resistance to the most common form of treatment: platinum based chemotherapy” (i.e., the taxane is not to blame). The article is unfairly titled “The Problem with Platinum” despite being about ovarian cancer and looks forward to “new approaches (that) promise to break through the platinum barrier”.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The article does not explain that platinum chemotherapy extends the life of patients by years, and that it is front-line because no replacement chemotherapy regimen has been demonstrated to be superior. This example reinforces the negative image of platinum chemotherapy among those who peer-review manuscripts on new Pt agents, review Pt grant applications, and read Pt publications. Yet Pt drugs are an essential part of many chemotherapeutic regimens. When asked why they studied cisplatin resistance, a world-known clinician shrugged and said simply, “because it will still be in the clinic in 50 years, so we need to continue to try and understand it”.</div><div class="NLM_p last">The critical path for researchers in experimental therapeutics is to translate discoveries toward the clinic.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> As such, the design, synthesis, and study of experimental Pt complexes are, by definition, translational. The critical questions are the following: How can Pt drugs be relevant to new discoveries in our understanding of cancer, and how can Pt drugs be used in concert with new therapeutic strategies? It is incumbent on metals-in-medicine experts to ask these questions because there are unique aspects to Pt drugs and their chemistry, which limit those outside the field to appropriately design experiments using Pt complexes; for this reason, collaboration is key. When the corresponding author recently published a study on the effect of DMSO on the cancer cell line cytotoxicity and mechanism of cell death of Pt drugs and the extent to which DMSO is used as the solvent for Pt drugs in the literature,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> he was met with some very positive<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and some very negative feedback (personal communication!). The fact that Pt complexes react with DMSO was already well-known within the metals-in-medicine community,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> which is dwarfed in size by the oncology community using the compound in experimental studies. The finding that over a third of the oncology and experimental therapeutic literature used DMSO as a solvent for Pt drugs was distressing as the implications for the extant literature were potentially profound,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and it was advised to not publish that observation as part of the study. However, alerting the wider oncology community that works with Pt drugs is critical (and others have sought to make researchers aware in other ways).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Key Challenges for the Field</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Below, we assess recent trends in the platinum medicine field and discuss key challenges for metals-in-medicine generally. The relevant pre-existing work is cited in each case, and it is hoped that this will stimulate interest and experimentation in new fields and entice experts in related fields into entering the waters. We chose four “recent trends” to give a sense of where we see current major developments and discuss “key challenges” that we believe deserve further investigation (we do not suggest they are novel, just underexplored). There is obviously a skew to these based on our interest in oncology experimental therapeutics and translational science, and we have attempted to discuss the most difficult questions. We are hopeful that these topics will stimulate thought and discussion on the topic and that they highlight much that lies fallow.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1 Seeing Is Believing: Microdose Imaging of Clinical and Experimental Pt Drugs in Humans</h3><div class="NLM_p">Image-based insight into drug tumor distribution is a powerful tool during preclinical drug development and for image-guided personalization of therapeutic regimens.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> For example, [<sup>18</sup>F]paclitaxel (FPAC) has been used for positron emission tomography (PET) imaging to show that uptake levels in breast tumors correlated with clinical response.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Such tools are underdeveloped for clinical and investigational Pt-based drugs, and we believe implementation will aid in answering questions related to tumor drug levels, clearance rates, off-target organ residence times, and side effects (perhaps including sites such as the inner ear that present a toxicity challenge). As it stands, the information that exists relating to patient tumor-drug localization has relied on direct measurement of bulk Pt levels in postsurgical tissue from non-small-cell lung cancer,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> which demonstrated a correlation between Pt levels and survival for 44 patients and more recently in a smaller study of muscle-invasive bladder cancer.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> A limitation of these valuable studies is that patients had received Pt chemotherapy over a month prior to tissue resection. While they are single time-point studies, the obvious advantage of directly measuring Pt levels is that the moiety measured is the one that exerts activity, and the challenge is that the proportion of total Pt responsible for cell-killing activity is not known but presumably a very small proportion of total Pt in the cell. Spectroscopies such as X-ray fluorescence spectroscopy (XFS, also known as synchrotron resonance induced X-ray fluorescence, SRIXE) and NanoSIMS (nanoscale surface ionization mass spectrometry) can provide spatial information on Pt localization, and one imagines a wealth of postchemotherapy samples are in pathology banks and available that may be amenable to such a study, but the challenge again remains that the limitation is that clinical samples are ex vivo samples from a single time-point.</div><div class="NLM_p">Radiolabeled Pt complexes have been generated for laboratory studies and could be used for animal biodistribution<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and time-course studies. Cisplatin has no carbon, and [<sup>3</sup>H] labeling is not feasible because protons on Pt ammine ligands exchange rapidly in water. Carboplatin has been labeled on the “leaving” cyclobutyl dicarboxylate ligand,<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48, 49)</a> limiting its utility as one is essentially tracing the nonpharmacologic leaving group rather than the bioactive moiety, particularly over longer time-points. Oxaliplatin’s 1,2-cyclohexylamine nonleaving ligand has been [<sup>14</sup>C] labeled, and this seems the most appropriate Pt radioligand to study for this reason.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In a similar way, satraplatin and miriplatin contain nonleaving amines useful for [<sup>14</sup>C] or [<sup>3</sup>H] labeling, but neither appears to be reported.</div><div class="NLM_p">An emerging theme in drug development is the concept of phase 0 studies that precede the usual phase I dose escalation studies. Phase 0 studies utilize a nonpharmacologic “microdose” that allows insight into the human pharmacokinetic profile.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Ideally, the investigational agent is labeled with [<sup>14</sup>C] for detection by accelerator mass spectrometry (AMS) or possibly another radioisotope with a long half-life, but less-sensitive mass spectrometry-based detection tools are also utilized. No report currently exists for Pt microdose studies in humans, though it seems achievable for complexes amenable to [<sup>14</sup>C] labeling (see above) and may be a potential method for comparing a small number of candidate Pt drugs. The development of a pharmacodynamic microdose study that aimed at assessing Pt-DNA adducts in subjects by isolating peripheral blood mononucleocyte cells (PBMCs) as a predictive biomarker was reported in 2013,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> but results have not been disclosed as of this writing.</div><div class="NLM_p">What is possible for temporal imaging strategies in human subjects with platinum drugs then? There are four accessible radioisotopes of Pt: <sup>191</sup>Pt (<i>t</i><sub>1/2</sub> = 3 days), <sup>193m</sup>Pt (<i>t</i><sub>1/2</sub> = 4.3 days), <sup>195m</sup>Pt (<i>t</i><sub>1/2</sub> = 4 days), and <sup>197</sup>Pt (<i>t</i><sub>1/2</sub> = 17 h)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> from which radiolabeled Pt complexes could be generated. By use of radiolabeled Pt, the structure of the drug itself is unmodified. All radioisotopes produce γ emission and would be amenable to either γ camera scintigraphy (producing 2D images) or single-photon emission computed tomography (SPECT) imaging (producing 3D images). Studies reporting the preparation of [<sup>191</sup>Pt]cisplatin (1985)<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and [<sup>193m</sup>Pt]cisplatin (1973)<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> have received follow-up; [<sup>191</sup>Pt]cisplatin appears to have been intended partly as a radiotherapeutic pharmacologic form of cisplatin that did not progress into humans<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and partly for imaging (see below), and the [<sup>193m</sup>Pt]cisplatin was not used for imaging. Multiple reports of preparations of [<sup>195m</sup>Pt]cisplatin exist from 1973 onward,<a onclick="showRef(event, 'ref55 ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref55 ref57 ref58 ref59 ref60">(55, 57-60)</a> and performance assessment showed that the minimum detection limit for a 2 cm tumor was 8 ppm.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><div class="NLM_p">All but one of the handful of imaging studies have utilized [<sup>195m</sup>Pt]cisplatin, and specific examples are shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>. The first report with [<sup>195m</sup>Pt]cisplatin displayed a γ camera image at very low resolution in a 35-year-old woman with metastatic carcinoma of the cervix<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A), and a similar strategy was independently reported the following year.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> A decade later, Owens et al. produced [<sup>191</sup>Pt]-labeled cisplatin, carboplatin, and the platinum(IV) clinical candidate, iproplatin, and γ camera images were used to assess liver and kidney levels in patients with a number of different malignancies, but tumor accumulation itself could not be discerned.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of images acquired from human subjects treated with radiolabeled cisplatin. (A) 1973. A 35-year old woman with metastatic carcinoma of the cervix imaged following injection with [<sup>195m</sup>Pt]cisplatin.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The strong activity arises from high concentrations in the kidneys. This research was originally published in <i>Journal of Nuclear Medicine</i>, and artwork is reproduced with permission: <contrib-group>Lange, R. C.; Spencer, R. P.; Harder, H. C.</contrib-group>The Antitumor Agent <i>cis</i>-Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>: Distribution Studies and Dose Calculations for <sup>193m</sup>Pt and <sup>195m</sup>Pt.  <cite>J. Nucl. Med.</cite> <span class="NLM_year">1973</span>, <em>14</em>, 191–195, Copyright by the Society of Nuclear Medicine and Molecular Imaging, Inc. (B) Images of a patient with astrocytoma (brain tumor) injected with [<sup>195m</sup>Pt]cisplatin either iv (left) or ia (right).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Low brain signal compared to surrounding tissue can be seen at left. The high signal (dark) at right corresponds to the tumor region. Reproduced from  <cite>Cancer Research</cite>, Copyright <span class="NLM_year">1989</span>, Volume <em>49</em>, pp 1877–1881 (<contrib-group>Shani, J.; Bertram, J.; Russell, C.; Dahalan, R.; Chen, D. C.; Parti, R.; Ahmadi, J.; Kempf, R. A.; Kawada, T. K.; Muggia, F. M.; Wolf, W.</contrib-group>Noninvasive Monitoring of Drug Biodistribution and Metabolism: Studies with Intraarterial Pt-195m-Cisplatin in Humans), with permission from AACR. (C) Static anterior images over the head, neck, and thorax region of a patient with metastatic lung cancer immediately after injection with [<sup>191</sup>Pt]cisplatin, with several tumors arrowed.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Reproduced with permission of Taylor & Francis Ltd. (<a href="http://www.tandfonline.com/" class="extLink">http://www.tandfonline.com/</a>), from  <cite>Acta Oncologica</cite>, <contrib-group>Areberg, J.; Bjorkman, S.; Einarsson, L.; Frankenberg, B.; Lundqvist, H.; Mattsson, S.; Norrgren, K.; Scheike, O.; Wallin, R.</contrib-group>Gamma Camera Imaging of Platinum in Tumours and Tissues of Patients after Administration of <sup>191</sup>Pt-Cisplatin. <span class="NLM_year">1999</span>, <em>38</em>, 221–228. (D) Anterior (frontal) view of healthy subject 5 h following injection of [<sup>195m</sup>Pt]cisplatin.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Reproduced with permission from <contrib-group>Sathekge, M.; Wagener, J.; Smith, S. V.; Soni, N.; Marjanovic-Painter, B.; Zinn, C.; Van De Wiele, C.; D’asseler, Y.; Perkins, G.; Zeevaart, J. R.</contrib-group>Biodistribution and Dosimetry of <sup>195m</sup>Pt-Cisplatin in Normal Volunteers. Imaging Agent for Single Photon Emission Computed Tomography.  <cite>Nuklearmedizin</cite> <span class="NLM_year">2013</span>, <em>52</em>, 222–227. (E) 1987. Composite 13 min images of [<sup>13</sup>N]cisplatin PET scans following iv administration, with the drug being infused during the data collection.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> This research was originally published in <i>Journal of Nuclear Medicine</i>, and artwork is reproduced with permission: <contrib-group>Ginos, J. Z.; Cooper, A. J.; Dhawan, V.; Lai, J. C.; Strother, S. C.; Alcock, N.; Rottenberg, D. A.</contrib-group>[<sup>13</sup>N]Cisplatin PET To Assess Pharmacokinetics of Intra-Arterial Versus Intravenous Chemotherapy for Malignant Brain Tumors.  <cite>J. Nucl. Med.</cite> <span class="NLM_year">1987</span>, <em>28</em>, 1844–1852, Copyright by the Society of Nuclear Medicine and Molecular Imaging, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first report to utilize imaging for clinical insight came from Wolf and co-workers (1989), who used scintigraphic imaging to assess [<sup>195m</sup>Pt]cisplatin levels in brain tumors of patients receiving intravenous (iv) versus intra-arterial (ia)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> administration (intra-arterial administration of chemotherapy via the carotid to maximize delivery of drug to brain tumors was of great clinical interest in the 1980s). Scans were collected each minute to create time–activity curves, and tumor signal (ipsilateral) was compared with the nontumor brain hemisphere (contralateral), revealing lower tumor or brain uptake of cisplatin administered iv and 3–10 times increased cisplatin levels when administered ia (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). Brain tumor could be clearly distinguished because of the very low surrounding brain Pt levels. Areberg et al. imaged [<sup>191</sup>Pt]cisplatin distribution in 14 patients, and in 5 cases they were able to distinguish tumor uptake in patients with a range of malignancies including oral, lung, and testis<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). Critically, tumor location was confirmed by separate computed tomography (CT) scans, and tumor Pt concentrations were derived from quantitated signal and compared against Pt pharmacokinetics. More recently, a study of [<sup>195m</sup>Pt]cisplatin scintigraphy distribution in five healthy volunteers has been reported (along with associated PK), with the highest organ exposure in kidneys (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">PET allows higher-resolution imaging than SPECT but also has a number of restrictions associated with it, including the limited number of radioisotopes able to produce positrons upon radioactive decay. While Pt radioisotopes do not appear to be amenable to PET imaging, [<sup>11</sup>C] and [<sup>18</sup>F] are the most regularly utilized radioisotopes in PET imaging, though not yet reported for Pt drugs. However, multiple syntheses of [<sup>13</sup>N]cisplatin have been reported,<a onclick="showRef(event, 'ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref67 ref68 ref69">(67-69)</a> the first in 1985. The challenge for clinical imaging is the short half-life of the <sup>13</sup>N radioisotope (<i>t</i><sub>1/2</sub> = 10 min), shorter even than [<sup>11</sup>C] (<i>t</i><sub>1/2</sub> = 20 min) and [<sup>18</sup>F] (<i>t</i><sub>1/2</sub> = 1.8 h). Only one report exists using [<sup>13</sup>N]cisplatin for PET imaging (compared with three reports on its preparation!).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Ginos et al. assessed biodistribution, blood clearance, and stability first in rats and could not detect displacement of the [<sup>13</sup>N] ammine ligand from cisplatin in deproteinized blood samples. PET studies were performed in two patients with glioblastoma following both i.v. and i.a. (carotid artery) injection, in conjunction with regular chemotherapy administration, producing brain/tumor concentrations of 30:1, with increasing tumor accumulation over 15 min (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>E).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><div class="NLM_p last">The images collated in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> demonstrate the evolution of radiolabeled cisplatin imaging over time. Three of the four patient studies (i.e., subjects with tumors) were published in the 1980s, and most of the studies are proofs-of-concept rather than clinical studies. Given that both scintigraphy/SPECT (Pt radioisotope) and PET imaging ([<sup>13</sup>N]) with cisplatin have been demonstrated as useful, why have they not been explored, both in animal models and in humans? There are a litany of clinical challenges for Pt drugs, including understanding the acquisition of resistance, virtually no knowledge at all of tumor drug concentrations, and the opportunities for using imaging for differentiating candidate Pt drugs. Producing a fluorinated analog of a Pt drug such as oxaliplatin (nonleaving amine ligand) is an unexplored possibility, provided the analog retains pharmacologic activity (and therefore relevance). Medical imaging technology has progressed significantly in the past 30 years, and identification of tumor sites can be achieved with [<sup>18</sup>F]fluorodeoxyglucose (FDG) and MRI/CT to facilitate interpretation of drug localization. Coordination between chemists, biologists, and clinicians will be needed for any clinical imaging program and could ultimately produce a clinical tool for identifying patient populations who would benefit from Pt-containing chemotherapeutic regimens.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2 Time for a New Drug</h3><div class="NLM_p">Cisplatin and carboplatin are workhorses of the clinic, and oxaliplatin has added a new spectrum of activity. Oxaliplatin was approved in the United States in 2002, and it is stated in the literature that it was first approved for clinical use in 1996 in France<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> (reflected in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> though we have been unable to identify a primary source for this date). Europe-wide approval for oxaliplatin occurred in 1999.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Aside from these three approved drugs, a range of Pt complexes have entered clinical trials in the United States and Europe (reviewed extensively in 2007<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> and 2010<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a>), the most notable being the Johnson Matthey products <i>cis</i>,<i>trans</i>,<i>cis</i>-[PtCl<sub>2</sub>(OH)<sub>2</sub>(isopropylamine)<sub>2</sub>], (iproplatin, JM9<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a>), <i>cis</i>,<i>trans</i>-[PtCl<sub>2</sub>(acetato)<sub>2</sub>(NH<sub>3</sub>)(cyclohexylamine)] (satraplatin, JM216<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a>), and <i>cis</i>-[PtCl<sub>2</sub>(NH<sub>3</sub>)(2-methylpyridine)] (picoplatin, JM473, AMD473, ZD0473<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a>) and the multinuclear complex [{<i>trans</i>-PtCl(NH<sub>3</sub>)<sub>2</sub>}2-μ-(<i>trans</i>-Pt(NH<sub>3</sub>)<sub>2</sub>(H<sub>2</sub>N(CH<sub>2</sub>)<sub>6</sub>NH<sub>2</sub>)<sub>2</sub>)]<sup>4+</sup> (BBR3464) developed by the Farrell lab.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> While cisplatin, carboplatin, and oxaliplatin are essentially approved worldwide, there are four drugs approved for clinical use in specific nations (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and <a class="ref internalNav" href="#fig4" aria-label="Figure 04">Figure 04</a>). Carboplatin was developed with the aim of producing a complex with cisplatin’s activity but without its toxicity. It is worth considering how the clinical activity of the more recent Pt drugs was identified.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of drugs registered for use in specific countries. In each case the <i>cis</i> nonleaving amines are at the left and the leaving groups are at the right.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Drugs Registered for Clinical Use (Structures Shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">registered</th><th class="colsep0 rowsep0" align="center">year</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cisplatin</td><td class="colsep0 rowsep0" align="left">worldwide</td><td class="colsep0 rowsep0" align="left">1978</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">72</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">carboplatin</td><td class="colsep0 rowsep0" align="left">worldwide</td><td class="colsep0 rowsep0" align="left">1989</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">100</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oxaliplatin</td><td class="colsep0 rowsep0" align="left">worldwide</td><td class="colsep0 rowsep0" align="left">1996</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">72</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nedaplatin</td><td class="colsep0 rowsep0" align="left">Japan</td><td class="colsep0 rowsep0" align="left">1995</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">72</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lobaplatin</td><td class="colsep0 rowsep0" align="left">China</td><td class="colsep0 rowsep0" align="left">2003</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">72</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">heptaplatin</td><td class="colsep0 rowsep0" align="left">Korea</td><td class="colsep0 rowsep0" align="left">1999</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">101</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">miriplatin</td><td class="colsep0 rowsep0" align="left">Japan</td><td class="colsep0 rowsep0" align="left">2009</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">96</a></td></tr></tbody></table></div></div><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> </h4><div class="NLM_p last"><b>Oxaliplatin</b> (originally called l-OHP) was one of many Pt complexes containing 1,2-diaminocyclohexane ligands synthesized based on the promising activity of these complexes.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> It was identified as a highly soluble analog that was active against L1210 murine leukemia cells in mice (the standard for front-line testing at the time) and was active against cisplatin-resistant L1210/DDP cells along with other mouse tumors.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> A study of oxaliplatin’s cytotoxicity against the NCI60 panel of cell lines identified oxaliplatin as highly active against colorectal cancer cell lines,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> and this led to clinical trials with 5-fluorouracil that produced improved responses and led to regulatory approval.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Despite challenges associated with peripheral neuropathy, oxaliplatin continues to enter clinical trials for efficacy against other agents, including rectal, pancreatic, and stomach cancers.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7"> </h4><div class="NLM_p last"><b>Nedaplatin</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 04">Figure 04</a>, originally termed 254-S<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a>) was approved for use in Japan in 1995, against a range of malignancies including head and neck cancers.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> It has the same nonleaving <i>cis</i>-ammine ligands as cisplatin and carboplatin, and a glycolato ligand as the leaving group. It was developed by Shionogi Pharmaceutical Company, Japan, based on a desire to develop a drug with lesser side effects than cisplatin. Nedaplatin was one of a small series of Pt glycolato complexes synthesized with various amine ligands, all of which were shown to be highly soluble.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Nedaplatin was found to be less toxic than cisplatin and active against a range of animal xenografts<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> and progressed to clinical trials. While it is generally thought of as a second-line platinum drug,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> a recent Japanese clinical trial comparing nedaplatin plus docetaxel with cisplatin plus docetaxel for advanced or relapsed squamous cell lung cancer found that survival was significantly longer, and side effects lessened, using nedaplatin instead of cisplatin.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> This suggests a greater role in the clinic may lie ahead for nedaplatin and more trials comparing nedaplatin with first-line drugs such as cisplatin and carboplatin.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> </h4><div class="NLM_p last"><b>Heptaplatin</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 04">Figure 04</a>, originally termed SKI 2053R) was approved in Korea in 1999 for the treatment of gastrointestinal malignancies.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The compound was part of a series of over 40 [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes with bidentate carboxylate leaving groups;<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> the name heptaplatin evidently arose from the seven-membered ring formed between the diamine nonleaving ligand and Pt. The in vivo activity against L1210 tumors was determined, and the most active complexes were tested against stomach cancer cell lines (for which there are limited treatment options) and found to be superior to cisplatin and carboplatin. Heptaplatin was selected as the lead among other analogs based on its aqueous solubility and stability, low nephrotoxicity, and activity against stomach cancer cell lines.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Clinical trials in Korea led to approval for use of the agent against advanced gastric cancers, in combination with 5-fluorouracil.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> </h4><div class="NLM_p last"><b>Lobaplatin</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 04">Figure 04</a>, originally termed D-19466) was originally developed in Germany by ASTA Pharma, has entered clinical trials in multiple nations,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> and was approved for use in China in 2003. It emerged from a series of Pt analogs containing a 1,2-bis(aminomethyl)cyclobutane ligand synthesized at ASTA Pharma, with bidentate lactate as the leaving group.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> It was selected for progression to clinical development based on aqueous solubility and stability, superior cytotoxicity to cisplatin against a number of cancer cell lines including melanoma and hepatoma lines, and an absence of nephrotoxicity in mice at a dose that was efficacious against P388 and L1210 tumors (and was more active than both cisplatin and carboplatin)<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> and entered clinical trials. The drug passed through several hands in Germany before being licensed for development in China. It is approved in China for the treatment of metastatic breast and small-cell lung cancer and acute myelogenous leukemia<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> and has been recommended for combination with paclitaxel as second-line treatment for esophageal cancer.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> </h4><div class="NLM_p"><b>Miriplatin</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 04">Figure 04</a>) was recently approved in Japan and is structurally distinct in that it features long alkyl chains on its carboxylate leaving groups (myristates) to confer lipophilicity.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The complex was specifically created for treatment of hepatocellular carcinoma (HCC). It has been shown that the excipient ethiodized oil (Lipiodol), composed of iodine in fatty acid esters derived from poppy seed, is selectively retained in HCC tumors when administered directly via the hepatic artery (a therapeutic strategy termed transarterial chemoembolization, TACE).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> TACE can act as a tumor drug-delivery strategy, and clinical trials with cisplatin suspended in ethiodized oil have been performed, but suspension of drugs insoluble in the oil presents challenges.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> To address this, Sasaki and co-workers prepared a series of “liposoluble” cyclohexane-1,2-diamine platinum(II) complexes with long-chain carboxylate (C<sub>10</sub>–C<sub>24</sub>) leaving groups.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The criteria for lead selection were “suspensibility” in ethiodized oil, Pt release from the suspension to aqueous saline, and in vivo antitumor activity against L1210 murine leukemia cells, and miriplatin, with myristate (tetradecanoate) leaving groups, was selected for preclinical and clinical trials (summarized in ref <a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">96</a>) and was ultimately approved. Dosage is 70 mg of drug suspended in 3.5 mL of ethiodized oil, administered to the patient once a day through a catheter inserted into the hepatic artery.</div><div class="NLM_p">The common requirements in the discovery stage for the newer agents described above were solubility, stability, and a reduction in side effects compared with cisplatin. None of these four agents (nedaplatin, heptaplatin, miriplatin, lobaplatin) have been reported to display superior activity to cisplatin/carboplatin, though they have been demonstrated to be comparable. This probably accounts for the fact that these drugs have received little clinical attention in the United States or Europe, and presumably commercial factors are also at play. These newer drugs can in a sense be considered “me-too” drugs<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> that were developed based on the known structure–activity rules for the “big three” Pt drugs,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> that is, a <i>cis</i> arrangement of two nonleaving amine ligands and two “leaving” ligands. Oxaliplatin can be excused from the “me too” accusation based on its different scope of activity against colorectal cancer. Miriplatin was specifically developed for a formulation that localized to HCC tumors in the liver, though the point stands that structurally it complies with the SAR of cisplatin. The reality is that in each case these later-generation complexes exist to replace another Pt drug rather than to introduce a new spectrum of activity, which is a common motivator for me-too drug development. The challenge is the need for the newer “me-too” Pt agent to demonstrate superiority over the clinical standard-of-care Pt drug, replacing one Pt drug with another; carboplatin succeeded in this, satraplatin did not.</div><div class="NLM_p">There are three strands for the future development of Pt-based drugs: first, the creation of me-too drugs; second, the continued identification of Pt drug combinations with other agents against specific cancers that provides improved patient benefit; and third, the generation of new Pt compounds that push the boundaries of Pt SAR for testing and identification of novel activity against malignancies poorly responsive to current Pt agents.</div><div class="NLM_p">We believe the greatest hope for Pt drug development lies in creating and identifying compounds with a new spectrum of activity, be it through phenotypic profiling of cancer cell line sensitivity or medicinal chemistry driven toward identifying a highly active complex against a malignancy of choice. A major challenge for clinical chemotherapy is drug resistance, and this is the case for most patients enrolled in phase I/II clinical trials being treated with an experimental drug. It seems unlikely that the solution to clinical resistance to a platinum drug will lie with a new Pt drug.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> This does not mean that there is little prospect for new Pt drugs to enter the clinic, but while testing new Pt compounds in cytotoxicity assays against cisplatin-resistant cell lines may inform on a possible alternative cell-killing mechanism to cisplatin, activity against cisplatin-refractory tumors is unlikely to be the basis of a clinical trial.</div><div class="NLM_p">However, one can envisage a Pt drug with a very similar activity profile to cisplatin that could result in replacement of cisplatin/carboplatin as front line drugs. One scenario could be a Pt drug that does not cause ototoxicity in patients. Ototoxicity in various forms (deafness, tinnitus) is not a dose-limiting toxicity as it does not prevent the patient from receiving the drug, but cisplatin can cause immediate and permanent alterations to a patient’s hearing, and the same is true for carboplatin.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The replacement of cisplatin with carboplatin in clinical regimens has been careful (why change something that works?) and requires side-by-side clinical trials. For example, in the case of nasopharyngeal cancer, most patients receive cisplatin as the front-line agent, despite the fact that individual trials have shown no difference in treatment efficacy<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> and that carboplatin was better tolerated. Ototoxicity is not avoided though, and while the mechanism has not been definitively determined, a mouse model exists for cisplatin-induced ototoxicity that could be a useful basis for counterscreening for Pt drugs that do not induce ototoxicity.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><div class="NLM_p">So what are the questions we should be asking of new agents? New clinical candidates that offer genuinely new activity are needed, including activity against intractable malignancies such as glioblastoma and other brain tumors, melanoma, and pancreatic cancer. Brain tumors are an interesting case in point. In the previous section it was noted that brain signal was extremely low during γ imaging of radiolabeled cisplatin; this appears to be because clinical platinum drugs are inefficient at crossing the blood–brain barrier (BBB). The brain/plasma ratio for cisplatin and carboplatin is between 1:5 and 1:10,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> whereas peripheral tissues demonstrate Pt levels closer to parity with plasma levels. A Pt development program driven by brain tumor cell accumulation (rather than cell line killing) could result in an agent with an improved activity profile against brain tumors. This is just one example; there are of course many such scenarios where pushing beyond simple phenotypic monolayer cell line killing could open up new avenues for Pt drug discovery.</div><div class="NLM_p">In that context, what preclinical Pt candidates appear to be in the pipeline? Information on Pt candidates progressing toward clinical trials is often limited, but Investigational New Drug approval for a clinical trial (in the U.S. or equivalent procedures elsewhere) is usually accompanied by a press release. There are also Web sites indexing clinical trials for various regions that can give insight into open trials with new platinum agents. One challenge is in identifying the structure of investigational agent, and in some cases similar structures can be inferred from literature published by founders of a given pharmaceutical company.</div><div class="NLM_p">The “phosphaplatin” complex, PT-112 (<b>1</b>), is being developed by Phosplatin Therapeutics (USA).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> It is currently listed as being in phase I clinical trials in the United States to evaluate its safety, tolerability, pharmacokinetics, and preliminary clinical effects.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Several academic publications by the lead author Rathindra Bose (who passed away in 2015) describe the “phosphaplatin” class of complexes (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The initial synthesized series includes both Pt(II) and Pt(IV) complexes with bidentate pyrophosphate complexes, containing <i>cis</i> ammine (NH<sub>3</sub>), ethane-1,2-diamine, and 1,2-diaminocyclohexane (dach) nonleaving groups.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> The complexes comply with Pt SAR rules, but the pyrophosphato ligand confers high aqueous solubility and does not hydrolyze over weeks in aqueous solution.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> The dach-containing complex termed “pyrodach-2” demonstrated greater cytotoxicity than cisplatin against cisplatin-resistant cells, in spite of lower cellular accumulation.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> A recent paper further assessed the dach complexes and revealed a lack of in vitro DNA interaction, little role for DNA repair genes in sensitivity, and differential gene expression changes in treated ovarian cancer cells, and the investigators have concluded that an alternative mechanism of action to cisplatin is at play.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> The same paper revealed that the <i>R</i>,<i>R</i> enantiomer of pyrodach-2, “RRD2”, was approved as an Investigational New Drug; hence it is the agent designated <b>1</b> by Phosplatin Therapeutics. Whether <b>1</b> truly acts by a mechanism divorced from DNA binding remains to be proven; the reduced cytotoxicity compared with cisplatin and the high tolerated doses in mice (>60 mg/kg iv)<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> are consistent with increased stability just like carboplatin and oxaliplatin, both of which contain bidentate leaving groups. Along with trials in the U.S. (drug to be administered intravenously), Phosplatin Therapeutics have also granted a regional license for development and commercialization of <b>1</b> in China and nearby countries.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of preclinical Pt complexes and related structures. <b>1</b> (<i>R</i>,<i>R</i>-<i>trans</i>-1,2-cyclohexanediamine dihydrogen pyrophosphate)platinum(II)) in development by Phosplatin Therapeutics. Dicycloplatin in development by Sopo-Xingda Pharmaceutical, containing carboplatin (structure highlighted in red, also shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) hydrogen-bonded to 1,1-cyclobutane dicarboxylic acid (CBDCA). The “Kowol” complex is not preclinical but is an exemplar from the literature of a Pt(IV) complex possessing axial ligands with pendent maleimide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Pt-containing therapeutic BTP-114<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> (<b>2</b>) (structure not disclosed) is in development by Placon Therapeutics (USA, scientific cofounder Stephen Lippard<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a>), which recently spun out from Blend Therapeutics (USA) to focus on Pt drugs.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a><b>2</b> was recently approved as an Investigational New Drug by the FDA.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a><b>2</b> has been disclosed to be a prodrug of cisplatin with a pendent maleimide group, which covalently binds to serum albumin, providing an extended plasma half-life.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Maleimides react with thiols, and human albumin contains a single thiol at residue 34<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> that has been demonstrated to be accessible to maleimide conjugation.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> On the basis of the disclosure information, it seems likely that <b>2</b> is a Pt(IV) complex with axial ligands containing functionalized maleimide groups. Pt(IV) complexes are thought of as “prodrugs” that release their axial ligands upon reduction to yield the square planar active Pt(II) complex.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a><b>2</b> may be similar to a concept reported by Kowol and co-workers in 2013,<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> where pendant maleimides were coupled to the axial ligands of Pt(IV) complexes (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). In the case of the Kowol complexes, the Pt(IV) complexes reacted with albumin rapidly (half-time of ∼1 h)<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> and showed tumor regression activity. Lippard and co-workers have published a series of asymmetric Pt(IV) complexes designed to noncovalently associate with albumin via their pendent fatty acids (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>),<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> but no information on an analogous covalent complex has been disclosed. Generally speaking, the albumin-binding prodrug strategy may in some ways parallel abraxane, the albumin-bound formulation of paclitaxel,<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> which was developed to circumvent toxicities associated with paclitaxel and its excipient. Molecules such as Evans Blue are avid albumin binders and used on that basis to assess BBB integrity (or similarly tethered to Pt(IV)).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Along with prolonged pharmacokinetics,<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a><b>2</b> may also be anticipated to benefit from the leaky tumor effect that can allow for high macromolecule accumulation in tumors.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic of a likely mechanism of action of a compound similar to <b>2</b>, based on disclosed description of mechanism.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> A Pt(IV) complex containing cisplatin in the equatorial plane, with a pendent maleimide on an axial ligand (left), conjugates with Cys34 of human albumin in the bloodstream. Following prolonged circulation, the Pt(IV) complex is ultimately reduced, yielding cisplain, which can then exert its anticancer activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> </h4><div class="NLM_p"><b>Dicycloplatin</b> is effectively a reformulation of carboplatin, wherein the excipient contains an extra molar equivalent of carboplatin’s leaving group, CBDCA, that is believed to hydrogen-bond with carboplatin and facilitate its solubilization.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Developed by Sopo-Xingda Pharmaceutical (China), it has greater solubility and stability in solution than carboplatin and equivalent activity to carboplatin<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> A number of clinical trials have been conducted in China, the most recent reported being a phase II study comparing paclitaxel plus carboplatin versus paclitaxel plus dicycloplatin in patients with advanced non-small-cell lung cancer,<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> with both combinations showing similar response and survival rates, concluding that a phase III trial of dicycloplatin is warranted to confirm efficacy.</div><div class="NLM_p">Along with new small molecules, there has been a significant emphasis on liposomal reformulations of platinum complexes.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(127, 128)</a> While slightly outside the intended scope of this article, there are some interesting points related to the Pt drug being delivered and the prodrugs generated as part of the formulations. The archetypal success story in nanoscale drug formulation is that of pegylated liposomal doxorubicin (marketed as Doxil).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The weak base doxorubicin is hyperaccumulated within the acidic lumen of the pegylated liposomes, creating a high “payload” per liposome. To date, a physicochemical property of cisplatin and its counterparts has not been identified that would allow noncovalent trapping at high levels (though there is no reason why a complex that can be acid-trapped cannot be created for liposomal loading). However, several liposomal preparations encapsulating unmodified cisplatin have been reported,<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> the most advanced being lipoplatin, a liposomal formulation of encapsulated cisplatin with a loading level of 1:10<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> that shows prolonged circulation and diminished toxicities. Lipoplatin has now progressed through phase I, II, and III trials, and it was granted orphan drug status by the EMEA in 2007 for treating pancreatic cancer.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> While clinical trials appear to be ongoing, it is not yet approved for full use in any market. Other liposomal formulations encapsulating unmodified Pt agents are also in preclinical development.</div><div class="NLM_p">Beyond lipoplatin, a panoply of liposomal and other nanoscale drug carriers containing Pt drugs are reported in the literature, some of which are progressing toward clinical trials. These involve a covalent attachment of the Pt complex to the nanocarrier to facilitate high Pt drug payload per nanoparticle. This attachment is conferred either via the axial ligand of a Pt(IV) prodrug containing cisplatin, carboplatin, or oxaliplatin that is released upon reduction<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> or via coordination of carboxylate leaving ligands (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). What is intriguing is that, unlike the liposomal formulations of intact Pt drugs, both conjugation strategies involve creating a new chemical entity (NCE) that presumably requires full safety assessment. For either strategy, when the Pt detaches from the nanoparticle, it produces a version of the active drug; for Pt(IV) attachment the intact drug is presumably yielded; for carboxylate-tethered Pt(II) drugs, the result is presumably a diaquated complex that is highly reactive<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> (this aspect of Pt release does not appear to have been explored in detail).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Schematic demonstrating the chelation of Pt-dach in DACH-Platin and (<b>3</b>). Release from the constructs presumably produces the hydrolyzed form of oxalipatin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Tethering strategies have led to Pt nanocarrier formulations that have entered clinical trials. For example, Nanocarrier Co. (Japan) have developed several micellar nanoparticles formed from block copolymers containing a polyamino acid core that coordinates to Pt(II) via carboxylate ligands, using both <i>cis</i>-diammine (cisplatin analog, termed Nanoplatin, {[Pt(1,2-diaminocyclohexane)]}-loaded polymeric micelles or NC-6004) and dach (oxaliplatin analog, termed DACH-Platin or NC 4016), schematically shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Both forms are currently in clinical trials against a range of malignancies in Japan and the U.S.<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135, 136)</a> An alternative leaving group is included in the oxaliplatin analog ProLindac (AP5346) (<b>3</b>),<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> where the Pt is loaded onto a hydroxypropylmethacrylamide (HPMA) biocompatible polymer via an O,N chelate (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Like DACH-Platin, <b>3</b> releases a hydrolyzed form of oxaliplatin. <b>3</b> entered phase I and phase II clinical trials but appears to have been discontinued.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><div class="NLM_p last">While it is clear that structure–activity rules are being adhered to, for both new small molecules and nanocarrier formulations, there is clearly scope for exploration of new chemotypes and new strategies for improving the activity over cisplatin and reducing the reactivity and toxicities compared with cisplatin both by modifying pharmacokinetics and targeting the Pt payload to tumors. The literature on drug delivery systems incorporating cisplatin and other active Pt complexes is expanding rapidly, and it is likely more will enter clinical trials in the near future.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Understanding Pt drug mechanism and activity and utilizing the various drug delivery mechanisms available to create new therapeutic opportunities clearly lead the way for the next Pt therapeutic to be approved for use in the clinic.</div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3 A Role for Pt in Antibody–Drug Conjugates?</h3><div class="NLM_p">The emergence of biologics including antibody-directed therapeutics is changing the chemotherapeutic landscape. A cornerstone of this technology are antibody–drug conjugates (ADCs), where a highly specific antibody is directed to a tumor-specific target, delivering a small molecule cytotoxin.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> There are three components to ADCs. First, a monoclonal antibody is directed toward a cancer-specific cell-surface target. Second, to the antibody is tethered a linker that connects with the cytotoxic “payload” that can be cleaved to release the cytotoxin. Third, a highly cytotoxic small molecule is conjugated to the linker. It is critical that the synthetic modification to conjugate the small molecule does not interfere with its activity. A number of ADCs are in development. For example, trastuzumab emtansine (marketed as Kadcyla) possesses an antibody that targets HER2-positive cells and delivers a maytansine-like molecule called DM1, a highly cytotoxic molecule that acts by binding to tubulin.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> A critical need for ADCs is that the conjugated cytotoxin is highly potent, as each ADC delivers a few cytotoxin molecules to the cell at most.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> In fact, molecules usually incorporated into ADCs are often natural-product-derived molecules targeting microtubules (such as maytansinoid or monomethyl auristatin) that are too toxic for systemic administration. ADCs allow such toxins to be administered as they are inactive until released where they are localized at the tumor site, improving the therapeutic window for these agents.</div><div class="NLM_p">Given the emerging clinical importance of ADCs and other antibody- and immune-directed therapeutic approaches, it is unsurprising that combination chemotherapies with Pt drugs are being explored as part of clinical trials.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> However, to date there is little exploration of the possibility of conjugating Pt drugs to antibodies in order to create ADCs. It is possible that that Pt drugs do not provide adequate cytotoxicity, but the improvement in therapeutic window and reduction in side effects such as ototoxicity may confer an advantage.</div><div class="NLM_p">The main study published describes a trastuzumab–Pt(II) conjugate to target HER2-positive cells.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> In this work, an oxaliplatin-like complex was conjugated to trastuzumab via a dipeptide linker that could be cleaved by the cellular protease cathepsin, rigidified to ensure that the Pt complex cannot reach around and coordinate with the antibody. This is important as it has been shown that cisplatin can coordinate with trastuzumab, though it does not affect trastuzumab’s antibody-binding region.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> A Pt/antibody ratio of 6:1 was reported, and the conjugation of Pt(II) did not affect the binding of trastuzumab to HER2 on breast cancer cells. The trastuzumab–Pt construct resulted in almost 4-fold higher cellular Pt levels compared with an equimolar dose of oxaliplatin, though it did not result in increased cytotoxicity. There are other examples of Pt-antibody constructs, for example, for utilization in mass cytometry, but these were not created with linkers or for therapeutic use.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Waalboer et al. report the use of Pt(II) complexes as bifunctional ADC linkers (as the linker, not as the active drug) connecting a model fluorophore with trastuzumab as proof-of-concept.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><div class="NLM_p last">Away from antibodies, an extensive literature exists on the general concept of targeting cancer cells by appending biomolecules to the axial ligands of Pt(IV) complexes.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> By way of example, axial coordination of peptides that bind to integrins has been reported with the intention of targeting cellular uptake to brain tumor cells.<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147, 148)</a> While promising, cellular targeting guided by small molecules is less likely to provide the exquisite specificity of antibodies directed against validated oncology targets. Pt ADC-related studies are in their infancy, but given that the therapeutic antibodies and the chemistry needed to conjugate bioactive small molecules are already in place, translational studies will answer the question of whether there is a role for Pt here. As with the natural-product-derived agents currently used, a survey back through the literature to find the most toxic Pt complexes (without great concern for therapeutic window) may mean a “new” Pt chemotype will become a clinical candidate.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">4 Chemical Biology for Cellular Fate and Mechanisms of Action of Cisplatin</h3><div class="NLM_p">The verdant field of chemical biology is underpinned by the use of chemical tools to gain insight into biological processes, including understanding of the mechanism of action of small molecule therapeutics. For example, target identification for a drug can be achieved with modified molecules containing a “click-able” pendant group that can be used for proteomic identification of protein targets of a small molecule, or fluorescent labeling to monitor cellular fate. For Pt drugs, the development of chemical biology is occurring at a time when new questions are being asked of the cellular targets of Pt drugs.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> For example, it is clear that Pt drugs interact with a range of protein targets, and understanding their mechanistic relevance (or lack of it) will require significant effort.</div><div class="NLM_p">Tracking Pt drugs in cells, and their interaction with biomolecules, is not straightforward. As mentioned earlier, few labeling strategies are available for native Pt drugs (i.e., without modification of their chemical structure). This has led to the development of Pt complexes with fluorophores, usually tethered to an amine ligand.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Examples include complexes conjugated to the fluorophores carboxyfluorescein diacetate (CFDA),<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a><i>N</i>-(7-nitro-2,1,3-benzoxadiazol-4-yl)ethane-1,2-diamine (NBD),<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> and BODIPY.<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153, 154)</a> These complexes have been used to track the localization of the complexes in a range of cell lines. An obvious limitation to adding a fluorophore to a small inorganic complex is that it may significantly alter the physicochemical properties and biological activity of the Pt complex and is limited by the assumption that the Pt-fluorophore connection is intact (otherwise it is free fluorophore being imaged).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><div class="NLM_p">To address these limitations and to allow “label-free” study of Pt drug fate, a number of alternative strategies have been pursued. For example, New and colleagues reported a fluorescent sensor that was used to “postlabel” monofunctional Pt species in fixed cells to image its localization.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Pt complexes have been reported that incorporate minimal structural changes to add a reactive handle for direct postlabeling of the complex. Bierbach and colleagues reported a Pt-acridine with a pendent azide group, and following cell treatment and fixation “click” chemistry was used to append a alkyne-functionalized Alexa Fluor 488 dye.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><div class="NLM_p">In this context, a series of studies by the DeRose group have reported modified Pt drugs with functionalizations that allow chemical biological postlabeling experiments to be performed, such as protein target identification, DNA and RNA binding studies, and in-cell detection.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> By incorporation of an azide or alkyne handle for click chemistry, relatively small changes to the host Pt complex can be made. The initial study reported an analog of picoplatin with an azide group appended to the 2-methylpyridine ligand (termed picazoplatin, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) that could be postlabeled with a fluorophore after reaction with DNA or RNA in vitro.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> RNA extracted from yeast cells (<i>S. cerevisiae</i>) treated with picazoplatin was postlabeled with Alexa Fluor 488 to demonstrate that tRNA is a cellular substrate for Pt drugs.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> A Pt complex containing a 2-azido-1,3-propanediamine nonleaving bidentate ligand (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) was shown by postlabeling to bind with bovine serum albumin as a model target protein.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Confocal images of a similar Pt complex postlabeled in HeLa cells demonstrated the potential for cell-based studies.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> The chemical biology tools now exist to interrogate the cellular targets of Pt drugs, both nucleic acids and protein, and to extend into detailed in vivo studies.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Scheme showing the structure of picazoplatin (with the structure of the clinical candidate picoplatin shown in red) and its reaction with biomolecules. Subsequently “click” chemistry can be used to conjugate an alkyne-functionalized reporter of choice (blue) to the bound picazoplatin via its pendent azide. A Pt complex containing a 2-azido-1,3-propanediamine nonleaving bidentate ligand is also shown at bottom left.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Platinum drugs play a critical role in the clinic and will continue to do so for many years to come. While Pt drugs have been extensively studied, new fields of biology pave the way for new discoveries and understanding of Pt drugs. The development of new Pt drugs that enter clinical trials is a realistic and achievable goal but requires boldness and sensitivity to the challenges that current Pt drugs can present to patients in the clinic: efficacy that is tempered by side effects—drugs of such damned nature.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01351" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew D. Hall</span> - <span class="hlFld-Affiliation affiliation">NCATS Chemical Genomics Center, National Center for Advancing Translational Sciences,
National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5073-442X" title="Orcid link">http://orcid.org/0000-0002-5073-442X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a6cec7cacacbc7e6cbc7cfca88c8cfce88c1c9d0"><span class="__cf_email__" data-cfemail="b7dfd6dbdbdad6f7dad6dedb99d9dedf99d0d8c1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dorian M. Cheff</span> - <span class="hlFld-Affiliation affiliation">NCATS Chemical Genomics Center, National Center for Advancing Translational Sciences,
National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34585" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34585" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Dorian M. Cheff</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=BIO-d7e1721-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dorian M. Cheff</b> received her Bachelor of Science degree in Neuroscience from the University of Michigan in 2015. She is now at the National Center for Advancing Translational Science, NIH, as a post-baccalaureate Intramural Research Training Award (IRTA) Fellow working on assay development and high-throughput drug screening for potential oncology-focused small molecule therapeutics. Her current research interests include efforts to screen Pt compound libraries.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Matthew D. Hall</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=BIO-d7e1726-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Matthew D. Hall</b> received his B.Sc. (Hons) in Science and his Ph.D. in Chemistry from the University of Sydney, Australia, under Professor T. W. Hambley, working on understanding the mechanism of action of platinum(IV) complexes. Following a 1-year postdoctoral fellowship with Professor Val C. Culotta at the Johns Hopkins School of Public Health, he joined the Laboratory of Cell Biology, National Cancer Institute (NCI), National Institutes of Health (NIH), under Dr. Michael Gottesman, studying (in part) the mechanisms of cisplatin resistance and multidrug resistance. He joined NCATS in 2015, where his group engages in assay development and high-throughput screening for early stage small molecule probe discovery, with an emphasis on challenges in oncology drug discovery, including challenges associated with Pt drug research.</p></figure></div><div class="ack" id="ACK-d7e1869-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24376" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24376" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Kyle Brimacombe for his assistance with figures. This research was supported [in part] by the Intramural Research Program of the NIH, National Center for Advancing Translational Sciences.</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50722" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50722" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="first last">After this paper was published February 28, 2017, a correction was made to the heptaplatin structure in Figure 4. The corrected version was reposted May 2, 2017.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i18" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i18"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i19" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i19"> Abbreviations Used</h2><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">AMS</td><td class="NLM_def"><p class="first last">accelerator mass spectrometry</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CBDCA</td><td class="NLM_def"><p class="first last">1,1-cyclobutanedicarboxylic acid</p></td></tr><tr><td class="NLM_term">CFDA</td><td class="NLM_def"><p class="first last">carboxyfluorescein diacetate</p></td></tr><tr><td class="NLM_term">CT</td><td class="NLM_def"><p class="first last">computed tomography</p></td></tr><tr><td class="NLM_term">dach</td><td class="NLM_def"><p class="first last">1,2-diaminocyclohexane</p></td></tr><tr><td class="NLM_term">FPAC</td><td class="NLM_def"><p class="first last">[<sup>18</sup>F]paclitaxel</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">HPMA</td><td class="NLM_def"><p class="first last">hydroxypropylmethacrylamide</p></td></tr><tr><td class="NLM_term">IA</td><td class="NLM_def"><p class="first last">intra-arterial</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">NanoSIMS</td><td class="NLM_def"><p class="first last">nanoscale surface ionization mass spectrometry</p></td></tr><tr><td class="NLM_term">NBD</td><td class="NLM_def"><p class="first last"><i>N</i>-(7-nitro-2,1,3-benzoxadiazol-4-yl)ethane-1,1-diamine</p></td></tr><tr><td class="NLM_term">NCE</td><td class="NLM_def"><p class="first last">new chemical entity</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononucleocyte</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SPECT</td><td class="NLM_def"><p class="first last">single photon emission computed tomography</p></td></tr><tr><td class="NLM_term">TACE</td><td class="NLM_def"><p class="first last">transarterial chemoembolization</p></td></tr><tr><td class="NLM_term">XFS/SRIXE</td><td class="NLM_def"><p class="first last">X-ray fluorescence spetroscopy</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33031" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33031" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 161 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Shakespeare, W.</span> <span class="citation_source-book">Cymbeline</span>;<span class="NLM_x"> </span><span class="NLM_year">1623</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1623&author=W.+Shakespeare&title=Cymbeline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DShakespeare%26aufirst%3DW.%26btitle%3DCymbeline%26date%3D1623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hoeschele, J. D.</span><span> </span><span class="NLM_article-title">Serendipity and the Prepared Mind: The Discovery of Cisplatin</span> <span class="citation_source-journal">F&M Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=54-68&author=J.+D.+Hoeschele&title=Serendipity+and+the+Prepared+Mind%3A+The+Discovery+of+Cisplatin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoeschele%26aufirst%3DJ.%2BD.%26atitle%3DSerendipity%2520and%2520the%2520Prepared%2520Mind%253A%2520The%2520Discovery%2520of%2520Cisplatin%26jtitle%3DF%2526M%2520Sci.%26date%3D2015%26volume%3D3%26spage%3D54%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kauffman, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentimalli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doldi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. D.</span><span> </span><span class="NLM_article-title">Michele Peyrone (1813–1883), Discoverer of Cisplatin</span> <span class="citation_source-journal">Platinum Met. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">250</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1595/147106710X534326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1595%2F147106710X534326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlelsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=250-256&author=G.+B.+Kauffmanauthor=R.+Pentimalliauthor=S.+Doldiauthor=M.+D.+Hall&title=Michele+Peyrone+%281813%E2%80%931883%29%2C+Discoverer+of+Cisplatin&doi=10.1595%2F147106710X534326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Michele Peyrone (1813-1883), discoverer of cisplatin</span></div><div class="casAuthors">Kauffman, George B.; Pentimalli, Raffaele; Doldi, Sandro; Hall, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Platinum Metals Review</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">250-256</span>CODEN:
                <span class="NLM_cas:coden">PTMRA3</span>;
        ISSN:<span class="NLM_cas:issn">1471-0676</span>.
    
            (<span class="NLM_cas:orgname">Johnson Matthey Public Ltd. Co.</span>)
        </div><div class="casAbstract">The Italian chemist Michele Peyrone (1813-1883) was the first to synthesize cisplatin (cis-diamminedichloro-platinum (II)), the basis of today's most widely used family of anticancer drugs.  This biog. article aims to present, for the first time in the English language, a summary of his life and the achievements that he made during his scientific career.  Originally trained in medicine, Peyrone moved to chem. and attended some of the most prestigious institutions in Europe in his time.  He wrote several publications describing his work on 'Peyrone's chloride' (PtCl2(NH3)2) and Magnus' green salt ([Pt(NH3)4] [PtCl4]).  He later turned his attention to agricultural science where he defended important advances in the understanding of plant growth.  Michele Peyrone's dedication to science is best summarised in the English translation of his first report on the synthesis of cisplatin: "I am detd. to pursue this subject with all my energies, without having regard for the difficulties to be encountered at every step in so expensive and delicate a research".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJIz5_9VPnEbVg90H21EOLACvtfcHk0lh_pnDt_A14mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlelsLzE&md5=b72147b95efb49aef15c9a8378139220</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1595%2F147106710X534326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1595%252F147106710X534326%26sid%3Dliteratum%253Aachs%26aulast%3DKauffman%26aufirst%3DG.%2BB.%26aulast%3DPentimalli%26aufirst%3DR.%26aulast%3DDoldi%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DMichele%2520Peyrone%2520%25281813%25E2%2580%25931883%2529%252C%2520Discoverer%2520of%2520Cisplatin%26jtitle%3DPlatinum%2520Met.%2520Rev.%26date%3D2010%26volume%3D54%26spage%3D250%26epage%3D256%26doi%3D10.1595%2F147106710X534326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kauffman, G. B.</span> <span class="citation_source-book">Alfred Werner, Founder of Coordination Chemistry</span>; <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Berlin</span>,<span class="NLM_x"> </span><span class="NLM_year">1966</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2F978-3-662-11104-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1966&author=G.+B.+Kauffman&title=Alfred+Werner%2C+Founder+of+Coordination+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2F978-3-662-11104-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-662-11104-8%26sid%3Dliteratum%253Aachs%26aulast%3DKauffman%26aufirst%3DG.%2BB.%26btitle%3DAlfred%2520Werner%252C%2520Founder%2520of%2520Coordination%2520Chemistry%26pub%3DSpringer-Verlag%26date%3D1966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Callaghan, R.</span><span> </span><span class="NLM_article-title">Providing a Molecular Mechanism for P-Glycoprotein; Why Would I Bother?</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1002</span><span class="refDoi"> DOI: 10.1042/BST20150131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1042%2FBST20150131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26517914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVegsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=995-1002&author=R.+Callaghan&title=Providing+a+Molecular+Mechanism+for+P-Glycoprotein%3B+Why+Would+I+Bother%3F&doi=10.1042%2FBST20150131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Providing a molecular mechanism for P-glycoprotein; why would I bother?</span></div><div class="casAuthors">Callaghan, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">995-1002</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">It is almost 40 years since the drug efflux pump P-glycoprotein (permeability glycoprotein or P-gp) was shown to confer multi-drug resistance in cancer cells.  This protein has been one of the most extensively investigated transport proteins due to its intriguing mechanism and its affect in oncol.  P-gp is known to interact with over 300 compds. and the ability to achieve this has not yet been revealed.  Following the binding of substrate and nucleotide, a complex series of conformational changes in the membrane and cytosolic domains translocates substrate across the membrane.  Despite over 30 years of biochem. investigation, the availability of structural data and a plethora of chem. tools to modulate its function, the mol. mechanism remains a mystery.  In addn., overcoming its activity in resistant cancer cells has not been achieved in the clinic, thereby garnering some degree of pessimism in the field.  This review highlights the progress that has been achieved in understanding this complex protein and the value of undertaking mol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyXWKocQQmcLVg90H21EOLACvtfcHk0lh_pnDt_A14mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVegsbvJ&md5=930f380ee70ad8b22bd94155ff2f62fe</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1042%2FBST20150131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20150131%26sid%3Dliteratum%253Aachs%26aulast%3DCallaghan%26aufirst%3DR.%26atitle%3DProviding%2520a%2520Molecular%2520Mechanism%2520for%2520P-Glycoprotein%253B%2520Why%2520Would%2520I%2520Bother%253F%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2015%26volume%3D43%26spage%3D995%26epage%3D1002%26doi%3D10.1042%2FBST20150131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Shen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouliot, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">706</span><span class="NLM_x">–</span> <span class="NLM_lpage">721</span><span class="refDoi"> DOI: 10.1124/pr.111.005637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1124%2Fpr.111.005637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=22659329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=706-721&author=D.+W.+Shenauthor=L.+M.+Pouliotauthor=M.+D.+Hallauthor=M.+M.+Gottesman&title=Cisplatin+Resistance%3A+A+Cellular+Self-Defense+Mechanism+Resulting+from+Multiple+Epigenetic+and+Genetic+Changes&doi=10.1124%2Fpr.111.005637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes</span></div><div class="casAuthors">Shen, Ding-Wu; Pouliot, Lynn M.; Hall, Matthew D.; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">706-721</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Cisplatin is one of the most effective broad-spectrum anticancer drugs.  Its effectiveness seems to be due to the unique properties of cisplatin, which enters cells via multiple pathways and forms multiple different DNA-platinum adducts while initiating a cellular self-defense system by activating or silencing a variety of different genes, resulting in dramatic epigenetic and/or genetic alternations.  As a result, the development of cisplatin resistance in human cancer cells in vivo and in vitro by necessity stems from bewilderingly complex genetic and epigenetic changes in gene expression and alterations in protein localization.  Extensive published evidence has demonstrated that pleiotropic alterations are frequently detected during development of resistance to this toxic metal compd.  Changes occur in almost every mechanism supporting cell survival, including cell growth-promoting pathways, apoptosis, developmental pathways, DNA damage repair, and endocytosis.  In general, dozens of genes are affected in cisplatin-resistant cells, including pathways involved in copper metab. as well as transcription pathways that alter the cytoskeleton, change cell surface presentation of proteins, and regulate epithelial-to-mesenchymal transition.  Decreased accumulation is one of the most common features resulting in cisplatin resistance.  This seems to be a consequence of numerous epigenetic and genetic changes leading to the loss of cell-surface binding sites and/or transporters for cisplatin, and decreased fluid phase endocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWIazi8GmR-LVg90H21EOLACvtfcHk0lj7thoCFyUzFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsw%253D%253D&md5=51d1f12ecd4376c1f2f280fd95ea5974</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fpr.111.005637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.111.005637%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%2BW.%26aulast%3DPouliot%26aufirst%3DL.%2BM.%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DCisplatin%2520Resistance%253A%2520A%2520Cellular%2520Self-Defense%2520Mechanism%2520Resulting%2520from%2520Multiple%2520Epigenetic%2520and%2520Genetic%2520Changes%26jtitle%3DPharmacol.%2520Rev.%26date%3D2012%26volume%3D64%26spage%3D706%26epage%3D721%26doi%3D10.1124%2Fpr.111.005637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">535</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.48.080907.180426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1146%2Fannurev.pharmtox.48.080907.180426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=17937596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFymsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=495-535&author=M.+D.+Hallauthor=M.+Okabeauthor=D.+W.+Shenauthor=X.+J.+Liangauthor=M.+M.+Gottesman&title=The+Role+of+Cellular+Accumulation+in+Determining+Sensitivity+to+Platinum-Based+Chemotherapy&doi=10.1146%2Fannurev.pharmtox.48.080907.180426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy</span></div><div class="casAuthors">Hall, Matthew D.; Okabe, Mitsunori; Shen, Ding-Wu; Liang, Xing-Jie; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">495-535</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The platinum (Pt) drugs cisplatin and carboplatin are heavily employed in chemotherapy regimens; however, similar to other classes of drugs, a no. of intrinsic and acquired resistance mechanisms hamper their effectiveness.  The method by which Pt drugs enter cells has traditionally been attributed to simple passive diffusion.  However, recent evidence suggests a no. of active uptake and efflux mechanisms are at play, and altered regulation of these transporters is responsible for the reduced accumulation of drug in resistant cells.  This review suggests a model that helps reconcile the disparate literature by describing multiple pathways for Pt-contg. drugs into and out of the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2jGsuc6lGB7Vg90H21EOLACvtfcHk0lj7thoCFyUzFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFymsrw%253D&md5=2f3166b6372bc03a5a87de503337cc1c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.48.080907.180426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.48.080907.180426%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DOkabe%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DD.%2BW.%26aulast%3DLiang%26aufirst%3DX.%2BJ.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DThe%2520Role%2520of%2520Cellular%2520Accumulation%2520in%2520Determining%2520Sensitivity%2520to%2520Platinum-Based%2520Chemotherapy%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2008%26volume%3D48%26spage%3D495%26epage%3D535%26doi%3D10.1146%2Fannurev.pharmtox.48.080907.180426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Basis for Design and Development of Platinum(IV) Anticancer Complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3403</span><span class="NLM_x">–</span> <span class="NLM_lpage">3411</span><span class="refDoi"> DOI: 10.1021/jm070280u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070280u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvFKqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3403-3411&author=M.+D.+Hallauthor=H.+R.+Mellorauthor=R.+Callaghanauthor=T.+W.+Hambley&title=Basis+for+Design+and+Development+of+Platinum%28IV%29+Anticancer+Complexes&doi=10.1021%2Fjm070280u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Basis for Design and Development of Platinum(IV) Anticancer Complexes</span></div><div class="casAuthors">Hall, Matthew D.; Mellor, Howard R.; Callaghan, Richard; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3403-3411</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Recent advances in design and development of anticancer Platinum(IV) Complexes are discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrST9_M1CnGgbVg90H21EOLACvtfcHk0lj6YPhJGo-bHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvFKqsLg%253D&md5=aaccf47b20d49d299f871846824cb61e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm070280u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070280u%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DMellor%26aufirst%3DH.%2BR.%26aulast%3DCallaghan%26aufirst%3DR.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DBasis%2520for%2520Design%2520and%2520Development%2520of%2520Platinum%2528IV%2529%2520Anticancer%2520Complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3403%26epage%3D3411%26doi%3D10.1021%2Fjm070280u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Platinum(IV) Antitumour Compounds: Their Bioinorganic Chemistry</span> <span class="citation_source-journal">Coord. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1016/S0010-8545(02)00026-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0010-8545%2802%2900026-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD38XntF2ktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2002&pages=49-67&author=M.+D.+Hallauthor=T.+W.+Hambley&title=Platinum%28IV%29+Antitumour+Compounds%3A+Their+Bioinorganic+Chemistry&doi=10.1016%2FS0010-8545%2802%2900026-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) antitumour compounds: their bioinorganic chemistry</span></div><div class="casAuthors">Hall, Matthew D.; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">49-67</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  This article reviews the studies undertaken into Pt(IV) antitumor compds. since Barnett Rosenberg 1st noted the activity of Pt(IV) complexes.  The chem. and pharmacol. properties of the drugs are discussed and both the reactions with individual biomols., which have received attention and the characterization of biotransformation products from animal and clin. trials are reviewed.  The bioinorg. chem. of Pt(IV) complexes has not previously been reviewed, and the purpose here is to provide insight into the requirements for the antitumor activity of Pt(IV) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkHxf962L07rVg90H21EOLACvtfcHk0lj6YPhJGo-bHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntF2ktbs%253D&md5=200992ab1e4313bea2f5c9b3f60ac26f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0010-8545%2802%2900026-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-8545%252802%252900026-7%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DPlatinum%2528IV%2529%2520Antitumour%2520Compounds%253A%2520Their%2520Bioinorganic%2520Chemistry%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2002%26volume%3D232%26spage%3D49%26epage%3D67%26doi%3D10.1016%2FS0010-8545%2802%2900026-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Fojo, T.</span><span> </span><span class="NLM_article-title">Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span><span class="refDoi"> DOI: 10.1634/theoncologist.2007-0090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1634%2Ftheoncologist.2007-0090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=277-283&author=T.+Fojo&title=Commentary%3A+Novel+Therapies+for+Cancer%3A+Why+Dirty+Might+Be+Better&doi=10.1634%2Ftheoncologist.2007-0090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2007-0090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2007-0090%26sid%3Dliteratum%253Aachs%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DCommentary%253A%2520Novel%2520Therapies%2520for%2520Cancer%253A%2520Why%2520Dirty%2520Might%2520Be%2520Better%26jtitle%3DOncologist%26date%3D2008%26volume%3D13%26spage%3D277%26epage%3D283%26doi%3D10.1634%2Ftheoncologist.2007-0090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Taylor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filby, A.</span><span> </span><span class="NLM_article-title">Health Impact Analysis of Cisplatin, Carboplatin, and Oxaliplatin</span> <span class="citation_source-journal">Johnson Matthey Technol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1595/205651317X693741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1595%2F205651317X693741" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=32-39&author=M.+Taylorauthor=A.+Filby&title=Health+Impact+Analysis+of+Cisplatin%2C+Carboplatin%2C+and+Oxaliplatin&doi=10.1595%2F205651317X693741"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1595%2F205651317X693741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1595%252F205651317X693741%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DFilby%26aufirst%3DA.%26atitle%3DHealth%2520Impact%2520Analysis%2520of%2520Cisplatin%252C%2520Carboplatin%252C%2520and%2520Oxaliplatin%26jtitle%3DJohnson%2520Matthey%2520Technol.%2520Rev.%26date%3D2017%26volume%3D61%26spage%3D32%26epage%3D39%26doi%3D10.1595%2F205651317X693741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Chabner, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. G.</span><span> </span><span class="NLM_article-title">Chemotherapy and the War on Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1038/nrc1529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2Fnrc1529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=15630416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVek" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-72&author=B.+A.+Chabnerauthor=T.+G.+Roberts&title=Chemotherapy+and+the+War+on+Cancer&doi=10.1038%2Fnrc1529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy and the war on cancer</span></div><div class="casAuthors">Chabner, Bruce A.; Roberts, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs.  Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry.  The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply.  This article chronicles the history of modern chemotherapy and identifies remaining challenges for the next generation of researchers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrszgbuDuTBobVg90H21EOLACvtfcHk0lj6YPhJGo-bHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVek&md5=d5c8b3dba59b9d6dcca473552525fa14</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrc1529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1529%26sid%3Dliteratum%253Aachs%26aulast%3DChabner%26aufirst%3DB.%2BA.%26aulast%3DRoberts%26aufirst%3DT.%2BG.%26atitle%3DChemotherapy%2520and%2520the%2520War%2520on%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D72%26doi%3D10.1038%2Fnrc1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Cleare, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeschele, J. D.</span><span> </span><span class="NLM_article-title">Studies on the Antitumor Activity of Group VIII Transition Metal Complexes. Part I. Platinum (II) Complexes</span> <span class="citation_source-journal">Bioinorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1016/S0006-3061(00)80249-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0006-3061%2800%2980249-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaE2cXms1GqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1973&pages=187-210&author=M.+J.+Cleareauthor=J.+D.+Hoeschele&title=Studies+on+the+Antitumor+Activity+of+Group+VIII+Transition+Metal+Complexes.+Part+I.+Platinum+%28II%29+Complexes&doi=10.1016%2FS0006-3061%2800%2980249-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of Group VIII transition metal complexes.  I.  Platinum(II) complexes</span></div><div class="casAuthors">Cleare, Michael J.; Hoeschele, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioinorganic Chemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-210</span>CODEN:
                <span class="NLM_cas:coden">BICHBX</span>;
        ISSN:<span class="NLM_cas:issn">0006-3061</span>.
    </div><div class="casAbstract">A wide variety of Pt(II) complexes were studied for antitumor activity against Sarcoma 180 in female mice.  In general only neutral complexes exhibited activity, whereas charged species were inactive and relatively nontoxic.  A series of complexes of the type cis-[PtA2X2] (where A2 is either 2 monodentate or 1 bidentate amine ligand and X2 is either 2 monodentate or 1 bidentate anionic ligand) were studied with A and B being systematically varied.  At least 10 potentially active antitumor drugs were identified, including cis-dichlorbis(methylamine)platinum(2+) [15273-32-2], diamminepropanedioatoplatinum(2+) [38780-43-7], and (1,2-ethanediammine-N,N')(2-methylpropanedioato)platinum(2+) [41575-97-7].  The trans isomers were inactive in comparison with active cis complexes, so the presence of cis-reactive ligands seems to be a necessary parameter for antitumor activity.  Complexes with highly reactive ligands such as cis-[Pt(NH3)2 (H2O)2](NO3)2 were highly toxic.  Pd(II) complexes analogous to the active Pt(II) compds. were themselves inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXyjKO1MKtVbVg90H21EOLACvtfcHk0liFuIthgmRzUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXms1GqsQ%253D%253D&md5=6bd976211b8c0dda0c3fa4000ef0d9f8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0006-3061%2800%2980249-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3061%252800%252980249-5%26sid%3Dliteratum%253Aachs%26aulast%3DCleare%26aufirst%3DM.%2BJ.%26aulast%3DHoeschele%26aufirst%3DJ.%2BD.%26atitle%3DStudies%2520on%2520the%2520Antitumor%2520Activity%2520of%2520Group%2520VIII%2520Transition%2520Metal%2520Complexes.%2520Part%2520I.%2520Platinum%2520%2528II%2529%2520Complexes%26jtitle%3DBioinorg.%2520Chem.%26date%3D1973%26volume%3D2%26spage%3D187%26epage%3D210%26doi%3D10.1016%2FS0006-3061%2800%2980249-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Silverman, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">2.4-Å Crystal Structure of the Asymmetric Platinum Complex [Pt(Ammine)(Cyclohexylamine)]<sup>2+</sup> Bound to a Dodecamer DNA Duplex</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">49743</span><span class="NLM_x">–</span> <span class="NLM_lpage">49749</span><span class="refDoi"> DOI: 10.1074/jbc.M206979200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1074%2Fjbc.M206979200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=49743-49749&author=A.+P.+Silvermanauthor=W.+Buauthor=S.+M.+Cohenauthor=S.+J.+Lippard&title=2.4-%C3%85+Crystal+Structure+of+the+Asymmetric+Platinum+Complex+%5BPt%28Ammine%29%28Cyclohexylamine%29%5D2%2B+Bound+to+a+Dodecamer+DNA+Duplex&doi=10.1074%2Fjbc.M206979200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M206979200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M206979200%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DA.%2BP.%26aulast%3DBu%26aufirst%3DW.%26aulast%3DCohen%26aufirst%3DS.%2BM.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3D2.4-%25C3%2585%2520Crystal%2520Structure%2520of%2520the%2520Asymmetric%2520Platinum%2520Complex%2520%255BPt%2528Ammine%2529%2528Cyclohexylamine%2529%255D2%252B%2520Bound%2520to%2520a%2520Dodecamer%2520DNA%2520Duplex%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D49743%26epage%3D49749%26doi%3D10.1074%2Fjbc.M206979200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">The Influence of Structure on the Activity and Toxicity of Pt Anti-Cancer Drugs</span> <span class="citation_source-journal">Coord. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span><span class="refDoi"> DOI: 10.1016/S0010-8545(97)00023-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0010-8545%2897%2900023-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=1997&pages=181-223&author=T.+W.+Hambley&title=The+Influence+of+Structure+on+the+Activity+and+Toxicity+of+Pt+Anti-Cancer+Drugs&doi=10.1016%2FS0010-8545%2897%2900023-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0010-8545%2897%2900023-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-8545%252897%252900023-4%26sid%3Dliteratum%253Aachs%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DThe%2520Influence%2520of%2520Structure%2520on%2520the%2520Activity%2520and%2520Toxicity%2520of%2520Pt%2520Anti-Cancer%2520Drugs%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D1997%26volume%3D166%26spage%3D181%26epage%3D223%26doi%3D10.1016%2FS0010-8545%2897%2900023-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Van Beusichem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, N.</span><span> </span><span class="NLM_article-title">Activation of the <i>trans</i> Geometry in Platinum Antitumor Complexes. Synthesis, Characterization, and Biological Activity of Complexes with the Planar Ligands Pyridine, N-Methylimidazole, Thiazole, and Quinoline. Crystal and Molecular Structure of <i>trans</i>-Dichlorobis(Thiazole)Platinum(II)</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">634</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span><span class="refDoi"> DOI: 10.1021/ic00030a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic00030a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaK38XpvVWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1992&pages=634-639&author=M.+Van+Beusichemauthor=N.+Farrell&title=Activation+of+the+trans+Geometry+in+Platinum+Antitumor+Complexes.+Synthesis%2C+Characterization%2C+and+Biological+Activity+of+Complexes+with+the+Planar+Ligands+Pyridine%2C+N-Methylimidazole%2C+Thiazole%2C+and+Quinoline.+Crystal+and+Molecular+Structure+of+trans-Dichlorobis%28Thiazole%29Platinum%28II%29&doi=10.1021%2Fic00030a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the trans geometry in platinum antitumor complexes.  Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole, and quinoline.  Crystal and molecular structure of trans-dichlorobis(thiazole)platinum(II)</span></div><div class="casAuthors">Van Beusichem, Marijo; Farrell, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">634-9</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    </div><div class="casAbstract">The presence of planar ligands in trans-[PtCl2(py)2] greatly enhances the cytotoxicity of such species, with respect both to their corresponding cis isomer and also to trans-[PtCl2(NH3)2].  The cytotoxicity of trans-[PtCl2(py)2] in murine tumor cell lines is equiv. to the anticancer drug cisplatin, cis-[PtCl2(NH3)2].  The generality of this effect was studied for a range of structures with planar ligands of formula trans-[PtCl2(L)(L')].  Three distinct series were examd.-(1) L = L' = py, N-methylimidazole (N-MeIm), and thiazole (Tz), (2) L = quinoline (quin), L' = MeRSO where (R = Me, CH2Ph, Ph), and (3) L = quinoline, L' = NH3.  The synthesis and chem. characterization of all new complexes are described.  An x-ray crystal structure detn. for trans-[PtCl2(Tz)2] confirmed the geometry with N-bound thiazole.  The crystals are monoclinic, space group C2/c, a 8.088(3), b 14.964(4), c 8.847(2) Å, β 99.50(2), Z = 4, R = 0.0545, Rw = 0.0655.  Pt has the expected square planar coordination with l(Pt-Cl) = 2.300(5) Å and l(Pt-N) = 2.024(18) and 2.077(17) Å.  Bond angles are normal with N(1)-Pt-N(2) = 180.0(1)°, N(1)-Pt-Cl(1) = 90.4(1)°, and N(2)-Pt-Cl(1A) = 89.6(1)°.  The intensity data were collected with MoKα radiation with λ = 0.71073 Å.  The thiazole rings are not coplanar but slightly tilted to each other at an angle of 14.3°.  The dihedral angles between the Pt coordination plane and the thiazole rings are 119.3 and 105.0°.  The biol. studies confirm the generality of activation of the trans geometry using planar ligands.  Cytotoxicity tests in murine leukemia (L1210) cell lines both sensitive and rendered resistant to cisplatin show that the complexes show equiv. cytostatic activity to that of cisplatin.  The activity is an order of magnitude greater than trans-[PtCl2(NH3)2].  The cytotoxicity is further marked by consistent activity in the cisplatin-resistant cell line.  Contrary to the well-established but empirical structure-activity relationships, the trans geometry can give platinum complexes with cytotoxicity equiv. to that of the analogous cis isomer.  The results point to a further source of platinum antitumor complexes acting by a different mol. mechanism to cisplatin with potential for antitumor activity complementary to that of the clin. used drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri6EQNAr6TNrVg90H21EOLACvtfcHk0liFuIthgmRzUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XpvVWgtQ%253D%253D&md5=c3800e101d3ab61e9251b60730dab333</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fic00030a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic00030a021%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBeusichem%26aufirst%3DM.%26aulast%3DFarrell%26aufirst%3DN.%26atitle%3DActivation%2520of%2520the%2520trans%2520Geometry%2520in%2520Platinum%2520Antitumor%2520Complexes.%2520Synthesis%252C%2520Characterization%252C%2520and%2520Biological%2520Activity%2520of%2520Complexes%2520with%2520the%2520Planar%2520Ligands%2520Pyridine%252C%2520N-Methylimidazole%252C%2520Thiazole%252C%2520and%2520Quinoline.%2520Crystal%2520and%2520Molecular%2520Structure%2520of%2520trans-Dichlorobis%2528Thiazole%2529Platinum%2528II%2529%26jtitle%3DInorg.%2520Chem.%26date%3D1992%26volume%3D31%26spage%3D634%26epage%3D639%26doi%3D10.1021%2Fic00030a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hearn, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Canelon, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizarro, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcdermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carragher, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, P. J.</span><span> </span><span class="NLM_article-title">Potent Organo-Osmium Compound Shifts Metabolism in Epithelial Ovarian Cancer Cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">E3800</span><span class="NLM_x">–</span> <span class="NLM_lpage">3805</span><span class="refDoi"> DOI: 10.1073/pnas.1500925112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1073%2Fpnas.1500925112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E3800-3805&author=J.+M.+Hearnauthor=I.+Romero-Canelonauthor=A.+F.+Munroauthor=Y.+Fuauthor=A.+M.+Pizarroauthor=M.+J.+Garnettauthor=U.+Mcdermottauthor=N.+O.+Carragherauthor=P.+J.+Sadler&title=Potent+Organo-Osmium+Compound+Shifts+Metabolism+in+Epithelial+Ovarian+Cancer+Cells&doi=10.1073%2Fpnas.1500925112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1500925112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1500925112%26sid%3Dliteratum%253Aachs%26aulast%3DHearn%26aufirst%3DJ.%2BM.%26aulast%3DRomero-Canelon%26aufirst%3DI.%26aulast%3DMunro%26aufirst%3DA.%2BF.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DPizarro%26aufirst%3DA.%2BM.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMcdermott%26aufirst%3DU.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DPotent%2520Organo-Osmium%2520Compound%2520Shifts%2520Metabolism%2520in%2520Epithelial%2520Ovarian%2520Cancer%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3DE3800%26epage%3D3805%26doi%3D10.1073%2Fpnas.1500925112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Google</span><span class="NLM_x">. Google Scholar. </span><a href="http://scholar.google.com/" class="extLink">http://scholar.google.com/</a> (accessed August 11,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Google.+Google+Scholar.+http%3A%2F%2Fscholar.google.com%2F+%28accessed+August+11%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sancton, T.; Le Quesne, N.</span><span> </span><span class="NLM_article-title">From Despair to Glory</span>.  <span class="citation_source-journal">Time International</span>; July 19,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=T.+Sancton&author=N.+Le+Quesne&title=From+Despair+to+Glory"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSancton%26aufirst%3DT.%26atitle%3DFrom%2520Despair%2520to%2520Glory%26jtitle%3DTime%2520International%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Armstrong, L.</span> <span class="citation_source-book">It’s Not About the Bike: My Journey Back to Life</span>; <span class="NLM_publisher-name">The Berkley Publishing Group</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=L.+Armstrong&title=It%E2%80%99s+Not+About+the+Bike%3A+My+Journey+Back+to+Life"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DL.%26btitle%3DIt%25E2%2580%2599s%2520Not%2520About%2520the%2520Bike%253A%2520My%2520Journey%2520Back%2520to%2520Life%26pub%3DThe%2520Berkley%2520Publishing%2520Group%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Schnell, F. M.</span><span> </span><span class="NLM_article-title">Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span><span class="refDoi"> DOI: 10.1634/theoncologist.8-2-187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1634%2Ftheoncologist.8-2-187" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=187-198&author=F.+M.+Schnell&title=Chemotherapy-Induced+Nausea+and+Vomiting%3A+The+Importance+of+Acute+Antiemetic+Control&doi=10.1634%2Ftheoncologist.8-2-187"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-2-187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-2-187%26sid%3Dliteratum%253Aachs%26aulast%3DSchnell%26aufirst%3DF.%2BM.%26atitle%3DChemotherapy-Induced%2520Nausea%2520and%2520Vomiting%253A%2520The%2520Importance%2520of%2520Acute%2520Antiemetic%2520Control%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26spage%3D187%26epage%3D198%26doi%3D10.1634%2Ftheoncologist.8-2-187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Karasawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyger, P. S.</span><span> </span><span class="NLM_article-title">An Integrated View of Cisplatin-Induced Nephrotoxicity and Ototoxicity</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.toxlet.2015.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.toxlet.2015.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26101797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyiurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2015&pages=219-227&author=T.+Karasawaauthor=P.+S.+Steyger&title=An+Integrated+View+of+Cisplatin-Induced+Nephrotoxicity+and+Ototoxicity&doi=10.1016%2Fj.toxlet.2015.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An integrated view of cisplatin-induced nephrotoxicity and ototoxicity</span></div><div class="casAuthors">Karasawa, Takatoshi; Steyger, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-227</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Cisplatin is one of the most widely-used drugs to treat cancers.  However, its nephrotoxic and ototoxic side-effects remain major clin. limitations.  Recent studies have improved our understanding of the mol. mechanisms of cisplatin-induced nephrotoxicity and ototoxicity.  While cisplatin binding to DNA is the major cytotoxic mechanism in proliferating (cancer) cells, nephrotoxicity and ototoxicity appear to result from toxic levels of reactive oxygen species and protein dysregulation within various cellular compartments.  In this review, we discuss mol. mechanisms of cisplatin-induced nephrotoxicity and ototoxicity.  We also discuss potential clin. strategies to prevent nephrotoxicity and ototoxicity and their current limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYhpFPdWYJwbVg90H21EOLACvtfcHk0lgVeDba0x-dQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyiurbI&md5=73d8dd65d26d256bddcb16e414417d6d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2015.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2015.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DKarasawa%26aufirst%3DT.%26aulast%3DSteyger%26aufirst%3DP.%2BS.%26atitle%3DAn%2520Integrated%2520View%2520of%2520Cisplatin-Induced%2520Nephrotoxicity%2520and%2520Ototoxicity%26jtitle%3DToxicol.%2520Lett.%26date%3D2015%26volume%3D237%26spage%3D219%26epage%3D227%26doi%3D10.1016%2Fj.toxlet.2015.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span> </span><span class="NLM_article-title">The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer</span>. In  <span class="citation_source-book">Wellcome Witnesses to Twentieth Century Medicine Seminars</span>; <span class="NLM_contrib-group">Christie, D. A.; Tansey, E. M.</span>, Eds.; Wellcome Witnesses to Twentieth Century Medicine, Vol. 30; <span class="NLM_publisher-name">The Trustee of the Wellcome Trust</span>: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+A.+Christie&author=E.+M.+Tansey&title=Wellcome+Witnesses+to+Twentieth+Century+Medicine+Seminars"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Discovery%252C%2520Use%2520and%2520Impact%2520of%2520Platinum%2520Salts%2520as%2520Chemotherapy%2520Agents%2520for%2520Cancer%26btitle%3DWellcome%2520Witnesses%2520to%2520Twentieth%2520Century%2520Medicine%2520Seminars%26aulast%3DChristie%26aufirst%3DD.%2BA.%26pub%3DThe%2520Trustee%2520of%2520the%2520Wellcome%2520Trust%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Carter, S. K.; Cleare, M. J.; Connors, T. A.; Conran, P. B.; Dienstbier, Z.; Ellerby, R. A.; Harder, M. C.; Hill, J. M.; Hindy, I.; Krakoff, I.; Roberts, J. J.; Robins, A. B.; Talley, R. W.; Thomson, A. J.; Wallace, H. J.; Williams, R. J.; Wiltshaw, E.</span> <span class="citation_source-book">Platinum Coordination Complexes in Cancer Chemotherapy</span>; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1974</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1974&author=S.+K.+Carter&author=M.+J.+Cleare&author=T.+A.+Connors&author=P.+B.+Conran&author=Z.+Dienstbier&author=R.+A.+Ellerby&author=M.+C.+Harder&author=J.+M.+Hill&author=I.+Hindy&author=I.+Krakoff&author=J.+J.+Roberts&author=A.+B.+Robins&author=R.+W.+Talley&author=A.+J.+Thomson&author=H.+J.+Wallace&author=R.+J.+Williams&author=E.+Wiltshaw&title=Platinum+Coordination+Complexes+in+Cancer+Chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DS.%2BK.%26btitle%3DPlatinum%2520Coordination%2520Complexes%2520in%2520Cancer%2520Chemotherapy%26pub%3DSpringer-Verlag%26date%3D1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hill, J. M.; Loeb, E.; Maclellan, A. S.; Hill, N. O.; Khan, A.; Kogler, J.</span><span> </span><span class="NLM_article-title">Further Clinical Experience with <i>cis</i>-Platinum(II) Diamminedichloride</span>. In  <span class="citation_source-book">Platinum Coordination Complexes in Cancer Chemotherapy</span>; <span class="NLM_contrib-group">Connors, T. A.; Roberts, J. J.</span>, Ed.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1974</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2F978-3-642-49306-5_10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1974&pages=145-152&author=J.+M.+Hill&author=E.+Loeb&author=A.+S.+Maclellan&author=N.+O.+Hill&author=A.+Khan&author=J.+Koglerauthor=T.+A.+Connors&author=J.+J.+Roberts&title=Platinum+Coordination+Complexes+in+Cancer+Chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-49306-5_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-49306-5_10%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DJ.%2BM.%26atitle%3DFurther%2520Clinical%2520Experience%2520with%2520cis-Platinum%2528II%2529%2520Diamminedichloride%26btitle%3DPlatinum%2520Coordination%2520Complexes%2520in%2520Cancer%2520Chemotherapy%26aulast%3DConnors%26aufirst%3DT.%2BA.%26pub%3DSpringer-Verlag%26date%3D1974%26spage%3D145%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harland, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddik, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcelwain, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiltshaw, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peckham, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrap, K. R.</span><span> </span><span class="NLM_article-title">Early Clinical Studies with <i>cis</i>-Diammine-1,1-Cyclobutane Dicarboxylate Platinum II</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1007/BF00257742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF00257742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=6761010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaL3s7ivFyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1982&pages=140-147&author=A.+H.+Calvertauthor=S.+J.+Harlandauthor=D.+R.+Newellauthor=Z.+H.+Siddikauthor=A.+C.+Jonesauthor=T.+J.+Mcelwainauthor=S.+Rajuauthor=E.+Wiltshawauthor=I.+E.+Smithauthor=J.+M.+Bakerauthor=M.+J.+Peckhamauthor=K.+R.+Harrap&title=Early+Clinical+Studies+with+cis-Diammine-1%2C1-Cyclobutane+Dicarboxylate+Platinum+II&doi=10.1007%2FBF00257742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II</span></div><div class="casAuthors">Calvert A H; Harland S J; Newell D R; Siddik Z H; Jones A C; McElwain T J; Raju S; Wiltshaw E; Smith I E; Baker J M; Peckham M J; Harrap K R</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">140-7</span>
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">cis-Diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8), an analogue of cisplatin showing reduced toxicity in preclinical studies, was evaluated in 60 patients.  Doses were given initially every 3 weeks and escalated from 20 to 520 mg/m2.  Following this, doses were given every 4 weeks and escalated from 300 to 500 mg/m2.  The dose-limiting toxicity, thrombocytopoenia, occurred in four-fifths of patients treated at 520 mg/m2, with the nadir occurring 3 weeks after treatment.  Leucopoenia and anaemia also occurred but were less severe.  Vomiting occurred in all patients receiving over 120 mg/m2 but seldom persisted beyond 24 h.  Serial measurements of 51Cr-EDTA clearances, urinary N-acetylglucosaminidase, urinary leucine aminopeptidase, and beta 2-microglobulin did not reveal significant evidence of nephrotoxicity.  Detriment to the audiogram has not been seen in the first 13 patients studied.  Pharmacological studies showed that most of the dose of platinum was excreted in the urine, and that impairment of renal function may be associated with drug retention and an increased risk of myelosuppression.  The previous therapy and age of the patient also affected the tolerance of the drug.  Clinical responses were seen in patients with ovarian carcinoma receiving greater than 120 mg/m2.  A further dose escalation was performed on a 4-week schedule in patients under 65 with good renal function.  The maximum dose it was possible to administer repeatedly without incurring myelosuppression was in the range 400-500 mg/m2.  JM8 is not significantly nephrotoxic and is less emetic than cisplatin.  It has antitumour activity in man and deserves wider evaluation, along with the other analogues under study in various centres, as an alternative to cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT378_1soZJrUH3Rlp_k91zfW6udTcc2eZF9z0uEGhzSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s7ivFyisg%253D%253D&md5=6c38034782d8df6263c086fa4baeebf6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2FBF00257742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00257742%26sid%3Dliteratum%253Aachs%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DHarland%26aufirst%3DS.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26aulast%3DJones%26aufirst%3DA.%2BC.%26aulast%3DMcelwain%26aufirst%3DT.%2BJ.%26aulast%3DRaju%26aufirst%3DS.%26aulast%3DWiltshaw%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DBaker%26aufirst%3DJ.%2BM.%26aulast%3DPeckham%26aufirst%3DM.%2BJ.%26aulast%3DHarrap%26aufirst%3DK.%2BR.%26atitle%3DEarly%2520Clinical%2520Studies%2520with%2520cis-Diammine-1%252C1-Cyclobutane%2520Dicarboxylate%2520Platinum%2520II%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1982%26volume%3D9%26spage%3D140%26epage%3D147%26doi%3D10.1007%2FBF00257742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Goodfield, J.</span> <span class="citation_source-book">Cancer under Siege</span>; <span class="NLM_publisher-name">Hutchinson</span>: <span class="NLM_publisher-loc">London, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">1975</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1975&author=J.+Goodfield&title=Cancer+under+Siege"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfield%26aufirst%3DJ.%26btitle%3DCancer%2520under%2520Siege%26pub%3DHutchinson%26date%3D1975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span> <span class="citation_source-book">Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug</span>; <span class="NLM_publisher-name">Verlag Helvetica Chimica Aeta and Wiley-VCH</span>: <span class="NLM_publisher-loc">Zürich, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cisplatin%3A+Chemistry+and+Biochemistry+of+a+Leading+Anticancer+Drug%3B+Verlag+Helvetica+Chimica+Aeta+and+Wiley-VCH%3A+Z%C3%BCrich%2C+Switzerland%2C+1999."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DCisplatin%253A%2520Chemistry%2520and%2520Biochemistry%2520of%2520a%2520Leading%2520Anticancer%2520Drug%26pub%3DVerlag%2520Helvetica%2520Chimica%2520Aeta%2520and%2520Wiley-VCH%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span>Twitter. <a href="https://twitter.com/" class="extLink">https://twitter.com/</a> (accessed August 11,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Twitter.+https%3A%2F%2Ftwitter.com%2F+%28accessed+August+11%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Descoeur, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzoccaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francois, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffre, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couette, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busserolles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courteix, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazdunski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eschalier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Authier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourinet, E.</span><span> </span><span class="NLM_article-title">Oxaliplatin-Induced Cold Hypersensitivity Is Due to Remodelling of Ion Channel Expression in Nociceptors</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">266</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.1002/emmm.201100134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Femmm.201100134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=21438154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmt1yhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=266-278&author=J.+Descoeurauthor=V.+Pereiraauthor=A.+Pizzoccaroauthor=A.+Francoisauthor=B.+Lingauthor=V.+Maffreauthor=B.+Couetteauthor=J.+Busserollesauthor=C.+Courteixauthor=J.+Noelauthor=M.+Lazdunskiauthor=A.+Eschalierauthor=N.+Authierauthor=E.+Bourinet&title=Oxaliplatin-Induced+Cold+Hypersensitivity+Is+Due+to+Remodelling+of+Ion+Channel+Expression+in+Nociceptors&doi=10.1002%2Femmm.201100134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors</span></div><div class="casAuthors">Descoeur, Juliette; Pereira, Vanessa; Pizzoccaro, Anne; Francois, Amaury; Ling, Bing; Maffre, Violette; Couette, Brigitte; Busserolles, Jerome; Courteix, Christine; Noel, Jacques; Lazdunski, Michel; Eschalier, Alain; Authier, Nicolas; Bourinet, Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">266-278</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cold hypersensitivity is the hallmark of oxaliplatin-induced neuropathy, which develops in nearly all patients under this chemotherapy.  To date, pain management strategies have failed to alleviate these symptoms, hence development of adapted analgesics is needed.  Here, we report that oxaliplatin exaggerates cold perception in mice as well as in patients.  These symptoms are mediated by primary afferent sensory neurons expressing the thermoreceptor TRPM8.  Mechanistically, oxaliplatin promotes over-excitability by drastically lowering the expression of distinct potassium channels (TREK1, TRAAK) and by increasing the expression of pro-excitatory channels such as the hyperpolarization-activated channels (HCNs).  These findings are corroborated by the anal. of TREK1-TRAAK null mice and use of the specific HCN inhibitor ivabradine, which abolishes the oxaliplatin-induced cold hypersensibility.  These results suggest that oxaliplatin exacerbates cold perception by modulating the transcription of distinct ionic conductances that together shape sensory neuron responses to cold.  The translational and clin. implication of these findings would be that ivabradine may represent a tailored treatment for oxaliplatin-induced neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLi-ACdibowbVg90H21EOLACvtfcHk0lh9XtC8tnIP7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmt1yhsrk%253D&md5=fe6a66edde85115e7a99b05693c94439</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Femmm.201100134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201100134%26sid%3Dliteratum%253Aachs%26aulast%3DDescoeur%26aufirst%3DJ.%26aulast%3DPereira%26aufirst%3DV.%26aulast%3DPizzoccaro%26aufirst%3DA.%26aulast%3DFrancois%26aufirst%3DA.%26aulast%3DLing%26aufirst%3DB.%26aulast%3DMaffre%26aufirst%3DV.%26aulast%3DCouette%26aufirst%3DB.%26aulast%3DBusserolles%26aufirst%3DJ.%26aulast%3DCourteix%26aufirst%3DC.%26aulast%3DNoel%26aufirst%3DJ.%26aulast%3DLazdunski%26aufirst%3DM.%26aulast%3DEschalier%26aufirst%3DA.%26aulast%3DAuthier%26aufirst%3DN.%26aulast%3DBourinet%26aufirst%3DE.%26atitle%3DOxaliplatin-Induced%2520Cold%2520Hypersensitivity%2520Is%2520Due%2520to%2520Remodelling%2520of%2520Ion%2520Channel%2520Expression%2520in%2520Nociceptors%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D266%26epage%3D278%26doi%3D10.1002%2Femmm.201100134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Schierl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohnloser, J.</span><span> </span><span class="NLM_article-title">Long-Term Platinum Excretion in Patients Treated with Cisplatin</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1007/BF00685736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF00685736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=7720180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK2M3js1Gluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=75-78&author=R.+Schierlauthor=B.+Rohrerauthor=J.+Hohnloser&title=Long-Term+Platinum+Excretion+in+Patients+Treated+with+Cisplatin&doi=10.1007%2FBF00685736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term platinum excretion in patients treated with cisplatin</span></div><div class="casAuthors">Schierl R; Rohrer B; Hohnloser J</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-8</span>
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">The purpose of this study was to determine long-term renal platinum excretion after chemotherapy with cisplatin.  We examined urinary platinum concentrations in 23 men at 150-3022 days after anticancer treatment for testicular neoplasm.  Spot urine samples were analyzed by voltammetry.  This new, subtle method with a detection limit of 2 pg platinum allows determination of even the natural background level.  Urinary platinum concentrations in our patients ranged between 0.74 and 77.24 micrograms/g creatinine, depending on the total delivered dose and follow-up period.  Regression analysis of the data showed two phases of long-term renal platinum excretion, one occurring at between 150 and 900 days of follow-up and the other with an onset at 900 days after cisplatin administration (r1(2) = 0.82, r2(2) = 0.88).  Two biological half-lives of 160 and 720 days were calculated.  Our results show that urinary platinum concentrations determined at 8 years after cisplatin therapy are 40 times higher than the background level (up to 0.02 micrograms/g creatinine).  Our findings on the long-term pharmacokinetics of this anticancer agent may facilitate further studies on sites of platinum storage in the human body as well as clinical studies on the late adverse effects of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbaoG3R9PV8Y3yKPtYViAGfW6udTcc2ea4T5IgclD6srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3js1Gluw%253D%253D&md5=695387ab341736a93877701636255d7c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2FBF00685736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00685736%26sid%3Dliteratum%253Aachs%26aulast%3DSchierl%26aufirst%3DR.%26aulast%3DRohrer%26aufirst%3DB.%26aulast%3DHohnloser%26aufirst%3DJ.%26atitle%3DLong-Term%2520Platinum%2520Excretion%2520in%2520Patients%2520Treated%2520with%2520Cisplatin%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1995%26volume%3D36%26spage%3D75%26epage%3D78%26doi%3D10.1007%2FBF00685736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Theon, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascoe, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krag, D. N.</span><span> </span><span class="NLM_article-title">Intratumoral Chemotherapy with Cisplatin in Oily Emulsion in Horses</span> <span class="citation_source-journal">J. Am. Vet. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">202</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=8428832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK3s7lsV2itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=1993&pages=261-267&author=A.+P.+Theonauthor=J.+R.+Pascoeauthor=G.+P.+Carlsonauthor=D.+N.+Krag&title=Intratumoral+Chemotherapy+with+Cisplatin+in+Oily+Emulsion+in+Horses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumoral chemotherapy with cisplatin in oily emulsion in horses</span></div><div class="casAuthors">Theon A P; Pascoe J R; Carlson G P; Krag D N</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Veterinary Medical Association</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-7</span>
        ISSN:<span class="NLM_cas:issn">0003-1488</span>.
    </div><div class="casAbstract">Twenty horses with 30 lesions were studied to evaluate the effects of intratumoral chemotherapy with cisplatin in sesame oil on equine sarcoids (n = 19), squamous cell carcinomas (n = 7), and squamous cell papillomas (n = 4).  Treatment consisted of 4 sessions of intratumoral cisplatin chemotherapy at 2-week intervals.  A controlled-release formulation of cisplatin in sesame oil was used to limit drug egress from the injection site.  Mean dosage per session was 0.97 (+/- 0.17, SEM) mg of cisplatin/cm3 of tumor tissue treated for tumor volumes ranging from 10 to 20 cm3.  Dosage tended to be slightly higher for smaller tumors and slightly lower for larger tumors.  Tumor regression was observed in all horses.  Complete response was observed in 18 of the sarcoids, 5 of the squamous cell carcinomas, and 4 of the squamous cell papillomas.  The mean relapse-free interval was 21.6 and 14 months in horses with sarcoid and carcinoma/papilloma, respectively.  The 1-year relapse-free rates were 87 and 65% for equine sarcoid and carcinoma/papilloma, respectively.  In horses with relapse, 70% had tumor recurrence outside the treated field.  Cisplatin-related local toxicosis was minimal.  Intratumoral cisplatin chemotherapy was found to be a practical and effective treatment of sarcoid and squamous cell carcinoma/papilloma in horses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKREFwGL5d7zslzEEsg76ufW6udTcc2ea4T5IgclD6srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s7lsV2itA%253D%253D&md5=f1d8119d94e2e6a29c090baecdb341ac</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTheon%26aufirst%3DA.%2BP.%26aulast%3DPascoe%26aufirst%3DJ.%2BR.%26aulast%3DCarlson%26aufirst%3DG.%2BP.%26aulast%3DKrag%26aufirst%3DD.%2BN.%26atitle%3DIntratumoral%2520Chemotherapy%2520with%2520Cisplatin%2520in%2520Oily%2520Emulsion%2520in%2520Horses%26jtitle%3DJ.%2520Am.%2520Vet.%2520Med.%2520Assoc.%26date%3D1993%26volume%3D202%26spage%3D261%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Theon, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdesian, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusterla, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galuppo, L. D.</span><span> </span><span class="NLM_article-title">Long-Term Outcome Associated with Intratumoral Chemotherapy with Cisplatin for Cutaneous Tumors in Equidae: 573 Cases (1995–2004)</span> <span class="citation_source-journal">J. Am. Vet. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">230</span><span class="NLM_x">, </span> <span class="NLM_fpage">1506</span><span class="NLM_x">–</span> <span class="NLM_lpage">1513</span><span class="refDoi"> DOI: 10.2460/javma.230.10.1506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2460%2Fjavma.230.10.1506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=17504043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsVGmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=2007&pages=1506-1513&author=A.+P.+Theonauthor=W.+D.+Wilsonauthor=K.+G.+Magdesianauthor=N.+Pusterlaauthor=J.+R.+Snyderauthor=L.+D.+Galuppo&title=Long-Term+Outcome+Associated+with+Intratumoral+Chemotherapy+with+Cisplatin+for+Cutaneous+Tumors+in+Equidae%3A+573+Cases+%281995%E2%80%932004%29&doi=10.2460%2Fjavma.230.10.1506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004)</span></div><div class="casAuthors">Theon, Alain P.; Wilson, W. David; Magdesian, K. Gary; Pusterla, Nicola; Snyder, Jack R.; Galuppo, Larry D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Veterinary Medical Association</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1506-1513</span>CODEN:
                <span class="NLM_cas:coden">JAVMA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-1488</span>.
    
            (<span class="NLM_cas:orgname">American Veterinary Medical Association</span>)
        </div><div class="casAbstract">Objective: To det. outcome assocd. with cutaneous tumors treated via intratumoral chemotherapy with cisplatin and identify risk factors affecting local tumor control and complications in equidae.  Design: Retrospective case series.  Animals: 573 equidae with 630 cutaneous tumors.  Procedures: Medical records of horses, mules, donkeys, and ponies with cutaneous tumors treated via intratumoral chemotherapy with cisplatin were analyzed.  Results: 549 horses, 13 mules, 8 donkeys, and 3 ponies with 630 histol. confirmed cutaneous tumors were included.  Tumors included sarcoids (n = 409), squamous cell carcinomas (151), soft tissue sarcomas (28), cutaneous lymphomas (26), and melanomas (16).  Overall cure rate, defined as local control at 4 years, was 93.3%.  For all tumor stages combined, cure rates after 1 course of treatment were 96.3% for sarcoids, 96% for lymphomas, 88% for squamous cell carcinomas, 85% for soft tissue sarcomas, and 81 % for melanomas.  Treatment protocol, tumor stage, and prior treatment were significant prognostic factors for tumor control.  Treatment efficacy was lower for large tumors, those with gross postoperative residual disease, and those that had been treated previously with other modalities.  Treatment was well tolerated.  Local reactions were more likely to occur and to be more severe after the third and fourth treatment sessions.  Conclusions and Clin. Relevance: Results confirmed the value of intratumoral chemotherapy with cisplatin for treatment of cutaneous tumors in equidae.  The results cannot be extrapolated to other formulations of cisplatin or other protocols that might be used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7YNWHcLKSF7Vg90H21EOLACvtfcHk0liND5dWEPLC4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsVGmtbs%253D&md5=0e29db20d601e80f756ed07ad0c296ce</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2460%2Fjavma.230.10.1506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2460%252Fjavma.230.10.1506%26sid%3Dliteratum%253Aachs%26aulast%3DTheon%26aufirst%3DA.%2BP.%26aulast%3DWilson%26aufirst%3DW.%2BD.%26aulast%3DMagdesian%26aufirst%3DK.%2BG.%26aulast%3DPusterla%26aufirst%3DN.%26aulast%3DSnyder%26aufirst%3DJ.%2BR.%26aulast%3DGaluppo%26aufirst%3DL.%2BD.%26atitle%3DLong-Term%2520Outcome%2520Associated%2520with%2520Intratumoral%2520Chemotherapy%2520with%2520Cisplatin%2520for%2520Cutaneous%2520Tumors%2520in%2520Equidae%253A%2520573%2520Cases%2520%25281995%25E2%2580%25932004%2529%26jtitle%3DJ.%2520Am.%2520Vet.%2520Med.%2520Assoc.%26date%3D2007%26volume%3D230%26spage%3D1506%26epage%3D1513%26doi%3D10.2460%2Fjavma.230.10.1506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Knapp, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denicola, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blevins, W. E.</span><span> </span><span class="NLM_article-title">Cisplatin Toxicity in Cats</span> <span class="citation_source-journal">J. Vet. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1111/j.1939-1676.1987.tb01983.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1111%2Fj.1939-1676.1987.tb01983.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3506619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL2sXktlaks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1987&pages=29-35&author=D.+W.+Knappauthor=R.+C.+Richardsonauthor=D.+B.+Denicolaauthor=G.+G.+Longauthor=W.+E.+Blevins&title=Cisplatin+Toxicity+in+Cats&doi=10.1111%2Fj.1939-1676.1987.tb01983.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin toxicity in cats</span></div><div class="casAuthors">Knapp, Deborah W.; Richardson, Ralph C.; DeNicola, Dennis B.; Long, Gerald G.; Blevins, William E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Veterinary Internal Medicine</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">JVIMEM</span>;
        ISSN:<span class="NLM_cas:issn">0891-6640</span>.
    </div><div class="casAbstract">Cisplatin (cis-diamminedichloroplatinum; Platinol) was administered to cats, divided into 3 groups.  In group 1, cisplatin was administered at a dose of 60 mg/m2.  In an attempt to avoid renal toxicity, saline diuresis was induced by administering 0.9% saline soln. i.v. at a rate of 20 mL/kg/h for 4 h before and 2 h after cisplatin administration.  All cats became dyspneic and died 48-96 h after cisplatin administration.  Postmortem findings included severe hydrothorax, pulmonary edema, and mediastinal edema.  In group 2, cats entered a trial comparing the effects of saline diuresis and cisplatin (60 mg/m2) with the effects of saline diuresis and placebo (0.9% saline soln.).  The cats in the saline control group remained completely normal, whereas the cats that received cisplatin developed clin. signs and gross postmortem pulmonary changes identical to those in the first group of cats.  Histopathol. examn. showed that the alveolar septa were thickened and congested, and contained macrophages, occasional neutrophils, thrombi, and small foci of necrosis and fibrin.  Microangiopathic changes were seen in the alveolar capillaries.  In the 3rd group, cats were treated with a lower dose of cisplatin.  Two cats that received 40 mg/m2 of cisplatin developed pulmonary changes similar to, but less severe than, those seen in the cats that received the higher dose of cisplatin.  One cat treated with 20 mg/m2 of cisplatin showed no pulmonary changes ante mortem or post mortem.  Apparently, there is species-specific, dose-related, primary pulmonary toxicity of cisplatin in cats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR0hPPllMjqLVg90H21EOLACvtfcHk0lg7TX71ZXKzqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktlaks7g%253D&md5=866d198e4118f3213a8570cfa0a717aa</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fj.1939-1676.1987.tb01983.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1939-1676.1987.tb01983.x%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DD.%2BW.%26aulast%3DRichardson%26aufirst%3DR.%2BC.%26aulast%3DDenicola%26aufirst%3DD.%2BB.%26aulast%3DLong%26aufirst%3DG.%2BG.%26aulast%3DBlevins%26aufirst%3DW.%2BE.%26atitle%3DCisplatin%2520Toxicity%2520in%2520Cats%26jtitle%3DJ.%2520Vet.%2520Intern.%2520Med.%26date%3D1987%26volume%3D1%26spage%3D29%26epage%3D35%26doi%3D10.1111%2Fj.1939-1676.1987.tb01983.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Bell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lage, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spirtos, N. M.</span><span> </span><span class="NLM_article-title">Randomized Phase III Trial of Three Versus Six Cycles of Adjuvant Carboplatin and Paclitaxel in Early Stage Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">432</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/j.ygyno.2006.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.ygyno.2006.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=16860852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1WmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2006&pages=432-439&author=J.+Bellauthor=M.+F.+Bradyauthor=R.+C.+Youngauthor=J.+Lageauthor=J.+L.+Walkerauthor=K.+Y.+Lookauthor=G.+S.+Roseauthor=N.+M.+Spirtos&title=Randomized+Phase+III+Trial+of+Three+Versus+Six+Cycles+of+Adjuvant+Carboplatin+and+Paclitaxel+in+Early+Stage+Epithelial+Ovarian+Carcinoma%3A+A+Gynecologic+Oncology+Group+Study&doi=10.1016%2Fj.ygyno.2006.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study</span></div><div class="casAuthors">Bell, Jeffrey; Brady, Mark F.; Young, Robert C.; Lage, Janice; Walker, Joan L.; Look, Katherine Y.; Rose, G. Scott; Spirtos, Nick M.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">432-439</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Objective: Compared to 3 cycles, to det. if 6 cycles of adjuvant carboplatin (C) and paclitaxel (P) significantly lower the rate of recurrence in surgically staged patients with stage IA grade 3, IB grade 3, clear cell, IC, and completely resected stage II epithelial ovarian cancer (EOC); and to compare toxicities.  Methods: Postoperatively, randomization was to either 3 or 6 cycles of chemotherapy consisting of P (175 mg/m2 over 3 h) and C (7.5 AUC over 30 min) every 21 days.  Recurrence was any clin. or radiol. evidence of new tumor.  Results: Of 457 patients, 427 (93%) were histol. and medically eligible.  While thorough surgical staging was required, it was incomplete or inadequately documented in 29% of otherwise eligible patients.  Median age was 55.5 years; 69% of patients had stage I disease.  Median follow-up is 6.8 years for 344 women alive at last contact.  Grade 3 or 4 neurotoxicity occurred in 4/211 (2%) and 24/212 (11%) treated patients on the 3- and 6-cycle regimens, resp. (p < 0.01); 6 cycles also caused significantly more severe anemia and granulocytopenia.  The recurrence rate for 6 cycles was 24% lower (hazard ratio [HR]: 0.761; 95% confidence interval [CI]: 0.51-1.13, p = 0.18), and the estd. probability of recurrence within 5 years was 20.1% (6 cycles) vs. 25.4% (3 cycles).  The overall death rate was similar for these regimens (HR: 1.02; 95% CI: 0.662-1.57).  Conclusions: Compared to 3 cycles, 6 cycles of C and P do not significantly alter the recurrence rate in high risk early stage EOC but are assocd. with more toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7p5Bzf60wVrVg90H21EOLACvtfcHk0lg7TX71ZXKzqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1WmsLw%253D&md5=1ab153d8d4c2990e1321741b4b6b2cba</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2006.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2006.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DJ.%26aulast%3DBrady%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BC.%26aulast%3DLage%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BL.%26aulast%3DLook%26aufirst%3DK.%2BY.%26aulast%3DRose%26aufirst%3DG.%2BS.%26aulast%3DSpirtos%26aufirst%3DN.%2BM.%26atitle%3DRandomized%2520Phase%2520III%2520Trial%2520of%2520Three%2520Versus%2520Six%2520Cycles%2520of%2520Adjuvant%2520Carboplatin%2520and%2520Paclitaxel%2520in%2520Early%2520Stage%2520Epithelial%2520Ovarian%2520Carcinoma%253A%2520A%2520Gynecologic%2520Oncology%2520Group%2520Study%26jtitle%3DGynecol.%2520Oncol.%26date%3D2006%26volume%3D102%26spage%3D432%26epage%3D439%26doi%3D10.1016%2Fj.ygyno.2006.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Vasey, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabra, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span> </span><span class="NLM_article-title">Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">1682</span><span class="NLM_x">–</span> <span class="NLM_lpage">1691</span><span class="refDoi"> DOI: 10.1093/jnci/djh323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1093%2Fjnci%2Fdjh323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=15547181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVSqsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=1682-1691&author=P.+A.+Vaseyauthor=G.+C.+Jaysonauthor=A.+Gordonauthor=H.+Gabraauthor=R.+Colemanauthor=R.+Atkinsonauthor=D.+Parkinauthor=J.+Paulauthor=A.+Hayauthor=S.+B.+Kaye&title=Phase+III+Randomized+Trial+of+Docetaxel-Carboplatin+Versus+Paclitaxel-Carboplatin+as+First-Line+Chemotherapy+for+Ovarian+Carcinoma&doi=10.1093%2Fjnci%2Fdjh323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma</span></div><div class="casAuthors">Vasey, Paul A.; Jayson, Gordon C.; Gordon, Alan; Gabra, Hani; Coleman, Rob; Atkinson, Ronnie; Parkin, David; Paul, James; Hay, Andrea; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1682-1691</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the std. of care for treatment of ovarian carcinoma.  We compared the combination of docetaxel-carboplatin with the combination of paclitaxel-carboplatin as first-line chemotherapy for stage Ic-IV epithelial ovarian or primary peritoneal cancer.  Methods: We randomly assigned 1077 patients to receive docetaxel at 75 mg/m2 of body surface area (1-h i.v. infusion) or paclitaxel at 175 mg/m2 (3-h i.v. infusion).  Both treatments then were followed by carboplatin to an area under the plasma concn.-time curve of 5.  The treatments were repeated every 3 wk for six cycles; in responding patients, an addnl. three cycles of single-agent carboplatin was permitted.  Survival curves were calcd. by the Kaplan-Meier method, and hazard ratios were estd. with the Cox proportional hazards model.  All statistical tests were two-sided.  Results: After a median follow-up of 23 mo, both groups had similar progression-free survival (medians of 15.0 mo for docetaxel-carboplatin and 14.8 mo for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, resp.; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, resp.; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, resp.; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.  However, docetaxel-carboplatin was assocd. with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade ≥2 neurosensory toxicity in 11% vs. 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade ≥2 neuromotor toxicity in 3% vs. 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).  Treatment with docetaxel-carboplatin was assocd. with statistically significantly more grade 3-4 neutropenia (94% vs. 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin, although myelosuppression did not influence dose delivery or patient safety.  Global quality of life was similar in both arms, but substantive differences in many symptom scores favored docetaxel.  Conclusions: Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response, although longer follow-up is required for a definitive statement on survival.  Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGF4Oxy6qx57Vg90H21EOLACvtfcHk0lg7TX71ZXKzqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVSqsrzJ&md5=708b4c48bcdd5cac03b014b0ef82ac9a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh323%26sid%3Dliteratum%253Aachs%26aulast%3DVasey%26aufirst%3DP.%2BA.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DGabra%26aufirst%3DH.%26aulast%3DColeman%26aufirst%3DR.%26aulast%3DAtkinson%26aufirst%3DR.%26aulast%3DParkin%26aufirst%3DD.%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DHay%26aufirst%3DA.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DPhase%2520III%2520Randomized%2520Trial%2520of%2520Docetaxel-Carboplatin%2520Versus%2520Paclitaxel-Carboplatin%2520as%2520First-Line%2520Chemotherapy%2520for%2520Ovarian%2520Carcinoma%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26spage%3D1682%26epage%3D1691%26doi%3D10.1093%2Fjnci%2Fdjh323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Holmes, D.</span><span> </span><span class="NLM_article-title">Ovarian Cancer: Beyond Resistance</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">527</span><span class="NLM_x">, </span> <span class="NLM_fpage">S217</span><span class="refDoi"> DOI: 10.1038/527S217a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2F527S217a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=527&publication_year=2015&pages=S217&author=D.+Holmes&title=Ovarian+Cancer%3A+Beyond+Resistance&doi=10.1038%2F527S217a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2F527S217a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F527S217a%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DD.%26atitle%3DOvarian%2520Cancer%253A%2520Beyond%2520Resistance%26jtitle%3DNature%26date%3D2015%26volume%3D527%26spage%3DS217%26doi%3D10.1038%2F527S217a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Holmes, D.</span><span> </span><span class="NLM_article-title">The Problem with Platinum</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">527</span><span class="NLM_x">, </span> <span class="NLM_fpage">S218</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1038/527S218a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2F527S218a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26605762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFagtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=527&publication_year=2015&pages=S218-219&author=D.+Holmes&title=The+Problem+with+Platinum&doi=10.1038%2F527S218a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The problem with platinum</span></div><div class="casAuthors">Holmes, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">527</span>
        (<span class="NLM_cas:issue">7579</span>),
    <span class="NLM_cas:pages">S218-S219</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ovarian cancer is difficult to treat, largely because tumors are often found late and develop resistance to initial treatment: platinum-based therapy.  New approaches promise to break through the platinum barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVjf3jPVtZp7Vg90H21EOLACvtfcHk0ljQuxnOi1XT6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFagtbzP&md5=20930f1ce5ec0519d9a7695956c37613</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2F527S218a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F527S218a%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DD.%26atitle%3DThe%2520Problem%2520with%2520Platinum%26jtitle%3DNature%26date%3D2015%26volume%3D527%26spage%3DS218%26epage%3D219%26doi%3D10.1038%2F527S218a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Colvis, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, C. P.</span><span> </span><span class="NLM_article-title">Innovation in Therapeutics Development at the NCATS</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">230</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1038/npp.2013.247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2Fnpp.2013.247" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=230-232&author=C.+M.+Colvisauthor=C.+P.+Austin&title=Innovation+in+Therapeutics+Development+at+the+NCATS&doi=10.1038%2Fnpp.2013.247"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.247%26sid%3Dliteratum%253Aachs%26aulast%3DColvis%26aufirst%3DC.%2BM.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26atitle%3DInnovation%2520in%2520Therapeutics%2520Development%2520at%2520the%2520NCATS%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D230%26epage%3D232%26doi%3D10.1038%2Fnpp.2013.247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telma, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madigan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldlust, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeschele, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">3913</span><span class="NLM_x">–</span> <span class="NLM_lpage">3922</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1158%2F0008-5472.CAN-14-0247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24812268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCqsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3913-3922&author=M.+D.+Hallauthor=K.+A.+Telmaauthor=K.+E.+Changauthor=T.+D.+Leeauthor=J.+P.+Madiganauthor=J.+R.+Lloydauthor=I.+S.+Goldlustauthor=J.+D.+Hoescheleauthor=M.+M.+Gottesman&title=Say+No+to+DMSO%3A+Dimethylsulfoxide+Inactivates+Cisplatin%2C+Carboplatin%2C+and+Other+Platinum+Complexes&doi=10.1158%2F0008-5472.CAN-14-0247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes</span></div><div class="casAuthors">Hall, Matthew D.; Telma, Katherine A.; Chang, Ki-Eun; Lee, Tobie D.; Madigan, James P.; Lloyd, John R.; Goldlust, Ian S.; Hoeschele, James D.; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3913-3922</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a consequence are extensively studied in the lab. setting.  In this study, we examd. the literature and found a significant no. of studies (11%-34%) in prominent cancer journals utilizing cisplatin dissolved in DMSO.  However, dissolving cisplatin in DMSO for lab.-based studies results in ligand displacement and changes to the structure of the complex.  We examd. the effect of DMSO on platinum complexes, including cisplatin, carboplatin, and oxaliplatin, finding that DMSO reacted with the complexes, inhibited their cytotoxicity and their ability to initiate cell death.  These results render a substantial portion of the literature on cisplatin uninterpretable.  Raising awareness of this significant issue in the cancer biol. community is crit., and we make recommendations on appropriate solvation of platinum drugs for research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobW5pF1M4oWLVg90H21EOLACvtfcHk0ljWu7r4Tj34FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCqsL%252FJ&md5=5597b73f3aa127dcfb1121f6ead387e2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0247%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DTelma%26aufirst%3DK.%2BA.%26aulast%3DChang%26aufirst%3DK.%2BE.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DMadigan%26aufirst%3DJ.%2BP.%26aulast%3DLloyd%26aufirst%3DJ.%2BR.%26aulast%3DGoldlust%26aufirst%3DI.%2BS.%26aulast%3DHoeschele%26aufirst%3DJ.%2BD.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DSay%2520No%2520to%2520DMSO%253A%2520Dimethylsulfoxide%2520Inactivates%2520Cisplatin%252C%2520Carboplatin%252C%2520and%2520Other%2520Platinum%2520Complexes%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3913%26epage%3D3922%26doi%3D10.1158%2F0008-5472.CAN-14-0247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Lowe, D.</span> DMSO Will Ruin Your Platinum Drugs. Take Heed. <a href="http://blogs.sciencemag.org/pipeline/archives/2014/05/12/dmso_will_ruin_your_platinum_drugs_take_heed" class="extLink">http://blogs.sciencemag.org/pipeline/archives/2014/05/12/dmso_will_ruin_your_platinum_drugs_take_heed</a> (accessed July 29,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lowe%2C+D.+DMSO+Will+Ruin+Your+Platinum+Drugs.+Take+Heed.+http%3A%2F%2Fblogs.sciencemag.org%2Fpipeline%2Farchives%2F2014%2F05%2F12%2Fdmso_will_ruin_your_platinum_drugs_take_heed+%28accessed+July+29%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DD.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kerrison, S. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, P. J.</span><span> </span><span class="NLM_article-title">Solvolysis of <i>cis</i>-[Pt(Nh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] in Dimethyl Sulphoxide and Reactions of Glycine with [PtCl<sub>3</sub>(Me<sub>2</sub>SO)]<sup>−</sup> as Probed by <sup>195</sup>Pt Nuclear Magnetic Resonance Shifts and <sup>195</sup>Pt–<sup>15</sup>N Coupling Constants</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">863</span><span class="refDoi"> DOI: 10.1039/C39770000861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC39770000861" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&pages=861-863&author=S.+J.+S.+Kerrisonauthor=P.+J.+Sadler&title=Solvolysis+of+cis-%5BPt%28Nh3%292Cl2%5D+in+Dimethyl+Sulphoxide+and+Reactions+of+Glycine+with+%5BPtCl3%28Me2SO%29%5D%E2%88%92+as+Probed+by+195Pt+Nuclear+Magnetic+Resonance+Shifts+and+195Pt%E2%80%9315N+Coupling+Constants&doi=10.1039%2FC39770000861"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1039%2FC39770000861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC39770000861%26sid%3Dliteratum%253Aachs%26aulast%3DKerrison%26aufirst%3DS.%2BJ.%2BS.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DSolvolysis%2520of%2520cis-%255BPt%2528Nh3%25292Cl2%255D%2520in%2520Dimethyl%2520Sulphoxide%2520and%2520Reactions%2520of%2520Glycine%2520with%2520%255BPtCl3%2528Me2SO%2529%255D%25E2%2588%2592%2520as%2520Probed%2520by%2520195Pt%2520Nuclear%2520Magnetic%2520Resonance%2520Shifts%2520and%2520195Pt%25E2%2580%259315N%2520Coupling%2520Constants%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D1977%26spage%3D861%26epage%3D863%26doi%3D10.1039%2FC39770000861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">De Vries, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Jong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span> </span><span class="NLM_article-title">Molecular Imaging as a Tool for Drug Development and Trial Design</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2585</span><span class="NLM_x">–</span> <span class="NLM_lpage">2587</span><span class="refDoi"> DOI: 10.1200/JCO.2015.61.6425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1200%2FJCO.2015.61.6425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26169612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=2585-2587&author=E.+G.+De+Vriesauthor=S.+De+Jongauthor=J.+A.+Gietema&title=Molecular+Imaging+as+a+Tool+for+Drug+Development+and+Trial+Design&doi=10.1200%2FJCO.2015.61.6425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular imaging as a tool for drug development and trial design</span></div><div class="casAuthors">de Vries, Elisabeth G. E.; de Jong, Steven; Gietema, Jourik A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2585-2587</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review discussing mol. imaging as a tool for drug development and trial design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZOEeBjKjpQbVg90H21EOLACvtfcHk0ljWu7r4Tj34FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVKmtg%253D%253D&md5=79a6f5d1423b527beea7210c5b00aa3e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.61.6425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.61.6425%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVries%26aufirst%3DE.%2BG.%26aulast%3DDe%2BJong%26aufirst%3DS.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520Imaging%2520as%2520a%2520Tool%2520for%2520Drug%2520Development%2520and%2520Trial%2520Design%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D2585%26epage%3D2587%26doi%3D10.1200%2FJCO.2015.61.6425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Kurdziel, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bear, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccumiskey, J. F.</span><span> </span><span class="NLM_article-title">Imaging Multidrug Resistance with 4-[<sup>18</sup>F]Fluoropaclitaxel</span> <span class="citation_source-journal">Nucl. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">823</span><span class="NLM_x">–</span> <span class="NLM_lpage">831</span><span class="refDoi"> DOI: 10.1016/j.nucmedbio.2007.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.nucmedbio.2007.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=17921033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFeiu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2007&pages=823-831&author=K.+A.+Kurdzielauthor=J.+D.+Kalenauthor=J.+I.+Hirschauthor=J.+D.+Wilsonauthor=R.+Agarwalauthor=D.+Barrettauthor=H.+D.+Bearauthor=J.+F.+Mccumiskey&title=Imaging+Multidrug+Resistance+with+4-%5B18F%5DFluoropaclitaxel&doi=10.1016%2Fj.nucmedbio.2007.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging multidrug resistance with 4-[18F]fluoropaclitaxel</span></div><div class="casAuthors">Kurdziel, Karen A.; Kalen, Joseph D.; Hirsch, Jerry I.; Wilson, John D.; Agarwal, Rakesh; Barrett, Daniel; Bear, Harry D.; McCumiskey, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">823-831</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Multidrug resistance (MDR) is a cause of treatment failure in many cancer patients.  MDR refers to a phenotype whereby a tumor is resistant to a large no. of natural chemotherapeutic drugs.  Having prior knowledge of the presence of such resistance would decrease morbidity from unsuccessful therapy and allow for the selection of individuals who may benefit from the coadministration of MDR-inhibiting drugs.  The Tc-99m-labeled single-photon-emitting radiotracers sestamibi and tetrofosmin have shown some predictive value.  However, positron-emitting radiotracers, which allow for dynamic quant. imaging, hold promise for a more accurate and specific identification of MDRtumors.MDR-expressing tumors are resistant to paclitaxel, which is commonly used as a chemotherapeutic agent. 4-[18F]Fluoropaclitaxel (FPAC) is a PET-radiolabeled analog of paclitaxel.  Preclin. studies have shown the uptake of FPAC to be inversely proportional to tumor MDR expression.  FPAC PET imaging in normal volunteers shows biodistribution to be similar to that in nonhuman primates.  Imaging in a breast cancer patient showed FPAC localization in a primary tumor that responded to chemotherapy, while failure to localize in mediastinal disease corresponded with only partial response.FPAC PET imaging shows promise for the noninvasive pretreatment identification of MDR-expressing tumors.  While much addnl. work is needed, this work represents a step toward image-guided personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXaHmVvKFbKbVg90H21EOLACvtfcHk0ljWu7r4Tj34FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFeiu7%252FN&md5=c02b8dffdcd6f0cd38cc8de142262bd5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2007.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2007.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKurdziel%26aufirst%3DK.%2BA.%26aulast%3DKalen%26aufirst%3DJ.%2BD.%26aulast%3DHirsch%26aufirst%3DJ.%2BI.%26aulast%3DWilson%26aufirst%3DJ.%2BD.%26aulast%3DAgarwal%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DD.%26aulast%3DBear%26aufirst%3DH.%2BD.%26aulast%3DMccumiskey%26aufirst%3DJ.%2BF.%26atitle%3DImaging%2520Multidrug%2520Resistance%2520with%25204-%255B18F%255DFluoropaclitaxel%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2007%26volume%3D34%26spage%3D823%26epage%3D831%26doi%3D10.1016%2Fj.nucmedbio.2007.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalhor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swisher, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba, Ii</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddik, Z. H.</span><span> </span><span class="NLM_article-title">Tissue Platinum Concentration and Tumor Response in Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3345</span><span class="NLM_x">–</span> <span class="NLM_lpage">3352</span><span class="refDoi"> DOI: 10.1200/JCO.2011.40.8120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1200%2FJCO.2011.40.8120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=22891266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3345-3352&author=E.+S.+Kimauthor=J.+J.+Leeauthor=G.+Heauthor=C.+W.+Chowauthor=J.+Fujimotoauthor=N.+Kalhorauthor=S.+G.+Swisherauthor=Ii+Wistubaauthor=D.+J.+Stewartauthor=Z.+H.+Siddik&title=Tissue+Platinum+Concentration+and+Tumor+Response+in+Non-Small-Cell+Lung+Cancer&doi=10.1200%2FJCO.2011.40.8120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue platinum concentration and tumor response in non-small-cell lung cancer</span></div><div class="casAuthors">Kim, Eric S.; Lee, J. Jack; He, Guangan; Chow, Chi-Wan; Fujimoto, Junya; Kalhor, Neda; Swisher, Stephen G.; Wistuba, Ignacio I.; Stewart, David J.; Siddik, Zahid H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3345-3352</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Platinum resistance is a major limitation in the treatment of advanced non-small-cell lung cancer (NSCLC).  Reduced intracellular drug accumulation is one of the most consistently identified features of platinum-resistant cell lines, but clin. data are limited.  We assessed the effects of tissue platinum concns. on response and survival in NSCLC.  Patients and Methods: We measured total platinum concns. by flameless at. absorption spectrophotometry in 44 archived fresh-frozen NSCLC specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy.  Tissue platinum concn. was correlated with percent redn. in tumor size on post- vs. prechemotherapy computed tomog. scans.  The relationship between tissue platinum concn. and survival was assessed by univariate and multicovariate Cox proportional hazards regression model anal. and Kaplan-Meier anal.  Results: Tissue platinum concn. correlated significantly with percent redn. in tumor size (P < .001).  The same correlations were seen with cisplatin, carboplatin, and all histol. subgroups.  Furthermore, there was no significant impact of potential variables such as no. of cycles and time lapse from last chemotherapy on platinum concn.  Patients with higher platinum concn. had longer time to recurrence (P = .034), progression-free survival (P = .018), and overall survival (P = .005) in the multicovariate Cox model anal. after adjusting for no. of cycles.  Conclusion: This clin. study established a relationship between tissue platinum concn. and response in NSCLC.  It suggests that reduced platinum accumulation might be an important mechanism of platinum resistance in the clin. setting.  Further studies investigating factors that modulate intracellular platinum concn. are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFMnMq23__QrVg90H21EOLACvtfcHk0litm9QOYtDmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FE&md5=efa46c60ca5de7a95c029737b95c0dd3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.8120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.8120%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DChow%26aufirst%3DC.%2BW.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DKalhor%26aufirst%3DN.%26aulast%3DSwisher%26aufirst%3DS.%2BG.%26aulast%3DWistuba%26aufirst%3DIi%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26atitle%3DTissue%2520Platinum%2520Concentration%2520and%2520Tumor%2520Response%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3345%26epage%3D3352%26doi%3D10.1200%2FJCO.2011.40.8120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Guancial, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, G.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abu-Farsakh, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span> </span><span class="NLM_article-title">Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0155503</span><span class="refDoi"> DOI: 10.1371/journal.pone.0155503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1371%2Fjournal.pone.0155503" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0155503&author=E.+A.+Guancialauthor=D.+Kilariauthor=G.-Q.+Xiaoauthor=S.+H.+Abu-Farsakhauthor=A.+Baranauthor=E.+M.+Messingauthor=E.+S.+Kim&title=Platinum+Concentration+and+Pathologic+Response+to+Cisplatin-Based+Neoadjuvant+Chemotherapy+in+Muscle-Invasive+Bladder+Cancer&doi=10.1371%2Fjournal.pone.0155503"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0155503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0155503%26sid%3Dliteratum%253Aachs%26aulast%3DGuancial%26aufirst%3DE.%2BA.%26aulast%3DKilari%26aufirst%3DD.%26aulast%3DXiao%26aufirst%3DG.-Q.%26aulast%3DAbu-Farsakh%26aufirst%3DS.%2BH.%26aulast%3DBaran%26aufirst%3DA.%26aulast%3DMessing%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DPlatinum%2520Concentration%2520and%2520Pathologic%2520Response%2520to%2520Cisplatin-Based%2520Neoadjuvant%2520Chemotherapy%2520in%2520Muscle-Invasive%2520Bladder%2520Cancer%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0155503%26doi%3D10.1371%2Fjournal.pone.0155503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Hoeschele, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. A.</span><span> </span><span class="NLM_article-title">Correlations of Physico-Chemical and Biological Properties with in Vivo Biodistribution Data for Platinum-195m-Labeled Chloroammineplatinum(II) Complexes</span> <span class="citation_source-journal">ACS Symp. Ser.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span><span class="refDoi"> DOI: 10.1021/bk-1980-0140.ch011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bk-1980-0140.ch011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=1980&pages=181-208&author=J.+D.+Hoescheleauthor=T.+A.+Butlerauthor=J.+A.+Roberts&title=Correlations+of+Physico-Chemical+and+Biological+Properties+with+in+Vivo+Biodistribution+Data+for+Platinum-195m-Labeled+Chloroammineplatinum%28II%29+Complexes&doi=10.1021%2Fbk-1980-0140.ch011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fbk-1980-0140.ch011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbk-1980-0140.ch011%26sid%3Dliteratum%253Aachs%26aulast%3DHoeschele%26aufirst%3DJ.%2BD.%26aulast%3DButler%26aufirst%3DT.%2BA.%26aulast%3DRoberts%26aufirst%3DJ.%2BA.%26atitle%3DCorrelations%2520of%2520Physico-Chemical%2520and%2520Biological%2520Properties%2520with%2520in%2520Vivo%2520Biodistribution%2520Data%2520for%2520Platinum-195m-Labeled%2520Chloroammineplatinum%2528II%2529%2520Complexes%26jtitle%3DACS%2520Symp.%2520Ser.%26date%3D1980%26volume%3D140%26spage%3D181%26epage%3D208%26doi%3D10.1021%2Fbk-1980-0140.ch011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Shen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawinowicz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Identification of Cytoskeletal [<sup>14</sup>C]Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">793</span><span class="refDoi"> DOI: 10.1124/mol.66.4.789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1124%2Fmol.66.4.789" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2004&pages=789-793&author=D.+W.+Shenauthor=X.+J.+Liangauthor=M.+A.+Gawinowiczauthor=M.+M.+Gottesman&title=Identification+of+Cytoskeletal+%5B14C%5DCarboplatin-Binding+Proteins+Reveals+Reduced+Expression+and+Disorganization+of+Actin+and+Filamin+in+Cisplatin-Resistant+Cell+Lines&doi=10.1124%2Fmol.66.4.789"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1124%2Fmol.66.4.789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.66.4.789%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%2BW.%26aulast%3DLiang%26aufirst%3DX.%2BJ.%26aulast%3DGawinowicz%26aufirst%3DM.%2BA.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DIdentification%2520of%2520Cytoskeletal%2520%255B14C%255DCarboplatin-Binding%2520Proteins%2520Reveals%2520Reduced%2520Expression%2520and%2520Disorganization%2520of%2520Actin%2520and%2520Filamin%2520in%2520Cisplatin-Resistant%2520Cell%2520Lines%26jtitle%3DMol.%2520Pharmacol.%26date%3D2004%26volume%3D66%26spage%3D789%26epage%3D793%26doi%3D10.1124%2Fmol.66.4.789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Hah, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stivers, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vere White, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, P. T.</span><span> </span><span class="NLM_article-title">Kinetics of Carboplatin-DNA Binding in Genomic DNA and Bladder Cancer Cells as Determined by Accelerator Mass Spectrometry</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.1021/tx060058c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx060058c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=622-626&author=S.+S.+Hahauthor=K.+M.+Stiversauthor=R.+W.+De+Vere+Whiteauthor=P.+T.+Henderson&title=Kinetics+of+Carboplatin-DNA+Binding+in+Genomic+DNA+and+Bladder+Cancer+Cells+as+Determined+by+Accelerator+Mass+Spectrometry&doi=10.1021%2Ftx060058c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Ftx060058c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx060058c%26sid%3Dliteratum%253Aachs%26aulast%3DHah%26aufirst%3DS.%2BS.%26aulast%3DStivers%26aufirst%3DK.%2BM.%26aulast%3DDe%2BVere%2BWhite%26aufirst%3DR.%2BW.%26aulast%3DHenderson%26aufirst%3DP.%2BT.%26atitle%3DKinetics%2520of%2520Carboplatin-DNA%2520Binding%2520in%2520Genomic%2520DNA%2520and%2520Bladder%2520Cancer%2520Cells%2520as%2520Determined%2520by%2520Accelerator%2520Mass%2520Spectrometry%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D622%26epage%3D626%26doi%3D10.1021%2Ftx060058c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Jong, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mckeage, M. J.</span><span> </span><span class="NLM_article-title">Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span><span class="refDoi"> DOI: 10.1124/jpet.111.181297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1124%2Fjpet.111.181297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=21606177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFemu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=537-547&author=N.+N.+Jongauthor=T.+Nakanishiauthor=J.+J.+Liuauthor=I.+Tamaiauthor=M.+J.+Mckeage&title=Oxaliplatin+Transport+Mediated+by+Organic+Cation%2FCarnitine+Transporters+OCTN1+and+OCTN2+in+Overexpressing+Human+Embryonic+Kidney+293+Cells+and+Rat+Dorsal+Root+Ganglion+Neurons&doi=10.1124%2Fjpet.111.181297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons</span></div><div class="casAuthors">Jong, Nancy N.; Nakanishi, Takeo; Liu, Johnson J.; Tamai, Ikumi; McKeage, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">537-547</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The org. cation/carnitine transporters OCTN1 and OCTN2 are related to other org. cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity.  In this study, we sought to det. whether OCTN1 and OCTN2 also transported oxaliplatin and to characterize their functional expression and contributions to its neuronal accumulation and neurotoxicity in dorsal root ganglion (DRG) neurons relative to those of OCTs.  [14C]Oxaliplatin uptake, platinum accumulation, and cytotoxicity were detd. in OCTN-overexpressing human embryonic kidney (HEK) 293 cells and primary cultures of rat DRG neurons.  Levels of mRNA and functional activities of rat (r)Octns and rOcts in rat DRG tissue and primary cultures were characterized using reverse transcription-polymerase chain reaction and uptake of model OCT/OCTN substrates, including [3H]1-methyl-4-phenylpyridinium (MPP+) (OCT1-3), [14C]tetraethylammonium bromide (TEA+) (OCT1-3 and OCTN1/2), [3H]ergothioneine (OCTN1), and [3H]L-carnitine (OCTN2).  HEK293 cells overexpressing rOctn1, rOctn2, human OCTN1, and human OCTN2 showed increased uptake and cytotoxicity of oxaliplatin compared with mock-transfected HEK293 controls; in addn., both uptake and cytotoxicity were inhibited by ergothioneine and L-carnitine.  The uptake of ergothioneine mediated by OCTN1 and of L-carnitine mediated by OCTN2 was decreased during oxaliplatin exposure.  ROctn1 and rOctn2 mRNA was readily detected in rat DRG tissue, and they were functionally active in cultured rat DRG neurons, more so than rOct1, rOct2, or rOct3.  DRG neuronal accumulation of [14C]oxaliplatin and platinum during oxaliplatin exposure depended on time, concn., temp., and sodium and was inhibited by ergothioneine and to a lesser extent by L-carnitine but not by MPP+.  Loss of DRG neuronal viability during oxaliplatin exposure was inhibited by ergothioneine but not by L-carnitine or MPP+.  OCTN1 and OCTN2 both transport oxaliplatin and are functionally expressed by DRG neurons.  OCTN1-mediated transport of oxaliplatin appears to contribute to its neuronal accumulation and treatment-limiting neurotoxicity more so than OCTN2 or OCTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVcdk40NbRYbVg90H21EOLACvtfcHk0lgZ9qvd5-_TRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFemu7s%253D&md5=3cbd5069a2276e8d0631859c5288f484</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181297%26sid%3Dliteratum%253Aachs%26aulast%3DJong%26aufirst%3DN.%2BN.%26aulast%3DNakanishi%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DTamai%26aufirst%3DI.%26aulast%3DMckeage%26aufirst%3DM.%2BJ.%26atitle%3DOxaliplatin%2520Transport%2520Mediated%2520by%2520Organic%2520Cation%252FCarnitine%2520Transporters%2520OCTN1%2520and%2520OCTN2%2520in%2520Overexpressing%2520Human%2520Embryonic%2520Kidney%2520293%2520Cells%2520and%2520Rat%2520Dorsal%2520Root%2520Ganglion%2520Neurons%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D537%26epage%3D547%26doi%3D10.1124%2Fjpet.111.181297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Rani, P. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naidu, M. U.</span><span> </span><span class="NLM_article-title">Phase 0 - Microdosing Strategy in Clinical Trials</span> <span class="citation_source-journal">Indian J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.4103/0253-7613.45147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.4103%2F0253-7613.45147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=21279177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC3M7lsFSgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=240-242&author=P.+U.+Raniauthor=M.+U.+Naidu&title=Phase+0+-+Microdosing+Strategy+in+Clinical+Trials&doi=10.4103%2F0253-7613.45147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 0 - Microdosing strategy in clinical trials</span></div><div class="casAuthors">Rani P Usha; Naidu M U R</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">240-2</span>
        ISSN:<span class="NLM_cas:issn">0253-7613</span>.
    </div><div class="casAbstract">Drug development is an activity that is long, complex and expensive.  In 2004, attrition in the drug development paradigm prompted the US Food and Drug Administration (FDA) to introduce its 'Critical Path' document, which highlighted the serious discordance between major scientific advances and limited drug development process.  One issue addressed was that of microdosing.  The concept of microdosing involves the use of extremely low, nonpharmacologically active doses of a drug to define the pharmacokinetic profile of the medication in human subjects.  Microdosing, thus, appears as a new viable concept in the 'toolbox' of the drug development activity.  It appears that microdosing strategy could complement standard animal-to-human scaling, redefining the existing concept of phase I clinical research.  In future, when research methods and technology involved in Phase 0 studies become more sophisticated, human microdosing may be applied to a number of drugs developed subsequently.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNNIg2EbPCTySm0e6ZOaemfW6udTcc2eYQlg3ZOOaeEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7lsFSgsQ%253D%253D&md5=2b013af26b15e5ec640b212fe0c15acf</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.4103%2F0253-7613.45147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0253-7613.45147%26sid%3Dliteratum%253Aachs%26aulast%3DRani%26aufirst%3DP.%2BU.%26aulast%3DNaidu%26aufirst%3DM.%2BU.%26atitle%3DPhase%25200%2520-%2520Microdosing%2520Strategy%2520in%2520Clinical%2520Trials%26jtitle%3DIndian%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D40%26spage%3D240%26epage%3D242%26doi%3D10.4103%2F0253-7613.45147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Cimino, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, P. T.</span><span> </span><span class="NLM_article-title">Personalized Medicine for Targeted and Platinum-Based Chemotherapy of Lung and Bladder Cancer</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.4155/bio.12.325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.4155%2Fbio.12.325" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=369-391&author=G.+D.+Ciminoauthor=C.+X.+Panauthor=P.+T.+Henderson&title=Personalized+Medicine+for+Targeted+and+Platinum-Based+Chemotherapy+of+Lung+and+Bladder+Cancer&doi=10.4155%2Fbio.12.325"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.4155%2Fbio.12.325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.12.325%26sid%3Dliteratum%253Aachs%26aulast%3DCimino%26aufirst%3DG.%2BD.%26aulast%3DPan%26aufirst%3DC.%2BX.%26aulast%3DHenderson%26aufirst%3DP.%2BT.%26atitle%3DPersonalized%2520Medicine%2520for%2520Targeted%2520and%2520Platinum-Based%2520Chemotherapy%2520of%2520Lung%2520and%2520Bladder%2520Cancer%26jtitle%3DBioanalysis%26date%3D2013%26volume%3D5%26spage%3D369%26epage%3D391%26doi%3D10.4155%2Fbio.12.325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Dowell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sancho, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, W.</span><span> </span><span class="NLM_article-title">Noninvasive Measurements for Studying the Tumoral Pharmacokinetics of Platinum Anticancer Drugs in Solid Tumors</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1016/S0169-409X(99)00059-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0169-409X%2899%2900059-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=111-126&author=J.+A.+Dowellauthor=A.+R.+Sanchoauthor=D.+Anandauthor=W.+Wolf&title=Noninvasive+Measurements+for+Studying+the+Tumoral+Pharmacokinetics+of+Platinum+Anticancer+Drugs+in+Solid+Tumors&doi=10.1016%2FS0169-409X%2899%2900059-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2899%2900059-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252899%252900059-9%26sid%3Dliteratum%253Aachs%26aulast%3DDowell%26aufirst%3DJ.%2BA.%26aulast%3DSancho%26aufirst%3DA.%2BR.%26aulast%3DAnand%26aufirst%3DD.%26aulast%3DWolf%26aufirst%3DW.%26atitle%3DNoninvasive%2520Measurements%2520for%2520Studying%2520the%2520Tumoral%2520Pharmacokinetics%2520of%2520Platinum%2520Anticancer%2520Drugs%2520in%2520Solid%2520Tumors%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2000%26volume%3D41%26spage%3D111%26epage%3D126%26doi%3D10.1016%2FS0169-409X%2899%2900059-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Baer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcauliffe, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. G.</span><span> </span><span class="NLM_article-title">Microscale Syntheses of Anti-Tumour Platinum Compounds Labelled with <sup>191</sup>Pt</span> <span class="citation_source-journal">Int. J. Appl. Radiat. Isot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1016/0020-708X(85)90064-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2F0020-708X%2885%2990064-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3888854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL2MXktlWmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1985&pages=181-184&author=J.+Baerauthor=R.+Harrisonauthor=C.+A.+Mcauliffeauthor=A.+Zakiauthor=H.+L.+Sharmaauthor=A.+G.+Smith&title=Microscale+Syntheses+of+Anti-Tumour+Platinum+Compounds+Labelled+with+191Pt&doi=10.1016%2F0020-708X%2885%2990064-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Microscale syntheses of anti-tumor platinum compounds labeled with platinum-191</span></div><div class="casAuthors">Baer, J.; Harrison, R.; McAuliffe, C. A.; Zaki, A.; Sharma, H. L.; Smith, A. G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-4</span>CODEN:
                <span class="NLM_cas:coden">IJARAY</span>;
        ISSN:<span class="NLM_cas:issn">0020-708X</span>.
    </div><div class="casAbstract">The microscale prepn. of cis-[191PtL2Cl2] (L = NH3, cyclopropylamine), cis, trans-[191PtCl2(OH)2(iso-PrNH2)2] (I), and cis-[191Pt(NH3)2Q] (II; H2Q = 1,1-cyclobutanedicarboxylic acid) was developed.  Generally, Na2[PtCl6]-H2[191PtCl6] are reduced by N2H4 to Na2[191PtCl4] which was converted to Na2[191PtI4] with the addn. of NaI.  Na2[191PtI4] reacted with the various amines to give cis-[191PtL12I2] (L1 = NH3, cyclopropylamine, iso-PrNH2).  cis-[191PtL2I2] were converted to cis-[191PtL2Cl2] via cis-[191PtL2(H2O)2](NO3)2 by treatment with AgNO3 and then NaCl or HCl.  cis-[191Pt(NH2Pr-iso)2Cl2] was obtained similarly and oxidized with H2O2 to give I.  Treatment of cis-[191Pt(NH3)2I2] with aq. AgNO3 and then H2Q gave II.  Thin-layer chromatog. was used to control the purity of the radiolabeled Pt complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDEhlmgcT-kbVg90H21EOLACvtfcHk0lgYDLsNPkWczQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktlWmtLg%253D&md5=5353775fd032964e48ac668ada0b0eb5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2F0020-708X%2885%2990064-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0020-708X%252885%252990064-X%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DJ.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DMcauliffe%26aufirst%3DC.%2BA.%26aulast%3DZaki%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DH.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BG.%26atitle%3DMicroscale%2520Syntheses%2520of%2520Anti-Tumour%2520Platinum%2520Compounds%2520Labelled%2520with%2520191Pt%26jtitle%3DInt.%2520J.%2520Appl.%2520Radiat.%2520Isot.%26date%3D1985%26volume%3D36%26spage%3D181%26epage%3D184%26doi%3D10.1016%2F0020-708X%2885%2990064-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Lange, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harder, H. C.</span><span> </span><span class="NLM_article-title">The Antitumor Agent <i>cis</i>-Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>: Distribution Studies and Dose Calculations for <sup>193m</sup>Pt and <sup>195m</sup>Pt</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1973&pages=191-195&author=R.+C.+Langeauthor=R.+P.+Spencerauthor=H.+C.+Harder&title=The+Antitumor+Agent+cis-Pt%28NH3%292Cl2%3A+Distribution+Studies+and+Dose+Calculations+for+193mPt+and+195mPt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DR.%2BC.%26aulast%3DSpencer%26aufirst%3DR.%2BP.%26aulast%3DHarder%26aufirst%3DH.%2BC.%26atitle%3DThe%2520Antitumor%2520Agent%2520cis-Pt%2528NH3%25292Cl2%253A%2520Distribution%2520Studies%2520and%2520Dose%2520Calculations%2520for%2520193mPt%2520and%2520195mPt%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1973%26volume%3D14%26spage%3D191%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Areberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wennerberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norrgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattsson, S.</span><span> </span><span class="NLM_article-title">Antitumor Effect of Radioactive Cisplatin (<sup>191</sup>Pt) on Nude Mice</span> <span class="citation_source-journal">Int. J. Radiat. Oncol., Biol., Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1016/S0360-3016(00)01419-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0360-3016%2800%2901419-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11172966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFegtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2001&pages=827-832&author=J.+Arebergauthor=J.+Wennerbergauthor=A.+Johnssonauthor=K.+Norrgrenauthor=S.+Mattsson&title=Antitumor+Effect+of+Radioactive+Cisplatin+%28191Pt%29+on+Nude+Mice&doi=10.1016%2FS0360-3016%2800%2901419-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effect of radioactive cisplatin (191Pt) on nude mice</span></div><div class="casAuthors">Areberg, J.; Wennerberg, J.; Johnsson, A.; Norrgren, K.; Mattsson, S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">827-832</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Purpose: To investigate the effect of 191Pt-cisplatin in vivo in terms of the antitumor effect and general toxicity on tumor-bearing nude mice.  Methods and Materials: Tumor-bearing (human squamous cell carcinoma, AB) nude mice were divided into 4 groups and given, i.p., physiol. saline (controls), cisplatin, 191Pt-cisplatin (80 MBq/mg), or 191Pt-cisplatin (160 MBq/mg), resp.  Mortality and wt. were used as parameters for monitoring the general toxic effect, while specific growth delay (SGD) and the area under the logarithm of the relative tumor size curve (AUC-log[RTS]) were used to evaluate the antitumor effect of the treatments.  Results: Both SGD and AUC-log(RTS) values showed that 191Pt-cisplatin was significantly (P < 0.05) more effective in retarding tumor growth than nonradioactive cisplatin.  No differences in mortality between the different groups could be obsd. and no significant differences in wt. change between the mice treated with cisplatin or 191Pt-cisplatin could be seen.  Conclusion: 191Pt-cisplatin is a more effective drug than nonradioactive cisplatin in retarding tumor growth on nude mice without adding systemic toxic effects.  Apparently, radioactive cisplatin may prove to be an alternative to conventional cisplatin; however, the possible toxic effects on organs at risk have to be thoroughly investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqJMj8-BZeQrVg90H21EOLACvtfcHk0ljSwBxEoPZTQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFegtrk%253D&md5=1153f2f33fb81ed5c98b65cddf5eaed3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0360-3016%2800%2901419-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0360-3016%252800%252901419-X%26sid%3Dliteratum%253Aachs%26aulast%3DAreberg%26aufirst%3DJ.%26aulast%3DWennerberg%26aufirst%3DJ.%26aulast%3DJohnsson%26aufirst%3DA.%26aulast%3DNorrgren%26aufirst%3DK.%26aulast%3DMattsson%26aufirst%3DS.%26atitle%3DAntitumor%2520Effect%2520of%2520Radioactive%2520Cisplatin%2520%2528191Pt%2529%2520on%2520Nude%2520Mice%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D2001%26volume%3D49%26spage%3D827%26epage%3D832%26doi%3D10.1016%2FS0360-3016%2800%2901419-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Smith, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassidy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bartolo, N.</span><span> </span><span class="NLM_article-title">Rapid and Reliable Synthesis of 195mPt-Cisplatin and 195mPt-Carboplatin for Use in Prognosis of Cancer</span> <span class="citation_source-journal">J. Labelled Compd. Radiopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">S756</span><span class="NLM_x">–</span> <span class="NLM_lpage">S758</span><span class="refDoi"> DOI: 10.1002/jlcr.25804401266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fjlcr.25804401266" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=S756-S758&author=S.+V.+Smithauthor=D.+Cassidyauthor=N.+Di+Bartolo&title=Rapid+and+Reliable+Synthesis+of+195mPt-Cisplatin+and+195mPt-Carboplatin+for+Use+in+Prognosis+of+Cancer&doi=10.1002%2Fjlcr.25804401266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.25804401266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.25804401266%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%2BV.%26aulast%3DCassidy%26aufirst%3DD.%26aulast%3DDi%2BBartolo%26aufirst%3DN.%26atitle%3DRapid%2520and%2520Reliable%2520Synthesis%2520of%2520195mPt-Cisplatin%2520and%2520195mPt-Carboplatin%2520for%2520Use%2520in%2520Prognosis%2520of%2520Cancer%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2001%26volume%3D44%26spage%3DS756%26epage%3DS758%26doi%3D10.1002%2Fjlcr.25804401266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Zeevaart, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagener, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marjanovic-Painter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathekge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. V.</span><span> </span><span class="NLM_article-title">Production of High Specific Activity (195m) Pt-Cisplatinum at South African Nuclear Energy Corporation for Phase 0 Clinical Trials in Healthy Individual Subjects</span> <span class="citation_source-journal">J. Labelled Compd. Radiopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span><span class="refDoi"> DOI: 10.1002/jlcr.3091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fjlcr.3091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24285528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCrs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=495-503&author=J.+R.+Zeevaartauthor=J.+Wagenerauthor=B.+Marjanovic-Painterauthor=M.+Sathekgeauthor=N.+Soniauthor=C.+Zinnauthor=G.+Perkinsauthor=S.+V.+Smith&title=Production+of+High+Specific+Activity+%28195m%29+Pt-Cisplatinum+at+South+African+Nuclear+Energy+Corporation+for+Phase+0+Clinical+Trials+in+Healthy+Individual+Subjects&doi=10.1002%2Fjlcr.3091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Production of high specific activity 195mPt-cisplatinum at South African Nuclear Energy Corporation for Phase 0 clinical trials in healthy individual subjects</span></div><div class="casAuthors">Zeevaart, Jan Rijn; Wagener, Judith; Marjanovic-Painter, Biljana; Sathekge, Mike; Soni, Nischal; Zinn, Christa; Perkins, Gary; Smith, Suzanne V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">495-503</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Platinum agents continue to be the main chemotherapeutic agents used in the first-line and second-line treatments of cancer patients.  It is important to fully understand the biol. profile of these compds. in order to optimize the dose given to each patient.  In a joint project with the Australian Nuclear Science and Technol. Organization and the Nuclear Medicine Department at Steve Biko Academic Hospital, South African Nuclear Energy Corporation synthesized and supplied 195mPt-cisplatinum (commonly referred to as cisplatin) for a clin. pilot study on healthy volunteers.  Enriched 194PtCl2 was prepd. by digestion of enriched 194Pt metal (>95%) followed by thermal decompn. over a 3 h period.  The 194PtCl2 was then placed in a quartz ampoule, was irradiated in SAFARI-1 up to 200 h, then decay cooled for a min. of 34 h prior to synthesis of final product. 195mPt(NH3)2I2, formed with the addn. of KI and NH4OH, was converted to the diaqua species [195mPt(NH3)2(H2O)2]2+ by reaction with AgNO3.  The conversion to 195mPt-cisplatinum was completed by the addn. of concd. HCl.  The final product yield was 51.7% ± 5.2% (n = 5).  The chem. and radionuclidic purity in each case was >95%.  The use of a high flux reactor position affords a higher specific activity product (15.9 ± 2.5 MBq/mg at end of synthesis) than previously found (5 MBq/mg).  Volunteers received between 108 and 126 MBq of radioactivity, which is equiv. to 6.8-10.0 mg of carrier cisplatinum.  Such high specific activities afforded a significant redn. (∼50%) in the chem. dose of a carrier cisplatinum, which represents less than 10% of a typical chemotherapeutic dose given to patients.  A good manufg. practice GMP compliant product was produced and was administered to 10 healthy volunteers as part of an ethically approved Phase 0 clin. trial.  The majority of the injected activity 27.5% ± 5.8% was excreted in the urine within 5 h post injection (p.i.).  Only 8.5% ± 3.1% of cisplatinum remained in blood pools at 5 h, which gradually cleared over the 6-day monitoring period p.i.  At the end of the study (6 days p.i.), a total of 37.4% ± 5.3% of the product had cleared from the blood into urine, and approx. 63% remained in the body.  The significantly lower concn. of carrier cisplatinum used for imaging resulted in a well-tolerated product.  Copyright © 2013 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjVN1R8YfhD7Vg90H21EOLACvtfcHk0lhbdgE8b63ITw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCrs7jO&md5=004bad0893e16b947023a7e392e5a6d6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3091%26sid%3Dliteratum%253Aachs%26aulast%3DZeevaart%26aufirst%3DJ.%2BR.%26aulast%3DWagener%26aufirst%3DJ.%26aulast%3DMarjanovic-Painter%26aufirst%3DB.%26aulast%3DSathekge%26aufirst%3DM.%26aulast%3DSoni%26aufirst%3DN.%26aulast%3DZinn%26aufirst%3DC.%26aulast%3DPerkins%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DS.%2BV.%26atitle%3DProduction%2520of%2520High%2520Specific%2520Activity%2520%2528195m%2529%2520Pt-Cisplatinum%2520at%2520South%2520African%2520Nuclear%2520Energy%2520Corporation%2520for%2520Phase%25200%2520Clinical%2520Trials%2520in%2520Healthy%2520Individual%2520Subjects%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2013%26volume%3D56%26spage%3D495%26epage%3D503%26doi%3D10.1002%2Fjlcr.3091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Anand, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, W.</span><span> </span><span class="NLM_article-title">A New, Semi-Automated System for the Micro-Scale Synthesis of [195mPt]Cisplatin Suitable for Clinical Studies</span> <span class="citation_source-journal">Int. J. Rad. Appl. Instrum. A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">814</span><span class="refDoi"> DOI: 10.1016/0883-2889(92)90247-C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2F0883-2889%2892%2990247-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1319424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK38zgvVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=809-814&author=D.+Anandauthor=W.+Wolf&title=A+New%2C+Semi-Automated+System+for+the+Micro-Scale+Synthesis+of+%5B195mPt%5DCisplatin+Suitable+for+Clinical+Studies&doi=10.1016%2F0883-2889%2892%2990247-C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A new, semi-automated system for the micro-scale synthesis of [195mPt]cisplatin suitable for clinical studies</span></div><div class="casAuthors">Anand D; Wolf W</div><div class="citationInfo"><span class="NLM_cas:title">International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">809-14</span>
        ISSN:<span class="NLM_cas:issn">0883-2889</span>.
    </div><div class="casAbstract">A new, semi-automated system for the microscale synthesis of [195mPt]cisplatin has been developed.  Radiochemical yields of up to 70% of pure [195mPt]cisplatin can be obtained routinely e.g. 555-629 MBq (15-17 mCi) from 925 MBq (25 mCi) of [195mPt]Pt metal.  Chemical losses during synthesis, and radiation exposure of personnel, have been minimized.  These increased yields are the consequence of the elimination of most transfers, and enhanced yields at most steps: ammination losses decreased from 27 to 7%, and at the diiodo- to di-acquo- conversion, from 34 to 11%.  The versatility of such a system is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfPfP9rchDjdy3lHz94U-GfW6udTcc2eYcIZnFYtWfJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zgvVWmsw%253D%253D&md5=5aded7bb8637ad7072b754faf60b2378</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0883-2889%2892%2990247-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2889%252892%252990247-C%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DD.%26aulast%3DWolf%26aufirst%3DW.%26atitle%3DA%2520New%252C%2520Semi-Automated%2520System%2520for%2520the%2520Micro-Scale%2520Synthesis%2520of%2520%255B195mPt%255DCisplatin%2520Suitable%2520for%2520Clinical%2520Studies%26jtitle%3DInt.%2520J.%2520Rad.%2520Appl.%2520Instrum.%2520A%26date%3D1992%26volume%3D43%26spage%3D809%26epage%3D814%26doi%3D10.1016%2F0883-2889%2892%2990247-C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Aalbersberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Wit-Van Der Veen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwaagstra, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codee-Van Der Schilden, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vegt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, W.</span><span> </span><span class="NLM_article-title">Preclinical Imaging Characteristics of 195m-Platinum Spect</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1382</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1382&author=E.+Aalbersbergauthor=L.+De+Wit-Van+Der+Veenauthor=O.+Zwaagstraauthor=K.+Codee-Van+Der+Schildenauthor=E.+Vegtauthor=W.+Vogel&title=Preclinical+Imaging+Characteristics+of+195m-Platinum+Spect"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAalbersberg%26aufirst%3DE.%26aulast%3DDe%2BWit-Van%2BDer%2BVeen%26aufirst%3DL.%26aulast%3DZwaagstra%26aufirst%3DO.%26aulast%3DCodee-Van%2BDer%2BSchilden%26aufirst%3DK.%26aulast%3DVegt%26aufirst%3DE.%26aulast%3DVogel%26aufirst%3DW.%26atitle%3DPreclinical%2520Imaging%2520Characteristics%2520of%2520195m-Platinum%2520Spect%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D1382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Buckley, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sharkawi, A. M.</span><span> </span><span class="NLM_article-title">Gamma Camera Scintigraphy of Tumours Using (195m)Pt-Cisplatin</span> <span class="citation_source-journal">Phys. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1325</span><span class="NLM_x">–</span> <span class="NLM_lpage">1332</span><span class="refDoi"> DOI: 10.1088/0031-9155/51/5/020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1088%2F0031-9155%2F51%2F5%2F020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=16481697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD28XivFCltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2006&pages=1325-1332&author=S.+E.+Buckleyauthor=P.+A.+Aliauthor=C.+J.+Evansauthor=A.+M.+El-Sharkawi&title=Gamma+Camera+Scintigraphy+of+Tumours+Using+%28195m%29Pt-Cisplatin&doi=10.1088%2F0031-9155%2F51%2F5%2F020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Gamma camera scintigraphy of tumours using 195mPt-cisplatin</span></div><div class="casAuthors">Buckley, S. E.; Ali, P. A.; Evans, C. J.; El-Sharkawi, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Physics in Medicine & Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1325-1332</span>CODEN:
                <span class="NLM_cas:coden">PHMBA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9155</span>.
    
            (<span class="NLM_cas:orgname">Institute of Physics Publishing</span>)
        </div><div class="casAbstract">Platinum enriched with 194Pt was irradiated for 4 days in NRG's TIRO 1 reactor, to produce 195mPt.  Spectral anal. of the product was performed using a calibrated hyper pure germanium detector and its constituent radioisotopes were identified as 195mPt, 199Au and 192Ir.  Using the detector's intrinsic efficiency calibration, their activities were estd. to be 1049, 133 and 5.8 MBq, resp.  The performance of the gamma camera was tested using quality control procedures recommended by the Institute of Physics and Engineering in Medicine (IPEM) and was found to be satisfactory.  A torso phantom was used to det. the min. detection limit (MDL) of 195mPt in a 2 cm diam. tumor using SPECT acquisitions (32 steps, 60 s per step).  The MDL was found to be 8 ppm assuming an administered patient dose of 50 MBq and a total cisplatin dose of 105 mg.  This work indicates that 195mPt-cisplatin is suitable for clin. scintigraphy and has led to the development of a clin. protocol that has been approved for a pilot study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppYj4VILSZ8rVg90H21EOLACvtfcHk0lgWIo8oMlGHxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivFCltLk%253D&md5=8f9737fa10cf945f99fa24bcc3a8c4ab</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1088%2F0031-9155%2F51%2F5%2F020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F0031-9155%252F51%252F5%252F020%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DS.%2BE.%26aulast%3DAli%26aufirst%3DP.%2BA.%26aulast%3DEvans%26aufirst%3DC.%2BJ.%26aulast%3DEl-Sharkawi%26aufirst%3DA.%2BM.%26atitle%3DGamma%2520Camera%2520Scintigraphy%2520of%2520Tumours%2520Using%2520%2528195m%2529Pt-Cisplatin%26jtitle%3DPhys.%2520Med.%2520Biol.%26date%3D2006%26volume%3D51%26spage%3D1325%26epage%3D1332%26doi%3D10.1088%2F0031-9155%2F51%2F5%2F020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Smith, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D. M.</span><span> </span><span class="NLM_article-title">Distribution and Retention of the Antitumor Agent 195mPt-<i>cis</i>-Dichlorodiammine Platinum (II) in Man</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1974&pages=349-351&author=H.+S.+Smithauthor=D.+M.+Taylor&title=Distribution+and+Retention+of+the+Antitumor+Agent+195mPt-cis-Dichlorodiammine+Platinum+%28II%29+in+Man"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DH.%2BS.%26aulast%3DTaylor%26aufirst%3DD.%2BM.%26atitle%3DDistribution%2520and%2520Retention%2520of%2520the%2520Antitumor%2520Agent%2520195mPt-cis-Dichlorodiammine%2520Platinum%2520%2528II%2529%2520in%2520Man%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1974%26volume%3D15%26spage%3D349%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Owens, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adam, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcauliffe, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowther, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. W.</span><span> </span><span class="NLM_article-title">In Vivo Distribution Studies of Radioactively Labelled Platinum Complexes; <i>cis</i>-Dichlorodiammine Platinum(II), <i>cis</i>-<i>trans</i>-Dichlorodihydroxy-<i>bis</i>-(Isopropylamine) Platinum(IV), <i>cis</i>-Dichloro-<i>bis</i>-Cyclopropylamine Platinum(II), and <i>cis</i>-Diammine 1,1-Cyclobutanedicarboxylate Platinum(II) in Patients with Malignant Disease, Using a Gamma Camera</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.1007/BF00258128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF00258128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3888431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaL2M3gt1Wmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1985&pages=253-257&author=S.+E.+Owensauthor=N.+Thatcherauthor=H.+Sharmaauthor=N.+Adamauthor=R.+Harrisonauthor=A.+Smithauthor=A.+Zakiauthor=J.+C.+Baerauthor=C.+A.+Mcauliffeauthor=D.+Crowtherauthor=B.+W.+Fox&title=In+Vivo+Distribution+Studies+of+Radioactively+Labelled+Platinum+Complexes%3B+cis-Dichlorodiammine+Platinum%28II%29%2C+cis-trans-Dichlorodihydroxy-bis-%28Isopropylamine%29+Platinum%28IV%29%2C+cis-Dichloro-bis-Cyclopropylamine+Platinum%28II%29%2C+and+cis-Diammine+1%2C1-Cyclobutanedicarboxylate+Platinum%28II%29+in+Patients+with+Malignant+Disease%2C+Using+a+Gamma+Camera&doi=10.1007%2FBF00258128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera</span></div><div class="casAuthors">Owens S E; Thatcher N; Sharma H; Adam N; Harrison R; Smith A; Zaki A; Baer J C; McAuliffe C A; Crowther D</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-7</span>
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">The in vivo distribution in man of the four platinum derivatives cis-dichlorodiammine platinum(II) (DDP), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV) (CHIP), cis-dichloro-bis-cyclopropylamine platinum(II) (CP), and cis-diammine 1, 1-cyclobutanedicarboxylate platinum(II) (CBDCA) has been observed.  The availability of these compounds labelled with the radioactive isotope of platinum, platinum-191, has made serial in vivo imaging of their distribution possible.  Injection of 17-35 MBq (5-28 mg) of the labelled compound IV was followed by imaging, using a gamma camera, with particular reference to the kidneys, liver, and tumour site.  Hepatic and renal clearances were observed in all nine patients, but no unequivocal evidence of tumour uptake was found.  The left kidney uptake was estimated at times up to 7 days after injection.  Mathematical analysis of some of the uptake curves failed to show any significant difference between the clearance times observed.  However, the two patients who received CBDCA did show a higher initial renal uptake, falling within the 1st day to levels comparable with those of the other compounds, and the three patients who received DDP showed consistently liver uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ00CmCmNs_b5XHngOXiV_fW6udTcc2eabQx-1HfW34bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M3gt1Wmuw%253D%253D&md5=e478d34790f17bdfa79d3c0da141922a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2FBF00258128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00258128%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DS.%2BE.%26aulast%3DThatcher%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DH.%26aulast%3DAdam%26aufirst%3DN.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DZaki%26aufirst%3DA.%26aulast%3DBaer%26aufirst%3DJ.%2BC.%26aulast%3DMcauliffe%26aufirst%3DC.%2BA.%26aulast%3DCrowther%26aufirst%3DD.%26aulast%3DFox%26aufirst%3DB.%2BW.%26atitle%3DIn%2520Vivo%2520Distribution%2520Studies%2520of%2520Radioactively%2520Labelled%2520Platinum%2520Complexes%253B%2520cis-Dichlorodiammine%2520Platinum%2528II%2529%252C%2520cis-trans-Dichlorodihydroxy-bis-%2528Isopropylamine%2529%2520Platinum%2528IV%2529%252C%2520cis-Dichloro-bis-Cyclopropylamine%2520Platinum%2528II%2529%252C%2520and%2520cis-Diammine%25201%252C1-Cyclobutanedicarboxylate%2520Platinum%2528II%2529%2520in%2520Patients%2520with%2520Malignant%2520Disease%252C%2520Using%2520a%2520Gamma%2520Camera%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1985%26volume%3D14%26spage%3D253%26epage%3D257%26doi%3D10.1007%2FBF00258128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Shani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertram, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahalan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muggia, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, W.</span><span> </span><span class="NLM_article-title">Noninvasive Monitoring of Drug Biodistribution and Metabolism: Studies with Intraarterial Pt-195m-Cisplatin in Humans</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1877</span><span class="NLM_x">–</span> <span class="NLM_lpage">1881</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1989&pages=1877-1881&author=J.+Shaniauthor=J.+Bertramauthor=C.+Russellauthor=R.+Dahalanauthor=D.+C.+Chenauthor=R.+Partiauthor=J.+Ahmadiauthor=R.+A.+Kempfauthor=T.+K.+Kawadaauthor=F.+M.+Muggiaauthor=W.+Wolf&title=Noninvasive+Monitoring+of+Drug+Biodistribution+and+Metabolism%3A+Studies+with+Intraarterial+Pt-195m-Cisplatin+in+Humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShani%26aufirst%3DJ.%26aulast%3DBertram%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DC.%26aulast%3DDahalan%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DD.%2BC.%26aulast%3DParti%26aufirst%3DR.%26aulast%3DAhmadi%26aufirst%3DJ.%26aulast%3DKempf%26aufirst%3DR.%2BA.%26aulast%3DKawada%26aufirst%3DT.%2BK.%26aulast%3DMuggia%26aufirst%3DF.%2BM.%26aulast%3DWolf%26aufirst%3DW.%26atitle%3DNoninvasive%2520Monitoring%2520of%2520Drug%2520Biodistribution%2520and%2520Metabolism%253A%2520Studies%2520with%2520Intraarterial%2520Pt-195m-Cisplatin%2520in%2520Humans%26jtitle%3DCancer%2520Res.%26date%3D1989%26volume%3D49%26spage%3D1877%26epage%3D1881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Areberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorkman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einarsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundqvist, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattsson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norrgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheike, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, R.</span><span> </span><span class="NLM_article-title">Gamma Camera Imaging of Platinum in Tumours and Tissues of Patients after Administration of 191Pt-Cisplatin</span> <span class="citation_source-journal">Acta Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1080%2F028418699431654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10227445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK1M3ktF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=221-228&author=J.+Arebergauthor=S.+Bjorkmanauthor=L.+Einarssonauthor=B.+Frankenbergauthor=H.+Lundqvistauthor=S.+Mattssonauthor=K.+Norrgrenauthor=O.+Scheikeauthor=R.+Wallin&title=Gamma+Camera+Imaging+of+Platinum+in+Tumours+and+Tissues+of+Patients+after+Administration+of+191Pt-Cisplatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Gamma camera imaging of platinum in tumours and tissues of patients after administration of 191Pt-cisplatin</span></div><div class="casAuthors">Areberg J; Bjorkman S; Einarsson L; Frankenberg B; Lundqvist H; Mattsson S; Norrgren K; Scheike O; Wallin R</div><div class="citationInfo"><span class="NLM_cas:title">Acta oncologica (Stockholm, Sweden)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-8</span>
        ISSN:<span class="NLM_cas:issn">0284-186X</span>.
    </div><div class="casAbstract">The aim of this study was to visualize non-invasively the uptake of platinum in tumours and tissues after treatment with cisplatin. 191Pt-cisplatin was synthesized from 191PtCl4 with rigorous pharmaceutical quality control.  The uptake of platinum by both tumorous and healthy tissues was studied by gamma camera imaging in 14 patients, 5 of whom showed a clear uptake of platinum in regions corresponding to known tumour sites.  Maximum concentrations of platinum in the tumours were on average 4.9+/-1.0 microg/g, when normalized to an administered amount of 180 mg cisplatin.  In all the patients, the liver was the organ that showed the highest uptake.  Platinum uptake was also seen in the spleen, gall bladder, gastrointestinal tract, bladder, kidneys, ureter, neck and mediastinum and urogenital region.  By using in-house production of 191Pt-cisplatin, it was possible to monitor the uptake of platinum in tumorous tissues and healthy organs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4zzS-26QlET0O18WR3iAofW6udTcc2eabQx-1HfW34bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3ktF2rtg%253D%253D&md5=e230aebbfe4b97ed283342015ae78f6c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1080%2F028418699431654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F028418699431654%26sid%3Dliteratum%253Aachs%26aulast%3DAreberg%26aufirst%3DJ.%26aulast%3DBjorkman%26aufirst%3DS.%26aulast%3DEinarsson%26aufirst%3DL.%26aulast%3DFrankenberg%26aufirst%3DB.%26aulast%3DLundqvist%26aufirst%3DH.%26aulast%3DMattsson%26aufirst%3DS.%26aulast%3DNorrgren%26aufirst%3DK.%26aulast%3DScheike%26aufirst%3DO.%26aulast%3DWallin%26aufirst%3DR.%26atitle%3DGamma%2520Camera%2520Imaging%2520of%2520Platinum%2520in%2520Tumours%2520and%2520Tissues%2520of%2520Patients%2520after%2520Administration%2520of%2520191Pt-Cisplatin%26jtitle%3DActa%2520Oncol.%26date%3D1999%26volume%3D38%26spage%3D221%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Sathekge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagener, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marjanovic-Painter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van De Wiele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’asseler, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeevaart, J. R.</span><span> </span><span class="NLM_article-title">Biodistribution and Dosimetry of 195mPt-Cisplatin in Normal Volunteers. Imaging Agent for Single Photon Emission Computed Tomography</span> <span class="citation_source-journal">Nuklearmedizin</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.3413/Nukmed-0599-13-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.3413%2FNukmed-0599-13-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24108524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1anurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=222-227&author=M.+Sathekgeauthor=J.+Wagenerauthor=S.+V.+Smithauthor=N.+Soniauthor=B.+Marjanovic-Painterauthor=C.+Zinnauthor=C.+Van+De+Wieleauthor=Y.+D%E2%80%99asselerauthor=G.+Perkinsauthor=J.+R.+Zeevaart&title=Biodistribution+and+Dosimetry+of+195mPt-Cisplatin+in+Normal+Volunteers.+Imaging+Agent+for+Single+Photon+Emission+Computed+Tomography&doi=10.3413%2FNukmed-0599-13-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Imaging agent for single photon emission computed tomography</span></div><div class="casAuthors">Sathekge, M.; Wagener, J.; Smith, S. V.; Soni, N.; Marjanovic-Painter, B.; Zinn, C.; Van de Wiele, C.; D'Asseler, Y.; Perkins, G.; Zeevaart, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Nuklearmedizin</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">222-227</span>CODEN:
                <span class="NLM_cas:coden">NMIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0029-5566</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">195mPt-cisplatin is regarded as a promising imaging agent for optimizing dosage in patients receiving cisplatin chemotherapy.  Methods: We investigated the whole-body distribution and radiation dosimetry of 195mPt-cisplatin in humans.  Whole-body scans were obtained up to 144 h after i.v. injection of 112.4 MBq 195mPt-cisplatin in each of five subjects.  Blood samples were taken at various times up to 144 h after injection.  Urine was collected up to 114 h after injection for calcn. of renal clearance and whole-body clearance.  Time/activity curves were generated by fitting the organ-specific geometric mean counts, obtained from regions of interest, on the resp. images as a function of the time after injection.  OLINDA software package was applied to calc. the adsorbed radiation dose for various organs.  Results: Most of the activity (32 ± 4%) was excreted in the urine during the first 5 h.  The effective clearance half-life derived from extrapolation o the whole-body curve was 40 h (1.7 days).  On av., the highest dose was received by the kidneys (mean dose received 2.68 ± 1.5 mGy/MBq), followed by the spleen (mean dose received 1.6 ± 0.8 mGy/MBq) followed by the liver (mean dose received 1.45 ± 0.38 mGy/MBq).  The estd. mean ED for the adult subject was 0.185 ± 0.034 mSv/MBq.  Conclusion: 195mPt-cisplatin proved a safe radiopharmaceutical with a favorable biodistribution for early and delayed imaging of pathol. above the diaphragm.  The ED obtained was 0.185 ± 0.034 mSv/MBq.  The highest organ dose was received by the kidneys (2.68 ± 1.5 mGy/MBq).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3SbBHnIM0krVg90H21EOLACvtfcHk0lj9L7YZK2ZSkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1anurs%253D&md5=a73b3e1e31b75ab73d0ab6ea9e0fb010</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3413%2FNukmed-0599-13-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3413%252FNukmed-0599-13-06%26sid%3Dliteratum%253Aachs%26aulast%3DSathekge%26aufirst%3DM.%26aulast%3DWagener%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%2BV.%26aulast%3DSoni%26aufirst%3DN.%26aulast%3DMarjanovic-Painter%26aufirst%3DB.%26aulast%3DZinn%26aufirst%3DC.%26aulast%3DVan%2BDe%2BWiele%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599asseler%26aufirst%3DY.%26aulast%3DPerkins%26aufirst%3DG.%26aulast%3DZeevaart%26aufirst%3DJ.%2BR.%26atitle%3DBiodistribution%2520and%2520Dosimetry%2520of%2520195mPt-Cisplatin%2520in%2520Normal%2520Volunteers.%2520Imaging%2520Agent%2520for%2520Single%2520Photon%2520Emission%2520Computed%2520Tomography%26jtitle%3DNuklearmedizin%26date%3D2013%26volume%3D52%26spage%3D222%26epage%3D227%26doi%3D10.3413%2FNukmed-0599-13-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Holschbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamkens, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamacher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stöcklin, G.</span><span> </span><span class="NLM_article-title">[13N]Cisplatin: A Fast and Efficient On-Line Synthesis Using a Solid State Support</span> <span class="citation_source-journal">Appl. Radiat. Isot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">744</span><span class="refDoi"> DOI: 10.1016/S0969-8043(96)00323-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0969-8043%2896%2900323-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaK2sXktVems7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1997&pages=739-744&author=M.+Holschbachauthor=W.+Hamkensauthor=A.+Steinbachauthor=K.+Hamacherauthor=G.+St%C3%B6cklin&title=%5B13N%5DCisplatin%3A+A+Fast+and+Efficient+On-Line+Synthesis+Using+a+Solid+State+Support&doi=10.1016%2FS0969-8043%2896%2900323-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">[13N]cisplatin: a fast and efficient online synthesis using a solid state support</span></div><div class="casAuthors">Holschbach, M.; Hamkens, W.; Steinbach, A.; Hamacher, K.; Stocklin, G.</div><div class="citationInfo"><span class="NLM_cas:title">Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">739-744</span>CODEN:
                <span class="NLM_cas:coden">ARISEF</span>;
        ISSN:<span class="NLM_cas:issn">0969-8043</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A new, convenient and fast on-column method using a strong anion exchange resin as the solid state support was developed for the online synthesis of nitrogen-13 (T1/2 = 9.96 min) labeled cisplatin ([13N]cisplatin).  The whole synthesis, including sterile formulation of the product, is accomplished within 15 min.  Using this method, after optimization of the reaction parameters, carrier-added [13N]cisplatin (1) can be obtained ready for injection in a decay-cor. radiochem. yield of 80% with a specific radioactivity of 30 MBq/μmol and a radiochem. purity of >98%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYfZniiOMm4rVg90H21EOLACvtfcHk0lj9L7YZK2ZSkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktVems7Y%253D&md5=1c381d8c584507090a79c4d6ddd4a722</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS0969-8043%2896%2900323-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-8043%252896%252900323-5%26sid%3Dliteratum%253Aachs%26aulast%3DHolschbach%26aufirst%3DM.%26aulast%3DHamkens%26aufirst%3DW.%26aulast%3DSteinbach%26aufirst%3DA.%26aulast%3DHamacher%26aufirst%3DK.%26aulast%3DSt%25C3%25B6cklin%26aufirst%3DG.%26atitle%3D%255B13N%255DCisplatin%253A%2520A%2520Fast%2520and%2520Efficient%2520On-Line%2520Synthesis%2520Using%2520a%2520Solid%2520State%2520Support%26jtitle%3DAppl.%2520Radiat.%2520Isot.%26date%3D1997%26volume%3D48%26spage%3D739%26epage%3D744%26doi%3D10.1016%2FS0969-8043%2896%2900323-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">De Spiegeleer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slegers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandecasteele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Den Bossche, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelstraete, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claeys, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Moerloose, P.</span><span> </span><span class="NLM_article-title">Microscale Synthesis of Nitrogen-13-Labeled Cisplatin</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1986&pages=399-403&author=B.+De+Spiegeleerauthor=G.+Slegersauthor=C.+Vandecasteeleauthor=W.+Van+Den+Bosscheauthor=K.+Schelstraeteauthor=A.+Claeysauthor=P.+De+Moerloose&title=Microscale+Synthesis+of+Nitrogen-13-Labeled+Cisplatin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSpiegeleer%26aufirst%3DB.%26aulast%3DSlegers%26aufirst%3DG.%26aulast%3DVandecasteele%26aufirst%3DC.%26aulast%3DVan%2BDen%2BBossche%26aufirst%3DW.%26aulast%3DSchelstraete%26aufirst%3DK.%26aulast%3DClaeys%26aufirst%3DA.%26aulast%3DDe%2BMoerloose%26aufirst%3DP.%26atitle%3DMicroscale%2520Synthesis%2520of%2520Nitrogen-13-Labeled%2520Cisplatin%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1986%26volume%3D27%26spage%3D399%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Haber, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenspire, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginos, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, D. A.</span><span> </span><span class="NLM_article-title">Synthesis of [13N]Cisplatin</span> <span class="citation_source-journal">J. Labelled Compd. Radiopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1002/jlcr.2580220512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fjlcr.2580220512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL2MXltFGlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1985&pages=509-516&author=M.+T.+Haberauthor=A.+J.+L.+Cooperauthor=K.+C.+Rosenspireauthor=J.+Z.+Ginosauthor=D.+A.+Rottenberg&title=Synthesis+of+%5B13N%5DCisplatin&doi=10.1002%2Fjlcr.2580220512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of [13N]cisplatin</span></div><div class="casAuthors">Haber, Martin T.; Cooper, Arthur J. L.; Rosenspire, Karen C.; Ginos, James Z.; Rottenberg, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">509-16</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    </div><div class="casAbstract">A method for the "carrier-added" synthesis of [13N]cisplatin  [98182-38-8] is described.  Yields were ∼1-4 mCi from 20-40 mCi of [13N]ammonia with a total synthesis time of 19-28 min.  The product was ∼96% radiochemically pure as judged by HPLC anal. and had a specific activity of ∼100 mCi/mmole in 1.0 mL of saline.  [13N]Cisplatin was administered i.p. to mice.  Of the tissues investigated, concn. of label was highest in kidneys.  At 10 min, considerable label in the blood, liver and kidney was in a form other than cisplatin.  However, no evidence was obtained that [13N]ammonia was released from [13N]cisplatin in vivo.  [13N]Cisplatin may be used to assess drug delivery to primary and metastatic brain tumors in patients receiving i.v. or intraarterial cisplatin chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHtBOxIHOnP7Vg90H21EOLACvtfcHk0liLP1HqPu92lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltFGlsr8%253D&md5=41a84ff68e641b25e3f55bf50b4ef748</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.2580220512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.2580220512%26sid%3Dliteratum%253Aachs%26aulast%3DHaber%26aufirst%3DM.%2BT.%26aulast%3DCooper%26aufirst%3DA.%2BJ.%2BL.%26aulast%3DRosenspire%26aufirst%3DK.%2BC.%26aulast%3DGinos%26aufirst%3DJ.%2BZ.%26aulast%3DRottenberg%26aufirst%3DD.%2BA.%26atitle%3DSynthesis%2520of%2520%255B13N%255DCisplatin%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D1985%26volume%3D22%26spage%3D509%26epage%3D516%26doi%3D10.1002%2Fjlcr.2580220512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Ginos, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhawan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strother, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, D. A.</span><span> </span><span class="NLM_article-title">[<sup>13</sup>N]Cisplatin PET to Assess Pharmacokinetics of Intra-Arterial Versus Intravenous Chemotherapy for Malignant Brain Tumors</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1844</span><span class="NLM_x">–</span> <span class="NLM_lpage">1852</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1987&pages=1844-1852&author=J.+Z.+Ginosauthor=A.+J.+Cooperauthor=V.+Dhawanauthor=J.+C.+Laiauthor=S.+C.+Strotherauthor=N.+Alcockauthor=D.+A.+Rottenberg&title=%5B13N%5DCisplatin+PET+to+Assess+Pharmacokinetics+of+Intra-Arterial+Versus+Intravenous+Chemotherapy+for+Malignant+Brain+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGinos%26aufirst%3DJ.%2BZ.%26aulast%3DCooper%26aufirst%3DA.%2BJ.%26aulast%3DDhawan%26aufirst%3DV.%26aulast%3DLai%26aufirst%3DJ.%2BC.%26aulast%3DStrother%26aufirst%3DS.%2BC.%26aulast%3DAlcock%26aufirst%3DN.%26aulast%3DRottenberg%26aufirst%3DD.%2BA.%26atitle%3D%255B13N%255DCisplatin%2520PET%2520to%2520Assess%2520Pharmacokinetics%2520of%2520Intra-Arterial%2520Versus%2520Intravenous%2520Chemotherapy%2520for%2520Malignant%2520Brain%2520Tumors%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1987%26volume%3D28%26spage%3D1844%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Graham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhsin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Oxaliplatin</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1038/nrd1287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2Fnrd1287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=11-12&author=J.+Grahamauthor=M.+Muhsinauthor=P.+Kirkpatrick&title=Oxaliplatin&doi=10.1038%2Fnrd1287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnrd1287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1287%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DMuhsin%26aufirst%3DM.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DOxaliplatin%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D11%26epage%3D12%26doi%3D10.1038%2Fnrd1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Wheate, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craig, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oun, R.</span><span> </span><span class="NLM_article-title">The Status of Platinum Anticancer Drugs in the Clinic and in Clinical Trials</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8113</span><span class="NLM_x">–</span> <span class="NLM_lpage">8127</span><span class="refDoi"> DOI: 10.1039/c0dt00292e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2Fc0dt00292e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=20593091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8113-8127&author=N.+J.+Wheateauthor=S.+Walkerauthor=G.+E.+Craigauthor=R.+Oun&title=The+Status+of+Platinum+Anticancer+Drugs+in+the+Clinic+and+in+Clinical+Trials&doi=10.1039%2Fc0dt00292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The status of platinum anticancer drugs in the clinic and in clinical trials</span></div><div class="casAuthors">Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8113-8127</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma.  Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance.  Over the last 30 years, 23 other platinum-based drugs have entered clin. trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations.  During this time there have been more failures than successes with the development of 14 drugs being halted during clin. trials.  Currently there are four drugs in the various phases of clin. trial (satraplatin, picoplatin, Lipoplatin and ProLindac).  No new small mol. platinum drug has entered clin. trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade.  In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clin. trials and those discontinued during clin. trials, and discuss the results in the context of where we believe the field will develop over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSuqxBzUTjbVg90H21EOLACvtfcHk0liSJVGd0jRRTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO&md5=bfa2fef3a7c3c4a3122a0fa60e45f804</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1039%2Fc0dt00292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt00292e%26sid%3Dliteratum%253Aachs%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DG.%2BE.%26aulast%3DOun%26aufirst%3DR.%26atitle%3DThe%2520Status%2520of%2520Platinum%2520Anticancer%2520Drugs%2520in%2520the%2520Clinic%2520and%2520in%2520Clinical%2520Trials%26jtitle%3DDalton%2520Trans.%26date%3D2010%26volume%3D39%26spage%3D8113%26epage%3D8127%26doi%3D10.1039%2Fc0dt00292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Bécouarn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agostini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trufflandier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulanger, V.</span><span> </span><span class="NLM_article-title">Oxaliplatin: Available Data in Non-Colorectal Gastrointestinal Malignancies</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span><span class="refDoi"> DOI: 10.1016/S1040-8428(01)00169-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS1040-8428%2801%2900169-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11738949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BD3MnptFClsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=265-272&author=Y.+B%C3%A9couarnauthor=C.+Agostiniauthor=N.+Trufflandierauthor=V.+Boulanger&title=Oxaliplatin%3A+Available+Data+in+Non-Colorectal+Gastrointestinal+Malignancies&doi=10.1016%2FS1040-8428%2801%2900169-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin: available data in non-colorectal gastrointestinal malignancies</span></div><div class="casAuthors">Becouarn Y; Agostini C; Trufflandier N; Boulanger V</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">265-72</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">Oxaliplatin is a third-generation platinum compound which has proven its efficacy alone or in combination with 5-fluorouracil (5-FU) and/or new anticancer drugs in advanced colorectal cancer.  Compared to the amount of available data in this cancer, little is known about the use of oxaliplatin in non-colorectal gastrointestinal malignancies. (1) The preclinical activity of the drug alone or in combination; (2) the phase I studies (oxaliplatin alone or in combination with irinotecan, raltitrexed, gemcitabine, folinic acid and 5-FU); (3) the phase II studies developed in gastric, pancreatic, biliary tract, hepatocellular carcinoma and malignant mesothelioma; and (4) some of the ongoing trials with regard to non-colorectal gastrointestinal malignancies are reviewed in this paper.  To date, oxaliplatin appears as a real candidate for clinical development in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8mY4KUE2d4Ob6AVA-44PTfW6udTcc2eYk3EO2KUHNV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnptFClsg%253D%253D&md5=43d603c7fab3dc93270cc631877e8689</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS1040-8428%2801%2900169-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1040-8428%252801%252900169-X%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A9couarn%26aufirst%3DY.%26aulast%3DAgostini%26aufirst%3DC.%26aulast%3DTrufflandier%26aufirst%3DN.%26aulast%3DBoulanger%26aufirst%3DV.%26atitle%3DOxaliplatin%253A%2520Available%2520Data%2520in%2520Non-Colorectal%2520Gastrointestinal%2520Malignancies%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2001%26volume%3D40%26spage%3D265%26epage%3D272%26doi%3D10.1016%2FS1040-8428%2801%2900169-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Boulikas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christofis, P.</span><span> </span><span class="NLM_article-title">Designing Platinum Compounds in Cancer: Structures and Mechanisms</span> <span class="citation_source-journal">Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=537-583&author=T.+Boulikasauthor=A.+Pantosauthor=E.+Bellisauthor=P.+Christofis&title=Designing+Platinum+Compounds+in+Cancer%3A+Structures+and+Mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoulikas%26aufirst%3DT.%26aulast%3DPantos%26aufirst%3DA.%26aulast%3DBellis%26aufirst%3DE.%26aulast%3DChristofis%26aufirst%3DP.%26atitle%3DDesigning%2520Platinum%2520Compounds%2520in%2520Cancer%253A%2520Structures%2520and%2520Mechanisms%26jtitle%3DCancer%2520Ther.%26date%3D2007%26volume%3D5%26spage%3D537%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Clavel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monfardini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gundersen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegenthaler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinedo, H. M.</span><span> </span><span class="NLM_article-title">Phase II Study of Iproplatin (CHIP, JM-9) in Advanced Testicular Cancers Progressing after Prior Chemotherapy</span> <span class="citation_source-journal">Eur. J. Cancer Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1348</span><span class="refDoi"> DOI: 10.1016/0277-5379(88)90226-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2F0277-5379%2888%2990226-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3181255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaL1M%252FjtV2jtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1988&pages=1345-1348&author=M.+Clavelauthor=S.+Monfardiniauthor=S.+Gundersenauthor=S.+Kayeauthor=P.+Siegenthalerauthor=J.+Renardauthor=M.+Van+Glabbekeauthor=H.+M.+Pinedo&title=Phase+II+Study+of+Iproplatin+%28CHIP%2C+JM-9%29+in+Advanced+Testicular+Cancers+Progressing+after+Prior+Chemotherapy&doi=10.1016%2F0277-5379%2888%2990226-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy</span></div><div class="casAuthors">Clavel M; Monfardini S; Gundersen S; Kaye S; Siegenthaler P; Renard J; van Glabbeke M; Pinedo H M</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer & clinical oncology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1345-8</span>
        ISSN:<span class="NLM_cas:issn">0277-5379</span>.
    </div><div class="casAbstract">Twenty-two patients with advanced testicular cancer received iproplatin at a dose of 180-240 mg/m2 every 4 weeks.  All the patients progressed or recurred after chemotherapy including cisplatin.  The most severe toxicity was thrombocytopenia with two toxic deaths after a first cycle of 240 and 180 mg/m2 respectively.  Nausea and vomiting were almost universal but mild in intensity.  One renal failure occurred 6 weeks after the first cycle while the tumor was progressing.  No antitumor activity was observed in this heavily pretreated population of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEQbLT51sM_tK0qsdY6Nc1fW6udTcc2eal8VWOfcrch7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1M%252FjtV2jtg%253D%253D&md5=bc3fe34619ce3efb008c4db44e565bda</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0277-5379%2888%2990226-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0277-5379%252888%252990226-X%26sid%3Dliteratum%253Aachs%26aulast%3DClavel%26aufirst%3DM.%26aulast%3DMonfardini%26aufirst%3DS.%26aulast%3DGundersen%26aufirst%3DS.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DSiegenthaler%26aufirst%3DP.%26aulast%3DRenard%26aufirst%3DJ.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26atitle%3DPhase%2520II%2520Study%2520of%2520Iproplatin%2520%2528CHIP%252C%2520JM-9%2529%2520in%2520Advanced%2520Testicular%2520Cancers%2520Progressing%2520after%2520Prior%2520Chemotherapy%26jtitle%3DEur.%2520J.%2520Cancer%2520Clin.%2520Oncol.%26date%3D1988%26volume%3D24%26spage%3D1345%26epage%3D1348%26doi%3D10.1016%2F0277-5379%2888%2990226-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Bhargava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaishampayan, U. N.</span><span> </span><span class="NLM_article-title">Satraplatin: Leading the New Generation of Oral Platinum Agents</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1787</span><span class="NLM_x">–</span> <span class="NLM_lpage">1797</span><span class="refDoi"> DOI: 10.1517/13543780903362437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1517%2F13543780903362437" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1787-1797&author=A.+Bhargavaauthor=U.+N.+Vaishampayan&title=Satraplatin%3A+Leading+the+New+Generation+of+Oral+Platinum+Agents&doi=10.1517%2F13543780903362437"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1517%2F13543780903362437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780903362437%26sid%3Dliteratum%253Aachs%26aulast%3DBhargava%26aufirst%3DA.%26aulast%3DVaishampayan%26aufirst%3DU.%2BN.%26atitle%3DSatraplatin%253A%2520Leading%2520the%2520New%2520Generation%2520of%2520Oral%2520Platinum%2520Agents%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1787%26epage%3D1797%26doi%3D10.1517%2F13543780903362437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beale, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span> </span><span class="NLM_article-title">Mini-Review: Discovery and Development of Platinum Complexes Designed to Circumvent Cisplatin Resistance</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1016/S0162-0134(99)00141-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0162-0134%2899%2900141-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1999&pages=111-115&author=L.+R.+Kellandauthor=S.+Y.+Sharpauthor=C.+F.+O%E2%80%99Neillauthor=F.+I.+Raynaudauthor=P.+J.+Bealeauthor=I.+R.+Judson&title=Mini-Review%3A+Discovery+and+Development+of+Platinum+Complexes+Designed+to+Circumvent+Cisplatin+Resistance&doi=10.1016%2FS0162-0134%2899%2900141-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2FS0162-0134%2899%2900141-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-0134%252899%252900141-5%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DC.%2BF.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DBeale%26aufirst%3DP.%2BJ.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26atitle%3DMini-Review%253A%2520Discovery%2520and%2520Development%2520of%2520Platinum%2520Complexes%2520Designed%2520to%2520Circumvent%2520Cisplatin%2520Resistance%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D1999%26volume%3D77%26spage%3D111%26epage%3D115%26doi%3D10.1016%2FS0162-0134%2899%2900141-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Manzotti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratesi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Domenico, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalletti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polizzi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span> </span><span class="NLM_article-title">BBR 3464: A Novel Triplatinum Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2626</span><span class="NLM_x">–</span> <span class="NLM_lpage">2634</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10914703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslentrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=2626-2634&author=C.+Manzottiauthor=G.+Pratesiauthor=E.+Mentaauthor=R.+Di+Domenicoauthor=E.+Cavallettiauthor=H.+H.+Fiebigauthor=L.+R.+Kellandauthor=N.+Farrellauthor=D.+Polizziauthor=R.+Supinoauthor=G.+Pezzoniauthor=F.+Zunino&title=BBR+3464%3A+A+Novel+Triplatinum+Complex%2C+Exhibiting+a+Preclinical+Profile+of+Antitumor+Efficacy+Different+from+Cisplatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin</span></div><div class="casAuthors">Manzotti, Carla; Pratesi, Graziella; Menta, Ernesto; Domenico, Roberto Di; Cavalletti, Ennio; Fiebig, Heinz H.; Kelland, Lloyd R.; Farrell, Nicholas; Polizzi, Donatella; Supino, Rosanna; Pezzoni, Gabriella; Zunino, Franco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2626-2634</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The triplatinum complex BBR 3464 was evaluated in a series of human tumor cell lines and tumor xenografts, with special emphasis on tumor types known to be resistant to cisplatin.  In a panel of seven human tumor cell lines naturally resistant to cisplatin (three ovarian tumors and four melanomas), BBR 3464 was extremely potent, with IC50 values at least 20-fold lower than cisplatin.  Against eight human tumor xenografts, including four tumors refractory to cisplatin, BBR 3464 was very active, producing a >80% inhibition of growth in seven of them.  The efficacy of BBR 3464 against cisplatin-resistant tumors was consistent with the ability of the drug to completely overcome resistance in three cell systems characterized by acquired resistance to cisplatin.  Moreover, BBR 3464 caused a more prolonged effect than cisplatin, which was reflected by higher specific growth delay values.  This prolonged effect is likely to be related to a more persistent perturbation of the cell cycle by BBR 3464 than by cisplatin, as shown in one ovarian tumor cell line.  Finally, the profile of sensitivity to BBR 3464 within the 60-cell-line screening panel of the National Cancer Institute, NIH (Bethesda, MD) differed from those of established drugs, thus supporting the hypothesis of a distinct mechanism of cytotoxic activity of BBR 3464.  This novel triplatinum complex, in the light of its innovative antitumor activity profile, has the potential to become a useful clin. agent for the treatment of unresponsive tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopg8SLf4JVV7Vg90H21EOLACvtfcHk0liriF8RwZg6YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslentrg%253D&md5=23e5bf1975dadbe2c77411ab21b7d969</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManzotti%26aufirst%3DC.%26aulast%3DPratesi%26aufirst%3DG.%26aulast%3DMenta%26aufirst%3DE.%26aulast%3DDi%2BDomenico%26aufirst%3DR.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DFiebig%26aufirst%3DH.%2BH.%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DFarrell%26aufirst%3DN.%26aulast%3DPolizzi%26aufirst%3DD.%26aulast%3DSupino%26aufirst%3DR.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DBBR%25203464%253A%2520A%2520Novel%2520Triplatinum%2520Complex%252C%2520Exhibiting%2520a%2520Preclinical%2520Profile%2520of%2520Antitumor%2520Efficacy%2520Different%2520from%2520Cisplatin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D2626%26epage%3D2634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Misset, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleiberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekradda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cvitkovic, E.</span><span> </span><span class="NLM_article-title">Oxaliplatin Clinical Activity: A Review</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1016/S1040-8428(00)00070-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS1040-8428%2800%2900070-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10936465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BD3cvmvFSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=75-93&author=J.+L.+Missetauthor=H.+Bleibergauthor=W.+Sutherlandauthor=M.+Bekraddaauthor=E.+Cvitkovic&title=Oxaliplatin+Clinical+Activity%3A+A+Review&doi=10.1016%2FS1040-8428%2800%2900070-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin clinical activity: a review</span></div><div class="casAuthors">Misset J L; Bleiberg H; Sutherland W; Bekradda M; Cvitkovic E</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-93</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">Oxaliplatin (Eloxatin), a recently developed third-generation cisplatin analogue with a 1,2-diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in a wide variety of tumour types.  Synergistic with 5-FU in colorectal cancer (CRC), the combination has proven efficacy in 5-FU-resistant advanced disease and in previously untreated CRC, as demonstrated in controlled phase III trials, while evaluation in the adjuvant setting is ongoing.  Due to its excellent safety profile, its unique mechanism of action and lack of cross-resistance with other active agents in CRC, oxaliplatin has also been combined with CPT-11 and Raltitrexed with promising results.  Trials in pretreated and untreated advanced ovarian cancer (AOC), as a single agent or in combination with cisplatin, cyclophosphamide or paclitaxel, indicate a yet to be defined role in AOC and confirm its lack of cross-resistance with cis/carboplatin.  Clinical investigations of single agent and combination therapies in breast, lung, prostate and germ-cell carcinomas, non-Hodgkin's lymphoma and malignant mesothelioma are being pursued.  While the role of oxaliplatin in medical oncology is yet to be fully defined, it appears to be an important new anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRR6rm3u9EVofh3YQQtAhNufW6udTcc2eYF3qexmvxIeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvmvFSjsQ%253D%253D&md5=05c3d3fa62e6ee0a8bcd8e4b59303f83</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS1040-8428%2800%2900070-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1040-8428%252800%252900070-6%26sid%3Dliteratum%253Aachs%26aulast%3DMisset%26aufirst%3DJ.%2BL.%26aulast%3DBleiberg%26aufirst%3DH.%26aulast%3DSutherland%26aufirst%3DW.%26aulast%3DBekradda%26aufirst%3DM.%26aulast%3DCvitkovic%26aufirst%3DE.%26atitle%3DOxaliplatin%2520Clinical%2520Activity%253A%2520A%2520Review%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2000%26volume%3D35%26spage%3D75%26epage%3D93%26doi%3D10.1016%2FS1040-8428%2800%2900070-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Tashiro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kidani, Y.</span><span> </span><span class="NLM_article-title">Antitumor Activity of a New Platinum Complex, Oxalato (<i>trans</i>-L-1,2-Diaminocyclohexane)Platinum (II): New Experimental Data</span> <span class="citation_source-journal">Biomed. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">260</span><span class="refDoi"> DOI: 10.1016/0753-3322(89)90004-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2F0753-3322%2889%2990004-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=2790145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL1MXkvV2qsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1989&pages=251-260&author=T.+Tashiroauthor=Y.+Kawadaauthor=Y.+Sakuraiauthor=Y.+Kidani&title=Antitumor+Activity+of+a+New+Platinum+Complex%2C+Oxalato+%28trans-L-1%2C2-Diaminocyclohexane%29Platinum+%28II%29%3A+New+Experimental+Data&doi=10.1016%2F0753-3322%2889%2990004-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum(II):  new experimental data</span></div><div class="casAuthors">Tashiro, T.; Kawada, Y.; Sakurai, Y.; Kidani, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-60</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    </div><div class="casAbstract">The antitumor activity of a new pl complex, oxalato (trans-l-1,2-diaminocyclohexane) platinum(II) (I), was studied.  This water-sol. pt complex had a more prominent life-prolonging effect in mice bearing leukemia L1210 than did cisplatin (DDP).  In addn., a subline of L1210 having a 40-fold resistance to DDP (L1210/DDP) had no cross-resistance to I both in vivo and in vitro.  Esp. in vivo I was more active against L1210/DDP than against the original L1210, and all mice were cured at 6.25 and 3.12 mg/kg.  I was also effective against several mouse tumors such as P38 leukemia, B16 melanoma, Lewis lung carcinoma, colon 26 and colon 38 adenocarcinomas, and M5076 fibrosarcoma, though its antitumor spectrum was somewhat different from that of DDP.  The synthesis of both DNa and RNA in L1210 cells was inhibited by ∼50% with exposure to 10 μM I for 1 h, followed by postincubation in drug-free medium for 6-24 h, while only the inhibition of DNA synthesis was obsd. by DDP in the same expt.  If severe toxicity is nt obsd. in preclin. study, I expected to be a new clin. active Pt complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXWZM8wczamrVg90H21EOLACvtfcHk0liRbvQzzU2nFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvV2qsbY%253D&md5=3d59bdb675f5fd518f4a1abcf9623bb4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2F0753-3322%2889%2990004-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0753-3322%252889%252990004-8%26sid%3Dliteratum%253Aachs%26aulast%3DTashiro%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DY.%26aulast%3DSakurai%26aufirst%3DY.%26aulast%3DKidani%26aufirst%3DY.%26atitle%3DAntitumor%2520Activity%2520of%2520a%2520New%2520Platinum%2520Complex%252C%2520Oxalato%2520%2528trans-L-1%252C2-Diaminocyclohexane%2529Platinum%2520%2528II%2529%253A%2520New%2520Experimental%2520Data%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D1989%26volume%3D43%26spage%3D251%26epage%3D260%26doi%3D10.1016%2F0753-3322%2889%2990004-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span>National Cancer Institute. Clinical Trials Information for Patients and Caregivers. <a href="http://www.cancer.gov/about-cancer/treatment/clinical-trials" class="extLink">http://www.cancer.gov/about-cancer/treatment/clinical-trials</a> (accessed August 11,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Cancer+Institute.+Clinical+Trials+Information+for+Patients+and+Caregivers.+http%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Ftreatment%2Fclinical-trials+%28accessed+August+11%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Shimada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itamochi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kigawa, J.</span><span> </span><span class="NLM_article-title">Nedaplatin: A Cisplatin Derivative in Cancer Chemotherapy</span> <span class="citation_source-journal">Cancer Manage. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span><span class="refDoi"> DOI: 10.2147/CMAR.S35785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2147%2FCMAR.S35785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=23696716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFCksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=67-76&author=M.+Shimadaauthor=H.+Itamochiauthor=J.+Kigawa&title=Nedaplatin%3A+A+Cisplatin+Derivative+in+Cancer+Chemotherapy&doi=10.2147%2FCMAR.S35785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Nedaplatin: a cisplatin derivative in cancer chemotherapy</span></div><div class="casAuthors">Shimada, Muneaki; Itamochi, Hiroaki; Kigawa, Junzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-76</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Nedaplatin, a cisplatin analog, has been developed to decrease the toxicities induced by cisplatin, such as nephrotoxicity and gastrointestinal toxicity.  The dose of nedaplatin is detd. by body surface area, not by the area under the curve (AUC).  The recommended therapeutic dose is 80-100 mg/m2, although the pharmacokinetic profile of nedaplatin is similar to that of carboplatin.  In our preliminary study, there was a favorable correlation between AUC and creatinine clearance (CL), suggesting that renal function should be considered when nedaplatin is administered.  Ishibashi's formula, i.e., DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance +4.47, would be predictable and useful for estg. the individual dose of nedaplatin.  Several Phase II studies have suggested that nedaplatin might be a useful second analog, esp. for patients with non-small cell lung cancer, esophageal cancer, uterine cervical cancer, head and neck cancer or urothelial cancer.  Further, nedaplatin was reported to be a useful chemotherapeutic agent with radiosensitizing properties; however, there is no Phase III study of nedaplatin, neither with chemotherapy nor with concurrent chemoradiotherapy, because nedaplatin is not commonly used throughout the world.  Further evaluation in a randomized controlled trial is warranted to demonstrate definitively the activity of nedaplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7whQ23DbyirVg90H21EOLACvtfcHk0liRbvQzzU2nFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFCksr8%253D&md5=fbfa5bc15615267da65b041c30ad60bb</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S35785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S35785%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DM.%26aulast%3DItamochi%26aufirst%3DH.%26aulast%3DKigawa%26aufirst%3DJ.%26atitle%3DNedaplatin%253A%2520A%2520Cisplatin%2520Derivative%2520in%2520Cancer%2520Chemotherapy%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2013%26volume%3D5%26spage%3D67%26epage%3D76%26doi%3D10.2147%2FCMAR.S35785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Totani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aono, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, Y.</span><span> </span><span class="NLM_article-title">Synthesis of (Glycolato-<i>O</i>,<i>O</i>′)Diammineplatinum(II) and Its Related Complexes</span> <span class="citation_source-journal">Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span><span class="refDoi"> DOI: 10.1246/cl.1986.429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1246%2Fcl.1986.429" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1986&pages=429-432&author=T.+Totaniauthor=K.+Aonoauthor=M.+Komuraauthor=Y.+Adachi&title=Synthesis+of+%28Glycolato-O%2CO%E2%80%B2%29Diammineplatinum%28II%29+and+Its+Related+Complexes&doi=10.1246%2Fcl.1986.429"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1246%2Fcl.1986.429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.1986.429%26sid%3Dliteratum%253Aachs%26aulast%3DTotani%26aufirst%3DT.%26aulast%3DAono%26aufirst%3DK.%26aulast%3DKomura%26aufirst%3DM.%26aulast%3DAdachi%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520%2528Glycolato-O%252CO%25E2%2580%25B2%2529Diammineplatinum%2528II%2529%2520and%2520Its%2520Related%2520Complexes%26jtitle%3DChem.%2520Lett.%26date%3D1986%26volume%3D15%26spage%3D429%26epage%3D432%26doi%3D10.1246%2Fcl.1986.429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Shiratori, O.</span><span> </span><span class="NLM_article-title">Anti-Tumor Activity of 254-S, a Platinum Complex, in Rodents</span> <span class="citation_source-journal">Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">636</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL28XmtFynur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1985&pages=635-636&author=O.+Shiratori&title=Anti-Tumor+Activity+of+254-S%2C+a+Platinum+Complex%2C+in+Rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of 254-S, a platinum complex, in rodents</span></div><div class="casAuthors">Shiratori, O.; Kasai, H.; Uchida, N.; Takeda, Y.; Totani, T.; Sato, K.</div><div class="citationInfo"><span class="NLM_cas:title"></span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">Anticancer Sect. 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">635-6</span>CODEN:
                <span class="NLM_cas:coden">55GNAX</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Univ. Tokyo Press</span>)
        </div><div class="casAbstract">(Glycolato-O,O')diammineplatinum (II) (254-S)  [95734-82-0] was tested for antitumor activity in rodents, and the results were compared with those of cisplatin (CDDP).  254-S exhibited high antitumor activity against solid tumors but only a moderate effect on leukemic tumors.  Its antitumor activity was better than that of CDDP.  The nephrotoxicity of 254-S was low when compared with CDDP.  When either drug was given in 5 successive i.v. administrations, the relationships between antitumor activities and toxic properties (gastrointestinal toxicity, nephrotoxicity and myelosuppression) in mice suggested the better selectivity of 254-S than CDDP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNhmZzTtiQtLVg90H21EOLACvtfcHk0liRbvQzzU2nFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XmtFynur8%253D&md5=6f841bac45ec19050ad59039290c8468</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShiratori%26aufirst%3DO.%26atitle%3DAnti-Tumor%2520Activity%2520of%2520254-S%252C%2520a%2520Platinum%2520Complex%252C%2520in%2520Rodents%26jtitle%3DRecent%2520Adv.%2520Chemother.%252C%2520Proc.%2520Int.%2520Congr.%2520Chemother.%252C%252014th%26date%3D1985%26spage%3D635%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Shukuya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel for Advanced or Relapsed Squamous Cell Carcinoma of the Lung (WJOG5208L): A Randomised, Open-Label, Phase 3 Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1630</span><span class="NLM_x">–</span> <span class="NLM_lpage">1638</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00305-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS1470-2045%2815%2900305-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26522337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslems7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1630-1638&author=T.+Shukuyaauthor=T.+Yamanakaauthor=T.+Setoauthor=H.+Dagaauthor=K.+Gotoauthor=H.+Sakaauthor=S.+Sugawaraauthor=T.+Takahashiauthor=S.+Yokotaauthor=H.+Kanedaauthor=T.+Kawaguchiauthor=S.+Nagaseauthor=T.+Oguriauthor=Y.+Iwamotoauthor=T.+Nishimuraauthor=Y.+Hattoriauthor=K.+Nakagawaauthor=Y.+Nakanishiauthor=N.+Yamamoto&title=Nedaplatin+Plus+Docetaxel+Versus+Cisplatin+Plus+Docetaxel+for+Advanced+or+Relapsed+Squamous+Cell+Carcinoma+of+the+Lung+%28WJOG5208L%29%3A+A+Randomised%2C+Open-Label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2815%2900305-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Shukuya, Takehito; Yamanaka, Takeharu; Seto, Takashi; Daga, Haruko; Goto, Koichi; Saka, Hideo; Sugawara, Shunichi; Takahashi, Toshiaki; Yokota, Soichiro; Kaneda, Hiroyasu; Kawaguchi, Tomoya; Nagase, Seisuke; Oguri, Tetsuya; Iwamoto, Yasuo; Nishimura, Takashi; Hattori, Yoshihiro; Nakagawa, Kazuhiko; Nakanishi, Yoichi; Yamamoto, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1630-1638</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The combination of nedaplatin, a cisplatin deriv., and docetaxel showed promising activity for advanced squamous cell lung carcinoma in a previous phase 1-2 study.  We compared nedaplatin plus docetaxel with cisplatin plus docetaxel in patients with previously untreated advanced or relapsed squamous cell lung carcinoma to det. effects on overall survival.  We did a randomised, open-label, phase 3 study at 53 institutions in Japan.  Eligibility criteria included pathol. proven squamous cell lung cancer with stage IIIB/IV or postoperative recurrence, age 20-74 years, Eastern Cooperative Oncol. Group performance status of 0-1, no previous chemotherapy or recurrence more than a year after previous adjuvant chemotherapy, and adequate organ function.  Patients were randomly assigned (1:1) to 100 mg/m2 nedaplatin and 60 mg/m2 docetaxel i.v., or 80 mg/m2 cisplatin and 60 mg/m2 docetaxel, every 3 wk for four to six cycles (at the treating oncologist's discretion).  Randomisation was done centrally at the West Japan Oncol. Group data center via a computer-generated allocation sequence with dynamic minimisation that balanced stage (IIIB/IV or postoperative recurrent), sex, and institution.  The primary endpoint was overall survival in the modified intention-to-treat population (ie, all patients who were randomly assigned and met the inclusion criteria).  Safety analyses were done in all randomly assigned patients who received at least one dose of the study regimen.  This trial is registered with the UMIN Clin. Trials Registry, no. UMIN000002015, and is closed to new participants.  Between July 6, 2009, and July 26, 2012, 355 patients were randomly assigned. 349 patients were included in the modified intention-to-treat anal. (177 in the nedaplatin group and 172 in the cisplatin group).  Overall survival was significantly longer in the nedaplatin group (median 13·6 mo, 95% CI 11·6-15·6) than in the cisplatin group (11·4 mo,10·2-12·2; hazard ratio 0·81, 95% CI 0·65-1·02; p=0·037, one-sided stratified log-rank test).  Grade 3 or worse nausea (seven of 177 patients in the nedaplatin group and 25 of 175 in the cisplatin group), fatigue (six vs 20), hyponatremia (24 vs 53), and hypokalemia (four vs 15) were more frequent in the cisplatin group than in the nedaplatin group, whereas grade 3 or worse leucopenia (98 vs 77), neutropenia (146 vs 123), and thrombocytopenia (16 vs none) were more frequent in the nedaplatin group than in the cisplatin group.  Treatment-related deaths occurred in four and three patients in nedaplatin and cisplatin groups, resp.  Overall survival was significantly longer with nedaplatin plus docetaxel than with cisplatin plus docetaxel, and the regimens had different safety profiles.  Nedaplatin plus docetaxel could be a new treatment option for advanced or relapsed squamous cell lung cancer.  West Japan Oncol. Group and Sanofi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRMD5nXRBk7Vg90H21EOLACvtfcHk0li1g8_I9mPF6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslems7zN&md5=8b8768e16f3d6a3ea9f1d4158c7f0042</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900305-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900305-8%26sid%3Dliteratum%253Aachs%26aulast%3DShukuya%26aufirst%3DT.%26aulast%3DYamanaka%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DDaga%26aufirst%3DH.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DSaka%26aufirst%3DH.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DKaneda%26aufirst%3DH.%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DS.%26aulast%3DOguri%26aufirst%3DT.%26aulast%3DIwamoto%26aufirst%3DY.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DHattori%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DNedaplatin%2520Plus%2520Docetaxel%2520Versus%2520Cisplatin%2520Plus%2520Docetaxel%2520for%2520Advanced%2520or%2520Relapsed%2520Squamous%2520Cell%2520Carcinoma%2520of%2520the%2520Lung%2520%2528WJOG5208L%2529%253A%2520A%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1630%26epage%3D1638%26doi%3D10.1016%2FS1470-2045%2815%2900305-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J.</span><span> </span><span class="NLM_article-title">Nedaplatin: A New Platinum for Squamous Lung Cancer?</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1573</span><span class="NLM_x">–</span> <span class="NLM_lpage">1574</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00400-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS1470-2045%2815%2900400-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26522336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC28znsVCitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1573-1574&author=Y.+Wuauthor=J.+Spicer&title=Nedaplatin%3A+A+New+Platinum+for+Squamous+Lung+Cancer%3F&doi=10.1016%2FS1470-2045%2815%2900400-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Nedaplatin: a new platinum for squamous lung cancer?</span></div><div class="casAuthors">Wu Yin; Spicer James</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1573-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfGmAznCJDLO98rul4nhSdfW6udTcc2eaaAmmNr0-aRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28znsVCitg%253D%253D&md5=6907a8f513478594cb47f650e860270f</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900400-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900400-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSpicer%26aufirst%3DJ.%26atitle%3DNedaplatin%253A%2520A%2520New%2520Platinum%2520for%2520Squamous%2520Lung%2520Cancer%253F%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1573%26epage%3D1574%26doi%3D10.1016%2FS1470-2045%2815%2900400-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Kim, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. S.</span><span> </span><span class="NLM_article-title">General Pharmacology of <i>cis</i>-Malonato[4R,5R)-4,5-<i>bis</i>-(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II)</span> <span class="citation_source-journal">Drug Res. (Stuttgart, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1080</span><span class="NLM_x">–</span> <span class="NLM_lpage">1088</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=7986249" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1994&pages=1080-1088&author=D.+K.+Kimauthor=J.+S.+Ahnauthor=G.+Ryuauthor=K.+H.+Kimauthor=C.+W.+Parkauthor=M.+S.+Kimauthor=M.+H.+Chungauthor=S.+G.+Shinauthor=Y.+H.+Suhauthor=Y.+S.+Kim&title=General+Pharmacology+of+cis-Malonato%5B4R%2C5R%29-4%2C5-bis-%28aminomethyl%29-2-isopropyl-1%2C3-dioxolane%5Dplatinum%28II%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DRyu%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DPark%26aufirst%3DC.%2BW.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DChung%26aufirst%3DM.%2BH.%26aulast%3DShin%26aufirst%3DS.%2BG.%26aulast%3DSuh%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BS.%26atitle%3DGeneral%2520Pharmacology%2520of%2520cis-Malonato%255B4R%252C5R%2529-4%252C5-bis-%2528aminomethyl%2529-2-isopropyl-1%252C3-dioxolane%255Dplatinum%2528II%2529%26jtitle%3DDrug%2520Res.%2520%2528Stuttgart%252C%2520Ger.%2529%26date%3D1994%26volume%3D44%26spage%3D1080%26epage%3D1088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Kim, D.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.-G.</span><span> </span><span class="NLM_article-title">Synthesis and Antitumor Activity of a Series of [2-Substituted-4,5-<i>bis</i>(Aminomethyl)-1,3-Dioxolane]Platinum(II) Complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1471</span><span class="NLM_x">–</span> <span class="NLM_lpage">1485</span><span class="refDoi"> DOI: 10.1021/jm00036a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00036a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1471-1485&author=D.-K.+Kimauthor=G.+Kimauthor=J.+Gamauthor=Y.-B.+Choauthor=H.-T.+Kimauthor=J.-H.+Taiauthor=K.+H.+Kimauthor=W.-S.+Hongauthor=J.-G.+Park&title=Synthesis+and+Antitumor+Activity+of+a+Series+of+%5B2-Substituted-4%2C5-bis%28Aminomethyl%29-1%2C3-Dioxolane%5DPlatinum%28II%29+Complexes&doi=10.1021%2Fjm00036a013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm00036a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00036a013%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.-K.%26aulast%3DKim%26aufirst%3DG.%26aulast%3DGam%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DY.-B.%26aulast%3DKim%26aufirst%3DH.-T.%26aulast%3DTai%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DJ.-G.%26atitle%3DSynthesis%2520and%2520Antitumor%2520Activity%2520of%2520a%2520Series%2520of%2520%255B2-Substituted-4%252C5-bis%2528Aminomethyl%2529-1%252C3-Dioxolane%255DPlatinum%2528II%2529%2520Complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1471%26epage%3D1485%26doi%3D10.1021%2Fjm00036a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Kim, D.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span> </span><span class="NLM_article-title">Antitumor Activity of <i>cis</i>-Malonato[(4R,5R)-4,5-<i>bis</i>(Aminomethy1)-2-Isopropyl-1,3-Dioxolanelplatinum(II), a New Platinum Analogue, as an Anticancer Agent</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span><span class="refDoi"> DOI: 10.1007/s002800050260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2Fs002800050260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=7850928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaK2MXkslGitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1995&pages=441-445&author=D.-K.+Kimauthor=H.-T.+Kimauthor=Y.-B.+Choauthor=J.+H.+Taiauthor=J.+S.+Ahnauthor=T.-S.+Kimauthor=K.+H.+Kimauthor=W.-S.+Hong&title=Antitumor+Activity+of+cis-Malonato%5B%284R%2C5R%29-4%2C5-bis%28Aminomethy1%29-2-Isopropyl-1%2C3-Dioxolanelplatinum%28II%29%2C+a+New+Platinum+Analogue%2C+as+an+Anticancer+Agent&doi=10.1007%2Fs002800050260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analog, as an anticancer agent</span></div><div class="casAuthors">Kim, Dae-Kee; Kim, Hun-Taek; Cho, Yong-Baik; Tai, Joo Ho; Ahn, Jae Suk; Kim, Taek-Soo; Kim, Key H.; Hong, Weon-Seon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-5</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">The in vitro and in vivo antitumor activity of a new antitumor platinum complex, cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) (SKI 2053R, NSC D644591), were evaluated and compared with those of cisplatin (CDDP) and carboplatin (CBDCA) using murine tumors.  SKI 2053R was highly active in vitro against both L1210 murine leukemia and its CDDP-resistant subline, L1210/DDP; the relative resistances were 20.0-, 14.5-, and 2.7-fold for CDDP, CBDCA, and SKI 2053R, resp.  SKI 2053R showed activity comparable with or superior to either CDDP or CBDCA in mice implanted with L1210.  In mice implanted with L1210/DDP, as compared with CBDCA, SKI 2053R showed high values for the percentage of treated survivors relative to controls and for nos. of cured mice, whereas CDDP had virtually no activity.  In mice implanted with P388, all three drugs were highly active, but the intensity of activity was shown to be ranked in the following order: SKI 2053R > CDDP > CBDCA.  The antitumor activity of SKI 2053R against Lewis lung carcinoma was comparable with that of both CDDP and CBDCA.  The antitumor activity of SKI 2053R was further investigated against two human tumor xenografts, KATO III (stomach adenocarcinoma) and WiDr (colon adenocarcinoma), implanted s.c. in nude mice and was compared with that of CDDP.  In SKI 2053R-treated groups, the time required for a mean tumor wt. of 1,000 mg was 33.1 days in KATO III xenografts and 35.0 days in WiDr xenografts as compared with 30.2 and 27.2 days in CDDP-treated groups, resp.  SKI 2053R achieved growth-inhibition rates comparable with those of CDDP against KATO III (65% vs. 59%) and WiDr xenografts (64% vs. 54%) on day 35.  These results indicate that SKI 2053R is an attractive candidate for further development as a clin. useful anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr67-hkqW73drVg90H21EOLACvtfcHk0lixOYB7-f_xww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkslGitbg%253D&md5=728ebb114ad68695442c1de41ce67902</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1007%2Fs002800050260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050260%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.-K.%26aulast%3DKim%26aufirst%3DH.-T.%26aulast%3DCho%26aufirst%3DY.-B.%26aulast%3DTai%26aufirst%3DJ.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DT.-S.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DW.-S.%26atitle%3DAntitumor%2520Activity%2520of%2520cis-Malonato%255B%25284R%252C5R%2529-4%252C5-bis%2528Aminomethy1%2529-2-Isopropyl-1%252C3-Dioxolanelplatinum%2528II%2529%252C%2520a%2520New%2520Platinum%2520Analogue%252C%2520as%2520an%2520Anticancer%2520Agent%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1995%26volume%3D35%26spage%3D441%26epage%3D445%26doi%3D10.1007%2Fs002800050260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Min, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H. R.</span><span> </span><span class="NLM_article-title">Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-Line Treatment in Patients with Advanced Gastric Cancer</span> <span class="citation_source-journal">J. Korean Med. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span><span class="refDoi"> DOI: 10.3346/jkms.2004.19.3.369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.3346%2Fjkms.2004.19.3.369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=15201502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Crsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=369-373&author=Y.+J.+Minauthor=S.-J.+Bangauthor=J.+W.+Shinauthor=D.+H.+Kimauthor=J.+H.+Parkauthor=G.+Y.+Kimauthor=B.+K.+Koauthor=D.+H.+Choiauthor=H.+R.+Cho&title=Combination+Chemotherapy+with+5-Fluorouracil+and+Heptaplatin+as+First-Line+Treatment+in+Patients+with+Advanced+Gastric+Cancer&doi=10.3346%2Fjkms.2004.19.3.369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer</span></div><div class="casAuthors">Min, Young Joo; Bang, Sung-Jo; Shin, Jung Woo; Kim, Do Ha; Park, Jae Hoo; Kim, Gyu Yeol; Ko, Byung Kyun; Choi, Dae Hwa; Cho, Hong Rae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Korean Medical Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">369-373</span>CODEN:
                <span class="NLM_cas:coden">JKMSEH</span>;
        ISSN:<span class="NLM_cas:issn">1011-8934</span>.
    
            (<span class="NLM_cas:orgname">Korean Academy of Medical Science</span>)
        </div><div class="casAbstract">Heptaplatin is a recently developed platinum deriv.  This agent has been reported to give a response rate of 17% as a single agent, and tolerable toxicity, in the treatment of advanced gastric cancer.  This study evaluated the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer.  Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited.  5-FU was administered over 120 h by continuous i.v. infusion from day 1 to 5, at a daily dose of 1000 mg/m2 and heptaplatin was administered over 1 h by i.v. infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 wk.  The response rate was 21%; median progression-free survival was 1.9 mo.  Median overall survival was 6.2 mo and the 1-yr survival rate was 29% for all patients.  The most frequent toxicity was proteinuria.  Toxicities were generally mild and reversible.  This study demonstrates that the 5-FU/heptaplatin combination is less active but tolerated in patients with advanced gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgvRLqD41Q77Vg90H21EOLACvtfcHk0lixOYB7-f_xww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Crsrs%253D&md5=97279e40a4b743b58f465088074d6c22</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3346%2Fjkms.2004.19.3.369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3346%252Fjkms.2004.19.3.369%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DY.%2BJ.%26aulast%3DBang%26aufirst%3DS.-J.%26aulast%3DShin%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DG.%2BY.%26aulast%3DKo%26aufirst%3DB.%2BK.%26aulast%3DChoi%26aufirst%3DD.%2BH.%26aulast%3DCho%26aufirst%3DH.%2BR.%26atitle%3DCombination%2520Chemotherapy%2520with%25205-Fluorouracil%2520and%2520Heptaplatin%2520as%2520First-Line%2520Treatment%2520in%2520Patients%2520with%2520Advanced%2520Gastric%2520Cancer%26jtitle%3DJ.%2520Korean%2520Med.%2520Sci.%26date%3D2004%26volume%3D19%26spage%3D369%26epage%3D373%26doi%3D10.3346%2Fjkms.2004.19.3.369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Mckeage, M. J.</span><span> </span><span class="NLM_article-title">Lobaplatin: A New Antitumour Platinum Drug</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span><span class="refDoi"> DOI: 10.1517/13543784.10.1.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1517%2F13543784.10.1.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11116285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpvFel" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2001&pages=119-128&author=M.+J.+Mckeage&title=Lobaplatin%3A+A+New+Antitumour+Platinum+Drug&doi=10.1517%2F13543784.10.1.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Lobaplatin: a new antitumour platinum drug</span></div><div class="casAuthors">McKeage, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-128</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review with 39 refs.  Lobaplatin (D-19466) is a diastereometric mixt. of platinum(II) complexes contg. a 1,2-bis(aminomethyl)cyclobutane stable ligand and lactic acid as the leaving group.  Its antitumor activity results from the formation of DNA-drug adducts, mainly as GG and AG intra-strand cross-links.  Lobaplatin influences the expression of the c-myc gene, which is involved in oncogenesis, apoptosis and cell proliferation.  Lobaplatin has activity in a wide range of preclin. tumor models and appears to overcome tumor resistance to cisplatin and carboplatin in some of these models.  In the body, lobaplatin remains largely intact until removed by glomerular filtration.  Exposure of the body to lobaplatin (AUC) correlates with dose, creatinine clearance and the degree of thrombocytopenia.  Phase I clin. trials of three quite different administration schedules found the same dose-limiting toxicity (thrombocytopenia) and similar max. tolerated doses (60 mg/m2 per 3 - 4 wk).  In Phase II trials, lobaplatin showed activity in patients with a variety of tumor types.  Many of the patients who responded to lobaplatin may also have responded to cisplatin and carboplatin because they had had no prior chemotherapy or had a prolonged remission after earlier treatment.  In conclusion, lobaplatin is a new platinum drug, which overcomes some forms of cisplatin resistance in preclin. tumor models.  Several potential clin. applications remain unexplored, such as its use in relapsed testicular cancer and in combination with other cancer chemotherapeutic agents and ionizing radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzV7y3v0DRdrVg90H21EOLACvtfcHk0lhWPmfH_f2oXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpvFel&md5=2c5090c19117c004efc82a04ad3c90a2</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1517%2F13543784.10.1.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.10.1.119%26sid%3Dliteratum%253Aachs%26aulast%3DMckeage%26aufirst%3DM.%2BJ.%26atitle%3DLobaplatin%253A%2520A%2520New%2520Antitumour%2520Platinum%2520Drug%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2001%26volume%3D10%26spage%3D119%26epage%3D128%26doi%3D10.1517%2F13543784.10.1.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Schumacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Respondek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">J, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitzel-Zerrahn, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegeli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgard, P.</span><span> </span><span class="NLM_article-title">Synthesis and Pharmacological Activity of Cyclobutane-Platinum (II) Complexes</span> <span class="citation_source-journal">Eur. Food Res. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1989&pages=163&author=W.+Schumacherauthor=J.+Respondekauthor=E.+Jauthor=F.+Hitzel-Zerrahnauthor=R.+Voegeliauthor=J.+Pohlauthor=P.+Hilgard&title=Synthesis+and+Pharmacological+Activity+of+Cyclobutane-Platinum+%28II%29+Complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DW.%26aulast%3DRespondek%26aufirst%3DJ.%26aulast%3DJ%26aufirst%3DE.%26aulast%3DHitzel-Zerrahn%26aufirst%3DF.%26aulast%3DVoegeli%26aufirst%3DR.%26aulast%3DPohl%26aufirst%3DJ.%26aulast%3DHilgard%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Activity%2520of%2520Cyclobutane-Platinum%2520%2528II%2529%2520Complexes%26jtitle%3DEur.%2520Food%2520Res.%2520Technol.%26date%3D1989%26volume%3D22%26spage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Voegeli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Respondek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgard, P.</span><span> </span><span class="NLM_article-title">D-19466, a New Cyclobutane-Platinum Complex with Antitumor Activity</span> <span class="citation_source-journal">J. Cancer Res. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">442</span><span class="refDoi"> DOI: 10.1007/BF01612990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF01612990" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1990&pages=439-442&author=R.+Voegeliauthor=W.+Schumacherauthor=J.+Engelauthor=J.+Respondekauthor=P.+Hilgard&title=D-19466%2C+a+New+Cyclobutane-Platinum+Complex+with+Antitumor+Activity&doi=10.1007%2FBF01612990"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2FBF01612990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01612990%26sid%3Dliteratum%253Aachs%26aulast%3DVoegeli%26aufirst%3DR.%26aulast%3DSchumacher%26aufirst%3DW.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRespondek%26aufirst%3DJ.%26aulast%3DHilgard%26aufirst%3DP.%26atitle%3DD-19466%252C%2520a%2520New%2520Cyclobutane-Platinum%2520Complex%2520with%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D1990%26volume%3D116%26spage%3D439%26epage%3D442%26doi%3D10.1007%2FBF01612990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><div class="note"><p class="first last">Adis R&D Profile.</p></div><span> </span><span class="NLM_article-title">Lobaplatin: D 19466</span>.  <span class="citation_source-journal">Drugs R&amp;D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span>.<span class="refDoi"> DOI: 10.2165/00126839-200304060-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2165%2F00126839-200304060-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=14584968" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Adis+R%26D+Profile.+Lobaplatin%3A+D+19466.+Drugs+R%26amp%3BD+2003%2C+4%2C+369%E2%80%93372.+10.2165%2F00126839-200304060-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2165%2F00126839-200304060-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00126839-200304060-00008%26sid%3Dliteratum%253Aachs%26atitle%3DLobaplatin%253A%2520D%252019466%26jtitle%3DDrugs%2520R%2526amp%253BD%26date%3D2003%26volume%3D4%26spage%3D369%26epage%3D372%26doi%3D10.2165%2F00126839-200304060-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Chen, M. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B. H.</span><span> </span><span class="NLM_article-title">The Efficacy and Toxicities of Combined Lobaplatin with Paclitaxel as a First-Line Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma</span> <span class="citation_source-journal">J. Thorac. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1749</span><span class="NLM_x">–</span> <span class="NLM_lpage">1755</span><span class="refDoi"> DOI: 10.3978/j.issn.2072-1439.2015.10.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.3978%2Fj.issn.2072-1439.2015.10.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26623097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC28rgsl2ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=1749-1755&author=M.+Q.+Chenauthor=C.+Chenauthor=H.+J.+Luauthor=B.+H.+Xu&title=The+Efficacy+and+Toxicities+of+Combined+Lobaplatin+with+Paclitaxel+as+a+First-Line+Chemotherapy+for+Advanced+Esophageal+Squamous+Cell+Carcinoma&doi=10.3978%2Fj.issn.2072-1439.2015.10.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma</span></div><div class="casAuthors">Chen Ming-Qiu; Chen Cheng; Lu Hai-Jie; Xu Ben-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1749-55</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">BACKGROUND:  To assess the efficacy and toxicities of combined lobaplatin with paclitaxel (LP) as a first line chemotherapy in esophageal cancer.  METHODS:  The clinical data of 45 patients with esophageal squamous cell carcinoma treated initially with lobaplatin-paclitaxel chemotherapy were collected and reviewed retrospectively.  The overall response, treatment toxicities and dysphagia relief were analyzed with SPSS software.  RESULTS:  The overall response rate was 42.2%, with 1 patient (2.2%) showing complete remission, 18 patients (40.0%) with partial remission, 19 (42.2%) with stable disease (SD), and 7 (15.6%) with progressive disease, respectively.  The most common hematological toxicity was leucopenia with grade 0, I, II, III and IV in 16 (35.6%), 10 (22.2%), 11 (24.4%), 7 (15.6%), and 1 patient (2.2%), respectively.  Thirty-seven patients (82.2%) experienced grade I-II nausea/vomiting without grade III-IV instances occurring.  Four patients (8.9%) experienced grade I hepatotoxicity.  No nephrotoxicity was observed.  Five in thirteen patients treated with concurrent chemoradiotherapy (CRT) suffered severe radiation pneumonitis.  The dysphagia resolved or improved in 32 patients (71%).  CONCLUSIONS:  Lobaplatin-paclitaxel showed a significant antitumor effect to squamous esophageal cancer with manageable toxicities.  Limitation of the surveillance time and the retrospective nature, the effect that based on these data formal prospective trials appear warranted and are needed prior to routine first line use of this regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhohMhvcF2mEBuFdjgVNKSfW6udTcc2eaW3oMPZgKKf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgsl2ltg%253D%253D&md5=ae3922ee56135bd4c61ce4b0283cd8f1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2072-1439.2015.10.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2072-1439.2015.10.23%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%2BQ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%2BJ.%26aulast%3DXu%26aufirst%3DB.%2BH.%26atitle%3DThe%2520Efficacy%2520and%2520Toxicities%2520of%2520Combined%2520Lobaplatin%2520with%2520Paclitaxel%2520as%2520a%2520First-Line%2520Chemotherapy%2520for%2520Advanced%2520Esophageal%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2015%26volume%3D7%26spage%3D1749%26epage%3D1755%26doi%3D10.3978%2Fj.issn.2072-1439.2015.10.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Tanaka, K.; Kunimatsu, T.; Shimakura, J.; Hanada, M.</span><span> </span><span class="NLM_article-title">Development of Miriplatin, a Novel Antitumor Platinum for Hepatocellular Carcinoma</span>.  <span class="citation_source-journal">Sumitomo Kagaku R&D Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">I1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=I1-12&author=K.+Tanaka&author=T.+Kunimatsu&author=J.+Shimakura&author=M.+Hanada&title=Development+of+Miriplatin%2C+a+Novel+Antitumor+Platinum+for+Hepatocellular+Carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520Miriplatin%252C%2520a%2520Novel%2520Antitumor%2520Platinum%2520for%2520Hepatocellular%2520Carcinoma%26jtitle%3DSumitomo%2520Kagaku%2520R%2526D%2520Rep.%26date%3D2011%26spage%3DI1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Horikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, Y.</span><span> </span><span class="NLM_article-title">Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review</span> <span class="citation_source-journal">AJR, Am. J. Roentgenol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">205</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">773</span><span class="refDoi"> DOI: 10.2214/AJR.15.14825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2214%2FAJR.15.14825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26397324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC283ltFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2015&pages=764-773&author=M.+Horikawaauthor=S.+Miyayamaauthor=T.+Irieauthor=T.+Kajiauthor=Y.+Arai&title=Development+of+Conventional+Transarterial+Chemoembolization+for+Hepatocellular+Carcinomas+in+Japan%3A+Historical%2C+Strategic%2C+and+Technical+Review&doi=10.2214%2FAJR.15.14825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review</span></div><div class="casAuthors">Horikawa Masahiro; Miyayama Shiro; Irie Toshiyuki; Kaji Tatsumi; Arai Yasuaki</div><div class="citationInfo"><span class="NLM_cas:title">AJR. American journal of roentgenology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">764-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This article reviews the development of transarterial chemoembolization (TACE) in Japan, particularly ethiodized oil-based conventional TACE, from historical, strategic, and technical points of view.  We also present the current status of standardized conventional TACE.  CONCLUSION:  Conventional TACE has been developed toward a more-selective and hemodynamic-conscious method, along with technical innovation and knowledge accumulation.  Standardization of this method is necessary for further scientific evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyjP-EcgsE8ny-c-E1v-fmfW6udTcc2eajMNi5TwXJr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ltFyntg%253D%253D&md5=a4ce91986596a8c7fca97385491852a0</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2214%2FAJR.15.14825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2214%252FAJR.15.14825%26sid%3Dliteratum%253Aachs%26aulast%3DHorikawa%26aufirst%3DM.%26aulast%3DMiyayama%26aufirst%3DS.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DKaji%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520Conventional%2520Transarterial%2520Chemoembolization%2520for%2520Hepatocellular%2520Carcinomas%2520in%2520Japan%253A%2520Historical%252C%2520Strategic%252C%2520and%2520Technical%2520Review%26jtitle%3DAJR%252C%2520Am.%2520J.%2520Roentgenol.%26date%3D2015%26volume%3D205%26spage%3D764%26epage%3D773%26doi%3D10.2214%2FAJR.15.14825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Nishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osaki, Y.</span><span> </span><span class="NLM_article-title">Transcatheter Arterial Embolic Therapies for Hepatocellular Carcinoma: A Literature Review</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">6877</span><span class="NLM_x">–</span> <span class="NLM_lpage">6886</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25503113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=6877-6886&author=H.+Nishikawaauthor=R.+Kitaauthor=T.+Kimuraauthor=Y.+Osaki&title=Transcatheter+Arterial+Embolic+Therapies+for+Hepatocellular+Carcinoma%3A+A+Literature+Review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review</span></div><div class="casAuthors">Nishikawa, Hiroki; Kita, Ryuichi; Kimura, Toru; Osaki, Yukio</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6877-6886</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Palliative therapies for hepatocellular carcinoma (HCC) include transcatheter arterial embolic therapies, radiation therapy and systemic chemotherapies such as sorafenib.  Conventional transcatheter arterial chemoembolization (cTACE) is the golden std. for the treatment of intermediate-stage HCC, and involves the administration of chemotherapuetic drugs, with or without lipiodol, by means of a catheter directly to the feeding artery of the targeted tumor followed by administration of embolic agents, while the concept of drug-eluting bead TACE (DEB-TACE) builds on the rationale for cTACE.  DEB-TACE has been demonstrated to substantially improve the pharmacokinetic profile of TACE, providing levels of consistency and repeatability in patients that are not available with cTACE.  On the other hand, the technique of radioembolization therapy for HCC involves the delivery of high-dose radiation via the hepatic artery.  In the present review, we summarize the current status of these transcatheter arterial embolic therapies in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLlmlisB-Fv7Vg90H21EOLACvtfcHk0lgTZUCJFsy8GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCjs70%253D&md5=d0b9d6b217c9cea791530ba0df3e24c8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishikawa%26aufirst%3DH.%26aulast%3DKita%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DOsaki%26aufirst%3DY.%26atitle%3DTranscatheter%2520Arterial%2520Embolic%2520Therapies%2520for%2520Hepatocellular%2520Carcinoma%253A%2520A%2520Literature%2520Review%26jtitle%3DAnticancer%2520Res.%26date%3D2014%26volume%3D34%26spage%3D6877%26epage%3D6886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Maeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span> </span><span class="NLM_article-title">Liposoluble Platinum (II) Complexes with Antitumor Activity</span> <span class="citation_source-journal">Jpn. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">525</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3015851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL28Xlt1KrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1986&pages=523-525&author=M.+Maedaauthor=N.+A.+Uchidaauthor=T.+Sasaki&title=Liposoluble+Platinum+%28II%29+Complexes+with+Antitumor+Activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Liposoluble platinum(II) complexes with antitumor activity</span></div><div class="casAuthors">Maeda, Mitsuaki; Uchida, Noriko A.; Sasaki, Takuma</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">523-5</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    </div><div class="casAbstract">Lipid-sol. bis(carboxylato)-cyclohexane-1,2-diammineplatinum(II) and bis(carboxylato)-cis-diammineplatinum(II) complexes were synthesized and tested for antitumor activity against leukemia L1210 cells in mice.  The former complexes had excellent antitumor activity without any toxicity to the host at the therapeutic dose when used with lipiodol as a carrier solvent.  The latter complexes had neither antitumor activity nor toxicity in vivo.  The former complexes were gradually released from lipiodol to saline in vitro; the latter were not.  The activity depended on the chain length of the carboxylato residue and also on the mol. shape of the ligand part of the complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6FW8vhmU3l7Vg90H21EOLACvtfcHk0lgTZUCJFsy8GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xlt1KrsL8%253D&md5=975e93841fd751ddbd565379991c9efd</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DM.%26aulast%3DUchida%26aufirst%3DN.%2BA.%26aulast%3DSasaki%26aufirst%3DT.%26atitle%3DLiposoluble%2520Platinum%2520%2528II%2529%2520Complexes%2520with%2520Antitumor%2520Activity%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D1986%26volume%3D77%26spage%3D523%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Monneret, C.</span><span> </span><span class="NLM_article-title">Platinum Anticancer Drugs. From Serendipity to Rational Design</span> <span class="citation_source-journal">Ann. Pharm. Fr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/j.pharma.2011.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.pharma.2011.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=22115131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFertb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2011&pages=286-295&author=C.+Monneret&title=Platinum+Anticancer+Drugs.+From+Serendipity+to+Rational+Design&doi=10.1016%2Fj.pharma.2011.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum anticancer drugs. From serendipity to rational design</span></div><div class="casAuthors">Monneret, C.</div><div class="citationInfo"><span class="NLM_cas:title">Annales Pharmaceutiques Francaises</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">286-295</span>CODEN:
                <span class="NLM_cas:coden">APFRAD</span>;
        ISSN:<span class="NLM_cas:issn">0003-4509</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The discovery of cis-platin was serendipitous.  In 1965, Rosenberg was looking into the effects of an elec. field on the growth of Escherichia coli bacteria.  He noticed that bacteria ceased to divide when placed in an elec. field but what Rosenberg also obsd. was a 300-fold increase in the size of the bacteria.  He attributed this to the fact that somehow the platinum-conducting plates were inducing cell growth but inhibiting cell division.  It was later deduced that the platinum species responsible for this was cis-platin.  Rosenberg hypothesized that if cis-platin could inhibit bacterial cell division it could also stop tumor cell growth.  This conjecture has proven correct and has led to the introduction of cis-platin in cancer therapy.  Indeed, in 1978, six years after clin. trials conducted by the NCI and Bristol-Myers-Squibb, the U.S.  Food and Drug Administration (FDA) approved cis-platin under the name of Platinol for treating patients with metastatic testicular or ovarian cancer in combination with other drugs but also for treating bladder cancer.  Bristol-Myers Squibb also licensed carboplatin, a second-generation platinum drug with fewer side effects, in 1979.  Carboplatin entered the U.S. market as Paraplatin in 1989 for initial treatment of advanced ovarian cancer in established combination with other approved chemotherapeutic agents.  Numerous platin derivs. have been further developed with more or less success and the third deriv. to be approved in 1994 was oxaliplatin under the name of Eloxatin.  It was the first platin-based drug to be active against metastatic colorectal cancer in combination with fluorouracil and folinic acid.  The two others platin-based drugs to be approved were nedaplatin (Aqupla) in Japan and lobaplatin in China, resp.  More recently, a strategy to overcome resistance due to interaction with thiol-contg. mols. led to the synthesis of picoplatin in which one of the amines linked to Pt was replaced by a bulky Me substituted pyridine allowing the drug more time to reach its target, DNA.  On the other hand, efforts which were made to find new orally administered analog led to satraplatin bearing to axial acetate groups.  Both drugs are still under clin. trials.  An alternatively route to the discovery of new derivs. turns to the development of improved delivery strategies such as liposomes and polymers.  Liposomal cis-platin or lipoplatin in under a phase III randomized clin. trial for patients suffering from small cell lung cancer whereas polymer-based drug, Prolindac is currently under investigation for pretreated ovarian cancers in up to eight European centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRuS3noNGs2LVg90H21EOLACvtfcHk0ljju6Xuw42Viw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFertb%252FI&md5=510a97a52d39a9a82d176b5acf6b9d6b</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.pharma.2011.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharma.2011.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DMonneret%26aufirst%3DC.%26atitle%3DPlatinum%2520Anticancer%2520Drugs.%2520From%2520Serendipity%2520to%2520Rational%2520Design%26jtitle%3DAnn.%2520Pharm.%2520Fr.%26date%3D2011%26volume%3D69%26spage%3D286%26epage%3D295%26doi%3D10.1016%2Fj.pharma.2011.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Lee, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuh, H. J.</span><span> </span><span class="NLM_article-title">Anti-Tumor Activity of Heptaplatin in Combination with 5-Fluorouracil or Paclitaxel against Human Head and Neck Cancer Cells in Vitro</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span><span class="refDoi"> DOI: 10.1097/01.cad.0000205033.08838.c7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1097%2F01.cad.0000205033.08838.c7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=377-384&author=J.+W.+Leeauthor=J.+K.+Parkauthor=S.+H.+Leeauthor=S.+Y.+Kimauthor=Y.+B.+Choauthor=H.+J.+Kuh&title=Anti-Tumor+Activity+of+Heptaplatin+in+Combination+with+5-Fluorouracil+or+Paclitaxel+against+Human+Head+and+Neck+Cancer+Cells+in+Vitro&doi=10.1097%2F01.cad.0000205033.08838.c7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1097%2F01.cad.0000205033.08838.c7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cad.0000205033.08838.c7%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DCho%26aufirst%3DY.%2BB.%26aulast%3DKuh%26aufirst%3DH.%2BJ.%26atitle%3DAnti-Tumor%2520Activity%2520of%2520Heptaplatin%2520in%2520Combination%2520with%25205-Fluorouracil%2520or%2520Paclitaxel%2520against%2520Human%2520Head%2520and%2520Neck%2520Cancer%2520Cells%2520in%2520Vitro%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2006%26volume%3D17%26spage%3D377%26epage%3D384%26doi%3D10.1097%2F01.cad.0000205033.08838.c7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Garattini, S.</span><span> </span><span class="NLM_article-title">Are Me-Too Drugs Justified?</span> <span class="citation_source-journal">J. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=9442441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK1c7gsVGhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1997&pages=283-294&author=S.+Garattini&title=Are+Me-Too+Drugs+Justified%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Are me-too drugs justified?</span></div><div class="casAuthors">Garattini S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nephrology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">283-94</span>
        ISSN:<span class="NLM_cas:issn">1121-8428</span>.
    </div><div class="casAbstract">The successful progress of pharmacology in the treatment of several diseases has led to the development of a powerful pharmaceutical industry with an estimated market of over $250 billion.  It is therefore understandable that as drug development and marketing has become a major business it has adopted the rules common to other commercial fields.  This is a potentially dangerous trend because it undermines what should be the main goal of drug development, i.e. to make active medicinal agents available to the patient with precise and reliable information, at the lowest possible cost, particularly when a national health system has to supply the drugs to patients who have too low an income to pay for them.  The huge drug market has also set in motion a competition among pharmaceutical firms.  This has meant that as soon as a prototype drug becomes available several other similarly active compounds immediately follow.  These followers are usually called "me-too drugs".  Me-too drugs can be broadly defined as chemically related to the prototype, or other chemical compounds which have an identical mechanism of action.  This increasing marketing of me-too drugs has been questioned, so pharmaceutical firms are justifying the development of not-so-innovative drugs.  The most common arguments can be summarized as follows: me-too drugs offer an improvement on the efficacy of the prototype; they show a different profile of adverse effects; they are effective in patients resistant to the prototype; they improve compliance in long-term treatment; they are less expensive than the prototype.  It is the purpose of this paper to review the evidence substantiating these statements, giving some figures regarding me-too drugs and presenting a few examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9ikU0p6ekImLFM_lbR1VmfW6udTcc2eYzD86zKrft2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7gsVGhsQ%253D%253D&md5=f52c1878d906d6c798931083a5cb8a07</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarattini%26aufirst%3DS.%26atitle%3DAre%2520Me-Too%2520Drugs%2520Justified%253F%26jtitle%3DJ.%2520Nephrol.%26date%3D1997%26volume%3D10%26spage%3D283%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Kennedy, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzharris, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colls, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, C. H.</span><span> </span><span class="NLM_article-title">Carboplatin Is Ototoxic</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1007/BF02897206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF02897206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=2192812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK3c3ptFGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1990&pages=232-234&author=I.+C.+Kennedyauthor=B.+M.+Fitzharrisauthor=B.+M.+Collsauthor=C.+H.+Atkinson&title=Carboplatin+Is+Ototoxic&doi=10.1007%2FBF02897206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Carboplatin is ototoxic</span></div><div class="casAuthors">Kennedy I C; Fitzharris B M; Colls B M; Atkinson C H</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-4</span>
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">For assessment of the ototoxic potential of carboplatin [cis-diammine-1,1-cyclobutane dicarboxylate platinum(II); CBDCA], pure-tone audiograms were evaluated in 27 patients receiving a total of 119 doses of carboplatin in the range of 300-400 mg/m2.  Pure-tone audiometry (PTA) was done immediately prior to and 4 weeks after the administration of 80 doses (67%).  Defining carboplatin ototoxicity as an increase of greater than or equal to 30 dB in auditory thresholds that was unexplainable by other causes, we identified 5 examples (19%).  Hearing loss tended to be cumulative with increasing dose and was always maximal at 8,000 Hz.  Two patients had an increase in auditory thresholds at 1,000 Hz, but this only amounted to 10 dB in each case.  Patients developing ototoxicity tended to be older.  Sex, the pre-treatment creatinine clearance, the pretreatment audiogram, the number of doses, and the cumulative dose did not emerge as being reliable predictors of subsequent ototoxicity.  We conclude that although carboplatin is ototoxic, clinically significant deafness does not occur with conventional dosing and routine audiometric monitoring is therefore unnecessary.  However, we suggest that caution should be exercised when carboplatin is given either at higher doses or for longer periods when there is concomitant use of other potentially ototoxic agents or when there is significant pre-existing auditory impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3L2hDNQQnD-dfST00W0BcfW6udTcc2eYzD86zKrft2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c3ptFGksg%253D%253D&md5=baec917338edde5b5799a7f52584b2eb</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2FBF02897206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02897206%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DI.%2BC.%26aulast%3DFitzharris%26aufirst%3DB.%2BM.%26aulast%3DColls%26aufirst%3DB.%2BM.%26aulast%3DAtkinson%26aufirst%3DC.%2BH.%26atitle%3DCarboplatin%2520Is%2520Ototoxic%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1990%26volume%3D26%26spage%3D232%26epage%3D234%26doi%3D10.1007%2FBF02897206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Chitapanarux, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorvidhaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamnerdsupaphon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumitsawan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tharavichitkul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukthomya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J.</span><span> </span><span class="NLM_article-title">Chemoradiation Comparing Cisplatin Versus Carboplatin in Locally Advanced Nasopharyngeal Cancer: Randomised, Non-Inferiority, Open Trial</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">–</span> <span class="NLM_lpage">1406</span><span class="refDoi"> DOI: 10.1016/j.ejca.2007.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.ejca.2007.03.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=1399-1406&author=I.+Chitapanaruxauthor=V.+Lorvidhayaauthor=P.+Kamnerdsupaphonauthor=Y.+Sumitsawanauthor=E.+Tharavichitkulauthor=V.+Sukthomyaauthor=J.+Ford&title=Chemoradiation+Comparing+Cisplatin+Versus+Carboplatin+in+Locally+Advanced+Nasopharyngeal+Cancer%3A+Randomised%2C+Non-Inferiority%2C+Open+Trial&doi=10.1016%2Fj.ejca.2007.03.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2007.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2007.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DChitapanarux%26aufirst%3DI.%26aulast%3DLorvidhaya%26aufirst%3DV.%26aulast%3DKamnerdsupaphon%26aufirst%3DP.%26aulast%3DSumitsawan%26aufirst%3DY.%26aulast%3DTharavichitkul%26aufirst%3DE.%26aulast%3DSukthomya%26aufirst%3DV.%26aulast%3DFord%26aufirst%3DJ.%26atitle%3DChemoradiation%2520Comparing%2520Cisplatin%2520Versus%2520Carboplatin%2520in%2520Locally%2520Advanced%2520Nasopharyngeal%2520Cancer%253A%2520Randomised%252C%2520Non-Inferiority%252C%2520Open%2520Trial%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D1399%26epage%3D1406%26doi%3D10.1016%2Fj.ejca.2007.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Minami, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sha, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schacht, J.</span><span> </span><span class="NLM_article-title">Antioxidant Protection in a New Animal Model of Cisplatin-Induced Ototoxicity</span> <span class="citation_source-journal">Hear. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">198</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1016/j.heares.2004.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.heares.2004.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=15567610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVSktrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2004&pages=137-143&author=S.+B.+Minamiauthor=S.+H.+Shaauthor=J.+Schacht&title=Antioxidant+Protection+in+a+New+Animal+Model+of+Cisplatin-Induced+Ototoxicity&doi=10.1016%2Fj.heares.2004.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Antioxidant protection in a new animal model of cisplatin-induced ototoxicity</span></div><div class="casAuthors">Minami, Shujiro B.; Sha, Su-Hua; Schacht, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">137-143</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mortality is a major complication in animal models of cisplatin-induced hearing loss due to the systemic toxicity of the drug.  Here we report on a novel two-cycle treatment in rats, each cycle consisting of four days of cisplatin injections (1 mg/kg, i.p., twice daily) sepd. by 10 days of rest.  This regimen, similar to clin. courses of cancer chemotherapy, produced significant hearing loss without mortality.  Auditory brain stem evoked responses were unchanged after the first cycle but were elevated by 40-50 dB at 16 and 20 kHz after the second.  Loss of outer hair cells occurred after the second cycle, predominantly in the base of the cochlea.  Total cochlear antioxidants declined progressively during drug treatment and were reduced to 60% of control values after the second cisplatin cycle.  Co-administration of salicylate (100 mg/kg, s.c., twice daily) during both cycles or during the second cycle restored antioxidant levels and reduced cisplatin-induced threshold shifts.  This model of cisplatin ototoxicity without mortality eliminates potentially confounding factors that may det. the survival of a special cohort of animals.  The results also support the notion that reactive oxygen species are involved in cisplatin ototoxicity and show the potential usefulness of antioxidant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-9hzG3oTsP7Vg90H21EOLACvtfcHk0lgRCwD0NDvHLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVSktrjE&md5=879b7ce0345fa5a1de8d175d086373fd</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.heares.2004.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.heares.2004.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DMinami%26aufirst%3DS.%2BB.%26aulast%3DSha%26aufirst%3DS.%2BH.%26aulast%3DSchacht%26aufirst%3DJ.%26atitle%3DAntioxidant%2520Protection%2520in%2520a%2520New%2520Animal%2520Model%2520of%2520Cisplatin-Induced%2520Ototoxicity%26jtitle%3DHear.%2520Res.%26date%3D2004%26volume%3D198%26spage%3D137%26epage%3D143%26doi%3D10.1016%2Fj.heares.2004.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Jacobs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccully, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balis, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span> </span><span class="NLM_article-title">Extracellular Fluid Concentrations of Cisplatin, Carboplatin, and Oxaliplatin in Brain, Muscle, and Blood Measured Using Microdialysis in Nonhuman Primates</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1007/s00280-009-1085-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2Fs00280-009-1085-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=19662415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Gmtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=817-824&author=S.+Jacobsauthor=C.+L.+Mccullyauthor=R.+F.+Murphyauthor=J.+Bacherauthor=F.+M.+Balisauthor=E.+Fox&title=Extracellular+Fluid+Concentrations+of+Cisplatin%2C+Carboplatin%2C+and+Oxaliplatin+in+Brain%2C+Muscle%2C+and+Blood+Measured+Using+Microdialysis+in+Nonhuman+Primates&doi=10.1007%2Fs00280-009-1085-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates</span></div><div class="casAuthors">Jacobs, Shana; McCully, Cynthia L.; Murphy, Robert F.; Bacher, John; Balis, Frank M.; Fox, Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">817-824</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cisplatin, carboplatin, and oxaliplatin are chem. reactive anticancer drugs with modest activity in brain tumors.  Previously, we have demonstrated that drug exposure in cerebrospinal fluid (CSF) for these platinum analogs is <5% of the plasma ultrafiltrate (UF) drug exposure in nonhuman primates.  Microdialysis is a minimally invasive in vivo method for sampling small mols. in the blood and tissue extracellular fluid (ECF).  The purpose of this study was to est. the penetration of platinum analogs into the brain ECF.  We measured free concns. of cisplatin, carboplatin, and oxaliplatin in ECF of brain, muscle, and blood of nonhuman primates using microdialysis and compared ECF platinum concns. in blood and brain to plasma UF and CSF concns. obtained using conventional sampling methods.  For all three platinum analogs, AUC0-4h for microdialysis sampling from the vein was similar to std. plasma UF sampling.  The median AUC0-4h ratio for vein to plasma UF was 1.1 (range, 0.9-1.4).  The platinum analogs had limited distribution (<5%) to the CSF and brain ECF.  CSF penetration predicts for the limited penetration of the platinum analogs into brain ECF, but concordance between CSF and brain ECF measurements was poor.  CSF oxaliplatin concns. (AUC0-4h, 0.4-0.9 μM h) were substantially lower than brain ECF concns. (AUC0-4h, 2.0-8.6 μM h).  The penetration of platinum analogs into CSF and brain is limited.  The differences in the CNS penetrations among the three platinum analogs are not clin. significant.  For cisplatin and carboplatin, CSF penetration appears to be a surrogate for brain extracellular free drug exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosO_rKJl_zN7Vg90H21EOLACvtfcHk0lh-bL5psZvPcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Gmtb4%253D&md5=4838b37481df0020afbdf5021486d407</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-1085-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-1085-7%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DS.%26aulast%3DMccully%26aufirst%3DC.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BF.%26aulast%3DBacher%26aufirst%3DJ.%26aulast%3DBalis%26aufirst%3DF.%2BM.%26aulast%3DFox%26aufirst%3DE.%26atitle%3DExtracellular%2520Fluid%2520Concentrations%2520of%2520Cisplatin%252C%2520Carboplatin%252C%2520and%2520Oxaliplatin%2520in%2520Brain%252C%2520Muscle%252C%2520and%2520Blood%2520Measured%2520Using%2520Microdialysis%2520in%2520Nonhuman%2520Primates%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2010%26volume%3D65%26spage%3D817%26epage%3D824%26doi%3D10.1007%2Fs00280-009-1085-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span>Phosplatin therapeutics. <a href="http://phosplatin.com" class="extLink">http://phosplatin.com</a> (accessed July 30,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phosplatin+therapeutics.+http%3A%2F%2Fphosplatin.com+%28accessed+July+30%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span>Phosplatin therapeutics. A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered Pt-112 Injection in Subjects with Advanced Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT02266745" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02266745</a> (accessed August 1,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phosplatin+therapeutics.+A+Phase+1%2C+Open-Label%2C+Dose-Escalation+Study+Evaluating+the+Safety%2C+Pharmacokinetics%2C+and+Clinical+Effects+of+Intravenously+Administered+Pt-112+Injection+in+Subjects+with+Advanced+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02266745+%28accessed+August+1%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Mishur, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, R. N.</span><span> </span><span class="NLM_article-title">Synthesis, X-Ray Crystallographic, and NMR Characterizations of Platinum(II) and Platinum(IV) Pyrophosphato Complexes</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">7972</span><span class="NLM_x">–</span> <span class="NLM_lpage">7982</span><span class="refDoi"> DOI: 10.1021/ic800237a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic800237a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=7972-7982&author=R.+J.+Mishurauthor=C.+Zhengauthor=T.+M.+Gilbertauthor=R.+N.+Bose&title=Synthesis%2C+X-Ray+Crystallographic%2C+and+NMR+Characterizations+of+Platinum%28II%29+and+Platinum%28IV%29+Pyrophosphato+Complexes&doi=10.1021%2Fic800237a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fic800237a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic800237a%26sid%3Dliteratum%253Aachs%26aulast%3DMishur%26aufirst%3DR.%2BJ.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DT.%2BM.%26aulast%3DBose%26aufirst%3DR.%2BN.%26atitle%3DSynthesis%252C%2520X-Ray%2520Crystallographic%252C%2520and%2520NMR%2520Characterizations%2520of%2520Platinum%2528II%2529%2520and%2520Platinum%2528IV%2529%2520Pyrophosphato%2520Complexes%26jtitle%3DInorg.%2520Chem.%26date%3D2008%26volume%3D47%26spage%3D7972%26epage%3D7982%26doi%3D10.1021%2Fic800237a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Bose, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishur, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayburn, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstetter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salley, T.</span><span> </span><span class="NLM_article-title">Non-DNA-Binding Platinum Anticancer Agents: Cytotoxic Activities of Platinum–Phosphato Complexes Towards Human Ovarian Cancer Cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">18314</span><span class="NLM_x">–</span> <span class="NLM_lpage">18319</span><span class="refDoi"> DOI: 10.1073/pnas.0803094105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1073%2Fpnas.0803094105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=18314-18319&author=R.+N.+Boseauthor=L.+Maurmannauthor=R.+J.+Mishurauthor=L.+Yasuiauthor=S.+Guptaauthor=W.+S.+Grayburnauthor=H.+Hofstetterauthor=T.+Salley&title=Non-DNA-Binding+Platinum+Anticancer+Agents%3A+Cytotoxic+Activities+of+Platinum%E2%80%93Phosphato+Complexes+Towards+Human+Ovarian+Cancer+Cells&doi=10.1073%2Fpnas.0803094105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803094105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803094105%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DR.%2BN.%26aulast%3DMaurmann%26aufirst%3DL.%26aulast%3DMishur%26aufirst%3DR.%2BJ.%26aulast%3DYasui%26aufirst%3DL.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DGrayburn%26aufirst%3DW.%2BS.%26aulast%3DHofstetter%26aufirst%3DH.%26aulast%3DSalley%26aufirst%3DT.%26atitle%3DNon-DNA-Binding%2520Platinum%2520Anticancer%2520Agents%253A%2520Cytotoxic%2520Activities%2520of%2520Platinum%25E2%2580%2593Phosphato%2520Complexes%2520Towards%2520Human%2520Ovarian%2520Cancer%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D18314%26epage%3D18319%26doi%3D10.1073%2Fpnas.0803094105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Bose, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belkacemi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majmudar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezvareh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nislow, C.</span><span> </span><span class="NLM_article-title">Absence of Activation of DNA Repair Genes and Excellent Efficacy of Phosphaplatins against Human Ovarian Cancers: Implications to Treat Resistant Cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8387</span><span class="NLM_x">–</span> <span class="NLM_lpage">8401</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00732</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00732" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8387-8401&author=R.+N.+Boseauthor=S.+Moghaddasauthor=L.+Belkacemiauthor=S.+Tripathiauthor=N.+R.+Adamsauthor=P.+Majmudarauthor=K.+Mccallauthor=H.+Dezvarehauthor=C.+Nislow&title=Absence+of+Activation+of+DNA+Repair+Genes+and+Excellent+Efficacy+of+Phosphaplatins+against+Human+Ovarian+Cancers%3A+Implications+to+Treat+Resistant+Cancers&doi=10.1021%2Facs.jmedchem.5b00732"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00732%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DR.%2BN.%26aulast%3DMoghaddas%26aufirst%3DS.%26aulast%3DBelkacemi%26aufirst%3DL.%26aulast%3DTripathi%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DN.%2BR.%26aulast%3DMajmudar%26aufirst%3DP.%26aulast%3DMccall%26aufirst%3DK.%26aulast%3DDezvareh%26aufirst%3DH.%26aulast%3DNislow%26aufirst%3DC.%26atitle%3DAbsence%2520of%2520Activation%2520of%2520DNA%2520Repair%2520Genes%2520and%2520Excellent%2520Efficacy%2520of%2520Phosphaplatins%2520against%2520Human%2520Ovarian%2520Cancers%253A%2520Implications%2520to%2520Treat%2520Resistant%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8387%26epage%3D8401%26doi%3D10.1021%2Facs.jmedchem.5b00732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Moghaddas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majmudar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezvareh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soans, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, R. N.</span><span> </span><span class="NLM_article-title">Phosphaplatins, Next Generation Platinum Antitumor Agents: A Paradigm Shift in Designing and Defining Molecular Targets</span> <span class="citation_source-journal">Inorg. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">393</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1016/j.ica.2012.05.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.ica.2012.05.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aqtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=2012&pages=173-181&author=S.+Moghaddasauthor=P.+Majmudarauthor=R.+Marinauthor=H.+Dezvarehauthor=C.+Qiauthor=E.+Soansauthor=R.+N.+Bose&title=Phosphaplatins%2C+Next+Generation+Platinum+Antitumor+Agents%3A+A+Paradigm+Shift+in+Designing+and+Defining+Molecular+Targets&doi=10.1016%2Fj.ica.2012.05.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphaplatins, next generation platinum antitumor agents: A paradigm shift in designing and defining molecular targets</span></div><div class="casAuthors">Moghaddas, Shadi; Majmudar, Pooja; Marin, Roberto; Dezvareh, Homa; Qi, Chunyan; Soans, Eroica; Bose, Rathindra N.</div><div class="citationInfo"><span class="NLM_cas:title">Inorganica Chimica Acta</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173-181</span>CODEN:
                <span class="NLM_cas:coden">ICHAA3</span>;
        ISSN:<span class="NLM_cas:issn">0020-1693</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Platinum(II)- and platinum(IV)-pyrophosphato-complexes (phosphaplatins) show excellent antitumor properties against a variety of human ovarian cancers, including cisplatin- and carboplatin-sensitive and resistant human cancers.  To identify the lead compd. of this class of non-DNA binding antitumor agents, stereoisomers of cis- and trans-1,2-cyclohexane-diamine(pyrophosphato)platinum(II) and of cis- and trans-1,2-cyclohexane-trans-dihydroxo-diamine(pyrophosphato)platinum(IV) were synthesized, and their in vitro efficacies were evaluated in a variety of human ovarian cancer cells including cisplatin- and carboplatin-resistant cancer cells.  Some of these compds. exhibited IC50 values as low as 0.40 μM, the lowest ever obsd. for any platinum anticancer drugs under identical conditions.  More importantly, these compds. are highly active against cisplatin- and carboplatin-sensitive and resistant cancers; examples of these cancer cells include cisplatin-sensitive A2780, acquired cisplatin- and carboplatin-resistant A2780/C30, and inherent cisplatin-resistant OVCAR-10 cells.  In vivo efficacy detd. by using human ovarian xenografts indeed confirmed that phosphaplatins are quite effective in treating ovarian cancers.  The superiority of phosphaplatins was obsd. in increased life span and tumor regression.  These non-DNA binding compds. exhibit cytotoxicity in ovarian cancers primarily through apoptosis via cell cycle arrest both at S and G2 phases largely in a dose independent manner.  Platinum(II) compds. showed reduced protein binding compared to either cisplatin or carboplatin.  Furthermore, protein binding by phosphaplatins was largely limited to extracellular and cytosolic compartments.  In vivo expts. revealed that platinum accumulations in kidney of mice were significantly less compared to cisplatin.  The max. tolerated dose was found be >60 mg/kg via i.v. administration.  Furthermore, rats treated with R,R-stereomer of the platinum(II) complex exhibited near normal white blood cell, platelet, and neutrophil counts indicating its non-toxic properties.  Furthermore, the lead compd. also stays in plasma for 24 h giving ample time to reach desired targets.  Taken together, these data indicate that phosphaplatins have the potential to treat resistant ovarian cancers, both acquired and de novo, without exhibiting severe toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWedAHz0XkfrVg90H21EOLACvtfcHk0lgnJKUm_3cbJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aqtrnM&md5=a0963f7bf7dec1630be346c75529a600</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.ica.2012.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ica.2012.05.040%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddas%26aufirst%3DS.%26aulast%3DMajmudar%26aufirst%3DP.%26aulast%3DMarin%26aufirst%3DR.%26aulast%3DDezvareh%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DC.%26aulast%3DSoans%26aufirst%3DE.%26aulast%3DBose%26aufirst%3DR.%2BN.%26atitle%3DPhosphaplatins%252C%2520Next%2520Generation%2520Platinum%2520Antitumor%2520Agents%253A%2520A%2520Paradigm%2520Shift%2520in%2520Designing%2520and%2520Defining%2520Molecular%2520Targets%26jtitle%3DInorg.%2520Chim.%2520Acta%26date%3D2012%26volume%3D393%26spage%3D173%26epage%3D181%26doi%3D10.1016%2Fj.ica.2012.05.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span>Businesswire. Phosplatin Therapeutics Announces the Execution of Regional Licensing Agreement for Its Novel Therapeutic Agent in Oncology, Pt-112. <a href="http://www.businesswire.com/news/home/20150818005165/en/Phosplatin-Therapeutics-Announces-Execution-Regional-Licensing-Agreement" class="extLink">http://www.businesswire.com/news/home/20150818005165/en/Phosplatin-Therapeutics-Announces-Execution-Regional-Licensing-Agreement</a> (accessed July 30,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Businesswire.+Phosplatin+Therapeutics+Announces+the+Execution+of+Regional+Licensing+Agreement+for+Its+Novel+Therapeutic+Agent+in+Oncology%2C+Pt-112.+http%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20150818005165%2Fen%2FPhosplatin-Therapeutics-Announces-Execution-Regional-Licensing-Agreement+%28accessed+July+30%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span>Placon Therapeutics. Placon Therapeutics Announces Company Launch and Fda Acceptance of IND for Novel Platinum Candidate BTP-114. <a href="http://www.placontx.com/wp-content/uploads/2016/03/FDA-Acceptance-of-IND-for-Novel-Platinum-Candidate-BTP-114_032316.pdf" class="extLink">http://www.placontx.com/wp-content/uploads/2016/03/FDA-Acceptance-of-IND-for-Novel-Platinum-Candidate-BTP-114_032316.pdf</a> (accessed July 29,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Placon+Therapeutics.+Placon+Therapeutics+Announces+Company+Launch+and+Fda+Acceptance+of+IND+for+Novel+Platinum+Candidate+BTP-114.+http%3A%2F%2Fwww.placontx.com%2Fwp-content%2Fuploads%2F2016%2F03%2FFDA-Acceptance-of-IND-for-Novel-Platinum-Candidate-BTP-114_032316.pdf+%28accessed+July+29%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span>Placon Therapeutics. <a href="http://www.placontx.com/" class="extLink">http://www.placontx.com/</a> (accessed July 30,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Placon+Therapeutics.+http%3A%2F%2Fwww.placontx.com%2F+%28accessed+July+30%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span>Thepharmaletter. Placon Therapeutics Spun out as Independent Company. <a href="http://www.thepharmaletter.com/article/placon-therapeutics-spun-out-as-independent-company" class="extLink">http://www.thepharmaletter.com/article/placon-therapeutics-spun-out-as-independent-company</a> (accessed July 29,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Thepharmaletter.+Placon+Therapeutics+Spun+out+as+Independent+Company.+http%3A%2F%2Fwww.thepharmaletter.com%2Farticle%2Fplacon-therapeutics-spun-out-as-independent-company+%28accessed+July+29%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Moreau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alargova, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meetze, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazinet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krawiec, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriksciukaite, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemelin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limsoo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramstack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockwood, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinde, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auyeung, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilodeau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span> </span><span class="NLM_article-title">Abstract 4484: BTP-114: An Albumin Binding Cisplatin Prodrug with Improved and Sustained Tumor Growth Inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">4484</span><span class="NLM_x">–</span> <span class="NLM_lpage">4484</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-4484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1158%2F1538-7445.AM2015-4484" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4484-4484&author=B.+Moreauauthor=R.+Alargovaauthor=A.+Brockmanauthor=K.+Whalenauthor=J.+Quinnauthor=K.+Meetzeauthor=P.+Bazinetauthor=M.+Dupontauthor=B.+Krawiecauthor=K.+Kriksciukaiteauthor=C.+Lemelinauthor=P.+Limsooauthor=H.+Ollerauthor=M.+Ramstackauthor=D.+Rockwoodauthor=R.+Shindeauthor=S.+Singhauthor=B.+Whiteauthor=T.+Auyeungauthor=C.+Dunbarauthor=M.+Bilodeauauthor=R.+Wooster&title=Abstract+4484%3A+BTP-114%3A+An+Albumin+Binding+Cisplatin+Prodrug+with+Improved+and+Sustained+Tumor+Growth+Inhibition&doi=10.1158%2F1538-7445.AM2015-4484"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-4484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-4484%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DB.%26aulast%3DAlargova%26aufirst%3DR.%26aulast%3DBrockman%26aufirst%3DA.%26aulast%3DWhalen%26aufirst%3DK.%26aulast%3DQuinn%26aufirst%3DJ.%26aulast%3DMeetze%26aufirst%3DK.%26aulast%3DBazinet%26aufirst%3DP.%26aulast%3DDupont%26aufirst%3DM.%26aulast%3DKrawiec%26aufirst%3DB.%26aulast%3DKriksciukaite%26aufirst%3DK.%26aulast%3DLemelin%26aufirst%3DC.%26aulast%3DLimsoo%26aufirst%3DP.%26aulast%3DOller%26aufirst%3DH.%26aulast%3DRamstack%26aufirst%3DM.%26aulast%3DRockwood%26aufirst%3DD.%26aulast%3DShinde%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DB.%26aulast%3DAuyeung%26aufirst%3DT.%26aulast%3DDunbar%26aufirst%3DC.%26aulast%3DBilodeau%26aufirst%3DM.%26aulast%3DWooster%26aufirst%3DR.%26atitle%3DAbstract%25204484%253A%2520BTP-114%253A%2520An%2520Albumin%2520Binding%2520Cisplatin%2520Prodrug%2520with%2520Improved%2520and%2520Sustained%2520Tumor%2520Growth%2520Inhibition%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4484%26epage%3D4484%26doi%3D10.1158%2F1538-7445.AM2015-4484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Smith, M. E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspersen, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morais, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, J. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caddick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chudasama, V.</span><span> </span><span class="NLM_article-title">A Platform for Efficient, Thiol-Stable Conjugation to Albumin’s Native Single Accessible Cysteine</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">7946</span><span class="NLM_x">–</span> <span class="NLM_lpage">7949</span><span class="refDoi"> DOI: 10.1039/C5OB01205H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC5OB01205H" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=7946-7949&author=M.+E.+B.+Smithauthor=M.+B.+Caspersenauthor=E.+Robinsonauthor=M.+Moraisauthor=A.+Maruaniauthor=J.+P.+M.+Nunesauthor=K.+Nichollsauthor=M.+J.+Saxtonauthor=S.+Caddickauthor=J.+R.+Bakerauthor=V.+Chudasama&title=A+Platform+for+Efficient%2C+Thiol-Stable+Conjugation+to+Albumin%E2%80%99s+Native+Single+Accessible+Cysteine&doi=10.1039%2FC5OB01205H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1039%2FC5OB01205H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB01205H%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BE.%2BB.%26aulast%3DCaspersen%26aufirst%3DM.%2BB.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DMorais%26aufirst%3DM.%26aulast%3DMaruani%26aufirst%3DA.%26aulast%3DNunes%26aufirst%3DJ.%2BP.%2BM.%26aulast%3DNicholls%26aufirst%3DK.%26aulast%3DSaxton%26aufirst%3DM.%2BJ.%26aulast%3DCaddick%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DChudasama%26aufirst%3DV.%26atitle%3DA%2520Platform%2520for%2520Efficient%252C%2520Thiol-Stable%2520Conjugation%2520to%2520Albumin%25E2%2580%2599s%2520Native%2520Single%2520Accessible%2520Cysteine%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2015%26volume%3D13%26spage%3D7946%26epage%3D7949%26doi%3D10.1039%2FC5OB01205H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Pichler, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffeter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dömötör, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enyedy, É. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groza, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köllensperger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanksi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowol, C. R.</span><span> </span><span class="NLM_article-title">Maleimide-Functionalised Platinum(IV) Complexes as a Synthetic Platform for Targeted Drug Delivery</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2249</span><span class="NLM_x">–</span> <span class="NLM_lpage">2251</span><span class="refDoi"> DOI: 10.1039/c3cc39258a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2Fc3cc39258a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=23396381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislyisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=2249-2251&author=V.+Pichlerauthor=J.+Mayrauthor=P.+Heffeterauthor=O.+D%C3%B6m%C3%B6t%C3%B6rauthor=%C3%89.+A.+Enyedyauthor=G.+Hermannauthor=D.+Grozaauthor=G.+K%C3%B6llenspergerauthor=M.+Galanksiauthor=W.+Bergerauthor=B.+K.+Kepplerauthor=C.+R.+Kowol&title=Maleimide-Functionalised+Platinum%28IV%29+Complexes+as+a+Synthetic+Platform+for+Targeted+Drug+Delivery&doi=10.1039%2Fc3cc39258a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery</span></div><div class="casAuthors">Pichler, Verena; Mayr, Josef; Heffeter, Petra; Doemoetoer, Orsolya; Enyedy, Eva A.; Hermann, Gerrit; Groza, Diana; Koellensperger, Gunda; Galanksi, Markus; Berger, Walter; Keppler, Bernhard K.; Kowol, Christian R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2249-2251</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Maleimide-functionalized Pt(IV) complexes [(N-N)Y2Pt(OCONHCH2CH2Imd)2] (N-N = trans-1,2-cyclohexanediamine, ethylenediamine; Y = Cl, Y2 = oxalato; Imd = maleimido, succinimido) were prepd. by oxidn. of Pt(II) complexes [(N-N)Y2Pt] and reaction with N-(2-isocyanatoethyl)succinimide or N-(2-isocyanatoethyl)maleimide.  Maleimide-substituted platinum complexes feature highly selective binding properties to thiol groups of thiol-contg. tumor-targeting mols. like human serum albumin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXGfxW_PNYibVg90H21EOLACvtfcHk0lhGOPLJgstlFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislyisbg%253D&md5=fb09e326dd09eed355a7dca7293b85fe</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1039%2Fc3cc39258a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc39258a%26sid%3Dliteratum%253Aachs%26aulast%3DPichler%26aufirst%3DV.%26aulast%3DMayr%26aufirst%3DJ.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DD%25C3%25B6m%25C3%25B6t%25C3%25B6r%26aufirst%3DO.%26aulast%3DEnyedy%26aufirst%3D%25C3%2589.%2BA.%26aulast%3DHermann%26aufirst%3DG.%26aulast%3DGroza%26aufirst%3DD.%26aulast%3DK%25C3%25B6llensperger%26aufirst%3DG.%26aulast%3DGalanksi%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26atitle%3DMaleimide-Functionalised%2520Platinum%2528IV%2529%2520Complexes%2520as%2520a%2520Synthetic%2520Platform%2520for%2520Targeted%2520Drug%2520Delivery%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D49%26spage%3D2249%26epage%3D2251%26doi%3D10.1039%2Fc3cc39258a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Zheng, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suntharalingam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">8790</span><span class="NLM_x">–</span> <span class="NLM_lpage">8798</span><span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.+R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+Prodrugs+Designed+to+Bind+Non-Covalently+to+Human+Serum+Albumin+for+Drug+Delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0lhGOPLJgstlFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520Prodrugs%2520Designed%2520to%2520Bind%2520Non-Covalently%2520to%2520Human%2520Serum%2520Albumin%2520for%2520Drug%2520Delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Kundranda, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, J.</span><span> </span><span class="NLM_article-title">Albumin-Bound Paclitaxel in Solid Tumors: Clinical Development and Future Directions</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3767</span><span class="NLM_x">–</span> <span class="NLM_lpage">3777</span><span class="refDoi"> DOI: 10.2147/DDDT.S88023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2147%2FDDDT.S88023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26244011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=3767-3777&author=M.+N.+Kundrandaauthor=J.+Niu&title=Albumin-Bound+Paclitaxel+in+Solid+Tumors%3A+Clinical+Development+and+Future+Directions&doi=10.2147%2FDDDT.S88023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin-bound paclitaxel in solid tumors: clinical development and future directions</span></div><div class="casAuthors">Kundranda, Madappa N.; Niu, Jiaxin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3767-3777</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities assocd. with the solvents used in the formulation of std. paclitaxel and to potentially improve efficacy.  Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclitaxel to tumors and decrease the incidence of serious toxicities, including severe allergic reactions.  To date, nab-paclitaxel has been indicated for the treat-ment of three solid tumors in the USA.  It was first approved for the treatment of metastatic breast cancer in 2005, followed by locally advanced or metastatic non-small-cell lung cancer in 2012, and most recently for metastatic pancreatic cancer in 2013.  Nab-paclitaxel is also under investigation for the treatment of a no. of other solid tumors.  This review highlights key clin. efficacy and safety outcomes of nab-paclitaxel in the solid tumors for which it is currently indicated, discusses ongoing trials that may provide new data for the expansion of nab-paclitaxel's indications into other solid tumors, and provides a clin. perspective on the use of nab-paclitaxel in practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5bBd89dzHbbVg90H21EOLACvtfcHk0lhGOPLJgstlFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOisbg%253D&md5=59eb234cc3342ced970e186ae29071a4</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S88023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S88023%26sid%3Dliteratum%253Aachs%26aulast%3DKundranda%26aufirst%3DM.%2BN.%26aulast%3DNiu%26aufirst%3DJ.%26atitle%3DAlbumin-Bound%2520Paclitaxel%2520in%2520Solid%2520Tumors%253A%2520Clinical%2520Development%2520and%2520Future%2520Directions%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D3767%26epage%3D3777%26doi%3D10.2147%2FDDDT.S88023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Manaenko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span> </span><span class="NLM_article-title">Comparison Evans Blue Injection Routes: Intravenous Versus Intraperitoneal, for Measurement of Blood-Brain Barrier in a Mice Hemorrhage Model</span> <span class="citation_source-journal">J. Neurosci. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1016/j.jneumeth.2010.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.jneumeth.2010.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=21168441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC3M7jvV2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2011&pages=206-210&author=A.+Manaenkoauthor=H.+Chenauthor=J.+Kammerauthor=J.+H.+Zhangauthor=J.+Tang&title=Comparison+Evans+Blue+Injection+Routes%3A+Intravenous+Versus+Intraperitoneal%2C+for+Measurement+of+Blood-Brain+Barrier+in+a+Mice+Hemorrhage+Model&doi=10.1016%2Fj.jneumeth.2010.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison Evans Blue injection routes: Intravenous versus intraperitoneal, for measurement of blood-brain barrier in a mice hemorrhage model</span></div><div class="casAuthors">Manaenko Anatol; Chen Hank; Kammer Jerome; Zhang John H; Tang Jiping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroscience methods</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">206-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  Intracerebral hemorrhage is one of the most devastating subtypes of stroke, leaving survivors with severe neurological deficits.  Disruption of the blood brain barrier (BBB) following hemorrhage results in the development of vasogenic brain edema, a most life-threatening event after such events as intracerebral hemorrhage (ICH).  The Evans Blue assay is a popular method for the quantification of BBB disruption.  Although this method is in common use, there are several protocols of the assay in the literature which vary in the route of administration, as well as the circulation time of the stain.  In this study, we compared the amounts of accumulated stain in brain tissue following intraperitoneal versus intravenous injection at 0.5, 3 and 24h of circulation time.  METHODS:  58 CD-1 mice were used.  Animals were divided into ICH (N=42), sham groups (N=6) and naive (N=10).  ICH animals received stereotactic injection of collagenase type VII into the right basal ganglia.  Sham animals received only needle trauma.  Evans Blue stain was injected 24h after collagenase injection or needle trauma.  The consistency of ICH produced was characterized by estimation of hematoma volume via hemoglobin assay and neurological evaluation.  RESULTS:  The produced hematoma and neurological deficits were well comparable between different experimental groups.  There was no statistically significant difference in the results of the Evans Blue assay with regard to administration route.  CONCLUSIONS:  The amount of Evans Blue stain accumulated in the brains of mice after ICH produced by collagenase injection was independent of the stain administration route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwm-8zIl3llcNIRw0GKUoEfW6udTcc2ebph5jQdXmKqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7jvV2juw%253D%253D&md5=6111a6fc0d6c6263e16c410d9407f2b2</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.jneumeth.2010.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneumeth.2010.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DManaenko%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DKammer%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DComparison%2520Evans%2520Blue%2520Injection%2520Routes%253A%2520Intravenous%2520Versus%2520Intraperitoneal%252C%2520for%2520Measurement%2520of%2520Blood-Brain%2520Barrier%2520in%2520a%2520Mice%2520Hemorrhage%2520Model%26jtitle%3DJ.%2520Neurosci.%2520Methods%26date%3D2011%26volume%3D195%26spage%3D206%26epage%3D210%26doi%3D10.1016%2Fj.jneumeth.2010.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Mcdonald, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baluk, P.</span><span> </span><span class="NLM_article-title">Significance of Blood Vessel Leakiness in Cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5381</span><span class="NLM_x">–</span> <span class="NLM_lpage">5385</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5381-5385&author=D.+M.+Mcdonaldauthor=P.+Baluk&title=Significance+of+Blood+Vessel+Leakiness+in+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcdonald%26aufirst%3DD.%2BM.%26aulast%3DBaluk%26aufirst%3DP.%26atitle%3DSignificance%2520of%2520Blood%2520Vessel%2520Leakiness%2520in%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5381%26epage%3D5385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Yu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remick, S. C.</span><span> </span><span class="NLM_article-title">Dicycloplatin, a Novel Platinum Analog in Chemotherapy: Synthesis of Chinese Pre-Clinical and Clinical Profile and Emerging Mechanistic Studies</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24403501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktV2isLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=455-463&author=J.+J.+Yuauthor=X.+Yangauthor=Q.+Songauthor=M.+D.+Muellerauthor=S.+C.+Remick&title=Dicycloplatin%2C+a+Novel+Platinum+Analog+in+Chemotherapy%3A+Synthesis+of+Chinese+Pre-Clinical+and+Clinical+Profile+and+Emerging+Mechanistic+Studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of Chinese pre-clinical and clinical profile and emerging mechanistic studies</span></div><div class="casAuthors">Yu, Jing Jie; Yang, Xuqing; Song, Qinhua; Mueller, Michael D.; Remick, Scot C.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1B</span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Dicycloplatin (DCP) has better soly. and stability than both cisplatin and carboplatin.  Pre-clin. and phase I studies demonstrated significant antitumor activity and fewer adverse events than carboplatin.  Phase II clin. trials in advanced non-small cell lung cancer found efficacy and safety of DCP-plus-paclitaxel comparable to carboplatin-plus-paclitaxel but better tolerability.  This article summarizes and reviews pre-clin. and clin. data for dicycloplatin from the Chinese medical literature.  We also report on new mechanistic findings in our lab. in West Virginia, USA.  Patient blood samples were collected for DCP-prototype detn. by liq. chromatog. mass spectrometry (LC-MS/MS).  Mol. studies of ovarian cancer celts treated with DCP or cisplatin were carried out for gene-signature profiling using immunoblotting.  Pharmacokinetic mass-spectrometry showed different spectrum profiles of DCP and carboplatin in plasma.  Plasma concn. of DCP prototype was 17.1 μg/mL 2h after administration, with a peak concn. of 26.9 μg/mL at 0.5 h.  Immunoblotting showed DCP-induced activation of DNA damage pathways, including double-phosphorylated checkpoint kinase 2 (CHK2) and breast cancer 1 (BRCA1) and triple-phosphorylated p53, compared to controls.  Cisplatin produced a similar profile, with increased p53 protein.  DCP and cisplatin activate DNA-damage response through similar pathways.  DCP may be more sol. and stable, and better-tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH1uuOD4c2VbVg90H21EOLACvtfcHk0li2PWOfloB09Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktV2isLY%253D&md5=205f6779a4061021bb18c1eee25aec60</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DM.%2BD.%26aulast%3DRemick%26aufirst%3DS.%2BC.%26atitle%3DDicycloplatin%252C%2520a%2520Novel%2520Platinum%2520Analog%2520in%2520Chemotherapy%253A%2520Synthesis%2520of%2520Chinese%2520Pre-Clinical%2520and%2520Clinical%2520Profile%2520and%2520Emerging%2520Mechanistic%2520Studies%26jtitle%3DAnticancer%2520Res.%26date%3D2014%26volume%3D34%26spage%3D455%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Li, G.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.-W.</span><span> </span><span class="NLM_article-title">Effect of Dicycloplatin, a Novel Platinum Chemotherapeutical Drug, on Inhibiting Cell Growth and Inducing Cell Apoptosis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e48994</span><span class="refDoi"> DOI: 10.1371/journal.pone.0048994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1371%2Fjournal.pone.0048994" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e48994&author=G.-Q.+Liauthor=X.-G.+Chenauthor=X.-P.+Wuauthor=J.-D.+Xieauthor=Y.-J.+Liangauthor=X.-Q.+Zhaoauthor=W.-Q.+Chenauthor=L.-W.+Fu&title=Effect+of+Dicycloplatin%2C+a+Novel+Platinum+Chemotherapeutical+Drug%2C+on+Inhibiting+Cell+Growth+and+Inducing+Cell+Apoptosis&doi=10.1371%2Fjournal.pone.0048994"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0048994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0048994%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.-Q.%26aulast%3DChen%26aufirst%3DX.-G.%26aulast%3DWu%26aufirst%3DX.-P.%26aulast%3DXie%26aufirst%3DJ.-D.%26aulast%3DLiang%26aufirst%3DY.-J.%26aulast%3DZhao%26aufirst%3DX.-Q.%26aulast%3DChen%26aufirst%3DW.-Q.%26aulast%3DFu%26aufirst%3DL.-W.%26atitle%3DEffect%2520of%2520Dicycloplatin%252C%2520a%2520Novel%2520Platinum%2520Chemotherapeutical%2520Drug%252C%2520on%2520Inhibiting%2520Cell%2520Growth%2520and%2520Inducing%2520Cell%2520Apoptosis%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De48994%26doi%3D10.1371%2Fjournal.pone.0048994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Liu, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, Z. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, Q. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. Y.</span><span> </span><span class="NLM_article-title">A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel as First-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancers</span> <span class="citation_source-journal">Arch. Med. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">724</span><span class="refDoi"> DOI: 10.5114/aoms.2014.44862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.5114%2Faoms.2014.44862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25276156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ggt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=717-724&author=K.+J.+Liuauthor=Z.+Z.+Guanauthor=Y.+Liangauthor=X.+Q.+Yangauthor=J.+Pengauthor=H.+Huangauthor=Q.+X.+Shaoauthor=M.+Z.+Wangauthor=Y.+Z.+Zhuauthor=C.+P.+Wuauthor=S.+B.+Wangauthor=J.+P.+Xiongauthor=Y.+X.+Baiauthor=S.+Y.+Yuauthor=Y.+Zhangauthor=X.+H.+Huauthor=J.+F.+Fengauthor=S.+X.+Wuauthor=S.+C.+Jiaoauthor=C.+C.+Zhouauthor=J.+Wangauthor=H.+Y.+Wu&title=A+Double-Blind%2C+Randomized+Phase+II+Study+of+Dicycloplatin+Plus+Paclitaxel+Versus+Carboplatin+Plus+Paclitaxel+as+First-Line+Therapy+for+Patients+with+Advanced+Non-Small-Cell+Lung+Cancers&doi=10.5114%2Faoms.2014.44862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers</span></div><div class="casAuthors">Liu, Ke-Jun; Guan, Zhong-Zhen; Liang, Ying; Yang, Xu-Qing; Peng, Jin; Huang, He; Shao, Qing-Xiang; Wang, Meng-Zhao; Zhu, Yun-Zhong; Wu, Chang-Ping; Wang, Shao-Bin; Xiong, Jian-Ping; Bai, Yu-Xian; Yu, Shi-Ying; Zhang, Yang; Hu, Xiao-Hua; Feng, Ji-Feng; Wu, Shi-Xiu; Jiao, Shun-Chang; Zhou, Cai-Cun; Wang, Jie; Wu, Hai-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Medical Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-724</span>CODEN:
                <span class="NLM_cas:coden">AMSRDQ</span>;
        ISSN:<span class="NLM_cas:issn">1734-1922</span>.
    
            (<span class="NLM_cas:orgname">Termedia Publishing House</span>)
        </div><div class="casAbstract">Introduction: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as firstline treatment for patients with advanced non-small-cell lung cancer (NSCLC).  Material and methods: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1 : 1) to receive dicycloplatin 450 mg/m2 or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m2 (D + P or C + P) every 3 wk for up to 4 to 6 cycles.  The primary endpoint was response rate.  Secondary endpoints included progression- free survival (PFS), overall survival (OS) and adverse events.  Results: The response rates for the D + P and C + P arm were 36.44% and 30.51%, resp. (p = 0.33).  The median PFS was 5.6 mo in the D + P arm and 4.7 mo in the C + P arm (p = 0.31).  The median OS was 14.9 mo for D + P and 12.9 mo for C + P (p = 0.37).  Adverse events in the two arms were well balanced.  The most common grade 3/4 adverse event was hematol. toxicity.  Conclusions: Patients treated with D + P had similar response and survival rates to those treated with C + P, and toxicities of both treatments were generally tolerable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph9Zf2cMstcbVg90H21EOLACvtfcHk0li_9AEHxVb8ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ggt7jO&md5=528336ed9d7dfabc17ad868c252de29a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.5114%2Faoms.2014.44862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Faoms.2014.44862%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BJ.%26aulast%3DGuan%26aufirst%3DZ.%2BZ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%2BQ.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DShao%26aufirst%3DQ.%2BX.%26aulast%3DWang%26aufirst%3DM.%2BZ.%26aulast%3DZhu%26aufirst%3DY.%2BZ.%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DS.%2BB.%26aulast%3DXiong%26aufirst%3DJ.%2BP.%26aulast%3DBai%26aufirst%3DY.%2BX.%26aulast%3DYu%26aufirst%3DS.%2BY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%2BH.%26aulast%3DFeng%26aufirst%3DJ.%2BF.%26aulast%3DWu%26aufirst%3DS.%2BX.%26aulast%3DJiao%26aufirst%3DS.%2BC.%26aulast%3DZhou%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%2BY.%26atitle%3DA%2520Double-Blind%252C%2520Randomized%2520Phase%2520II%2520Study%2520of%2520Dicycloplatin%2520Plus%2520Paclitaxel%2520Versus%2520Carboplatin%2520Plus%2520Paclitaxel%2520as%2520First-Line%2520Therapy%2520for%2520Patients%2520with%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancers%26jtitle%3DArch.%2520Med.%2520Sci.%26date%3D2014%26volume%3D10%26spage%3D717%26epage%3D724%26doi%3D10.5114%2Faoms.2014.44862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, H.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, X.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, R.-G.</span><span> </span><span class="NLM_article-title">Advances in Drug Delivery System for Platinum Agents Based Combination Therapy</span> <span class="citation_source-journal">Cancer Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.7497/j.issn.2095-3941.2015.0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.7497%2Fj.issn.2095-3941.2015.0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26779373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=362-374&author=X.+Kangauthor=H.-H.+Xiaoauthor=H.-Q.+Songauthor=X.-B.+Jingauthor=L.-S.+Yanauthor=R.-G.+Qi&title=Advances+in+Drug+Delivery+System+for+Platinum+Agents+Based+Combination+Therapy&doi=10.7497%2Fj.issn.2095-3941.2015.0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in drug delivery system for platinum agents based combination therapy</span></div><div class="casAuthors">Kang, Xiang; Xiao, Hai-Hua; Song, Hai-Qin; Jing, Xia-Bin; Yan, Le-San; Qi, Ruo-Gu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4Spec.Iss.</span>),
    <span class="NLM_cas:pages">362-374</span>CODEN:
                <span class="NLM_cas:coden">CBMADQ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Tianjin Medical University Cancer Institute and Hospital</span>)
        </div><div class="casAbstract">Platinum-based anticancer agents are widely used as first-line drugs in cancer chemotherapy for various solid tumors.  However, great side effects and occurrence of resistance remain as the major drawbacks for almost all the platinum drugs developed.  To conquer these problems, new strategies should be adopted for platinum drug based chemotherapy.  Modern nanotechnol. has been widely employed in the delivery of various therapeutics and diagnostic.  It provides the possibility of targeted delivery of a certain anticancer drug to the tumor site, which could minimize toxicity and optimize the drug efficacy.  Here, in this review, we focused on the recent progress in polymer based drug delivery systems for platinum-based combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6c7l6YI7qmbVg90H21EOLACvtfcHk0li_9AEHxVb8ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVaqs7g%253D&md5=086ed651b447b0d2563c81c555c26702</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.7497%2Fj.issn.2095-3941.2015.0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7497%252Fj.issn.2095-3941.2015.0063%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DH.-H.%26aulast%3DSong%26aufirst%3DH.-Q.%26aulast%3DJing%26aufirst%3DX.-B.%26aulast%3DYan%26aufirst%3DL.-S.%26aulast%3DQi%26aufirst%3DR.-G.%26atitle%3DAdvances%2520in%2520Drug%2520Delivery%2520System%2520for%2520Platinum%2520Agents%2520Based%2520Combination%2520Therapy%26jtitle%3DCancer%2520Biol.%2520Med.%26date%3D2015%26volume%3D12%26spage%3D362%26epage%3D374%26doi%3D10.7497%2Fj.issn.2095-3941.2015.0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Xue, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X. J.</span><span> </span><span class="NLM_article-title">Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">10452</span><span class="NLM_x">–</span> <span class="NLM_lpage">10464</span><span class="refDoi"> DOI: 10.1021/nn405004f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn405004f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOmsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=10452-10464&author=X.+Xueauthor=M.+D.+Hallauthor=Q.+Zhangauthor=P.+C.+Wangauthor=M.+M.+Gottesmanauthor=X.+J.+Liang&title=Nanoscale+Drug+Delivery+Platforms+Overcome+Platinum-Based+Resistance+in+Cancer+Cells+Due+to+Abnormal+Membrane+Protein+Trafficking&doi=10.1021%2Fnn405004f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking</span></div><div class="casAuthors">Xue, Xue; Hall, Matthew D.; Zhang, Qiang; Wang, Paul C.; Gottesman, Michael M.; Liang, Xing-Jie</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">10452-10464</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of cellular resistance to platinum-based chemotherapies is often assocd. with reduced intracellular platinum concns.  In some models, this redn. is due to abnormal membrane protein trafficking, resulting in reduced uptake by transporters at the cell surface.  Given the central role of platinum drugs in the clinic, it is crit. to overcome cisplatin resistance by bypassing the plasma membrane barrier to significantly increase the intracellular cisplatin concn. enough to inhibit the proliferation of cisplatin-resistant cells.  Therefore, rational design of appropriate nanoscale drug delivery platforms (nDDPs) loaded with cisplatin or other platinum analogs as payloads is a possible strategy to solve this problem.  This review will focus on the known mechanism of membrane trafficking in cisplatin-resistant cells and the development and employment of nDDPs to improve cell uptake of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY72iH-5DvhrVg90H21EOLACvtfcHk0li_9AEHxVb8ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOmsLzK&md5=cf4f50585f7ab097c93fd8ae516ff37c</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fnn405004f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn405004f%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DX.%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DP.%2BC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DLiang%26aufirst%3DX.%2BJ.%26atitle%3DNanoscale%2520Drug%2520Delivery%2520Platforms%2520Overcome%2520Platinum-Based%2520Resistance%2520in%2520Cancer%2520Cells%2520Due%2520to%2520Abnormal%2520Membrane%2520Protein%2520Trafficking%26jtitle%3DACS%2520Nano%26date%3D2013%26volume%3D7%26spage%3D10452%26epage%3D10464%26doi%3D10.1021%2Fnn405004f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Duggan, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, G. M.</span><span> </span><span class="NLM_article-title">Pegylated Liposomal Doxorubicin</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">2531</span><span class="NLM_x">–</span> <span class="NLM_lpage">2558</span><span class="refDoi"> DOI: 10.2165/11207510-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2165%2F11207510-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=22141391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1aqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2531-2558&author=S.+T.+Dugganauthor=G.+M.+Keating&title=Pegylated+Liposomal+Doxorubicin&doi=10.2165%2F11207510-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma</span></div><div class="casAuthors">Duggan, Sean T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2531-2558</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Pegylated liposomal doxorubicin (Caelyx, Doxil) represents an improved formulation of conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic profile.  This article reviews the efficacy and tolerability of pegylated liposomal doxorubicin in metastatic breast cancer, progressive ovarian cancer, relapsed or refractory multiple myeloma and AIDS-related Kaposi's sarcoma, as well as summarizing its pharmacol. properties.  In three randomized, open-label, multicentre trials, monotherapy with pegylated liposomal doxorubicin was as effective as doxorubicin or capecitabine in the first-line treatment of metastatic breast cancer, and as effective as vinorelbine or combination mitomycin plus vinblastine in taxane-refractory metastatic breast cancer.  Pegylated liposomal doxorubicin alone was as effective as topotecan or gemcitabine alone in patients with progressive ovarian cancer resistant or refractory to platinum- or paclitaxel-based therapy, according to the results of three randomized multicentre trials.  In addn., in patients with progressive ovarian cancer who had received prior platinum-based therapy, progression-free survival was significantly longer with pegylated liposomal doxorubicin plus carboplatin than with paclitaxel plus carboplatin, according to the results of a randomized, open-label multicentre trial.  Combination therapy with pegylated liposomal doxorubicin plus bortezomib was more effective than bortezomib alone in patients with relapsed or refractory multiple myeloma, according to the results of a randomized, open-label, multinational trial.  Randomized multinational trials also demonstrated the efficacy of pegylated liposomal doxorubicin in patients with advanced AIDS-related Kaposi's sarcoma.  Pegylated liposomal doxorubicin exhibited a relatively favorable safety profile compared with conventional doxorubicin and other available chemotherapy agents.  The most common treatment-related adverse events included myelosuppression, palmar-plantar erythrodysesthesia and stomatitis, although these are manageable with appropriate supportive measures.  To conclude, pegylated liposomal doxorubicin is a useful option in the treatment of various malignancies, including metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBGBjVK3YlF7Vg90H21EOLACvtfcHk0ljLUMBPGWlmaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1aqtro%253D&md5=3ef7823018be550e9f487cd861efc5ae</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.2165%2F11207510-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11207510-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%2BT.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DPegylated%2520Liposomal%2520Doxorubicin%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D2531%26epage%3D2558%26doi%3D10.2165%2F11207510-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span> </span><span class="NLM_article-title">Application of Liposomal Technologies for Delivery of Platinum Analogs in Oncology</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3309</span><span class="NLM_x">–</span> <span class="NLM_lpage">3319</span><span class="refDoi"> DOI: 10.2147/IJN.S38354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2147%2FIJN.S38354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24023517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FosF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=3309-3319&author=D.+Liuauthor=C.+Heauthor=A.+Z.+Wangauthor=W.+Lin&title=Application+of+Liposomal+Technologies+for+Delivery+of+Platinum+Analogs+in+Oncology&doi=10.2147%2FIJN.S38354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Application of liposomal technologies for delivery of platinum analogs in oncology</span></div><div class="casAuthors">Liu Demin; He Chunbai; Wang Andrew Z; Lin Wenbin</div><div class="citationInfo"><span class="NLM_cas:title">International journal of nanomedicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3309-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics.  While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties.  Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further.  Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin.  Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin®), SPI-77, Lipoplatin®, Lipoxal®, and LiPlaCis®.  Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery.  In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles.  We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9qo79Plh9RWGmni0r9GoKfW6udTcc2eZnDovIUANBOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FosF2jtA%253D%253D&md5=8f8281ea8e2b4bffc63d948c7b960fba</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.2147%2FIJN.S38354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S38354%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%2BZ.%26aulast%3DLin%26aufirst%3DW.%26atitle%3DApplication%2520of%2520Liposomal%2520Technologies%2520for%2520Delivery%2520of%2520Platinum%2520Analogs%2520in%2520Oncology%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2013%26volume%3D8%26spage%3D3309%26epage%3D3319%26doi%3D10.2147%2FIJN.S38354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">European Medicines Agency</span><span class="NLM_x">. Public Summary of Positive Opinionfor Orphan Designation of Cisplatin (Liposomal) for the Treatmentof Pancreatic Cancer. </span> <span class="citation_source-book">Pre-Authorization Evaluation of Medicines for Human Use</span>; <span class="NLM_publisher-name">Committee for Orphan Medicinal Products</span>: <span class="NLM_publisher-loc">London</span>, November 30,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=European+Medicines+Agency&title=Pre-Authorization+Evaluation+of+Medicines+for+Human+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DPre-Authorization%2520Evaluation%2520of%2520Medicines%2520for%2520Human%2520Use%26pub%3DCommittee%2520for%2520Orphan%2520Medicinal%2520Products%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Han, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Z.</span><span> </span><span class="NLM_article-title">Recent Advances in Platinum (Iv) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1268</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span><span class="refDoi"> DOI: 10.1002/med.21360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fmed.21360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26280923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1KjsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1268-1299&author=X.+Hanauthor=J.+Sunauthor=Y.+Wangauthor=Z.+He&title=Recent+Advances+in+Platinum+%28Iv%29+Complex-Based+Delivery+Systems+to+Improve+Platinum+%28II%29+Anticancer+Therapy&doi=10.1002%2Fmed.21360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy</span></div><div class="casAuthors">Han, Xiaopeng; Sun, Jin; Wang, Yongjun; He, Zhonggui</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1268-1299</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Cisplatin and its platinum (Pt) (II) derivs. play a key role in the fight against various human cancers such as testicular, ovarian, head and neck, lung tumors.  However, their application in clinic is limited due to dose- dependent toxicities and acquired drug resistances, which have prompted extensive research effort toward the development of more effective Pt (II) delivery strategies.  The synthesis of Pt (IV) complex is one such an area of intense research fields, which involves their in vivo conversion into active Pt (II) mols. under the reducing intracellular environment, and has demonstrated encouraging preclin. and clin. outcomes.  Compared with Pt (II) complexes, Pt (IV) complexes not only exhibit an increased stability and reduced side effects, but also facilitate the i.v.-to-oral switch in cancer chemotherapy.  The overview briefly analyzes statuses of Pt (II) complex that are in clin. use, and then focuses on the development of Pt (IV) complexes.  Finally, recent advances in Pt (IV) complexes in combination with nanocarriers are highlighted, addressing the shortcomings of Pt (IV) complexes, such as their instability in blood and irreversibly binding to plasma proteins and nonspecific distribution, and taking advantage of passive and active targeting effect to improve Pt (II) anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoorUB6a37jSbVg90H21EOLACvtfcHk0ljLUMBPGWlmaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1KjsLrI&md5=7c99c1bbe8eb959b26ae3c3fa649ba1d</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2Fmed.21360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21360%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DZ.%26atitle%3DRecent%2520Advances%2520in%2520Platinum%2520%2528Iv%2529%2520Complex-Based%2520Delivery%2520Systems%2520to%2520Improve%2520Platinum%2520%2528II%2529%2520Anticancer%2520Therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D1268%26epage%3D1299%26doi%3D10.1002%2Fmed.21360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Martin, R. B.</span><span> </span><span class="NLM_article-title">Platinum Complexes: Hydrolysis and Binding to N(7) and N(1) of Purines</span>. In  <span class="citation_source-book">Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug</span>; <span class="NLM_contrib-group">Lippart, B.</span>, Ed.; <span class="NLM_publisher-name">Verlag Helvetica Chimica Acta</span>: <span class="NLM_publisher-loc">Zürich, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2F9783906390420.ch7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=181-205&author=R.+B.+Martinauthor=B.+Lippart&title=Cisplatin%3A+Chemistry+and+Biochemistry+of+a+Leading+Anticancer+Drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1002%2F9783906390420.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783906390420.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BB.%26atitle%3DPlatinum%2520Complexes%253A%2520Hydrolysis%2520and%2520Binding%2520to%2520N%25287%2529%2520and%2520N%25281%2529%2520of%2520Purines%26btitle%3DCisplatin%253A%2520Chemistry%2520and%2520Biochemistry%2520of%2520a%2520Leading%2520Anticancer%2520Drug%26aulast%3DLippart%26aufirst%3DB.%26pub%3DVerlag%2520Helvetica%2520Chimica%2520Acta%26date%3D2006%26spage%3D181%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Kataoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, Y.</span><span> </span><span class="NLM_article-title">Block Copolymer Micelles for Drug Delivery: Design, Characterization and Biological Significance</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span><span class="refDoi"> DOI: 10.1016/S0169-409X(00)00124-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0169-409X%2800%2900124-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11251249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvVajs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2001&pages=113-131&author=K.+Kataokaauthor=A.+Haradaauthor=Y.+Nagasaki&title=Block+Copolymer+Micelles+for+Drug+Delivery%3A+Design%2C+Characterization+and+Biological+Significance&doi=10.1016%2FS0169-409X%2800%2900124-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Block copolymer micelles for drug delivery: design, characterization and biological significance</span></div><div class="casAuthors">Kataoka, K.; Harada, A.; Nagasaki, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-131</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 94 refs.  Recently, colloidal carrier systems have been receiving much attention in the field of drug targeting because of their high loading capacity for drugs as well as their unique disposition characteristics in the body.  This paper highlights the utility of polymeric micelles formed through the multimol. assembly of block copolymers as novel core-shell typed colloidal carriers for drug and gene targeting.  The process of micellization in aq. milieu is described in detail based on differences in the driving force of core segregation, including hydrophobic interaction, electrostatic interaction, metal complexation, and hydrogen bonding of constituent block copolymers.  The segregated core embedded in the hydrophilic palisade is shown to function as a reservoir for genes, enzymes, and a variety of drugs with diverse characteristics.  Functionalization of the outer surface of the polymeric micelle to modify its physicochem. and biol. properties is reviewed from the standpoint of designing micellar carrier systems for receptor-mediated drug delivery.  Further, the distribution of polymeric micelles is described to demonstrate their long-circulating characteristics and significant tumor accumulation, emphasizing their promising utility in tumor-targeting therapy.  As an important perspective on carrier systems based on polymeric micelles, their feasibility as non-viral gene vectors is also summarized in this review article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUrMDCJxgepbVg90H21EOLACvtfcHk0lj2qG7FvZmZRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvVajs78%253D&md5=00f04e4f6e4071c41db0403f8232d170</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900124-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900124-1%26sid%3Dliteratum%253Aachs%26aulast%3DKataoka%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DA.%26aulast%3DNagasaki%26aufirst%3DY.%26atitle%3DBlock%2520Copolymer%2520Micelles%2520for%2520Drug%2520Delivery%253A%2520Design%252C%2520Characterization%2520and%2520Biological%2520Significance%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D47%26spage%3D113%26epage%3D131%26doi%3D10.1016%2FS0169-409X%2800%2900124-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span>M.D. Anderson Cancer Center, NanoCarrier Co., Ltd. A Phase 1 Dose-Escalation and Pharmacokinetic Study of Nc-4016 in Patients with Advanced Solid Tumors or Lymphoma. <a href="https://clinicaltrials.gov/ct2/show/NCT01999491" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01999491</a> (accessed August 01,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=M.D.+Anderson+Cancer+Center%2C+NanoCarrier+Co.%2C+Ltd.+A+Phase+1+Dose-Escalation+and+Pharmacokinetic+Study+of+Nc-4016+in+Patients+with+Advanced+Solid+Tumors+or+Lymphoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01999491+%28accessed+August+01%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span>Nanocarrier. Research and Development Pipeline. <a href="http://www.nanocarrier.co.jp/en/research/pipeline/index.html" class="extLink">http://www.nanocarrier.co.jp/en/research/pipeline/index.html</a> (accessed July 30,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nanocarrier.+Research+and+Development+Pipeline.+http%3A%2F%2Fwww.nanocarrier.co.jp%2Fen%2Fresearch%2Fpipeline%2Findex.html+%28accessed+July+30%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Nowotnik, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cvitkovic, E.</span><span> </span><span class="NLM_article-title">Prolindac (Ap5346): A Review of the Development of an HPMA DACH Platinum Polymer Therapeutic</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1214</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span><span class="refDoi"> DOI: 10.1016/j.addr.2009.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.addr.2009.06.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1214-1219&author=D.+P.+Nowotnikauthor=E.+Cvitkovic&title=Prolindac+%28Ap5346%29%3A+A+Review+of+the+Development+of+an+HPMA+DACH+Platinum+Polymer+Therapeutic&doi=10.1016%2Fj.addr.2009.06.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2009.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2009.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DNowotnik%26aufirst%3DD.%2BP.%26aulast%3DCvitkovic%26aufirst%3DE.%26atitle%3DProlindac%2520%2528Ap5346%2529%253A%2520A%2520Review%2520of%2520the%2520Development%2520of%2520an%2520HPMA%2520DACH%2520Platinum%2520Polymer%2520Therapeutic%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2009%26volume%3D61%26spage%3D1214%26epage%3D1219%26doi%3D10.1016%2Fj.addr.2009.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Duncan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicent, M. J.</span><span> </span><span class="NLM_article-title">Do Hpma Copolymer Conjugates Have a Future as Clinically Useful Nanomedicines? A Critical Overview of Current Status and Future Opportunities</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span><span class="refDoi"> DOI: 10.1016/j.addr.2009.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.addr.2009.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=272-282&author=R.+Duncanauthor=M.+J.+Vicent&title=Do+Hpma+Copolymer+Conjugates+Have+a+Future+as+Clinically+Useful+Nanomedicines%3F+A+Critical+Overview+of+Current+Status+and+Future+Opportunities&doi=10.1016%2Fj.addr.2009.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2009.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2009.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DDuncan%26aufirst%3DR.%26aulast%3DVicent%26aufirst%3DM.%2BJ.%26atitle%3DDo%2520Hpma%2520Copolymer%2520Conjugates%2520Have%2520a%2520Future%2520as%2520Clinically%2520Useful%2520Nanomedicines%253F%2520A%2520Critical%2520Overview%2520of%2520Current%2520Status%2520and%2520Future%2520Opportunities%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D272%26epage%3D282%26doi%3D10.1016%2Fj.addr.2009.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Carter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Antibody-Drug Conjugates for Cancer Therapy</span> <span class="citation_source-journal">Cancer J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1097/PPO.0b013e318172d704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1097%2FPPO.0b013e318172d704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=18536555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlWlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=154-169&author=P.+J.+Carterauthor=P.+D.+Senter&title=Antibody-Drug+Conjugates+for+Cancer+Therapy&doi=10.1097%2FPPO.0b013e318172d704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Carter, Paul J.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-169</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The antibody-drug conjugate (ADC) concept is to use an antibody to deliver a cytotoxic drug selectively to a target such as a tumor-assocd. antigen.  Such conjugates represent a broadly applicable approach to enhance the antitumor activity of antibodies and improve the tumor-to-normal tissue selectivity of chemotherapy.  Crit. parameters for ADC development include target antigen selection, conjugate internalization by tumor cells, drug potency and stability of the linker between drug and antibody.  Other important considerations include the conjugation methods, drug-to-antibody ratio, and the effects of drug conjugation on antibody properties.  Highly potent drugs with more stable linkers have been attached to a new generation of antibodies to create conjugates with pronounced antitumor activities in preclin. studies and encouraging results in early stage clin. trials.  This review details these advances, discusses some of the remaining challenges, and overviews ADCs currently in clin. trials for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXcG9SMjwzf7Vg90H21EOLACvtfcHk0lj2qG7FvZmZRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlWlsLo%253D&md5=457f161e8dda16b17f74a269af4a17dd</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1097%2FPPO.0b013e318172d704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0b013e318172d704%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DP.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody-Drug%2520Conjugates%2520for%2520Cancer%2520Therapy%26jtitle%3DCancer%2520J.%26date%3D2008%26volume%3D14%26spage%3D154%26epage%3D169%26doi%3D10.1097%2FPPO.0b013e318172d704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Ado-Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for Her2-Positive Breast Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6949</span><span class="NLM_x">–</span> <span class="NLM_lpage">6964</span><span class="refDoi"> DOI: 10.1021/jm500766w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500766w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6949-6964&author=J.+M.+Lambertauthor=R.+V.+Chari&title=Ado-Trastuzumab+Emtansine+%28T-DM1%29%3A+An+Antibody-Drug+Conjugate+%28ADC%29+for+Her2-Positive+Breast+Cancer&doi=10.1021%2Fjm500766w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer</span></div><div class="casAuthors">Lambert, John M.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6949-6964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker.  Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active deriv. of DM1 is subsequently released by proteolytic degrdn. of the antibody moiety within the lysosome.  Initial clin. evaluation led to a phase III trial in advanced HER2-pos. breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine.  In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-pos. metastatic breast cancer who had previously received trastuzumab and a taxane, sep. or in combination, the first ADC to receive full approval based on a randomized study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAu4MvRWFwLVg90H21EOLACvtfcHk0lgV78hYTxY2Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7rE&md5=3ddee50cc227097126dd47e7683a6ac7</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm500766w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500766w%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DAdo-Trastuzumab%2520Emtansine%2520%2528T-DM1%2529%253A%2520An%2520Antibody-Drug%2520Conjugate%2520%2528ADC%2529%2520for%2520Her2-Positive%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6949%26epage%3D6964%26doi%3D10.1021%2Fjm500766w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Mehmood, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qasem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeeshan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jehangir, E.</span><span> </span><span class="NLM_article-title">Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibody Treatments</span> <span class="citation_source-journal">Oncol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.4081/oncol.2014.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.4081%2Foncol.2014.256" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=97-108&author=R.+K.+Mehmoodauthor=J.+Parkerauthor=S.+Ahmedauthor=E.+Qasemauthor=A.+A.+Mohammedauthor=M.+Zeeshanauthor=E.+Jehangir&title=Review+of+Cisplatin+and+Oxaliplatin+in+Current+Immunogenic+and+Monoclonal+Antibody+Treatments&doi=10.4081%2Foncol.2014.256"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.4081%2Foncol.2014.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4081%252Foncol.2014.256%26sid%3Dliteratum%253Aachs%26aulast%3DMehmood%26aufirst%3DR.%2BK.%26aulast%3DParker%26aufirst%3DJ.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DQasem%26aufirst%3DE.%26aulast%3DMohammed%26aufirst%3DA.%2BA.%26aulast%3DZeeshan%26aufirst%3DM.%26aulast%3DJehangir%26aufirst%3DE.%26atitle%3DReview%2520of%2520Cisplatin%2520and%2520Oxaliplatin%2520in%2520Current%2520Immunogenic%2520and%2520Monoclonal%2520Antibody%2520Treatments%26jtitle%3DOncol.%2520Rev.%26date%3D2014%26volume%3D8%26spage%3D97%26epage%3D108%26doi%3D10.4081%2Foncol.2014.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Huang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span> </span><span class="NLM_article-title">Biological Evaluation of a Novel Herceptin-Platinum (II) Conjugate for Efficient and Cancer Cell Specific Delivery</span> <span class="citation_source-journal">Biomed. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1016/j.biopha.2015.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.biopha.2015.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26211591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVeksL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2015&pages=116-122&author=R.+Huangauthor=Y.+Sunauthor=X.+Y.+Zhangauthor=B.+W.+Sunauthor=Q.+C.+Wangauthor=J.+Zhu&title=Biological+Evaluation+of+a+Novel+Herceptin-Platinum+%28II%29+Conjugate+for+Efficient+and+Cancer+Cell+Specific+Delivery&doi=10.1016%2Fj.biopha.2015.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery</span></div><div class="casAuthors">Huang, Rong; Sun, Yu; Zhang, Xiang-yang; Sun, Bai-wang; Wang, Qiu-cui; Zhu, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-122</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Platinum-based drugs have been widely used for the treatment of malignant tumors.  However, their applications are limited by severe side effects for their lack of selectivity for cancer cells.  The development of antibody drug conjugates (ADCs) have provided a platform to reduce drug toxicity and improve drug efficacy.  Here we describe a nover conjugate comprising of Herceptin (an anti-HER2 antibody) and platinum drug via a cathepsin B cleavable dipetide for enhancing drug accumulation and HER2-pos. cancer cell specific delivery.  This conjugate is believed to be cleaved by cathepsin B, leading to a 1,6-elimination reaction and activation of drug release.  Herceptin-Pt(II) is evaluated to have approx. loaded with 6.4 mol platinum drugs per mol of antibody.  We demonstrate that Herceptin-Pt(II) retain high and selective binding affinity for HER2 protein and HER2-pos. SK-BR-3 cancer cells.  The in vitro cytotoxicity tests indicate that Herceptin-Pt(II) exhibits much higher cytotoxicity than oxaliplatin against SK-BR-3 cells.  More importantly, Herceptin-Pt(II) shows no obvious inhibition against the growth of both MCF-7 and MDA-MB-231 cells, which express lower levels of HER2.  Furthermore, compared with free oxaliplatin, Herceptin significantly improved the cellular uptake of platinum drugs in SK-BR-3 cells.  In summary, Herceptin-platinum (II) conjugate is a remarkable and potent platform for efficient and cancer cell specific delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp4caYAhtmNbVg90H21EOLACvtfcHk0lgV78hYTxY2Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVeksL%252FO&md5=78c38ba2afa07c50ec7c9bb38a6b4c9e</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2015.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2015.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BY.%26aulast%3DSun%26aufirst%3DB.%2BW.%26aulast%3DWang%26aufirst%3DQ.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DBiological%2520Evaluation%2520of%2520a%2520Novel%2520Herceptin-Platinum%2520%2528II%2529%2520Conjugate%2520for%2520Efficient%2520and%2520Cancer%2520Cell%2520Specific%2520Delivery%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2015%26volume%3D73%26spage%3D116%26epage%3D122%26doi%3D10.1016%2Fj.biopha.2015.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Lasorsa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Losacco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobazzi, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzariti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natile, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnesano, F.</span><span> </span><span class="NLM_article-title">Probing the Interaction between Cisplatin and the Therapeutic Monoclonal Antibody Trastuzumab</span> <span class="citation_source-journal">RSC Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">29229</span><span class="NLM_x">–</span> <span class="NLM_lpage">29236</span><span class="refDoi"> DOI: 10.1039/C6RA04337B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC6RA04337B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVOntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=29229-29236&author=A.+Lasorsaauthor=M.+Losaccoauthor=R.+M.+Iacobazziauthor=L.+Porcelliauthor=A.+Azzaritiauthor=G.+Natileauthor=F.+Arnesano&title=Probing+the+Interaction+between+Cisplatin+and+the+Therapeutic+Monoclonal+Antibody+Trastuzumab&doi=10.1039%2FC6RA04337B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab</span></div><div class="casAuthors">Lasorsa, Alessia; Losacco, Maurizio; Iacobazzi, Rosa Maria; Porcelli, Letizia; Azzariti, Amalia; Natile, Giovanni; Arnesano, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">29229-29236</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Trastuzumab (Herceptin) is a fully humanized monoclonal Ig γ-1 (IgG1) antibody directed against the HER2/neu receptor, which is up-regulated in about 20-25% of gastric and breast cancer patients.  The combination of trastuzumab with cisplatin results in a favorable toxicity profile in the case of advanced HER2-pos. gastric and gastroesophageal cancers, gaining the approval by the U.  S. FDA in 2010. However, the current literature reveals no at. details about platinum drug-trastuzumab interactions, probably because of size limitations.  Our research aim has been to probe the interaction between the monoclonal antibody trastuzumab and cisplatin by means of electrospray mass spectrometry anal. within the "divide and conquer" approach and 1H, 15N-HSQC NMR spectroscopy (using 15N-labeled cisplatin).  We demonstrate that trastuzumab is able to bind platinum and that there is no involvement of the residues belonging to the antigen-binding region so that the receptor recognition is not affected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzZyw236U9YrVg90H21EOLACvtfcHk0lgV78hYTxY2Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVOntr0%253D&md5=acafafadd64cfdf6917a026172fa576e</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1039%2FC6RA04337B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6RA04337B%26sid%3Dliteratum%253Aachs%26aulast%3DLasorsa%26aufirst%3DA.%26aulast%3DLosacco%26aufirst%3DM.%26aulast%3DIacobazzi%26aufirst%3DR.%2BM.%26aulast%3DPorcelli%26aufirst%3DL.%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DNatile%26aufirst%3DG.%26aulast%3DArnesano%26aufirst%3DF.%26atitle%3DProbing%2520the%2520Interaction%2520between%2520Cisplatin%2520and%2520the%2520Therapeutic%2520Monoclonal%2520Antibody%2520Trastuzumab%26jtitle%3DRSC%2520Adv.%26date%3D2016%26volume%3D6%26spage%3D29229%26epage%3D29236%26doi%3D10.1039%2FC6RA04337B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Mei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maecker, H. T.</span><span> </span><span class="NLM_article-title">Platinum-Conjugated Antibodies for Application in Mass Cytometry</span> <span class="citation_source-journal">Cytometry, Part A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1002/cyto.a.22778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fcyto.a.22778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26355391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28Xksl2qsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=292-300&author=H.+E.+Meiauthor=M.+D.+Leipoldauthor=H.+T.+Maecker&title=Platinum-Conjugated+Antibodies+for+Application+in+Mass+Cytometry&doi=10.1002%2Fcyto.a.22778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum-conjugated antibodies for application in mass cytometry</span></div><div class="casAuthors">Mei, Henrik E.; Leipold, Michael D.; Maecker, Holden T.</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry, Part A</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-300</span>CODEN:
                <span class="NLM_cas:coden">CPAYAV</span>;
        ISSN:<span class="NLM_cas:issn">1552-4922</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mass cytometry has overcome limitations of fluorescent single cell cytometry by allowing for the measurement of up to currently ∼40 different parameters on a single cell level.  However, the cellular proteome comprises many more potential analytes, and current mass cytometry instrumentation allows for theor. up to 121 different mass detection channels.  The labeling of specific probes with appropriate metal ions is a significant hurdle for exploiting more of mass cytometry's anal. capacity.  To this end, we here describe the labeling of antibody with natural abundance or isotopically purified platinum as formulated in cisplatin and circumventing the use of chelator-loaded polymers.  We confirm the utility of cisplatin-antibody-conjugates for surface, intracellular, and phosphoepitope-specific immunophenotyping, as well as for application in cell surface CD45-based barcoding.  Cisplatin-labeling of antibody increases the anal. capacity of the CyTOF platform by two channels based on available reagents, and has the potential to add a total of six channels for detection of specific probes, thus helping to better extend the anal. mass range of mass cytometers. © 2015 International Society for Advancement of Cytometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorrsgfqkQvM7Vg90H21EOLACvtfcHk0lg_Czrv1mLqNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xksl2qsbc%253D&md5=237ede329da694217c65d93b1fa1005a</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.22778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.22778%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DH.%2BE.%26aulast%3DLeipold%26aufirst%3DM.%2BD.%26aulast%3DMaecker%26aufirst%3DH.%2BT.%26atitle%3DPlatinum-Conjugated%2520Antibodies%2520for%2520Application%2520in%2520Mass%2520Cytometry%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2016%26volume%3D89%26spage%3D292%26epage%3D300%26doi%3D10.1002%2Fcyto.a.22778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Waalboer, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muns, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sijbrandi, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schasfoort, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haselberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somsen, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houthoff, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dongen, G. A.</span><span> </span><span class="NLM_article-title">Platinum(II) as Bifunctional Linker in Antibody-Drug Conjugate Formation: Coupling of a 4-Nitrobenzo-2-Oxa-1,3-Diazole Fluorophore to Trastuzumab as a Model</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1002/cmdc.201402496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fcmdc.201402496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25809281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFWlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=797-803&author=D.+C.+Waalboerauthor=J.+A.+Munsauthor=N.+J.+Sijbrandiauthor=R.+B.+Schasfoortauthor=R.+Haselbergauthor=G.+W.+Somsenauthor=H.+J.+Houthoffauthor=G.+A.+Van+Dongen&title=Platinum%28II%29+as+Bifunctional+Linker+in+Antibody-Drug+Conjugate+Formation%3A+Coupling+of+a+4-Nitrobenzo-2-Oxa-1%2C3-Diazole+Fluorophore+to+Trastuzumab+as+a+Model&doi=10.1002%2Fcmdc.201402496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(II) as bifunctional linker in antibody-drug conjugate formation: Coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model</span></div><div class="casAuthors">Waalboer, Dennis C. J.; Muns, Joey A.; Sijbrandi, Niels J.; Schasfoort, Richard B. M.; Haselberg, Rob; Somsen, Govert W.; Houthoff, Hendrik-Jan; van Dongen, Guus A. M. S.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">797-803</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The potential of platinum(II) as a bifunctional linker in the coordination of small mols., such as imaging agents or (cytotoxic) drugs, to monoclonal antibodies (mAbs) was investigated with a 4-nitrobenzo-2-oxa-1,3-diazole (NBD) fluorophore and trastuzumab (Herceptin®) as a model antibody.  The effect of ligand and reaction conditions on conjugation efficiency was explored for [Pt(en)(L-NBD)Cl](NO3) (en=ethylenediamine), with L=N-heteroarom., N-alkyl amine, or thioether.  Conjugation proceeded most efficiently at pH 8.0 in the presence of NaClO4 or Na2SO4 in tricine or HEPES buffer.  Reaction of N-coordinated complexes (20 equiv) with trastuzumab at 37 °C for 2 h, followed by removal of weakly bound complexes with excess thiourea, afforded conjugates with an NBD/mAb ratio of 1.5-2.9 that were stable in phosphate-buffered saline at room temp. for at least 48 h.  In contrast, thioether-coordinated complexes afforded unstable conjugates.  Finally, surface plasmon resonance anal. showed no loss in binding affinity of trastuzumab after conjugation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn2KJu_pLNwLVg90H21EOLACvtfcHk0lg_Czrv1mLqNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFWlu7k%253D&md5=d25d03ee976ad98150a6c3e7dd299570</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402496%26sid%3Dliteratum%253Aachs%26aulast%3DWaalboer%26aufirst%3DD.%2BC.%26aulast%3DMuns%26aufirst%3DJ.%2BA.%26aulast%3DSijbrandi%26aufirst%3DN.%2BJ.%26aulast%3DSchasfoort%26aufirst%3DR.%2BB.%26aulast%3DHaselberg%26aufirst%3DR.%26aulast%3DSomsen%26aufirst%3DG.%2BW.%26aulast%3DHouthoff%26aufirst%3DH.%2BJ.%26aulast%3DVan%2BDongen%26aufirst%3DG.%2BA.%26atitle%3DPlatinum%2528II%2529%2520as%2520Bifunctional%2520Linker%2520in%2520Antibody-Drug%2520Conjugate%2520Formation%253A%2520Coupling%2520of%2520a%25204-Nitrobenzo-2-Oxa-1%252C3-Diazole%2520Fluorophore%2520to%2520Trastuzumab%2520as%2520a%2520Model%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D797%26epage%3D803%26doi%3D10.1002%2Fcmdc.201402496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Johnstone, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suntharalingam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span> <span class="citation_source-journal">Chem. Rev. (Washington, DC, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">3436</span><span class="NLM_x">–</span> <span class="NLM_lpage">3486</span><span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=3436-3486&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=The+Next+Generation+of+Platinum+Drugs%3A+Targeted+Pt%28II%29+Agents%2C+Nanoparticle+Delivery%2C+and+Pt%28IV%29+Prodrugs&doi=10.1021%2Facs.chemrev.5b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span></div><div class="casAuthors">Johnstone, Timothy C.; Suntharalingam, Kogularamanan; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3436-3486</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic.  Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs.  The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs.  In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs.  The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished.  We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compds., platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes.  Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles.  Addnl. nanoformulations, including supramol. self-assembled structures, proteins, peptides, metal-org. frameworks, and coordination polymers, will then be described.  Finally, the significant clin. progress made by nanoparticle formulations of platinum(II) agents will be reviewed.  We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKCOwDrVtJrVg90H21EOLACvtfcHk0lg_Czrv1mLqNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D&md5=d7adf3279441d8e56bddf501f06cda6e</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00597%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Next%2520Generation%2520of%2520Platinum%2520Drugs%253A%2520Targeted%2520Pt%2528II%2529%2520Agents%252C%2520Nanoparticle%2520Delivery%252C%2520and%2520Pt%2528IV%2529%2520Prodrugs%26jtitle%3DChem.%2520Rev.%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2016%26volume%3D116%26spage%3D3436%26epage%3D3486%26doi%3D10.1021%2Facs.chemrev.5b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Mukhopadhyay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haskel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1021/bc070031k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc070031k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWhtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=39-49&author=S.+Mukhopadhyayauthor=C.+M.+Barnesauthor=A.+Haskelauthor=S.+M.+Shortauthor=K.+R.+Barnesauthor=S.+J.+Lippard&title=Conjugated+Platinum%28IV%29-Peptide+Complexes+for+Targeting+Angiogenic+Tumor+Vasculature&doi=10.1021%2Fbc070031k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature</span></div><div class="casAuthors">Mukhopadhyay, Sumitra; Barnes, Carmen M.; Haskel, Ariel; Short, Sarah M.; Barnes, Katie R.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-49</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The integrins αvβ3 and αvβ5 and the membrane-spanning surface protein aminopeptidase N (APN) are highly expressed in tumor-induced angiogenesis, making them attractive targets for therapeutic intervention.  Both integrins and APN recognize a broad range of peptides contg. RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) motifs, resp.  Here, we describe the design, synthesis, and characterization of a series of mono- and difunctionalized platinum(IV) complexes in which a conjugated peptide motif, contg. RGD, (CRGDC)c, (RGDfK)c, or NGR, is appended as a "tumor-homing device" to target tumor endothelial cells selectively over healthy cells. Platinum(IV)-peptide complexes with nonspecific amino acids or peptide moieties were prepd. as controls.  Concn.-response curves of these compds. were evaluated against primary proliferating endothelial cells and tumor cell lines and compared to those of cisplatin, a well-described platinum-based chemotherapeutic agent.  The Pt(IV)-RGD conjugates were highly and specifically cytotoxic to cell lines contg. αvβ3 and αvβ5, approaching the activity of cisplatin.  The Pt(IV)-NGR complexes were less active than Pt(IV)-RGD-contg. compds. but more active than nonspecific Pt-peptide controls.  Integrin αvβ3 mediated, at least in part, the anti-proliferative effect of a Pt(IV)-RGD conjugate, as demonstrated by a decreased inhibitory response when endothelial cells were either (1) incubated with an excess of αvβ3/αvβ5-specific RGD pentapeptides or (2) transfected with RNAi for β3, but not β1, integrins.  These results suggest a rational approach to improved chemotherapy with Pt(IV)-peptide conjugates by selective drug delivery to the tumor compartment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl92LLNxja-rVg90H21EOLACvtfcHk0liFMfKsc7pRKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWhtbzJ&md5=d12897f15d2582321ee037868e81c87c</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fbc070031k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc070031k%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DS.%26aulast%3DBarnes%26aufirst%3DC.%2BM.%26aulast%3DHaskel%26aufirst%3DA.%26aulast%3DShort%26aufirst%3DS.%2BM.%26aulast%3DBarnes%26aufirst%3DK.%2BR.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DConjugated%2520Platinum%2528IV%2529-Peptide%2520Complexes%2520for%2520Targeting%2520Angiogenic%2520Tumor%2520Vasculature%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D39%26epage%3D49%26doi%3D10.1021%2Fbc070031k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Massaguer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Canto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escribano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrabes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artigas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchan, V.</span><span> </span><span class="NLM_article-title">Integrin-Targeted Delivery into Cancer Cells of a Pt(IV) Pro-Drug through Conjugation to Rgd-Containing Peptides</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1039/C4DT02710H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC4DT02710H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25369773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGisr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=202-212&author=A.+Massaguerauthor=A.+Gonzalez-Cantoauthor=E.+Escribanoauthor=S.+Barrabesauthor=G.+Artigasauthor=V.+Morenoauthor=V.+Marchan&title=Integrin-Targeted+Delivery+into+Cancer+Cells+of+a+Pt%28IV%29+Pro-Drug+through+Conjugation+to+Rgd-Containing+Peptides&doi=10.1039%2FC4DT02710H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides</span></div><div class="casAuthors">Massaguer, Anna; Gonzalez-Canto, Alejandro; Escribano, Esther; Barrabes, Silvia; Artigas, Gerard; Moreno, Virtudes; Marchan, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">202-212</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Conjugates of a Pt(IV) deriv. of picoplatin with monomeric (Pt-c(RGDfK)), (5) and tetrameric (Pt-RAFT-{c(RGDfK)}4), (6) RGD-contg. peptides were synthesized with the aim of exploiting their selectivity and high affinity for αVβ3 and αVβ5 integrins for targeted delivery of this anticancer metallodrug to tumor cells overexpressing these receptors.  Solid- and soln.-phase approaches in combination with click chem. were used for the prepn. of the conjugates, which were characterized by high resoln. ESI MS and NMR.  αVβ3 And αVβ5 integrin expression was evaluated in a broad panel of human cancer and non-malignant cells.  SK-MEL-28 melanoma cells were selected based on the high expression levels of both integrins, while CAPAN-1 pancreatic cancer cells and 1BR3G fibroblasts were selected as the neg. control.  Internalization expts. revealed a good correlation between integrin expression and the cellular uptake of the corresponding fluorescein-labeled peptides and that the internalization capacity of the tetrameric RGD-contg. peptide was considerably higher than that of the monomeric one.  Cytotoxic expts. indicated that the antitumor activity of picoplatin in melanoma cells was increased by 2.6-fold when its Pt(IV) deriv. was conjugated to c(RGDfK) (IC50 = 12.8 ± 2.1 μM) and by 20-fold when conjugated to RAFT-{c(RGDfK)}4 (IC50 = 1.7 ± 0.6 μM).  In contrast, the cytotoxicity of the conjugates was inhibited in control cells lacking αVβ3 and αVβ5 integrin expression.  Finally, cellular uptake studies by ICP-MS confirmed a good correlation between the levels of expression of integrins, intracellular platinum accumulation and antitumor activity.  Indeed, accumulation and cytotoxicity were much higher in SK-MEL-28 cells than in CAPAN-1, being particularly higher in the case of the tetrameric conjugate.  The overall results highlight that the great ability of RAFT-{c(RGDfK)}4 to bind to and to be internalized by integrins overexpressed in SK-MEL-28 cells results in higher accumulation of the Pt(IV) complex, leading to a high antitumor activity.  These studies provide new insights into the potential of targeting αVβ3 and αVβ5 integrins with Pt(IV) anticancer pro-drugs conjugated to tumor-targeting devices based on RGD-contg. peptides, particularly on how multivalency can improve both the selectivity and potency of such metallodrugs by increasing cellular accumulation in tumor tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIlGCFXdzfPbVg90H21EOLACvtfcHk0liFMfKsc7pRKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGisr3F&md5=9df742389cee81f670e03c5aafb7282b</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1039%2FC4DT02710H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4DT02710H%26sid%3Dliteratum%253Aachs%26aulast%3DMassaguer%26aufirst%3DA.%26aulast%3DGonzalez-Canto%26aufirst%3DA.%26aulast%3DEscribano%26aufirst%3DE.%26aulast%3DBarrabes%26aufirst%3DS.%26aulast%3DArtigas%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DMarchan%26aufirst%3DV.%26atitle%3DIntegrin-Targeted%2520Delivery%2520into%2520Cancer%2520Cells%2520of%2520a%2520Pt%2528IV%2529%2520Pro-Drug%2520through%2520Conjugation%2520to%2520Rgd-Containing%2520Peptides%26jtitle%3DDalton%2520Trans.%26date%3D2015%26volume%3D44%26spage%3D202%26epage%3D212%26doi%3D10.1039%2FC4DT02710H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Gibson, D.</span><span> </span><span class="NLM_article-title">The Mechanism of Action of Platinum Anticancer Agents--What Do We Really Know About It?</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">10681</span><span class="NLM_x">–</span> <span class="NLM_lpage">10689</span><span class="refDoi"> DOI: 10.1039/b918871c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2Fb918871c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=10681-10689&author=D.+Gibson&title=The+Mechanism+of+Action+of+Platinum+Anticancer+Agents%2D%2DWhat+Do+We+Really+Know+About+It%3F&doi=10.1039%2Fb918871c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1039%2Fb918871c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb918871c%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DThe%2520Mechanism%2520of%2520Action%2520of%2520Platinum%2520Anticancer%2520Agents--What%2520Do%2520We%2520Really%2520Know%2520About%2520It%253F%26jtitle%3DDalton%2520Trans.%26date%3D2009%26volume%3D48%26spage%3D10681%26epage%3D10689%26doi%3D10.1039%2Fb918871c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Klein, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Platinum Drug Distribution in Cancer Cells and Tumors</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">4911</span><span class="NLM_x">–</span> <span class="NLM_lpage">4920</span><span class="refDoi"> DOI: 10.1021/cr9001066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9001066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGktbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=4911-4920&author=A.+V.+Kleinauthor=T.+W.+Hambley&title=Platinum+Drug+Distribution+in+Cancer+Cells+and+Tumors&doi=10.1021%2Fcr9001066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum Drug Distribution in Cancer Cells and Tumors</span></div><div class="casAuthors">Klein, Alice V.; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4911-4920</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the recent advances made in the understanding of how the platinum drug enter and exit cells, their intracellular behavior and distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorm8HZ2Ow8obVg90H21EOLACvtfcHk0liFMfKsc7pRKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGktbrK&md5=52e875daab0f8922c581179d988b094c</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fcr9001066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9001066%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DA.%2BV.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DPlatinum%2520Drug%2520Distribution%2520in%2520Cancer%2520Cells%2520and%2520Tumors%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D4911%26epage%3D4920%26doi%3D10.1021%2Fcr9001066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Molenaar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teuben, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heetebrij, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reedijk, J.</span><span> </span><span class="NLM_article-title">New Insights in the Cellular Processing of Platinum Antitumor Compounds, Using Fluorophore-Labeled Platinum Complexes and Digital Fluorescence Microscopy</span> <span class="citation_source-journal">JBIC, J. Biol. Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1007/s007750000153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2Fs007750000153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11085656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=655-665&author=C.+Molenaarauthor=J.+M.+Teubenauthor=R.+J.+Heetebrijauthor=H.+J.+Tankeauthor=J.+Reedijk&title=New+Insights+in+the+Cellular+Processing+of+Platinum+Antitumor+Compounds%2C+Using+Fluorophore-Labeled+Platinum+Complexes+and+Digital+Fluorescence+Microscopy&doi=10.1007%2Fs007750000153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy</span></div><div class="casAuthors">Molenaar, Chris; Teuben, Jan-Maarten; Heetebrij, Robert J.; Tanke, Hans J.; Reedijk, Jan</div><div class="citationInfo"><span class="NLM_cas:title">JBIC, Journal of Biological Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-665</span>CODEN:
                <span class="NLM_cas:coden">JJBCFA</span>;
        ISSN:<span class="NLM_cas:issn">0949-8257</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The cellular distribution and processing pathways of two platinum compds., modeling the antitumor drug cisplatin (cDDP) in human osteosarcoma (U2-OS) cells is reported.  A [Pt(en)Cl2] entity has been covalently linked to a carboxyfluorescein diacetate (CFDA) moiety and to a dinitrophenyl (DNP) moiety.  The two different constructs were administered to living cell cultures that were analyzed using digital fluorescence microscopy.  The non-fluorescent CFDA construct becomes fluorescent after cellular uptake and subsequent acetate hydrolysis by esterases, and is therefore suitable to monitor platinum in living cells; the DNP construct can be visualized by immunocytochem. and consequently serves as a control.  Both complexes were readily internalized by the cells, and localized throughout the whole cell.  After 2-3 h the complex accumulated in the nucleus, but 6-8 h after incubation a punctuate staining of a cytoplasmic region was obsd., that persisted and became more pronounced after 24 h.  The overall fluorescence in the cell decreased over time, implying a secretion of the platinum complex.  Surprisingly, the accumulation remained visible after 72 h.  Co-localization expts. with a Golgi app.-selective stain indicate the involvement of Golgi vesicles in intracellular processing of cisplatin-derived complexes.  Immunocytochem. studies, using the DNP deriv., resulted in very similar images as obtained with the CFDA construct.  CFDA-boc (a non-platinum-contg. fluorescein deriv.) was used as control: a faint staining throughout the whole cell was obsd.  Cisplatin-resistant U2-OS/Pt cells showed staining patterns very similar to the U2-OS cells using both platinum constructs.  This study illustrates that only a very small portion of the platinum complex eventually remains bound to DNA, as after 24 h no significant fluorescence could be obsd. in the nucleus.  Cisplatin-derived complexes with fluorescent tags afford a new insight into the cellular processing of these complexes and therefore may contribute to further unraveling of the mechanism of platinum antitumor complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1jhTmbtSu_bVg90H21EOLACvtfcHk0ljLRaNVuQCU3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1Gkurg%253D&md5=d2ccdb9612fed820d117245012efa594</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1007%2Fs007750000153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs007750000153%26sid%3Dliteratum%253Aachs%26aulast%3DMolenaar%26aufirst%3DC.%26aulast%3DTeuben%26aufirst%3DJ.%2BM.%26aulast%3DHeetebrij%26aufirst%3DR.%2BJ.%26aulast%3DTanke%26aufirst%3DH.%2BJ.%26aulast%3DReedijk%26aufirst%3DJ.%26atitle%3DNew%2520Insights%2520in%2520the%2520Cellular%2520Processing%2520of%2520Platinum%2520Antitumor%2520Compounds%252C%2520Using%2520Fluorophore-Labeled%2520Platinum%2520Complexes%2520and%2520Digital%2520Fluorescence%2520Microscopy%26jtitle%3DJBIC%252C%2520J.%2520Biol.%2520Inorg.%2520Chem.%26date%3D2000%26volume%3D5%26spage%3D655%26epage%3D665%26doi%3D10.1007%2Fs007750000153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Benedetti, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabolizadeh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipping, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, N. P.</span><span> </span><span class="NLM_article-title">Effects of Noncovalent Platinum Drug–Protein Interactions on Drug Efficacy: Use of Fluorescent Conjugates as Probes for Drug Metabolism</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">–</span> <span class="NLM_lpage">948</span><span class="refDoi"> DOI: 10.1021/mp2000583</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2000583" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVCntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=940-948&author=B.+T.+Benedettiauthor=E.+J.+Petersonauthor=P.+Kabolizadehauthor=A.+Mart%C3%ADnezauthor=R.+Kippingauthor=N.+P.+Farrell&title=Effects+of+Noncovalent+Platinum+Drug%E2%80%93Protein+Interactions+on+Drug+Efficacy%3A+Use+of+Fluorescent+Conjugates+as+Probes+for+Drug+Metabolism&doi=10.1021%2Fmp2000583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Noncovalent Platinum Drug-Protein Interactions on Drug Efficacy: Use of Fluorescent Conjugates as Probes for Drug Metabolism</span></div><div class="casAuthors">Benedetti, Brad T.; Peterson, Erica J.; Kabolizadeh, Peyman; Martinez, Alberto; Kipping, Ralph; Farrell, Nicholas P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">940-948</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The overall efficacy of Pt based drugs is limited by metabolic deactivation through covalent drug-protein binding.  In this study the factors affecting cytotoxicity in the presence of glutathione, human serum albumin (HSA) and whole serum binding with cisplatin, BBR3464, and TriplatinNC, a "noncovalent" deriv. of BBR3464, were investigated.  Upon treatment with buthionine sulfoximine (BSO), to reduce cellular glutathione levels, cisplatin and BBR3464-induced apoptosis was augmented whereas TriplatinNC-induced cytotoxicity was unaltered.  Treatment of A2780 ovarian carcinoma cells with HSA-bound cisplatin (cisplatin/HSA) and cisplatin preincubated with whole serum showed dramatic decreases in cytotoxicity, cellular accumulation, and DNA adduct formation compared to treatment with cisplatin alone.  Similar effects are seen with BBR3464.  In contrast, TriplatinNC, the HSA-bound deriv. (TriplatinNC/HSA), and TriplatinNC pretreated with whole serum retained identical cytotoxic profiles and equal levels of cellular accumulation at all time points.  Confocal microscopy of both TriplatinNC-NBD, a fluorescent deriv. of TriplatinNC, and TriplatinNC-NBD/HSA showed nuclear/nucleolar localization patterns, distinctly different from the lysosomal localization pattern seen with HSA.  Cisplatin-NBD, a fluorescent deriv. of cisplatin, was shown to accumulate in the nucleus and throughout the cytoplasm while the localization of cisplatin-NBD/HSA was limited to lysosomal regions of the cytoplasm.  The results suggest that TriplatinNC can avoid high levels of metabolic deactivation currently seen with clin. Pt chemotherapeutics, and therefore retain a unique cytotoxic profile after cellular administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxV4dRhBw_NLVg90H21EOLACvtfcHk0ljLRaNVuQCU3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVCntb4%253D&md5=a8f72f2d13d66440db7a189a5e544d5f</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fmp2000583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2000583%26sid%3Dliteratum%253Aachs%26aulast%3DBenedetti%26aufirst%3DB.%2BT.%26aulast%3DPeterson%26aufirst%3DE.%2BJ.%26aulast%3DKabolizadeh%26aufirst%3DP.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DKipping%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DN.%2BP.%26atitle%3DEffects%2520of%2520Noncovalent%2520Platinum%2520Drug%25E2%2580%2593Protein%2520Interactions%2520on%2520Drug%2520Efficacy%253A%2520Use%2520of%2520Fluorescent%2520Conjugates%2520as%2520Probes%2520for%2520Drug%2520Metabolism%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2011%26volume%3D8%26spage%3D940%26epage%3D948%26doi%3D10.1021%2Fmp2000583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Miller, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askevold, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span> </span><span class="NLM_article-title">Platinum Compounds for High-Resolution in Vivo Cancer Imaging</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1131</span><span class="NLM_x">–</span> <span class="NLM_lpage">1135</span><span class="refDoi"> DOI: 10.1002/cmdc.201300502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fcmdc.201300502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24504646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVekt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1131-1135&author=M.+A.+Millerauthor=B.+Askevoldauthor=K.+S.+Yangauthor=R.+H.+Kohlerauthor=R.+Weissleder&title=Platinum+Compounds+for+High-Resolution+in+Vivo+Cancer+Imaging&doi=10.1002%2Fcmdc.201300502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum Compounds for High-Resolution In Vivo Cancer Imaging</span></div><div class="casAuthors">Miller, Miles A.; Askevold, Bjorn; Yang, Katherine S.; Kohler, Rainer H.; Weissleder, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1131-1135</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Platinum(II) compds., principally cisplatin and carboplatin, are commonly used front-line cancer therapeutics.  Despite their widespread use and continued interest in the development of new derivs., including nanoformulations with improved properties, it has been difficult to visualize platinum compds. in live subjects, in real time, and with subcellular resoln.  Here, we present four novel cisplatin- and carboplatin-derived fluorescent imaging compds. for quant. intravital cancer imaging.  We conjugated 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-daiza-s-indacene (BODIPY) to PtII complexes to generate derivs. with robust in vivo fluorescence and retained DNA-damaging and cytotoxic properties.  We successfully applied these compds. to image pharmacokinetics and tumor uptake in a xenograft cancer mouse model.  By using a genetic reporter of single-cell DNA damage for in vivo imaging, Pt drug accumulation and resultant DNA damage could be monitored in individual tumor cells, at subcellular resoln., and in real time in a live animal model of cancer.  These derivs. represent promising imaging tools that will be useful in understanding further the distribution and interactions of platinum within tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvplifjSYPt7Vg90H21EOLACvtfcHk0ljLRaNVuQCU3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVekt7k%253D&md5=7ff23d3297f04be571c770a0b14f6a16</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300502%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BA.%26aulast%3DAskevold%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DK.%2BS.%26aulast%3DKohler%26aufirst%3DR.%2BH.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DPlatinum%2520Compounds%2520for%2520High-Resolution%2520in%2520Vivo%2520Cancer%2520Imaging%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1131%26epage%3D1135%26doi%3D10.1002%2Fcmdc.201300502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Jagodinsky, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulima, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poprawski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. D.</span><span> </span><span class="NLM_article-title">Evaluation of Fluorophore-Tethered Platinum Complexes to Monitor the Fate of Cisplatin Analogs</span> <span class="citation_source-journal">JBIC, J. Biol. Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1081</span><span class="NLM_x">–</span> <span class="NLM_lpage">1095</span><span class="refDoi"> DOI: 10.1007/s00775-015-1290-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2Fs00775-015-1290-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26323351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVaisLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1081-1095&author=J.+C.+Jagodinskyauthor=A.+Sulimaauthor=Y.+Caoauthor=J.+E.+Poprawskiauthor=B.+N.+Blackmanauthor=J.+R.+Lloydauthor=R.+E.+Swensonauthor=M.+M.+Gottesmanauthor=M.+D.+Hall&title=Evaluation+of+Fluorophore-Tethered+Platinum+Complexes+to+Monitor+the+Fate+of+Cisplatin+Analogs&doi=10.1007%2Fs00775-015-1290-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs</span></div><div class="casAuthors">Jagodinsky, Justin C.; Sulima, Agnieszka; Cao, Yiqi; Poprawski, Joanna E.; Blackman, Burchelle N.; Lloyd, John R.; Swenson, Rolf E.; Gottesman, Michael M.; Hall, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">JBIC, Journal of Biological Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1081-1095</span>CODEN:
                <span class="NLM_cas:coden">JJBCFA</span>;
        ISSN:<span class="NLM_cas:issn">0949-8257</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a consequence have been extensively studied in the lab. setting, sometimes by generating fluorophore-tagged analogs.  Here, we synthesized two Pt(II) complexes contg. ethane-1,2-diamine ligands linked to a BODIPY fluorophore, and compared their biol. activity with previously reported Pt(II) complexes conjugated to carboxyfluorescein and carboxyfluorescein diacetate.  The cytotoxicity and DNA damage capacity of Pt-fluorophore complexes was compared to cisplatin, and the Pt-BODIPY complexes were found to be more cytotoxic with reduced cytotoxicity in cisplatin-resistant cells.  Microscopy revealed a predominately cytosolic localization, with nuclear distribution at higher concns.  Spheroids grown from parent and resistant cells revealed penetration of Pt-BODIPY into spheroids, and retention of the cisplatin-resistant spheroid phenotype.  While most activity profiles were retained for the Pt-BODIPY complexes, accumulation in resistant cells was only slightly affected, suggesting that some aspects of Pt-fluorophore cellular pharmacol. deviate from cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0bql22wYtrVg90H21EOLACvtfcHk0lio0YwpDW0V0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVaisLfO&md5=33269481f79d3d8e81007a0fa0952e26</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1007%2Fs00775-015-1290-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00775-015-1290-2%26sid%3Dliteratum%253Aachs%26aulast%3DJagodinsky%26aufirst%3DJ.%2BC.%26aulast%3DSulima%26aufirst%3DA.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DPoprawski%26aufirst%3DJ.%2BE.%26aulast%3DBlackman%26aufirst%3DB.%2BN.%26aulast%3DLloyd%26aufirst%3DJ.%2BR.%26aulast%3DSwenson%26aufirst%3DR.%2BE.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DEvaluation%2520of%2520Fluorophore-Tethered%2520Platinum%2520Complexes%2520to%2520Monitor%2520the%2520Fate%2520of%2520Cisplatin%2520Analogs%26jtitle%3DJBIC%252C%2520J.%2520Biol.%2520Inorg.%2520Chem.%26date%3D2015%26volume%3D20%26spage%3D1081%26epage%3D1095%26doi%3D10.1007%2Fs00775-015-1290-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Shen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, B. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charles, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, E. J.</span><span> </span><span class="NLM_article-title">Fluorescent Sensing of Monofunctional Platinum Species</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6312</span><span class="NLM_x">–</span> <span class="NLM_lpage">6314</span><span class="refDoi"> DOI: 10.1039/C4CC08077G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC4CC08077G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25760940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1OmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=6312-6314&author=C.+Shenauthor=B.+D.+W.+Harrisauthor=L.+J.+Dawsonauthor=K.+A.+Charlesauthor=T.+W.+Hambleyauthor=E.+J.+New&title=Fluorescent+Sensing+of+Monofunctional+Platinum+Species&doi=10.1039%2FC4CC08077G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent sensing of monofunctional platinum species</span></div><div class="casAuthors">Shen, Clara; Harris, Benjamin D. W.; Dawson, Lucy J.; Charles, Kellie A.; Hambley, Trevor W.; New, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">6312-6314</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We report here FDCPt1, a novel selective fluorescent sensor for monofunctional platinum species.  In the presence of such species, FDCPt1 exhibits a 70-fold increase in fluorescence emission, and can be used to monitor the metab. of Pt(II)-based complexes in colorectal cancer cells.  This probe is therefore expected to be valuable in studying changes in Pt coordination and distribution during chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_LtQgEYE1MLVg90H21EOLACvtfcHk0lio0YwpDW0V0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1OmtLc%253D&md5=7a5d1712a6d27ef4ca0ba5e0d3f4d2ac</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1039%2FC4CC08077G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC08077G%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DB.%2BD.%2BW.%26aulast%3DDawson%26aufirst%3DL.%2BJ.%26aulast%3DCharles%26aufirst%3DK.%2BA.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26aulast%3DNew%26aufirst%3DE.%2BJ.%26atitle%3DFluorescent%2520Sensing%2520of%2520Monofunctional%2520Platinum%2520Species%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26spage%3D6312%26epage%3D6314%26doi%3D10.1039%2FC4CC08077G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Ding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suryadi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrs, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucera, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bierbach, U.</span><span> </span><span class="NLM_article-title">Using Fluorescent Post-Labeling to Probe the Subcellular Localization of DNA-Targeted Platinum</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3350</span><span class="NLM_x">–</span> <span class="NLM_lpage">3354</span><span class="refDoi"> DOI: 10.1002/anie.201210079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fanie.201210079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=3350-3354&author=S.+Dingauthor=X.+Qiaoauthor=J.+Suryadiauthor=G.+S.+Marrsauthor=G.+L.+Kuceraauthor=U.+Bierbach&title=Using+Fluorescent+Post-Labeling+to+Probe+the+Subcellular+Localization+of+DNA-Targeted+Platinum&doi=10.1002%2Fanie.201210079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1002%2Fanie.201210079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201210079%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DS.%26aulast%3DQiao%26aufirst%3DX.%26aulast%3DSuryadi%26aufirst%3DJ.%26aulast%3DMarrs%26aufirst%3DG.%2BS.%26aulast%3DKucera%26aufirst%3DG.%2BL.%26aulast%3DBierbach%26aufirst%3DU.%26atitle%3DUsing%2520Fluorescent%2520Post-Labeling%2520to%2520Probe%2520the%2520Subcellular%2520Localization%2520of%2520DNA-Targeted%2520Platinum%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D3350%26epage%3D3354%26doi%3D10.1002%2Fanie.201210079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Multifunctional Pt(II) Reagents: Covalent Modifications of Pt Complexes Enable Diverse Structural Variation and in-Cell Detection</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span><span class="refDoi"> DOI: 10.1021/acs.accounts.5b00322</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.5b00322" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=56-66&author=J.+D.+Whiteauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Multifunctional+Pt%28II%29+Reagents%3A+Covalent+Modifications+of+Pt+Complexes+Enable+Diverse+Structural+Variation+and+in-Cell+Detection&doi=10.1021%2Facs.accounts.5b00322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional Pt(II) Reagents: Covalent Modifications of Pt Complexes Enable Diverse Structural Variation and In-Cell Detection</span></div><div class="casAuthors">White, Jonathan D.; Haley, Michael M.; DeRose, Victoria J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-66</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To enhance the functionality of Pt-based reagents, several strategies have been developed that utilize Pt compds. modified with small, reactive handles.  This Account encapsulates work done by us and other groups regarding the use of Pt(II) compds. with reactive handles for subsequent elaboration with fluorophores or other functional moieties.  Described strategies include the incorporation of substituents for well-known condensation or nucleophilic displacement-type reactions and their use, for example, to tether spectroscopic handles to Pt reagents for in vivo investigation.  Other chief uses of displacement-type reactions have included tethering various small mols. exhibiting pharmacol. activity directly to Pt, thus adding synergistic effects.  Click chem.-based ligation techniques have also been applied, primarily with azide- and alkyne-appended Pt complexes.  Orthogonally reactive click chem. reactions have proven invaluable when more traditional nucleophilic displacement reactions induce side-reactivity with the Pt center or when systematic functionalization of a larger no. of Pt complexes is desired.  Addnl., a diverse assortment of Pt-fluorophore conjugates have been tethered via click chem. conjugation.In addn. to providing a convenient synthetic path for diversifying Pt compds., the use of click-capable Pt complexes has proved a powerful strategy for postbinding covalent modification and detection with fluorescent probes.  This strategy bypasses undesirable influences of the fluorophore camouflaged as reactivity due to Pt that may be present when detecting preattached Pt-fluorophore conjugates.  Using postbinding strategies, Pt reagent distributions in HeLa and lung carcinoma (NCI-H460) cell cultures were obsd. with two different azide-modified Pt compds., a monofunctional Pt(II)-acridine type and a difunctional Pt(II)-neutral complex.  In addn., cellular distribution was obsd. with an alkyne-appended difunctional Pt(II)-neutral complex analogous in structure to the aforementioned difunctional azide-Pt(II) reagent.  In all cases, significant accumulation of Pt in the nucleolus of cells was obsd., in addn. to broader localization in the nucleus and cytoplasm of the cell.  Using the same strategy of postbinding click modification with fluorescent probes, Pt adducts were detected and roughly quantified on rRNA and tRNA from Pt-treated Saccharomyces cerevisiae; rRNA adducts were found to be relatively long-lived and not targeted for immediate degrdn.  Finally, the utility and feasibility of the alkyne-appended Pt(II) compd. has been further demonstrated with a turn-on fluorophore, dansyl azide, in fluorescent detection of DNA in vitro.  In all, these modifications utilizing reactive handles have allowed for the diversification of new Pt reagents, as well as providing cellular localization information on the modified Pt compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGjFtBGJz6bVg90H21EOLACvtfcHk0lio0YwpDW0V0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVKjtA%253D%253D&md5=970ee8014f7d331730938aec5cc3255a</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.5b00322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.5b00322%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DMultifunctional%2520Pt%2528II%2529%2520Reagents%253A%2520Covalent%2520Modifications%2520of%2520Pt%2520Complexes%2520Enable%2520Diverse%2520Structural%2520Variation%2520and%2520in-Cell%2520Detection%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2016%26volume%3D49%26spage%3D56%26epage%3D66%26doi%3D10.1021%2Facs.accounts.5b00322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborn, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Picazoplatin, an Azide-Containing Platinum(II) Derivative for Target Analysis by Click Chemistry</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">11680</span><span class="NLM_x">–</span> <span class="NLM_lpage">11683</span><span class="refDoi"> DOI: 10.1021/ja402453k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja402453k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=11680-11683&author=J.+D.+Whiteauthor=M.+F.+Osbornauthor=A.+D.+Moghaddamauthor=L.+E.+Guzmanauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Picazoplatin%2C+an+Azide-Containing+Platinum%28II%29+Derivative+for+Target+Analysis+by+Click+Chemistry&doi=10.1021%2Fja402453k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Picazoplatin, an Azide-Containing Platinum(II) Derivative for Target Analysis by Click Chemistry</span></div><div class="casAuthors">White, Jonathan D.; Osborn, Maire F.; Moghaddam, Alan D.; Guzman, Lindsay E.; Haley, Michael M.; DeRose, Victoria J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">11680-11683</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the broad use of platinum-based chemotherapeutics, identification of their full range of cellular targets remains a significant challenge.  In order to identify, visualize, and isolate cellular targets of Pt(II) complexes, we have modified the chemotherapeutic drug picoplatin with an azide moiety for subsequent click reactivity.  The new compd. picazoplatin readily binds DNA and RNA oligonucleotides and undergoes facile post-labeling click reactions to alkyne-fluorophore conjugates.  Pt-fluorophore click reactions in rRNA purified from drug-treated Saccharomyces cerevisiae demonstrate its potential for future in vivo efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobeJ8Hr79T4rVg90H21EOLACvtfcHk0ljC7zz1ithCBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgur3F&md5=b973d9c9d069af55729033bbd6e361e7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fja402453k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja402453k%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DOsborn%26aufirst%3DM.%2BF.%26aulast%3DMoghaddam%26aufirst%3DA.%2BD.%26aulast%3DGuzman%26aufirst%3DL.%2BE.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DPicazoplatin%252C%2520an%2520Azide-Containing%2520Platinum%2528II%2529%2520Derivative%2520for%2520Target%2520Analysis%2520by%2520Click%2520Chemistry%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D11680%26epage%3D11683%26doi%3D10.1021%2Fja402453k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Osborn, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Platinum-Rna Modifications Following Drug Treatment in <i>S. Cerevisiae</i> Identified by Click Chemistry and Enzymatic Mapping</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2404</span><span class="NLM_x">–</span> <span class="NLM_lpage">2411</span><span class="refDoi"> DOI: 10.1021/cb500395z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500395z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2404-2411&author=M.+F.+Osbornauthor=J.+D.+Whiteauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Platinum-Rna+Modifications+Following+Drug+Treatment+in+S.+Cerevisiae+Identified+by+Click+Chemistry+and+Enzymatic+Mapping&doi=10.1021%2Fcb500395z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fcb500395z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500395z%26sid%3Dliteratum%253Aachs%26aulast%3DOsborn%26aufirst%3DM.%2BF.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DPlatinum-Rna%2520Modifications%2520Following%2520Drug%2520Treatment%2520in%2520S.%2520Cerevisiae%2520Identified%2520by%2520Click%2520Chemistry%2520and%2520Enzymatic%2520Mapping%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D2404%26epage%3D2411%26doi%3D10.1021%2Fcb500395z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Moghaddam, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loes, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Convenient Detection of Metal-DNA, Metal-RNA, and Metal-Protein Adducts with a Click-Modified Pt(II) Complex</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3536</span><span class="NLM_x">–</span> <span class="NLM_lpage">3539</span><span class="refDoi"> DOI: 10.1039/C4DT02649G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC4DT02649G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=3536-3539&author=A.+D.+Moghaddamauthor=J.+D.+Whiteauthor=R.+M.+Cunninghamauthor=A.+N.+Loesauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Convenient+Detection+of+Metal-DNA%2C+Metal-RNA%2C+and+Metal-Protein+Adducts+with+a+Click-Modified+Pt%28II%29+Complex&doi=10.1039%2FC4DT02649G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1039%2FC4DT02649G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4DT02649G%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DA.%2BD.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DCunningham%26aufirst%3DR.%2BM.%26aulast%3DLoes%26aufirst%3DA.%2BN.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DConvenient%2520Detection%2520of%2520Metal-DNA%252C%2520Metal-RNA%252C%2520and%2520Metal-Protein%2520Adducts%2520with%2520a%2520Click-Modified%2520Pt%2528II%2529%2520Complex%26jtitle%3DDalton%2520Trans.%26date%3D2015%26volume%3D44%26spage%3D3536%26epage%3D3539%26doi%3D10.1039%2FC4DT02649G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Wirth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginzburg, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakharov, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Azide Vs Alkyne Functionalization in Pt(II) Complexes for Post-Treatment Click Modification: Solid-State Structure, Fluorescent Labeling, and Cellular Fate</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">15169</span><span class="NLM_x">–</span> <span class="NLM_lpage">15175</span><span class="refDoi"> DOI: 10.1021/jacs.5b09108</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b09108" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=15169-15175&author=R.+Wirthauthor=J.+D.+Whiteauthor=A.+D.+Moghaddamauthor=A.+L.+Ginzburgauthor=L.+N.+Zakharovauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Azide+Vs+Alkyne+Functionalization+in+Pt%28II%29+Complexes+for+Post-Treatment+Click+Modification%3A+Solid-State+Structure%2C+Fluorescent+Labeling%2C+and+Cellular+Fate&doi=10.1021%2Fjacs.5b09108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Azide vs Alkyne Functionalization in Pt(II) Complexes for Post-treatment Click Modification: Solid-State Structure, Fluorescent Labeling, and Cellular Fate</span></div><div class="casAuthors">Wirth, Regina; White, Jonathan D.; Moghaddam, Alan D.; Ginzburg, Aurora L.; Zakharov, Lev N.; Haley, Michael M.; DeRose, Victoria J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">15169-15175</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tracking of Pt(II) complexes is of crucial importance toward understanding Pt interactions with cellular biomols.  Post-treatment fluorescent labeling of functionalized Pt(II)-based agents using the bioorthogonal Cu(I)-catalyzed azide-alkyne cycloaddn. (CuAAC) reaction has recently been reported as a promising approach.  Here we describe an azide-functionalized Pt(II) complex, cis-[Pt(2-azidobutyl)amido-1,3-propanediamine)Cl2] (1), contg. the cis geometry and difunctional reactivity of cisplatin, and present a comparative study with its previously described alkyne-functionalized congener.  Single-crystal X-ray diffraction reveals a dramatic change in the solid-state arrangement with exchange of the alkyne for an azide moiety wherein 1 is dominated by a pseudo-chain of Pt-Pt dimers and antiparallel alignment of the azide substituents, in comparison with a circular arrangement supported by CH/π(C≡C) interactions in the alkyne version.  In vitro studies indicate similar DNA binding and click reactivity of both congeners obsd. by fluorescent labeling.  Interestingly, complex 1 shows in vitro enhanced click reactivity in comparison to a previously reported azide-appended Pt(II) complex.  Despite their similar behavior in vitro, preliminary in cellulo HeLa studies indicate a superior imaging potential of azide-functionalized 1.  Post-treatment fluorescent labeling of 1 obsd. by confocal fluorescence microscopy shows nuclear and intense nucleolar localization.  These results demonstrate the potential of 1 in different cell line localization studies and for future isolation and purifn. of Pt-bound targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfj_swPULuT7Vg90H21EOLACvtfcHk0lj6GmuvfkLFNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjur%252FO&md5=2b636ad1f0177c0be0c880b54ab49edf</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b09108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b09108%26sid%3Dliteratum%253Aachs%26aulast%3DWirth%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DMoghaddam%26aufirst%3DA.%2BD.%26aulast%3DGinzburg%26aufirst%3DA.%2BL.%26aulast%3DZakharov%26aufirst%3DL.%2BN.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DAzide%2520Vs%2520Alkyne%2520Functionalization%2520in%2520Pt%2528II%2529%2520Complexes%2520for%2520Post-Treatment%2520Click%2520Modification%253A%2520Solid-State%2520Structure%252C%2520Fluorescent%2520Labeling%252C%2520and%2520Cellular%2520Fate%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D15169%26epage%3D15175%26doi%3D10.1021%2Fjacs.5b09108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 51 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Benelita T. Elie, Karen Hubbard, Buddhadev Layek, Won Seok Yang, Swayam Prabha, Joe W. Ramos, <span class="NLM_string-name hlFld-ContribAuthor">Maria Contel</span>. </span><span class="cited-content_cbyCitation_article-title">Auranofin-Based Analogues Are Effective Against Clear Cell Renal Carcinoma In Vivo and Display No Significant Systemic Toxicity. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2020,</strong> <em>3 </em>
                                    (4)
                                     , 644-654. <a href="https://doi.org/10.1021/acsptsci.9b00107" title="DOI URL">https://doi.org/10.1021/acsptsci.9b00107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.9b00107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.9b00107%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DAuranofin-Based%252BAnalogues%252BAre%252BEffective%252BAgainst%252BClear%252BCell%252BRenal%252BCarcinoma%252BIn%252BVivo%252Band%252BDisplay%252BNo%252BSignificant%252BSystemic%252BToxicity%26aulast%3DElie%26aufirst%3DBenelita%2BT.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D22112019%26date%3D17042020%26date%3D09042020%26volume%3D3%26issue%3D4%26spage%3D644%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiyuan Yao, Christopher M. Tracy, <span class="NLM_string-name hlFld-ContribAuthor">Ulrich Bierbach</span>. </span><span class="cited-content_cbyCitation_article-title">Cysteine-Directed Bioconjugation of a Platinum(II)–Acridine Anticancer Agent. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (1)
                                     , 43-46. <a href="https://doi.org/10.1021/acs.inorgchem.8b02717" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.8b02717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.8b02717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.8b02717%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DCysteine-Directed%252BBioconjugation%252Bof%252Ba%252BPlatinum%252528II%252529%2525E2%252580%252593Acridine%252BAnticancer%252BAgent%26aulast%3DYao%26aufirst%3DXiyuan%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D23092018%26date%3D13122018%26volume%3D58%26issue%3D1%26spage%3D43%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Md Kausar Raza, Srishti Gautam, Prodip Howlader, Arnab Bhattacharyya, Paturu Kondaiah, <span class="NLM_string-name hlFld-ContribAuthor">Akhil R. Chakravarty</span>. </span><span class="cited-content_cbyCitation_article-title">Pyriplatin-Boron-Dipyrromethene Conjugates for Imaging and Mitochondria-Targeted Photodynamic Therapy. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2018,</strong> <em>57 </em>
                                    (22)
                                     , 14374-14385. <a href="https://doi.org/10.1021/acs.inorgchem.8b02546" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.8b02546</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.8b02546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.8b02546%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DPyriplatin-Boron-Dipyrromethene%252BConjugates%252Bfor%252BImaging%252Band%252BMitochondria-Targeted%252BPhotodynamic%252BTherapy%26aulast%3DRaza%26aufirst%3DMd%2BKausar%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07092018%26date%3D30102018%26volume%3D57%26issue%3D22%26spage%3D14374%26epage%3D14385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin M.  Knopf</span>, <span class="hlFld-ContribAuthor ">Brendan L.  Murphy</span>, <span class="hlFld-ContribAuthor ">Samantha N.  MacMillan</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Baskin</span>, <span class="hlFld-ContribAuthor ">Martin P.  Barr</span>, <span class="hlFld-ContribAuthor ">Eszter  Boros</span>, and <span class="hlFld-ContribAuthor ">Justin J.  Wilson</span>  . </span><span class="cited-content_cbyCitation_article-title">In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (40)
                                     , 14302-14314. <a href="https://doi.org/10.1021/jacs.7b08640" title="DOI URL">https://doi.org/10.1021/jacs.7b08640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b08640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b08640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DIn%252BVitro%252BAnticancer%252BActivity%252Band%252Bin%252BVivo%252BBiodistribution%252Bof%252BRhenium%252528I%252529%252BTricarbonyl%252BAqua%252BComplexes%26aulast%3DKnopf%26aufirst%3DKevin%2BM.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D14082017%26date%3D26092017%26date%3D11102017%26volume%3D139%26issue%3D40%26spage%3D14302%26epage%3D14314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enrique  Ortega</span>, <span class="hlFld-ContribAuthor ">Gloria  Vigueras</span>, <span class="hlFld-ContribAuthor ">Francisco José  Ballester</span>, <span class="hlFld-ContribAuthor ">José  Ruiz</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting translation: a promising strategy for anticancer metallodrugs. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2021,</strong> <em>446 </em>, 214129. <a href="https://doi.org/10.1016/j.ccr.2021.214129" title="DOI URL">https://doi.org/10.1016/j.ccr.2021.214129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2021.214129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2021.214129%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DTargeting%252Btranslation%25253A%252Ba%252Bpromising%252Bstrategy%252Bfor%252Banticancer%252Bmetallodrugs%26aulast%3DOrtega%26aufirst%3DEnrique%26date%3D2021%26volume%3D446%26spage%3D214129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sophia  Harringer</span>, <span class="hlFld-ContribAuthor ">Michaela  Hejl</span>, <span class="hlFld-ContribAuthor ">Éva A.  Enyedy</span>, <span class="hlFld-ContribAuthor ">Michael A.  Jakupec</span>, <span class="hlFld-ContribAuthor ">Mathea S.  Galanski</span>, <span class="hlFld-ContribAuthor ">Bernhard K.  Keppler</span>, <span class="hlFld-ContribAuthor ">Paul J.  Dyson</span>, <span class="hlFld-ContribAuthor ">Hristo P.  Varbanov</span>. </span><span class="cited-content_cbyCitation_article-title">Multifunctional Pt(
              iv
              ) prodrug candidates featuring the carboplatin core and deferoxamine. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2021,</strong> <em>50 </em>
                                    (23)
                                     , 8167-8178. <a href="https://doi.org/10.1039/D1DT00214G" title="DOI URL">https://doi.org/10.1039/D1DT00214G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1DT00214G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1DT00214G%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DMultifunctional%252BPt%252528%252Biv%252B%252529%252Bprodrug%252Bcandidates%252Bfeaturing%252Bthe%252Bcarboplatin%252Bcore%252Band%252Bdeferoxamine%26aulast%3DHarringer%26aufirst%3DSophia%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D23%26spage%3D8167%26epage%3D8178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angelina Z.  Petrović</span>, <span class="hlFld-ContribAuthor ">Dušan C.  Ćoćić</span>, <span class="hlFld-ContribAuthor ">Dirk  Bockfeld</span>, <span class="hlFld-ContribAuthor ">Marko  Živanović</span>, <span class="hlFld-ContribAuthor ">Nevena  Milivojević</span>, <span class="hlFld-ContribAuthor ">Katarina  Virijević</span>, <span class="hlFld-ContribAuthor ">Nenad  Janković</span>, <span class="hlFld-ContribAuthor ">Andreas  Scheurer</span>, <span class="hlFld-ContribAuthor ">Milan  Vraneš</span>, <span class="hlFld-ContribAuthor ">Jovana V.  Bogojeski</span>. </span><span class="cited-content_cbyCitation_article-title">Biological activity of bis(pyrazolylpyridine) and terpiridine Os(
              ii
              ) complexes in the presence of biocompatible ionic liquids. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (11)
                                     , 2749-2770. <a href="https://doi.org/10.1039/D0QI01540G" title="DOI URL">https://doi.org/10.1039/D0QI01540G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QI01540G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QI01540G%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%2520Frontiers%26atitle%3DBiological%252Bactivity%252Bof%252Bbis%252528pyrazolylpyridine%252529%252Band%252Bterpiridine%252BOs%252528%252Bii%252B%252529%252Bcomplexes%252Bin%252Bthe%252Bpresence%252Bof%252Bbiocompatible%252Bionic%252Bliquids%26aulast%3DPetrovi%25C4%2587%26aufirst%3DAngelina%2BZ.%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D11%26spage%3D2749%26epage%3D2770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tasha R.  Steel</span>, <span class="hlFld-ContribAuthor ">Kelvin K.H.  Tong</span>, <span class="hlFld-ContribAuthor ">Tilo  Söhnel</span>, <span class="hlFld-ContribAuthor ">Stephen M.F.  Jamieson</span>, <span class="hlFld-ContribAuthor ">L. James  Wright</span>, <span class="hlFld-ContribAuthor ">James D.  Crowley</span>, <span class="hlFld-ContribAuthor ">Muhammad  Hanif</span>, <span class="hlFld-ContribAuthor ">Christian G.  Hartinger</span>. </span><span class="cited-content_cbyCitation_article-title">Homodinuclear organometallics of ditopic N,N-chelates: Synthesis, reactivity and in vitro anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">Inorganica Chimica Acta</span><span> <strong>2021,</strong> <em>518 </em>, 120220. <a href="https://doi.org/10.1016/j.ica.2020.120220" title="DOI URL">https://doi.org/10.1016/j.ica.2020.120220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ica.2020.120220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ica.2020.120220%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganica%2520Chimica%2520Acta%26atitle%3DHomodinuclear%252Borganometallics%252Bof%252Bditopic%252BN%25252CN-chelates%25253A%252BSynthesis%25252C%252Breactivity%252Band%252Bin%252Bvitro%252Banticancer%252Bactivity%26aulast%3DSteel%26aufirst%3DTasha%2BR.%26date%3D2021%26volume%3D518%26spage%3D120220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caitlin E.  Miron</span>, <span class="hlFld-ContribAuthor ">Laura  Staalduinen</span>, <span class="hlFld-ContribAuthor ">Alana M.  Rangaswamy</span>, <span class="hlFld-ContribAuthor ">Mickey  Chen</span>, <span class="hlFld-ContribAuthor ">Yushi  Liang</span>, <span class="hlFld-ContribAuthor ">Zongchao  Jia</span>, <span class="hlFld-ContribAuthor ">Jean‐Louis  Mergny</span>, <span class="hlFld-ContribAuthor ">Anne  Petitjean</span>. </span><span class="cited-content_cbyCitation_article-title">Going Platinum to the Tune of a Remarkable Guanine Quadruplex Binder: Solution‐ and Solid‐State Investigations.. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (5)
                                     , 2530-2537. <a href="https://doi.org/10.1002/ange.202012520" title="DOI URL">https://doi.org/10.1002/ange.202012520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202012520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202012520%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DGoing%252BPlatinum%252Bto%252Bthe%252BTune%252Bof%252Ba%252BRemarkable%252BGuanine%252BQuadruplex%252BBinder%25253A%252BSolution%2525E2%252580%252590%252Band%252BSolid%2525E2%252580%252590State%252BInvestigations.%26aulast%3DMiron%26aufirst%3DCaitlin%2BE.%26date%3D2021%26date%3D2020%26volume%3D133%26issue%3D5%26spage%3D2530%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caitlin E.  Miron</span>, <span class="hlFld-ContribAuthor ">Laura  Staalduinen</span>, <span class="hlFld-ContribAuthor ">Alana M.  Rangaswamy</span>, <span class="hlFld-ContribAuthor ">Mickey  Chen</span>, <span class="hlFld-ContribAuthor ">Yushi  Liang</span>, <span class="hlFld-ContribAuthor ">Zongchao  Jia</span>, <span class="hlFld-ContribAuthor ">Jean‐Louis  Mergny</span>, <span class="hlFld-ContribAuthor ">Anne  Petitjean</span>. </span><span class="cited-content_cbyCitation_article-title">Going Platinum to the Tune of a Remarkable Guanine Quadruplex Binder: Solution‐ and Solid‐State Investigations.. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (5)
                                     , 2500-2507. <a href="https://doi.org/10.1002/anie.202012520" title="DOI URL">https://doi.org/10.1002/anie.202012520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202012520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202012520%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DGoing%252BPlatinum%252Bto%252Bthe%252BTune%252Bof%252Ba%252BRemarkable%252BGuanine%252BQuadruplex%252BBinder%25253A%252BSolution%2525E2%252580%252590%252Band%252BSolid%2525E2%252580%252590State%252BInvestigations.%26aulast%3DMiron%26aufirst%3DCaitlin%2BE.%26date%3D2021%26date%3D2020%26volume%3D60%26issue%3D5%26spage%3D2500%26epage%3D2507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">G.  Trommetter</span>, <span class="hlFld-ContribAuthor ">D.  Dumoulin</span>, <span class="hlFld-ContribAuthor ">G.  Billon</span>. </span><span class="cited-content_cbyCitation_article-title">Development and validation of DGT passive samplers for the quantification of Ir, Pd, Pt, Rh and Ru: A challenging application in waters impacted by urban activities. </span><span class="cited-content_cbyCitation_journal-name">Talanta</span><span> <strong>2021,</strong> <em>223 </em>, 121707. <a href="https://doi.org/10.1016/j.talanta.2020.121707" title="DOI URL">https://doi.org/10.1016/j.talanta.2020.121707</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.talanta.2020.121707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.talanta.2020.121707%26sid%3Dliteratum%253Aachs%26jtitle%3DTalanta%26atitle%3DDevelopment%252Band%252Bvalidation%252Bof%252BDGT%252Bpassive%252Bsamplers%252Bfor%252Bthe%252Bquantification%252Bof%252BIr%25252C%252BPd%25252C%252BPt%25252C%252BRh%252Band%252BRu%25253A%252BA%252Bchallenging%252Bapplication%252Bin%252Bwaters%252Bimpacted%252Bby%252Burban%252Bactivities%26aulast%3DTrommetter%26aufirst%3DG.%26date%3D2021%26volume%3D223%26spage%3D121707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Sun</span>, <span class="hlFld-ContribAuthor ">Yunlong  Lu</span>, <span class="hlFld-ContribAuthor ">Mianli  Bian</span>, <span class="hlFld-ContribAuthor ">Zhibin  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Ma</span>, <span class="hlFld-ContribAuthor ">Wukun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113098. <a href="https://doi.org/10.1016/j.ejmech.2020.113098" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113098%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPt%252528II%252529%252Band%252BAu%252528III%252529%252Bcomplexes%252Bcontaining%252BSchiff-base%252Bligands%25253A%252BA%252Bpromising%252Bsource%252Bfor%252Bantitumor%252Btreatment%26aulast%3DSun%26aufirst%3DYing%26date%3D2021%26volume%3D211%26spage%3D113098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wan-Qiong  Huang</span>, <span class="hlFld-ContribAuthor ">Chuan-Xian  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Zi-Xin  Li</span>, <span class="hlFld-ContribAuthor ">Chen  Pan</span>, <span class="hlFld-ContribAuthor ">Yun-Zhou  Chen</span>, <span class="hlFld-ContribAuthor ">Xin  Lian</span>, <span class="hlFld-ContribAuthor ">Wai-Lun  Man</span>, <span class="hlFld-ContribAuthor ">Wen-Xiu  Ni</span>. </span><span class="cited-content_cbyCitation_article-title">A cytotoxic nitrido-osmium(
              vi
              ) complex induces caspase-mediated apoptosis in HepG2 cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (47)
                                     , 17173-17182. <a href="https://doi.org/10.1039/D0DT02715D" title="DOI URL">https://doi.org/10.1039/D0DT02715D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT02715D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT02715D%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DA%252Bcytotoxic%252Bnitrido-osmium%252528%252Bvi%252B%252529%252Bcomplex%252Binduces%252Bcaspase-mediated%252Bapoptosis%252Bin%252BHepG2%252Bcancer%252Bcells%26aulast%3DHuang%26aufirst%3DWan-Qiong%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D47%26spage%3D17173%26epage%3D17182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atrayee  Banaspati</span>, <span class="hlFld-ContribAuthor ">Md Kausar  Raza</span>, <span class="hlFld-ContribAuthor ">Tridib K.  Goswami</span>. </span><span class="cited-content_cbyCitation_article-title">Ni(II) curcumin complexes for cellular imaging and photo-triggered in vitro anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112632. <a href="https://doi.org/10.1016/j.ejmech.2020.112632" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112632</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112632%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNi%252528II%252529%252Bcurcumin%252Bcomplexes%252Bfor%252Bcellular%252Bimaging%252Band%252Bphoto-triggered%252Bin%2525C2%2525A0vitro%252Banticancer%252Bactivity%26aulast%3DBanaspati%26aufirst%3DAtrayee%26date%3D2020%26volume%3D204%26spage%3D112632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi-Yuan  Yang</span>, <span class="hlFld-ContribAuthor ">Qian-Qian  Cao</span>, <span class="hlFld-ContribAuthor ">Yun-Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Fang  Xu</span>, <span class="hlFld-ContribAuthor ">Cai-Xing  Deng</span>, <span class="hlFld-ContribAuthor ">Rajesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Xiao-Min  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiu-Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen-Feng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, structural characterization and antitumor activity of six rare earth metal complexes with 8-hydroxyquinoline derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2020,</strong> <em>211 </em>, 111175. <a href="https://doi.org/10.1016/j.jinorgbio.2020.111175" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2020.111175</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2020.111175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2020.111175%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DSynthesis%25252C%252Bstructural%252Bcharacterization%252Band%252Bantitumor%252Bactivity%252Bof%252Bsix%252Brare%252Bearth%252Bmetal%252Bcomplexes%252Bwith%252B8-hydroxyquinoline%252Bderivatives%26aulast%3DYang%26aufirst%3DQi-Yuan%26date%3D2020%26volume%3D211%26spage%3D111175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mathilde  Bouché</span>, <span class="hlFld-ContribAuthor ">Cécilia  Hognon</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Grandemange</span>, <span class="hlFld-ContribAuthor ">Antonio  Monari</span>, <span class="hlFld-ContribAuthor ">Philippe C.  Gros</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in iron-complexes as drug candidates for cancer therapy: reactivity, mechanism of action and metabolites. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (33)
                                     , 11451-11466. <a href="https://doi.org/10.1039/D0DT02135K" title="DOI URL">https://doi.org/10.1039/D0DT02135K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT02135K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT02135K%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DRecent%252Badvances%252Bin%252Biron-complexes%252Bas%252Bdrug%252Bcandidates%252Bfor%252Bcancer%252Btherapy%25253A%252Breactivity%25252C%252Bmechanism%252Bof%252Baction%252Band%252Bmetabolites%26aulast%3DBouch%25C3%25A9%26aufirst%3DMathilde%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D33%26spage%3D11451%26epage%3D11466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunyan  Jia</span>, <span class="hlFld-ContribAuthor ">Yanwei  Cong</span>, <span class="hlFld-ContribAuthor ">Shaoping  Pu</span>, <span class="hlFld-ContribAuthor ">Linxiang  Cai</span>, <span class="hlFld-ContribAuthor ">Yunshuang  Zhong</span>, <span class="hlFld-ContribAuthor ">Xinzhong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiali  Liao</span>, <span class="hlFld-ContribAuthor ">Yamin  Li</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Chuanzhu  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization, and biological activity of new mixed ammine/amine platinum(IV) complexes. </span><span class="cited-content_cbyCitation_journal-name">Applied Organometallic Chemistry</span><span> <strong>2020,</strong> <em>34 </em>
                                    (8)
                                     <a href="https://doi.org/10.1002/aoc.5680" title="DOI URL">https://doi.org/10.1002/aoc.5680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/aoc.5680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Faoc.5680%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Organometallic%2520Chemistry%26atitle%3DSynthesis%25252C%252Bcharacterization%25252C%252Band%252Bbiological%252Bactivity%252Bof%252Bnew%252Bmixed%252Bammine%25252Famine%252Bplatinum%252528IV%252529%252Bcomplexes%26aulast%3DJia%26aufirst%3DChunyan%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed S.  Al-Janabi</span>, <span class="hlFld-ContribAuthor ">Waseem A.  Al-Jumaili</span>, <span class="hlFld-ContribAuthor ">Lamaan J.  Al-Hayaly</span>, <span class="hlFld-ContribAuthor ">Subhi A.  Al-Jibori</span>, <span class="hlFld-ContribAuthor ">Harry  Schmidt</span>, <span class="hlFld-ContribAuthor ">Christoph  Wagner</span>, <span class="hlFld-ContribAuthor ">Graeme  Hogarth</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and in vitro cytotoxicity studies of Pd(II) and Pt(II) acetamide complexes: Molecular structures of trans-[PdCl2(bzmta)2].DMF (bzmta = 2-acetylamino-6-methylbenzothiazole) and cis-[PtCl2(bzta)2].2DMF (bzta = 2-acetylaminobenzothiazole). </span><span class="cited-content_cbyCitation_journal-name">Polyhedron</span><span> <strong>2020,</strong> <em>185 </em>, 114591. <a href="https://doi.org/10.1016/j.poly.2020.114591" title="DOI URL">https://doi.org/10.1016/j.poly.2020.114591</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.poly.2020.114591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.poly.2020.114591%26sid%3Dliteratum%253Aachs%26jtitle%3DPolyhedron%26atitle%3DSynthesis%252Band%252Bin%252Bvitro%252Bcytotoxicity%252Bstudies%252Bof%252BPd%252528II%252529%252Band%252BPt%252528II%252529%252Bacetamide%252Bcomplexes%25253A%252BMolecular%252Bstructures%252Bof%252Btrans-%25255BPdCl2%252528bzmta%2525292%25255D.DMF%252B%252528bzmta%2525C2%2525A0%25253D%2525C2%2525A02-acetylamino-6-methylbenzothiazole%252529%252Band%252Bcis-%25255BPtCl2%252528bzta%2525292%25255D.2DMF%252B%252528bzta%2525C2%2525A0%25253D%2525C2%2525A02-acetylaminobenzothiazole%252529%26aulast%3DAl-Janabi%26aufirst%3DAhmed%2BS.%26date%3D2020%26volume%3D185%26spage%3D114591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mathilde  Bouché</span>, <span class="hlFld-ContribAuthor ">Bruno  Vincent</span>, <span class="hlFld-ContribAuthor ">Thierry  Achard</span>, <span class="hlFld-ContribAuthor ">Stéphane  Bellemin-Laponnaz</span>. </span><span class="cited-content_cbyCitation_article-title">N-Heterocyclic Carbene Platinum(IV) as Metallodrug Candidates: Synthesis and 195Pt NMR Chemical Shift Trend. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (14)
                                     , 3148. <a href="https://doi.org/10.3390/molecules25143148" title="DOI URL">https://doi.org/10.3390/molecules25143148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25143148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25143148%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DN-Heterocyclic%252BCarbene%252BPlatinum%252528IV%252529%252Bas%252BMetallodrug%252BCandidates%25253A%252BSynthesis%252Band%252B195Pt%252BNMR%252BChemical%252BShift%252BTrend%26aulast%3DBouch%25C3%25A9%26aufirst%3DMathilde%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D14%26spage%3D3148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manish  Kumar</span>, <span class="hlFld-ContribAuthor ">Gyanendra  Kumar</span>, <span class="hlFld-ContribAuthor ">Arun  Kant</span>, <span class="hlFld-ContribAuthor ">Dhanraj T.  Masram</span>. </span><span class="cited-content_cbyCitation_article-title">Role of Metallodrugs in Medicinal Inorganic Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 71-113. <a href="https://doi.org/10.1002/9781119640868.ch3" title="DOI URL">https://doi.org/10.1002/9781119640868.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119640868.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119640868.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DRole%252Bof%252BMetallodrugs%252Bin%252BMedicinal%252BInorganic%252BChemistry%26aulast%3DKumar%26aufirst%3DManish%26date%3D2020%26date%3D2020%26spage%3D71%26epage%3D113%26pub%3DWiley%26atitle%3DAdvances%252Bin%252BMetallodrugs%26aulast%3DShahid%25E2%2580%2590ul%25E2%2580%2590Islam%26date%3D2020%26date%3D2020%26volume%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Hit/Lead Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 97-131. <a href="https://doi.org/10.1002/9781119607311.ch2" title="DOI URL">https://doi.org/10.1002/9781119607311.ch2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119607311.ch2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119607311.ch2%26sid%3Dliteratum%253Aachs%26atitle%3DHit%25252FLead%252BDiscovery%26date%3D2020%26date%3D2020%26spage%3D97%26epage%3D131%26pub%3DWiley%26atitle%3DMedicinal%252BChemistry%252Bfor%252BPractitioners%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2020%26date%3D2020%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Structural Alerts for Toxicity. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 305-379. <a href="https://doi.org/10.1002/9781119607311.ch5" title="DOI URL">https://doi.org/10.1002/9781119607311.ch5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119607311.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119607311.ch5%26sid%3Dliteratum%253Aachs%26atitle%3DStructural%252BAlerts%252Bfor%252BToxicity%26date%3D2020%26date%3D2020%26spage%3D305%26epage%3D379%26pub%3DWiley%26atitle%3DMedicinal%252BChemistry%252Bfor%252BPractitioners%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2020%26date%3D2020%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zahra  Yekke-ghasemi</span>, <span class="hlFld-ContribAuthor ">Mohammad  Ramezani</span>, <span class="hlFld-ContribAuthor ">Joel T.  Mague</span>, <span class="hlFld-ContribAuthor ">Reza  Takjoo</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization and bioactivity studies of new dithiocarbazate complexes. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (21)
                                     , 8878-8889. <a href="https://doi.org/10.1039/D0NJ01187H" title="DOI URL">https://doi.org/10.1039/D0NJ01187H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ01187H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ01187H%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DSynthesis%25252C%252Bcharacterization%252Band%252Bbioactivity%252Bstudies%252Bof%252Bnew%252Bdithiocarbazate%252Bcomplexes%26aulast%3DYekke-ghasemi%26aufirst%3DZahra%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D21%26spage%3D8878%26epage%3D8889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sophia  Sarpong-Kumankomah</span>, <span class="hlFld-ContribAuthor ">Maria  Contel</span>, <span class="hlFld-ContribAuthor ">Jürgen  Gailer</span>. </span><span class="cited-content_cbyCitation_article-title">SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography B</span><span> <strong>2020,</strong> <em>1145 </em>, 122093. <a href="https://doi.org/10.1016/j.jchromb.2020.122093" title="DOI URL">https://doi.org/10.1016/j.jchromb.2020.122093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jchromb.2020.122093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jchromb.2020.122093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520B%26atitle%3DSEC%252Bhyphenated%252Bto%252Ba%252Bmultielement-specific%252Bdetector%252Bunravels%252Bthe%252Bdegradation%252Bpathway%252Bof%252Ba%252Bbimetallic%252Banticancer%252Bcomplex%252Bin%252Bhuman%252Bplasma%26aulast%3DSarpong-Kumankomah%26aufirst%3DSophia%26date%3D2020%26volume%3D1145%26spage%3D122093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Jin</span>, <span class="hlFld-ContribAuthor ">Meng-lin  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhao-Hui  Wu</span>, <span class="hlFld-ContribAuthor ">Yu  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (14)
                                     , 2322-2334. <a href="https://doi.org/10.2174/0929867326666190204123101" title="DOI URL">https://doi.org/10.2174/0929867326666190204123101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190204123101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190204123101%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DProgress%252Bof%252BIndividualized%252BChemotherapy%252Bfor%252BGastric%252BCarcinoma%252BUnder%252Bthe%252BGuidance%252Bof%252BGenetic%252BTesting%26aulast%3DJin%26aufirst%3DXin%26date%3D2020%26volume%3D27%26issue%3D14%26spage%3D2322%26epage%3D2334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liam J.  Stephens</span>, <span class="hlFld-ContribAuthor ">Aviva  Levina</span>, <span class="hlFld-ContribAuthor ">Iman  Trinh</span>, <span class="hlFld-ContribAuthor ">Victoria L.  Blair</span>, <span class="hlFld-ContribAuthor ">Melissa V.  Werrett</span>, <span class="hlFld-ContribAuthor ">Peter A.  Lay</span>, <span class="hlFld-ContribAuthor ">Philip C.  Andrews</span>. </span><span class="cited-content_cbyCitation_article-title">Ruthenium(II)–Arene Thiocarboxylates: Identification of a Stable Dimer Selectively Cytotoxic to Invasive Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2020,</strong> <em>21 </em>
                                    (8)
                                     , 1188-1200. <a href="https://doi.org/10.1002/cbic.201900676" title="DOI URL">https://doi.org/10.1002/cbic.201900676</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.201900676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.201900676%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DRuthenium%252528II%252529%2525E2%252580%252593Arene%252BThiocarboxylates%25253A%252BIdentification%252Bof%252Ba%252BStable%252BDimer%252BSelectively%252BCytotoxic%252Bto%252BInvasive%252BBreast%252BCancer%252BCells%26aulast%3DStephens%26aufirst%3DLiam%2BJ.%26date%3D2020%26date%3D2019%26volume%3D21%26issue%3D8%26spage%3D1188%26epage%3D1200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tatiyana V.  Serebryanskaya</span>, <span class="hlFld-ContribAuthor ">Mikhail A.  Kinzhalov</span>, <span class="hlFld-ContribAuthor ">Vladimir  Bakulev</span>, <span class="hlFld-ContribAuthor ">Georgii  Alekseev</span>, <span class="hlFld-ContribAuthor ">Anastasiya  Andreeva</span>, <span class="hlFld-ContribAuthor ">Pavel V.  Gushchin</span>, <span class="hlFld-ContribAuthor ">Aleksandra V.  Protas</span>, <span class="hlFld-ContribAuthor ">Andrey S.  Smirnov</span>, <span class="hlFld-ContribAuthor ">Taras L.  Panikorovskii</span>, <span class="hlFld-ContribAuthor ">Petra  Lippmann</span>, <span class="hlFld-ContribAuthor ">Ingo  Ott</span>, <span class="hlFld-ContribAuthor ">Cyril M.  Verbilo</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Zuraev</span>, <span class="hlFld-ContribAuthor ">Alexander S.  Bunev</span>, <span class="hlFld-ContribAuthor ">Vadim P.  Boyarskiy</span>, <span class="hlFld-ContribAuthor ">Nina A.  Kasyanenko</span>. </span><span class="cited-content_cbyCitation_article-title">Water soluble palladium(
              ii
              ) and platinum(
              ii
              ) acyclic diaminocarbene complexes: solution behavior, DNA binding, and antiproliferative activity. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (15)
                                     , 5762-5773. <a href="https://doi.org/10.1039/D0NJ00060D" title="DOI URL">https://doi.org/10.1039/D0NJ00060D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ00060D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ00060D%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DWater%252Bsoluble%252Bpalladium%252528%252Bii%252B%252529%252Band%252Bplatinum%252528%252Bii%252B%252529%252Bacyclic%252Bdiaminocarbene%252Bcomplexes%25253A%252Bsolution%252Bbehavior%25252C%252BDNA%252Bbinding%25252C%252Band%252Bantiproliferative%252Bactivity%26aulast%3DSerebryanskaya%26aufirst%3DTatiyana%2BV.%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D15%26spage%3D5762%26epage%3D5773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Quan</span>, <span class="hlFld-ContribAuthor ">Zuantao  Lin</span>, <span class="hlFld-ContribAuthor ">Yuebin  Lin</span>, <span class="hlFld-ContribAuthor ">Yanchun  Wei</span>, <span class="hlFld-ContribAuthor ">Liu  Lei</span>, <span class="hlFld-ContribAuthor ">Yaxi  Li</span>, <span class="hlFld-ContribAuthor ">Gongjun  Tan</span>, <span class="hlFld-ContribAuthor ">Min  Xiao</span>, <span class="hlFld-ContribAuthor ">Tianfu  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Glucose-modification of cisplatin to facilitate cellular uptake, mitigate toxicity to normal cells, and improve anti-cancer effect in cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1203 </em>, 127361. <a href="https://doi.org/10.1016/j.molstruc.2019.127361" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.127361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.127361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.127361%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DGlucose-modification%252Bof%252Bcisplatin%252Bto%252Bfacilitate%252Bcellular%252Buptake%25252C%252Bmitigate%252Btoxicity%252Bto%252Bnormal%252Bcells%25252C%252Band%252Bimprove%252Banti-cancer%252Beffect%252Bin%252Bcancer%252Bcells%26aulast%3DQuan%26aufirst%3DLi%26date%3D2020%26volume%3D1203%26spage%3D127361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiyan  Zhao</span>, <span class="hlFld-ContribAuthor ">Jie  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Fang</span>, <span class="hlFld-ContribAuthor ">Bowen  Chang</span>, <span class="hlFld-ContribAuthor ">Qingxi  Meng</span>, <span class="hlFld-ContribAuthor ">Mingxue  Li</span>, <span class="hlFld-ContribAuthor ">Chunzhang  Wang</span>, <span class="hlFld-ContribAuthor ">Xianfeng  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization and bioactivities of a new covalent copper(II) compound derived from {P2Mo5O23}6− and thiosemicarbazones. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (1)
                                     , 126781. <a href="https://doi.org/10.1016/j.bmcl.2019.126781" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126781</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126781%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%25252C%252Bcharacterization%252Band%252Bbioactivities%252Bof%252Ba%252Bnew%252Bcovalent%252Bcopper%252528II%252529%252Bcompound%252Bderived%252Bfrom%252B%25257BP2Mo5O23%25257D6%2525E2%252588%252592%252Band%252Bthiosemicarbazones%26aulast%3DZhao%26aufirst%3DHaiyan%26date%3D2020%26volume%3D30%26issue%3D1%26spage%3D126781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Avijita  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Multifunctional, heterometallic ruthenium-platinum complexes with medicinal applications. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2019,</strong> <em>401 </em>, 213067. <a href="https://doi.org/10.1016/j.ccr.2019.213067" title="DOI URL">https://doi.org/10.1016/j.ccr.2019.213067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2019.213067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2019.213067%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DMultifunctional%25252C%252Bheterometallic%252Bruthenium-platinum%252Bcomplexes%252Bwith%252Bmedicinal%252Bapplications%26aulast%3DJain%26aufirst%3DAvijita%26date%3D2019%26volume%3D401%26spage%3D213067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James D.  Hoeschele</span>, <span class="hlFld-ContribAuthor ">Matthew D.  Hall</span>, <span class="hlFld-ContribAuthor ">Bernhard  Lippert</span>. </span><span class="cited-content_cbyCitation_article-title">Pt antitumor drugs and their chemistry – Special issue to commemorate the 40th Anniversary Cisplatin Celebration and Cancer Research Symposium. </span><span class="cited-content_cbyCitation_journal-name">Inorganica Chimica Acta</span><span> <strong>2019,</strong> <em>498 </em>, 119139. <a href="https://doi.org/10.1016/j.ica.2019.119139" title="DOI URL">https://doi.org/10.1016/j.ica.2019.119139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ica.2019.119139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ica.2019.119139%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganica%2520Chimica%2520Acta%26atitle%3DPt%252Bantitumor%252Bdrugs%252Band%252Btheir%252Bchemistry%252B%2525E2%252580%252593%252BSpecial%252Bissue%252Bto%252Bcommemorate%252Bthe%252B40th%252BAnniversary%252BCisplatin%252BCelebration%252Band%252BCancer%252BResearch%252BSymposium%26aulast%3DHoeschele%26aufirst%3DJames%2BD.%26date%3D2019%26volume%3D498%26spage%3D119139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Snežana K.  Bjelogrlić</span>, <span class="hlFld-ContribAuthor ">Tamara R.  Todorović</span>, <span class="hlFld-ContribAuthor ">Milan  Kojić</span>, <span class="hlFld-ContribAuthor ">Milan  Senćanski</span>, <span class="hlFld-ContribAuthor ">Milan  Nikolić</span>, <span class="hlFld-ContribAuthor ">Aleksandar  Višnjevac</span>, <span class="hlFld-ContribAuthor ">Jovana  Araškov</span>, <span class="hlFld-ContribAuthor ">Marija  Miljković</span>, <span class="hlFld-ContribAuthor ">Christian D.  Muller</span>, <span class="hlFld-ContribAuthor ">Nenad R.  Filipović</span>. </span><span class="cited-content_cbyCitation_article-title">Pd(II) complexes with N-heteroaromatic hydrazone ligands: Anticancer activity, in silico and experimental target identification. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2019,</strong> <em>199 </em>, 110758. <a href="https://doi.org/10.1016/j.jinorgbio.2019.110758" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2019.110758</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2019.110758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2019.110758%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DPd%252528II%252529%252Bcomplexes%252Bwith%252BN-heteroaromatic%252Bhydrazone%252Bligands%25253A%252BAnticancer%252Bactivity%25252C%252Bin%252Bsilico%252Band%252Bexperimental%252Btarget%252Bidentification%26aulast%3DBjelogrli%25C4%2587%26aufirst%3DSne%25C5%25BEana%2BK.%26date%3D2019%26volume%3D199%26spage%3D110758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benelita T.  Elie</span>, <span class="hlFld-ContribAuthor ">Karen  Hubbard</span>, <span class="hlFld-ContribAuthor ">Yuriy  Pechenyy</span>, <span class="hlFld-ContribAuthor ">Buddhadev  Layek</span>, <span class="hlFld-ContribAuthor ">Swayam  Prabha</span>, <span class="hlFld-ContribAuthor ">Maria  Contel</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical evaluation of an unconventional ruthenium‐gold‐based chemotherapeutic: RANCE‐1, in clear cell renal cell carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2019,</strong> <em>8 </em>
                                    (9)
                                     , 4304-4314. <a href="https://doi.org/10.1002/cam4.2322" title="DOI URL">https://doi.org/10.1002/cam4.2322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.2322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.2322%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DPreclinical%252Bevaluation%252Bof%252Ban%252Bunconventional%252Bruthenium%2525E2%252580%252590gold%2525E2%252580%252590based%252Bchemotherapeutic%25253A%252BRANCE%2525E2%252580%2525901%25252C%252Bin%252Bclear%252Bcell%252Brenal%252Bcell%252Bcarcinoma%26aulast%3DElie%26aufirst%3DBenelita%2BT.%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D9%26spage%3D4304%26epage%3D4314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fengfan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Dong</span>, <span class="hlFld-ContribAuthor ">Qiwen  Shi</span>, <span class="hlFld-ContribAuthor ">Jianli  Chen</span>, <span class="hlFld-ContribAuthor ">Weike  Su</span>. </span><span class="cited-content_cbyCitation_article-title">Improving the anticancer activity of platinum(
              iv
              ) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (39)
                                     , 22240-22247. <a href="https://doi.org/10.1039/C9RA03690C" title="DOI URL">https://doi.org/10.1039/C9RA03690C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA03690C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA03690C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DImproving%252Bthe%252Banticancer%252Bactivity%252Bof%252Bplatinum%252528%252Biv%252B%252529%252Bprodrugs%252Busing%252Ba%252Bdual-targeting%252Bstrategy%252Bwith%252Ba%252Bdichloroacetate%252Baxial%252Bligand%26aulast%3DLiu%26aufirst%3DFengfan%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D39%26spage%3D22240%26epage%3D22247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hélène  Lajous</span>, <span class="hlFld-ContribAuthor ">Bénédicte  Lelièvre</span>, <span class="hlFld-ContribAuthor ">Elodie  Vauléon</span>, <span class="hlFld-ContribAuthor ">Philippe  Lecomte</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Garcion</span>. </span><span class="cited-content_cbyCitation_article-title">Rethinking Alkylating(-Like) Agents for Solid Tumor Management. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2019,</strong> <em>40 </em>
                                    (5)
                                     , 342-357. <a href="https://doi.org/10.1016/j.tips.2019.03.003" title="DOI URL">https://doi.org/10.1016/j.tips.2019.03.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2019.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2019.03.003%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DRethinking%252BAlkylating%252528-Like%252529%252BAgents%252Bfor%252BSolid%252BTumor%252BManagement%26aulast%3DLajous%26aufirst%3DH%25C3%25A9l%25C3%25A8ne%26date%3D2019%26volume%3D40%26issue%3D5%26spage%3D342%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hristo P.  Varbanov</span>, <span class="hlFld-ContribAuthor ">Fabien  Kuttler</span>, <span class="hlFld-ContribAuthor ">Damiano  Banfi</span>, <span class="hlFld-ContribAuthor ">Gerardo  Turcatti</span>, <span class="hlFld-ContribAuthor ">Paul J.  Dyson</span>, . </span><span class="cited-content_cbyCitation_article-title">Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2019,</strong> <em>14 </em>
                                    (1)
                                     , e0211268. <a href="https://doi.org/10.1371/journal.pone.0211268" title="DOI URL">https://doi.org/10.1371/journal.pone.0211268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0211268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0211268%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DScreening-based%252Bapproach%252Bto%252Bdiscover%252Beffective%252Bplatinum-based%252Bchemotherapies%252Bfor%252Bcancers%252Bwith%252Bpoor%252Bprognosis%26aulast%3DVarbanov%26aufirst%3DHristo%2BP.%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D1%26spage%3De0211268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francisco J.  Ballester</span>, <span class="hlFld-ContribAuthor ">Enrique  Ortega</span>, <span class="hlFld-ContribAuthor ">Vanesa  Porto</span>, <span class="hlFld-ContribAuthor ">Hana  Kostrhunova</span>, <span class="hlFld-ContribAuthor ">Nerea  Davila-Ferreira</span>, <span class="hlFld-ContribAuthor ">Delia  Bautista</span>, <span class="hlFld-ContribAuthor ">Viktor  Brabec</span>, <span class="hlFld-ContribAuthor ">Fernando  Domínguez</span>, <span class="hlFld-ContribAuthor ">M. Dolores  Santana</span>, <span class="hlFld-ContribAuthor ">José  Ruiz</span>. </span><span class="cited-content_cbyCitation_article-title">New half-sandwich ruthenium(
              ii
              ) complexes as proteosynthesis inhibitors in cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (8)
                                     , 1140-1143. <a href="https://doi.org/10.1039/C8CC09211G" title="DOI URL">https://doi.org/10.1039/C8CC09211G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8CC09211G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8CC09211G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DNew%252Bhalf-sandwich%252Bruthenium%252528%252Bii%252B%252529%252Bcomplexes%252Bas%252Bproteosynthesis%252Binhibitors%252Bin%252Bcancer%252Bcells%26aulast%3DBallester%26aufirst%3DFrancisco%2BJ.%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D8%26spage%3D1140%26epage%3D1143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengken  Chen</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of a novel platinum(II) complex possessing bioreductive groups for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2019,</strong> <em>30 </em>
                                    (1)
                                     , 243-246. <a href="https://doi.org/10.1016/j.cclet.2018.04.010" title="DOI URL">https://doi.org/10.1016/j.cclet.2018.04.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2018.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2018.04.010%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Ba%252Bnovel%252Bplatinum%252528II%252529%252Bcomplex%252Bpossessing%252Bbioreductive%252Bgroups%252Bfor%252Bcancer%252Btherapy%26aulast%3DChen%26aufirst%3DChengken%26date%3D2019%26volume%3D30%26issue%3D1%26spage%3D243%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Snežana  Bjelogrlić</span>, <span class="hlFld-ContribAuthor ">Tamara R.  Todorović</span>, <span class="hlFld-ContribAuthor ">Ilija  Cvijetić</span>, <span class="hlFld-ContribAuthor ">Marko V.  Rodić</span>, <span class="hlFld-ContribAuthor ">Miroslava  Vujčić</span>, <span class="hlFld-ContribAuthor ">Sanja  Marković</span>, <span class="hlFld-ContribAuthor ">Jovana  Araškov</span>, <span class="hlFld-ContribAuthor ">Barbara  Janović</span>, <span class="hlFld-ContribAuthor ">Fathi  Emhemmed</span>, <span class="hlFld-ContribAuthor ">Christian D.  Muller</span>, <span class="hlFld-ContribAuthor ">Nenad R.  Filipović</span>. </span><span class="cited-content_cbyCitation_article-title">A novel binuclear hydrazone-based Cd(II) complex is a strong pro-apoptotic inducer with significant activity against 2D and 3D pancreatic cancer stem cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2019,</strong> <em>190 </em>, 45-66. <a href="https://doi.org/10.1016/j.jinorgbio.2018.10.002" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2018.10.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2018.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2018.10.002%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DA%252Bnovel%252Bbinuclear%252Bhydrazone-based%252BCd%252528II%252529%252Bcomplex%252Bis%252Ba%252Bstrong%252Bpro-apoptotic%252Binducer%252Bwith%252Bsignificant%252Bactivity%252Bagainst%252B2D%252Band%252B3D%252Bpancreatic%252Bcancer%252Bstem%252Bcells%26aulast%3DBjelogrli%25C4%2587%26aufirst%3DSne%25C5%25BEana%26date%3D2019%26volume%3D190%26spage%3D45%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veysel T.  Yilmaz</span>, <span class="hlFld-ContribAuthor ">Ceyda  Icsel</span>, <span class="hlFld-ContribAuthor ">Muhittin  Aygun</span>, <span class="hlFld-ContribAuthor ">Merve  Erkisa</span>, <span class="hlFld-ContribAuthor ">Engin  Ulukaya</span>. </span><span class="cited-content_cbyCitation_article-title">Pd(II) and Pt(II) saccharinate complexes of bis(diphenylphosphino)propane/butane: Synthesis, structure, antiproliferative activity and mechanism of action. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 534-547. <a href="https://doi.org/10.1016/j.ejmech.2018.09.035" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.035%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPd%252528II%252529%252Band%252BPt%252528II%252529%252Bsaccharinate%252Bcomplexes%252Bof%252Bbis%252528diphenylphosphino%252529propane%25252Fbutane%25253A%252BSynthesis%25252C%252Bstructure%25252C%252Bantiproliferative%252Bactivity%252Band%252Bmechanism%252Bof%252Baction%26aulast%3DYilmaz%26aufirst%3DVeysel%2BT.%26date%3D2018%26volume%3D158%26spage%3D534%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Ma</span>, <span class="hlFld-ContribAuthor ">Hanfang  Liu</span>, <span class="hlFld-ContribAuthor ">Zhuoqing  Xi</span>, <span class="hlFld-ContribAuthor ">Jiuzhou  Hou</span>, <span class="hlFld-ContribAuthor ">Yingguang  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Niu</span>, <span class="hlFld-ContribAuthor ">Tong  Liu</span>, <span class="hlFld-ContribAuthor ">Shuning  Bi</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Chaojie  Wang</span>, <span class="hlFld-ContribAuthor ">Jiajia  Wang</span>, <span class="hlFld-ContribAuthor ">Songqiang  Xie</span>, <span class="hlFld-ContribAuthor ">Peng G.  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Protected and De-protected Platinum(IV) Glycoconjugates With GLUT1 and OCT2-Mediated Selective Cancer Targeting: Demonstrated Enhanced Transporter-Mediated Cytotoxic Properties in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2018,</strong> <em>6 </em><a href="https://doi.org/10.3389/fchem.2018.00386" title="DOI URL">https://doi.org/10.3389/fchem.2018.00386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2018.00386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2018.00386%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DProtected%252Band%252BDe-protected%252BPlatinum%252528IV%252529%252BGlycoconjugates%252BWith%252BGLUT1%252Band%252BOCT2-Mediated%252BSelective%252BCancer%252BTargeting%25253A%252BDemonstrated%252BEnhanced%252BTransporter-Mediated%252BCytotoxic%252BProperties%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DMa%26aufirst%3DJing%26date%3D2018%26date%3D2018%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandra  Moreira-Pais</span>, <span class="hlFld-ContribAuthor ">Rita  Ferreira</span>, <span class="hlFld-ContribAuthor ">Rui  Gil da Costa</span>. </span><span class="cited-content_cbyCitation_article-title">Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2018,</strong> <em>208 </em>, 1-9. <a href="https://doi.org/10.1016/j.lfs.2018.07.010" title="DOI URL">https://doi.org/10.1016/j.lfs.2018.07.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2018.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2018.07.010%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DPlatinum-induced%252Bmuscle%252Bwasting%252Bin%252Bcancer%252Bchemotherapy%25253A%252BMechanisms%252Band%252Bpotential%252Btargets%252Bfor%252Btherapeutic%252Bintervention%26aulast%3DMoreira-Pais%26aufirst%3DAlexandra%26date%3D2018%26volume%3D208%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi-Yuan  Yang</span>, <span class="hlFld-ContribAuthor ">Qian-Qian  Cao</span>, <span class="hlFld-ContribAuthor ">Qi-Pin  Qin</span>, <span class="hlFld-ContribAuthor ">Cai-Xing  Deng</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen-Feng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Syntheses, Crystal Structures, and Antitumor Activities of Copper(II) and Nickel(II) Complexes with 2-((2-(Pyridin-2-yl)hydrazono)methyl)quinolin-8-ol. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (7)
                                     , 1874. <a href="https://doi.org/10.3390/ijms19071874" title="DOI URL">https://doi.org/10.3390/ijms19071874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19071874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19071874%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DSyntheses%25252C%252BCrystal%252BStructures%25252C%252Band%252BAntitumor%252BActivities%252Bof%252BCopper%252528II%252529%252Band%252BNickel%252528II%252529%252BComplexes%252Bwith%252B2-%252528%2525282-%252528Pyridin-2-yl%252529hydrazono%252529methyl%252529quinolin-8-ol%26aulast%3DYang%26aufirst%3DQi-Yuan%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D7%26spage%3D1874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dulal  Musib</span>, <span class="hlFld-ContribAuthor ">Md Kausar  Raza</span>, <span class="hlFld-ContribAuthor ">Somashree  Kundu</span>, <span class="hlFld-ContribAuthor ">Mithun  Roy</span>. </span><span class="cited-content_cbyCitation_article-title">Modulating In Vitro Photodynamic Activities of Copper(II) Complexes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Inorganic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (19)
                                     , 2011-2018. <a href="https://doi.org/10.1002/ejic.201800081" title="DOI URL">https://doi.org/10.1002/ejic.201800081</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejic.201800081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejic.201800081%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Inorganic%2520Chemistry%26atitle%3DModulating%252BIn%252BVitro%252BPhotodynamic%252BActivities%252Bof%252BCopper%252528II%252529%252BComplexes%26aulast%3DMusib%26aufirst%3DDulal%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D19%26spage%3D2011%26epage%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Hanif</span>, <span class="hlFld-ContribAuthor ">Christian G  Hartinger</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer metallodrugs: where is the next cisplatin?. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (6)
                                     , 615-617. <a href="https://doi.org/10.4155/fmc-2017-0317" title="DOI URL">https://doi.org/10.4155/fmc-2017-0317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0317%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAnticancer%252Bmetallodrugs%25253A%252Bwhere%252Bis%252Bthe%252Bnext%252Bcisplatin%25253F%26aulast%3DHanif%26aufirst%3DMuhammad%26date%3D2018%26volume%3D10%26issue%3D6%26spage%3D615%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julien  Egly</span>, <span class="hlFld-ContribAuthor ">Mathilde  Bouché</span>, <span class="hlFld-ContribAuthor ">Weighang  Chen</span>, <span class="hlFld-ContribAuthor ">Aline  Maisse-François</span>, <span class="hlFld-ContribAuthor ">Thierry  Achard</span>, <span class="hlFld-ContribAuthor ">Stéphane  Bellemin-Laponnaz</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Structural Characterization and Anti-Proliferative Activity of (κ
              1
              -
              C
              )- and (κ
              2
              -
              C
              ,
              S
              )-Pt
              II
              Complexes Bearing Thioether-Functionalized N-Heterocyclic Carbenes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Inorganic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (2)
                                     , 159-166. <a href="https://doi.org/10.1002/ejic.201701183" title="DOI URL">https://doi.org/10.1002/ejic.201701183</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejic.201701183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejic.201701183%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Inorganic%2520Chemistry%26atitle%3DSynthesis%25252C%252BStructural%252BCharacterization%252Band%252BAnti-Proliferative%252BActivity%252Bof%252B%252528%2525CE%2525BA%252B1%252B-%252BC%252B%252529-%252Band%252B%252528%2525CE%2525BA%252B2%252B-%252BC%252B%25252C%252BS%252B%252529-Pt%252BII%252BComplexes%252BBearing%252BThioether-Functionalized%252BN-Heterocyclic%252BCarbenes%26aulast%3DEgly%26aufirst%3DJulien%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D2%26spage%3D159%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandra  Curci</span>, <span class="hlFld-ContribAuthor ">Giovanni  Natile</span>, <span class="hlFld-ContribAuthor ">Nicola  Margiotta</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Targeting and Delivery of Platinum Chemotherapeutics ☆. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14282-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14282-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14282-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14282-9%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BTargeting%252Band%252BDelivery%252Bof%252BPlatinum%252BChemotherapeutics%252B%2525E2%252598%252586%26aulast%3DCurci%26aufirst%3DAlessandra%26date%3D2018%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah  Theiner</span>, <span class="hlFld-ContribAuthor ">Márkó  Grabarics</span>, <span class="hlFld-ContribAuthor ">Luis  Galvez</span>, <span class="hlFld-ContribAuthor ">Hristo P.  Varbanov</span>, <span class="hlFld-ContribAuthor ">Nadine S.  Sommerfeld</span>, <span class="hlFld-ContribAuthor ">Markus  Galanski</span>, <span class="hlFld-ContribAuthor ">Bernhard K.  Keppler</span>, <span class="hlFld-ContribAuthor ">Gunda  Koellensperger</span>. </span><span class="cited-content_cbyCitation_article-title">The impact of whole human blood on the kinetic inertness of platinum(
              iv
              ) prodrugs – an HPLC-ICP-MS study. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2018,</strong> <em>47 </em>
                                    (15)
                                     , 5252-5258. <a href="https://doi.org/10.1039/C7DT04537A" title="DOI URL">https://doi.org/10.1039/C7DT04537A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7DT04537A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7DT04537A%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DThe%252Bimpact%252Bof%252Bwhole%252Bhuman%252Bblood%252Bon%252Bthe%252Bkinetic%252Binertness%252Bof%252Bplatinum%252528%252Biv%252B%252529%252Bprodrugs%252B%2525E2%252580%252593%252Ban%252BHPLC-ICP-MS%252Bstudy%26aulast%3DTheiner%26aufirst%3DSarah%26date%3D2018%26date%3D2018%26volume%3D47%26issue%3D15%26spage%3D5252%26epage%3D5258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mathilde  Bouché</span>, <span class="hlFld-ContribAuthor ">Antoine  Bonnefont</span>, <span class="hlFld-ContribAuthor ">Thierry  Achard</span>, <span class="hlFld-ContribAuthor ">Stéphane  Bellemin-Laponnaz</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring diversity in platinum(
              iv
              ) N-heterocyclic carbene complexes: synthesis, characterization, reactivity and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2018,</strong> <em>47 </em>
                                    (33)
                                     , 11491-11502. <a href="https://doi.org/10.1039/C8DT02113A" title="DOI URL">https://doi.org/10.1039/C8DT02113A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8DT02113A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8DT02113A%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DExploring%252Bdiversity%252Bin%252Bplatinum%252528%252Biv%252B%252529%252BN-heterocyclic%252Bcarbene%252Bcomplexes%25253A%252Bsynthesis%25252C%252Bcharacterization%25252C%252Breactivity%252Band%252Bbiological%252Bevaluation%26aulast%3DBouch%25C3%25A9%26aufirst%3DMathilde%26date%3D2018%26date%3D2018%26volume%3D47%26issue%3D33%26spage%3D11491%26epage%3D11502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiaocheng  Wen</span>, <span class="hlFld-ContribAuthor ">Zihua  Chen</span>, <span class="hlFld-ContribAuthor ">Zhikang  Chen</span>, <span class="hlFld-ContribAuthor ">Jinxiang  Chen</span>, <span class="hlFld-ContribAuthor ">Ran  Wang</span>, <span class="hlFld-ContribAuthor ">Changhao  Huang</span>, <span class="hlFld-ContribAuthor ">Weijie  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (29)
                                     , 47998-48011. <a href="https://doi.org/10.18632/oncotarget.18208" title="DOI URL">https://doi.org/10.18632/oncotarget.18208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.18208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.18208%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DEphA2%252Baffects%252Bthe%252Bsensitivity%252Bof%252Boxaliplatin%252Bby%252Binducing%252BEMT%252Bin%252Boxaliplatin-resistant%252Bgastric%252Bcancer%252Bcells%26aulast%3DWen%26aufirst%3DQiaocheng%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D29%26spage%3D47998%26epage%3D48011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hristo P.  Varbanov</span>, <span class="hlFld-ContribAuthor ">Daniel  Ortiz</span>, <span class="hlFld-ContribAuthor ">Doris  Höfer</span>, <span class="hlFld-ContribAuthor ">Laure  Menin</span>, <span class="hlFld-ContribAuthor ">Markus  Galanski</span>, <span class="hlFld-ContribAuthor ">Bernhard K.  Keppler</span>, <span class="hlFld-ContribAuthor ">Paul J.  Dyson</span>. </span><span class="cited-content_cbyCitation_article-title">Oxaliplatin reacts with DMSO only in the presence of water. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2017,</strong> <em>46 </em>
                                    (28)
                                     , 8929-8932. <a href="https://doi.org/10.1039/C7DT01628J" title="DOI URL">https://doi.org/10.1039/C7DT01628J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7DT01628J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7DT01628J%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DOxaliplatin%252Breacts%252Bwith%252BDMSO%252Bonly%252Bin%252Bthe%252Bpresence%252Bof%252Bwater%26aulast%3DVarbanov%26aufirst%3DHristo%2BP.%26date%3D2017%26date%3D2017%26volume%3D46%26issue%3D28%26spage%3D8929%26epage%3D8932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of cisplatin, carboplatin, and oxaliplatin. In each case the <i>cis</i> nonleaving amines are at the left and the leaving groups (chloride, bidentate dicarboxylate, or oxalate) are at the right.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Publications indexed in PubMed referring to the drugs, cisplatin, carboplatin, or oxaliplatin in the title or abstract, displayed by year. (B) As a comparison, publications describing the FDA-registered DNA-damaging agents chlorambucil, mitomycin, mitaxantrone, and bleomycin. (C) Publications describing “blockbuster” oncology therapeutics paclitaxel, doxorubicin, imatinib, and trastuzumab.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of images acquired from human subjects treated with radiolabeled cisplatin. (A) 1973. A 35-year old woman with metastatic carcinoma of the cervix imaged following injection with [<sup>195m</sup>Pt]cisplatin.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The strong activity arises from high concentrations in the kidneys. This research was originally published in <i>Journal of Nuclear Medicine</i>, and artwork is reproduced with permission: <contrib-group>Lange, R. C.; Spencer, R. P.; Harder, H. C.</contrib-group>The Antitumor Agent <i>cis</i>-Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>: Distribution Studies and Dose Calculations for <sup>193m</sup>Pt and <sup>195m</sup>Pt.  <cite>J. Nucl. Med.</cite> <span class="NLM_year">1973</span>, <em>14</em>, 191–195, Copyright by the Society of Nuclear Medicine and Molecular Imaging, Inc. (B) Images of a patient with astrocytoma (brain tumor) injected with [<sup>195m</sup>Pt]cisplatin either iv (left) or ia (right).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Low brain signal compared to surrounding tissue can be seen at left. The high signal (dark) at right corresponds to the tumor region. Reproduced from  <cite>Cancer Research</cite>, Copyright <span class="NLM_year">1989</span>, Volume <em>49</em>, pp 1877–1881 (<contrib-group>Shani, J.; Bertram, J.; Russell, C.; Dahalan, R.; Chen, D. C.; Parti, R.; Ahmadi, J.; Kempf, R. A.; Kawada, T. K.; Muggia, F. M.; Wolf, W.</contrib-group>Noninvasive Monitoring of Drug Biodistribution and Metabolism: Studies with Intraarterial Pt-195m-Cisplatin in Humans), with permission from AACR. (C) Static anterior images over the head, neck, and thorax region of a patient with metastatic lung cancer immediately after injection with [<sup>191</sup>Pt]cisplatin, with several tumors arrowed.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Reproduced with permission of Taylor & Francis Ltd. (<a href="http://www.tandfonline.com/" class="extLink">http://www.tandfonline.com/</a>), from  <cite>Acta Oncologica</cite>, <contrib-group>Areberg, J.; Bjorkman, S.; Einarsson, L.; Frankenberg, B.; Lundqvist, H.; Mattsson, S.; Norrgren, K.; Scheike, O.; Wallin, R.</contrib-group>Gamma Camera Imaging of Platinum in Tumours and Tissues of Patients after Administration of <sup>191</sup>Pt-Cisplatin. <span class="NLM_year">1999</span>, <em>38</em>, 221–228. (D) Anterior (frontal) view of healthy subject 5 h following injection of [<sup>195m</sup>Pt]cisplatin.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Reproduced with permission from <contrib-group>Sathekge, M.; Wagener, J.; Smith, S. V.; Soni, N.; Marjanovic-Painter, B.; Zinn, C.; Van De Wiele, C.; D’asseler, Y.; Perkins, G.; Zeevaart, J. R.</contrib-group>Biodistribution and Dosimetry of <sup>195m</sup>Pt-Cisplatin in Normal Volunteers. Imaging Agent for Single Photon Emission Computed Tomography.  <cite>Nuklearmedizin</cite> <span class="NLM_year">2013</span>, <em>52</em>, 222–227. (E) 1987. Composite 13 min images of [<sup>13</sup>N]cisplatin PET scans following iv administration, with the drug being infused during the data collection.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> This research was originally published in <i>Journal of Nuclear Medicine</i>, and artwork is reproduced with permission: <contrib-group>Ginos, J. Z.; Cooper, A. J.; Dhawan, V.; Lai, J. C.; Strother, S. C.; Alcock, N.; Rottenberg, D. A.</contrib-group>[<sup>13</sup>N]Cisplatin PET To Assess Pharmacokinetics of Intra-Arterial Versus Intravenous Chemotherapy for Malignant Brain Tumors.  <cite>J. Nucl. Med.</cite> <span class="NLM_year">1987</span>, <em>28</em>, 1844–1852, Copyright by the Society of Nuclear Medicine and Molecular Imaging, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of drugs registered for use in specific countries. In each case the <i>cis</i> nonleaving amines are at the left and the leaving groups are at the right.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of preclinical Pt complexes and related structures. <b>1</b> (<i>R</i>,<i>R</i>-<i>trans</i>-1,2-cyclohexanediamine dihydrogen pyrophosphate)platinum(II)) in development by Phosplatin Therapeutics. Dicycloplatin in development by Sopo-Xingda Pharmaceutical, containing carboplatin (structure highlighted in red, also shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) hydrogen-bonded to 1,1-cyclobutane dicarboxylic acid (CBDCA). The “Kowol” complex is not preclinical but is an exemplar from the literature of a Pt(IV) complex possessing axial ligands with pendent maleimide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic of a likely mechanism of action of a compound similar to <b>2</b>, based on disclosed description of mechanism.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> A Pt(IV) complex containing cisplatin in the equatorial plane, with a pendent maleimide on an axial ligand (left), conjugates with Cys34 of human albumin in the bloodstream. Following prolonged circulation, the Pt(IV) complex is ultimately reduced, yielding cisplain, which can then exert its anticancer activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Schematic demonstrating the chelation of Pt-dach in DACH-Platin and (<b>3</b>). Release from the constructs presumably produces the hydrolyzed form of oxalipatin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/medium/jm-2016-01351d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Scheme showing the structure of picazoplatin (with the structure of the clinical candidate picoplatin shown in red) and its reaction with biomolecules. Subsequently “click” chemistry can be used to conjugate an alkyne-functionalized reporter of choice (blue) to the bound picazoplatin via its pendent azide. A Pt complex containing a 2-azido-1,3-propanediamine nonleaving bidentate ligand is also shown at bottom left.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-11/acs.jmedchem.6b01351/20170602/images/large/jm-2016-01351d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01351&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84205" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84205" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 161 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Shakespeare, W.</span> <span class="citation_source-book">Cymbeline</span>;<span class="NLM_x"> </span><span class="NLM_year">1623</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1623&author=W.+Shakespeare&title=Cymbeline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DShakespeare%26aufirst%3DW.%26btitle%3DCymbeline%26date%3D1623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hoeschele, J. D.</span><span> </span><span class="NLM_article-title">Serendipity and the Prepared Mind: The Discovery of Cisplatin</span> <span class="citation_source-journal">F&M Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=54-68&author=J.+D.+Hoeschele&title=Serendipity+and+the+Prepared+Mind%3A+The+Discovery+of+Cisplatin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoeschele%26aufirst%3DJ.%2BD.%26atitle%3DSerendipity%2520and%2520the%2520Prepared%2520Mind%253A%2520The%2520Discovery%2520of%2520Cisplatin%26jtitle%3DF%2526M%2520Sci.%26date%3D2015%26volume%3D3%26spage%3D54%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kauffman, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentimalli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doldi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. D.</span><span> </span><span class="NLM_article-title">Michele Peyrone (1813–1883), Discoverer of Cisplatin</span> <span class="citation_source-journal">Platinum Met. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">250</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1595/147106710X534326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1595%2F147106710X534326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlelsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=250-256&author=G.+B.+Kauffmanauthor=R.+Pentimalliauthor=S.+Doldiauthor=M.+D.+Hall&title=Michele+Peyrone+%281813%E2%80%931883%29%2C+Discoverer+of+Cisplatin&doi=10.1595%2F147106710X534326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Michele Peyrone (1813-1883), discoverer of cisplatin</span></div><div class="casAuthors">Kauffman, George B.; Pentimalli, Raffaele; Doldi, Sandro; Hall, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Platinum Metals Review</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">250-256</span>CODEN:
                <span class="NLM_cas:coden">PTMRA3</span>;
        ISSN:<span class="NLM_cas:issn">1471-0676</span>.
    
            (<span class="NLM_cas:orgname">Johnson Matthey Public Ltd. Co.</span>)
        </div><div class="casAbstract">The Italian chemist Michele Peyrone (1813-1883) was the first to synthesize cisplatin (cis-diamminedichloro-platinum (II)), the basis of today's most widely used family of anticancer drugs.  This biog. article aims to present, for the first time in the English language, a summary of his life and the achievements that he made during his scientific career.  Originally trained in medicine, Peyrone moved to chem. and attended some of the most prestigious institutions in Europe in his time.  He wrote several publications describing his work on 'Peyrone's chloride' (PtCl2(NH3)2) and Magnus' green salt ([Pt(NH3)4] [PtCl4]).  He later turned his attention to agricultural science where he defended important advances in the understanding of plant growth.  Michele Peyrone's dedication to science is best summarised in the English translation of his first report on the synthesis of cisplatin: "I am detd. to pursue this subject with all my energies, without having regard for the difficulties to be encountered at every step in so expensive and delicate a research".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJIz5_9VPnEbVg90H21EOLACvtfcHk0ljMoIzHIGrQxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlelsLzE&md5=b72147b95efb49aef15c9a8378139220</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1595%2F147106710X534326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1595%252F147106710X534326%26sid%3Dliteratum%253Aachs%26aulast%3DKauffman%26aufirst%3DG.%2BB.%26aulast%3DPentimalli%26aufirst%3DR.%26aulast%3DDoldi%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DMichele%2520Peyrone%2520%25281813%25E2%2580%25931883%2529%252C%2520Discoverer%2520of%2520Cisplatin%26jtitle%3DPlatinum%2520Met.%2520Rev.%26date%3D2010%26volume%3D54%26spage%3D250%26epage%3D256%26doi%3D10.1595%2F147106710X534326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kauffman, G. B.</span> <span class="citation_source-book">Alfred Werner, Founder of Coordination Chemistry</span>; <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Berlin</span>,<span class="NLM_x"> </span><span class="NLM_year">1966</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2F978-3-662-11104-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1966&author=G.+B.+Kauffman&title=Alfred+Werner%2C+Founder+of+Coordination+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2F978-3-662-11104-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-662-11104-8%26sid%3Dliteratum%253Aachs%26aulast%3DKauffman%26aufirst%3DG.%2BB.%26btitle%3DAlfred%2520Werner%252C%2520Founder%2520of%2520Coordination%2520Chemistry%26pub%3DSpringer-Verlag%26date%3D1966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Callaghan, R.</span><span> </span><span class="NLM_article-title">Providing a Molecular Mechanism for P-Glycoprotein; Why Would I Bother?</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1002</span><span class="refDoi"> DOI: 10.1042/BST20150131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1042%2FBST20150131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26517914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVegsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=995-1002&author=R.+Callaghan&title=Providing+a+Molecular+Mechanism+for+P-Glycoprotein%3B+Why+Would+I+Bother%3F&doi=10.1042%2FBST20150131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Providing a molecular mechanism for P-glycoprotein; why would I bother?</span></div><div class="casAuthors">Callaghan, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">995-1002</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">It is almost 40 years since the drug efflux pump P-glycoprotein (permeability glycoprotein or P-gp) was shown to confer multi-drug resistance in cancer cells.  This protein has been one of the most extensively investigated transport proteins due to its intriguing mechanism and its affect in oncol.  P-gp is known to interact with over 300 compds. and the ability to achieve this has not yet been revealed.  Following the binding of substrate and nucleotide, a complex series of conformational changes in the membrane and cytosolic domains translocates substrate across the membrane.  Despite over 30 years of biochem. investigation, the availability of structural data and a plethora of chem. tools to modulate its function, the mol. mechanism remains a mystery.  In addn., overcoming its activity in resistant cancer cells has not been achieved in the clinic, thereby garnering some degree of pessimism in the field.  This review highlights the progress that has been achieved in understanding this complex protein and the value of undertaking mol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyXWKocQQmcLVg90H21EOLACvtfcHk0ljMoIzHIGrQxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVegsbvJ&md5=930f380ee70ad8b22bd94155ff2f62fe</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1042%2FBST20150131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20150131%26sid%3Dliteratum%253Aachs%26aulast%3DCallaghan%26aufirst%3DR.%26atitle%3DProviding%2520a%2520Molecular%2520Mechanism%2520for%2520P-Glycoprotein%253B%2520Why%2520Would%2520I%2520Bother%253F%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2015%26volume%3D43%26spage%3D995%26epage%3D1002%26doi%3D10.1042%2FBST20150131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Shen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouliot, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">706</span><span class="NLM_x">–</span> <span class="NLM_lpage">721</span><span class="refDoi"> DOI: 10.1124/pr.111.005637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1124%2Fpr.111.005637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=22659329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=706-721&author=D.+W.+Shenauthor=L.+M.+Pouliotauthor=M.+D.+Hallauthor=M.+M.+Gottesman&title=Cisplatin+Resistance%3A+A+Cellular+Self-Defense+Mechanism+Resulting+from+Multiple+Epigenetic+and+Genetic+Changes&doi=10.1124%2Fpr.111.005637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes</span></div><div class="casAuthors">Shen, Ding-Wu; Pouliot, Lynn M.; Hall, Matthew D.; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">706-721</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Cisplatin is one of the most effective broad-spectrum anticancer drugs.  Its effectiveness seems to be due to the unique properties of cisplatin, which enters cells via multiple pathways and forms multiple different DNA-platinum adducts while initiating a cellular self-defense system by activating or silencing a variety of different genes, resulting in dramatic epigenetic and/or genetic alternations.  As a result, the development of cisplatin resistance in human cancer cells in vivo and in vitro by necessity stems from bewilderingly complex genetic and epigenetic changes in gene expression and alterations in protein localization.  Extensive published evidence has demonstrated that pleiotropic alterations are frequently detected during development of resistance to this toxic metal compd.  Changes occur in almost every mechanism supporting cell survival, including cell growth-promoting pathways, apoptosis, developmental pathways, DNA damage repair, and endocytosis.  In general, dozens of genes are affected in cisplatin-resistant cells, including pathways involved in copper metab. as well as transcription pathways that alter the cytoskeleton, change cell surface presentation of proteins, and regulate epithelial-to-mesenchymal transition.  Decreased accumulation is one of the most common features resulting in cisplatin resistance.  This seems to be a consequence of numerous epigenetic and genetic changes leading to the loss of cell-surface binding sites and/or transporters for cisplatin, and decreased fluid phase endocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWIazi8GmR-LVg90H21EOLACvtfcHk0ljDoR7ZjUltyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsw%253D%253D&md5=51d1f12ecd4376c1f2f280fd95ea5974</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fpr.111.005637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.111.005637%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%2BW.%26aulast%3DPouliot%26aufirst%3DL.%2BM.%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DCisplatin%2520Resistance%253A%2520A%2520Cellular%2520Self-Defense%2520Mechanism%2520Resulting%2520from%2520Multiple%2520Epigenetic%2520and%2520Genetic%2520Changes%26jtitle%3DPharmacol.%2520Rev.%26date%3D2012%26volume%3D64%26spage%3D706%26epage%3D721%26doi%3D10.1124%2Fpr.111.005637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">535</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.48.080907.180426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1146%2Fannurev.pharmtox.48.080907.180426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=17937596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFymsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=495-535&author=M.+D.+Hallauthor=M.+Okabeauthor=D.+W.+Shenauthor=X.+J.+Liangauthor=M.+M.+Gottesman&title=The+Role+of+Cellular+Accumulation+in+Determining+Sensitivity+to+Platinum-Based+Chemotherapy&doi=10.1146%2Fannurev.pharmtox.48.080907.180426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy</span></div><div class="casAuthors">Hall, Matthew D.; Okabe, Mitsunori; Shen, Ding-Wu; Liang, Xing-Jie; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">495-535</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The platinum (Pt) drugs cisplatin and carboplatin are heavily employed in chemotherapy regimens; however, similar to other classes of drugs, a no. of intrinsic and acquired resistance mechanisms hamper their effectiveness.  The method by which Pt drugs enter cells has traditionally been attributed to simple passive diffusion.  However, recent evidence suggests a no. of active uptake and efflux mechanisms are at play, and altered regulation of these transporters is responsible for the reduced accumulation of drug in resistant cells.  This review suggests a model that helps reconcile the disparate literature by describing multiple pathways for Pt-contg. drugs into and out of the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2jGsuc6lGB7Vg90H21EOLACvtfcHk0ljDoR7ZjUltyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFymsrw%253D&md5=2f3166b6372bc03a5a87de503337cc1c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.48.080907.180426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.48.080907.180426%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DOkabe%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DD.%2BW.%26aulast%3DLiang%26aufirst%3DX.%2BJ.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DThe%2520Role%2520of%2520Cellular%2520Accumulation%2520in%2520Determining%2520Sensitivity%2520to%2520Platinum-Based%2520Chemotherapy%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2008%26volume%3D48%26spage%3D495%26epage%3D535%26doi%3D10.1146%2Fannurev.pharmtox.48.080907.180426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Basis for Design and Development of Platinum(IV) Anticancer Complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3403</span><span class="NLM_x">–</span> <span class="NLM_lpage">3411</span><span class="refDoi"> DOI: 10.1021/jm070280u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070280u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvFKqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3403-3411&author=M.+D.+Hallauthor=H.+R.+Mellorauthor=R.+Callaghanauthor=T.+W.+Hambley&title=Basis+for+Design+and+Development+of+Platinum%28IV%29+Anticancer+Complexes&doi=10.1021%2Fjm070280u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Basis for Design and Development of Platinum(IV) Anticancer Complexes</span></div><div class="casAuthors">Hall, Matthew D.; Mellor, Howard R.; Callaghan, Richard; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3403-3411</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Recent advances in design and development of anticancer Platinum(IV) Complexes are discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrST9_M1CnGgbVg90H21EOLACvtfcHk0ljDoR7ZjUltyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvFKqsLg%253D&md5=aaccf47b20d49d299f871846824cb61e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm070280u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070280u%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DMellor%26aufirst%3DH.%2BR.%26aulast%3DCallaghan%26aufirst%3DR.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DBasis%2520for%2520Design%2520and%2520Development%2520of%2520Platinum%2528IV%2529%2520Anticancer%2520Complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3403%26epage%3D3411%26doi%3D10.1021%2Fjm070280u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Platinum(IV) Antitumour Compounds: Their Bioinorganic Chemistry</span> <span class="citation_source-journal">Coord. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1016/S0010-8545(02)00026-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0010-8545%2802%2900026-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD38XntF2ktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2002&pages=49-67&author=M.+D.+Hallauthor=T.+W.+Hambley&title=Platinum%28IV%29+Antitumour+Compounds%3A+Their+Bioinorganic+Chemistry&doi=10.1016%2FS0010-8545%2802%2900026-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) antitumour compounds: their bioinorganic chemistry</span></div><div class="casAuthors">Hall, Matthew D.; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">49-67</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  This article reviews the studies undertaken into Pt(IV) antitumor compds. since Barnett Rosenberg 1st noted the activity of Pt(IV) complexes.  The chem. and pharmacol. properties of the drugs are discussed and both the reactions with individual biomols., which have received attention and the characterization of biotransformation products from animal and clin. trials are reviewed.  The bioinorg. chem. of Pt(IV) complexes has not previously been reviewed, and the purpose here is to provide insight into the requirements for the antitumor activity of Pt(IV) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkHxf962L07rVg90H21EOLACvtfcHk0lh1l62wiq49hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntF2ktbs%253D&md5=200992ab1e4313bea2f5c9b3f60ac26f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0010-8545%2802%2900026-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-8545%252802%252900026-7%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DPlatinum%2528IV%2529%2520Antitumour%2520Compounds%253A%2520Their%2520Bioinorganic%2520Chemistry%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2002%26volume%3D232%26spage%3D49%26epage%3D67%26doi%3D10.1016%2FS0010-8545%2802%2900026-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Fojo, T.</span><span> </span><span class="NLM_article-title">Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span><span class="refDoi"> DOI: 10.1634/theoncologist.2007-0090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1634%2Ftheoncologist.2007-0090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=277-283&author=T.+Fojo&title=Commentary%3A+Novel+Therapies+for+Cancer%3A+Why+Dirty+Might+Be+Better&doi=10.1634%2Ftheoncologist.2007-0090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2007-0090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2007-0090%26sid%3Dliteratum%253Aachs%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DCommentary%253A%2520Novel%2520Therapies%2520for%2520Cancer%253A%2520Why%2520Dirty%2520Might%2520Be%2520Better%26jtitle%3DOncologist%26date%3D2008%26volume%3D13%26spage%3D277%26epage%3D283%26doi%3D10.1634%2Ftheoncologist.2007-0090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Taylor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filby, A.</span><span> </span><span class="NLM_article-title">Health Impact Analysis of Cisplatin, Carboplatin, and Oxaliplatin</span> <span class="citation_source-journal">Johnson Matthey Technol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1595/205651317X693741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1595%2F205651317X693741" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=32-39&author=M.+Taylorauthor=A.+Filby&title=Health+Impact+Analysis+of+Cisplatin%2C+Carboplatin%2C+and+Oxaliplatin&doi=10.1595%2F205651317X693741"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1595%2F205651317X693741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1595%252F205651317X693741%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DFilby%26aufirst%3DA.%26atitle%3DHealth%2520Impact%2520Analysis%2520of%2520Cisplatin%252C%2520Carboplatin%252C%2520and%2520Oxaliplatin%26jtitle%3DJohnson%2520Matthey%2520Technol.%2520Rev.%26date%3D2017%26volume%3D61%26spage%3D32%26epage%3D39%26doi%3D10.1595%2F205651317X693741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Chabner, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. G.</span><span> </span><span class="NLM_article-title">Chemotherapy and the War on Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1038/nrc1529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2Fnrc1529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=15630416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVek" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-72&author=B.+A.+Chabnerauthor=T.+G.+Roberts&title=Chemotherapy+and+the+War+on+Cancer&doi=10.1038%2Fnrc1529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy and the war on cancer</span></div><div class="casAuthors">Chabner, Bruce A.; Roberts, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs.  Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry.  The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply.  This article chronicles the history of modern chemotherapy and identifies remaining challenges for the next generation of researchers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrszgbuDuTBobVg90H21EOLACvtfcHk0lh1l62wiq49hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVek&md5=d5c8b3dba59b9d6dcca473552525fa14</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrc1529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1529%26sid%3Dliteratum%253Aachs%26aulast%3DChabner%26aufirst%3DB.%2BA.%26aulast%3DRoberts%26aufirst%3DT.%2BG.%26atitle%3DChemotherapy%2520and%2520the%2520War%2520on%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D72%26doi%3D10.1038%2Fnrc1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Cleare, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeschele, J. D.</span><span> </span><span class="NLM_article-title">Studies on the Antitumor Activity of Group VIII Transition Metal Complexes. Part I. Platinum (II) Complexes</span> <span class="citation_source-journal">Bioinorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1016/S0006-3061(00)80249-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0006-3061%2800%2980249-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaE2cXms1GqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1973&pages=187-210&author=M.+J.+Cleareauthor=J.+D.+Hoeschele&title=Studies+on+the+Antitumor+Activity+of+Group+VIII+Transition+Metal+Complexes.+Part+I.+Platinum+%28II%29+Complexes&doi=10.1016%2FS0006-3061%2800%2980249-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of Group VIII transition metal complexes.  I.  Platinum(II) complexes</span></div><div class="casAuthors">Cleare, Michael J.; Hoeschele, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioinorganic Chemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-210</span>CODEN:
                <span class="NLM_cas:coden">BICHBX</span>;
        ISSN:<span class="NLM_cas:issn">0006-3061</span>.
    </div><div class="casAbstract">A wide variety of Pt(II) complexes were studied for antitumor activity against Sarcoma 180 in female mice.  In general only neutral complexes exhibited activity, whereas charged species were inactive and relatively nontoxic.  A series of complexes of the type cis-[PtA2X2] (where A2 is either 2 monodentate or 1 bidentate amine ligand and X2 is either 2 monodentate or 1 bidentate anionic ligand) were studied with A and B being systematically varied.  At least 10 potentially active antitumor drugs were identified, including cis-dichlorbis(methylamine)platinum(2+) [15273-32-2], diamminepropanedioatoplatinum(2+) [38780-43-7], and (1,2-ethanediammine-N,N')(2-methylpropanedioato)platinum(2+) [41575-97-7].  The trans isomers were inactive in comparison with active cis complexes, so the presence of cis-reactive ligands seems to be a necessary parameter for antitumor activity.  Complexes with highly reactive ligands such as cis-[Pt(NH3)2 (H2O)2](NO3)2 were highly toxic.  Pd(II) complexes analogous to the active Pt(II) compds. were themselves inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXyjKO1MKtVbVg90H21EOLACvtfcHk0lh1l62wiq49hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXms1GqsQ%253D%253D&md5=6bd976211b8c0dda0c3fa4000ef0d9f8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0006-3061%2800%2980249-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3061%252800%252980249-5%26sid%3Dliteratum%253Aachs%26aulast%3DCleare%26aufirst%3DM.%2BJ.%26aulast%3DHoeschele%26aufirst%3DJ.%2BD.%26atitle%3DStudies%2520on%2520the%2520Antitumor%2520Activity%2520of%2520Group%2520VIII%2520Transition%2520Metal%2520Complexes.%2520Part%2520I.%2520Platinum%2520%2528II%2529%2520Complexes%26jtitle%3DBioinorg.%2520Chem.%26date%3D1973%26volume%3D2%26spage%3D187%26epage%3D210%26doi%3D10.1016%2FS0006-3061%2800%2980249-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Silverman, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">2.4-Å Crystal Structure of the Asymmetric Platinum Complex [Pt(Ammine)(Cyclohexylamine)]<sup>2+</sup> Bound to a Dodecamer DNA Duplex</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">49743</span><span class="NLM_x">–</span> <span class="NLM_lpage">49749</span><span class="refDoi"> DOI: 10.1074/jbc.M206979200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1074%2Fjbc.M206979200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=49743-49749&author=A.+P.+Silvermanauthor=W.+Buauthor=S.+M.+Cohenauthor=S.+J.+Lippard&title=2.4-%C3%85+Crystal+Structure+of+the+Asymmetric+Platinum+Complex+%5BPt%28Ammine%29%28Cyclohexylamine%29%5D2%2B+Bound+to+a+Dodecamer+DNA+Duplex&doi=10.1074%2Fjbc.M206979200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M206979200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M206979200%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DA.%2BP.%26aulast%3DBu%26aufirst%3DW.%26aulast%3DCohen%26aufirst%3DS.%2BM.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3D2.4-%25C3%2585%2520Crystal%2520Structure%2520of%2520the%2520Asymmetric%2520Platinum%2520Complex%2520%255BPt%2528Ammine%2529%2528Cyclohexylamine%2529%255D2%252B%2520Bound%2520to%2520a%2520Dodecamer%2520DNA%2520Duplex%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D49743%26epage%3D49749%26doi%3D10.1074%2Fjbc.M206979200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">The Influence of Structure on the Activity and Toxicity of Pt Anti-Cancer Drugs</span> <span class="citation_source-journal">Coord. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span><span class="refDoi"> DOI: 10.1016/S0010-8545(97)00023-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0010-8545%2897%2900023-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=1997&pages=181-223&author=T.+W.+Hambley&title=The+Influence+of+Structure+on+the+Activity+and+Toxicity+of+Pt+Anti-Cancer+Drugs&doi=10.1016%2FS0010-8545%2897%2900023-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0010-8545%2897%2900023-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-8545%252897%252900023-4%26sid%3Dliteratum%253Aachs%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DThe%2520Influence%2520of%2520Structure%2520on%2520the%2520Activity%2520and%2520Toxicity%2520of%2520Pt%2520Anti-Cancer%2520Drugs%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D1997%26volume%3D166%26spage%3D181%26epage%3D223%26doi%3D10.1016%2FS0010-8545%2897%2900023-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Van Beusichem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, N.</span><span> </span><span class="NLM_article-title">Activation of the <i>trans</i> Geometry in Platinum Antitumor Complexes. Synthesis, Characterization, and Biological Activity of Complexes with the Planar Ligands Pyridine, N-Methylimidazole, Thiazole, and Quinoline. Crystal and Molecular Structure of <i>trans</i>-Dichlorobis(Thiazole)Platinum(II)</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">634</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span><span class="refDoi"> DOI: 10.1021/ic00030a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic00030a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaK38XpvVWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1992&pages=634-639&author=M.+Van+Beusichemauthor=N.+Farrell&title=Activation+of+the+trans+Geometry+in+Platinum+Antitumor+Complexes.+Synthesis%2C+Characterization%2C+and+Biological+Activity+of+Complexes+with+the+Planar+Ligands+Pyridine%2C+N-Methylimidazole%2C+Thiazole%2C+and+Quinoline.+Crystal+and+Molecular+Structure+of+trans-Dichlorobis%28Thiazole%29Platinum%28II%29&doi=10.1021%2Fic00030a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the trans geometry in platinum antitumor complexes.  Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole, and quinoline.  Crystal and molecular structure of trans-dichlorobis(thiazole)platinum(II)</span></div><div class="casAuthors">Van Beusichem, Marijo; Farrell, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">634-9</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    </div><div class="casAbstract">The presence of planar ligands in trans-[PtCl2(py)2] greatly enhances the cytotoxicity of such species, with respect both to their corresponding cis isomer and also to trans-[PtCl2(NH3)2].  The cytotoxicity of trans-[PtCl2(py)2] in murine tumor cell lines is equiv. to the anticancer drug cisplatin, cis-[PtCl2(NH3)2].  The generality of this effect was studied for a range of structures with planar ligands of formula trans-[PtCl2(L)(L')].  Three distinct series were examd.-(1) L = L' = py, N-methylimidazole (N-MeIm), and thiazole (Tz), (2) L = quinoline (quin), L' = MeRSO where (R = Me, CH2Ph, Ph), and (3) L = quinoline, L' = NH3.  The synthesis and chem. characterization of all new complexes are described.  An x-ray crystal structure detn. for trans-[PtCl2(Tz)2] confirmed the geometry with N-bound thiazole.  The crystals are monoclinic, space group C2/c, a 8.088(3), b 14.964(4), c 8.847(2) Å, β 99.50(2), Z = 4, R = 0.0545, Rw = 0.0655.  Pt has the expected square planar coordination with l(Pt-Cl) = 2.300(5) Å and l(Pt-N) = 2.024(18) and 2.077(17) Å.  Bond angles are normal with N(1)-Pt-N(2) = 180.0(1)°, N(1)-Pt-Cl(1) = 90.4(1)°, and N(2)-Pt-Cl(1A) = 89.6(1)°.  The intensity data were collected with MoKα radiation with λ = 0.71073 Å.  The thiazole rings are not coplanar but slightly tilted to each other at an angle of 14.3°.  The dihedral angles between the Pt coordination plane and the thiazole rings are 119.3 and 105.0°.  The biol. studies confirm the generality of activation of the trans geometry using planar ligands.  Cytotoxicity tests in murine leukemia (L1210) cell lines both sensitive and rendered resistant to cisplatin show that the complexes show equiv. cytostatic activity to that of cisplatin.  The activity is an order of magnitude greater than trans-[PtCl2(NH3)2].  The cytotoxicity is further marked by consistent activity in the cisplatin-resistant cell line.  Contrary to the well-established but empirical structure-activity relationships, the trans geometry can give platinum complexes with cytotoxicity equiv. to that of the analogous cis isomer.  The results point to a further source of platinum antitumor complexes acting by a different mol. mechanism to cisplatin with potential for antitumor activity complementary to that of the clin. used drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri6EQNAr6TNrVg90H21EOLACvtfcHk0lgPUzHGFTDXBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XpvVWgtQ%253D%253D&md5=c3800e101d3ab61e9251b60730dab333</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fic00030a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic00030a021%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBeusichem%26aufirst%3DM.%26aulast%3DFarrell%26aufirst%3DN.%26atitle%3DActivation%2520of%2520the%2520trans%2520Geometry%2520in%2520Platinum%2520Antitumor%2520Complexes.%2520Synthesis%252C%2520Characterization%252C%2520and%2520Biological%2520Activity%2520of%2520Complexes%2520with%2520the%2520Planar%2520Ligands%2520Pyridine%252C%2520N-Methylimidazole%252C%2520Thiazole%252C%2520and%2520Quinoline.%2520Crystal%2520and%2520Molecular%2520Structure%2520of%2520trans-Dichlorobis%2528Thiazole%2529Platinum%2528II%2529%26jtitle%3DInorg.%2520Chem.%26date%3D1992%26volume%3D31%26spage%3D634%26epage%3D639%26doi%3D10.1021%2Fic00030a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hearn, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Canelon, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizarro, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcdermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carragher, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, P. J.</span><span> </span><span class="NLM_article-title">Potent Organo-Osmium Compound Shifts Metabolism in Epithelial Ovarian Cancer Cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">E3800</span><span class="NLM_x">–</span> <span class="NLM_lpage">3805</span><span class="refDoi"> DOI: 10.1073/pnas.1500925112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1073%2Fpnas.1500925112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=E3800-3805&author=J.+M.+Hearnauthor=I.+Romero-Canelonauthor=A.+F.+Munroauthor=Y.+Fuauthor=A.+M.+Pizarroauthor=M.+J.+Garnettauthor=U.+Mcdermottauthor=N.+O.+Carragherauthor=P.+J.+Sadler&title=Potent+Organo-Osmium+Compound+Shifts+Metabolism+in+Epithelial+Ovarian+Cancer+Cells&doi=10.1073%2Fpnas.1500925112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1500925112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1500925112%26sid%3Dliteratum%253Aachs%26aulast%3DHearn%26aufirst%3DJ.%2BM.%26aulast%3DRomero-Canelon%26aufirst%3DI.%26aulast%3DMunro%26aufirst%3DA.%2BF.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DPizarro%26aufirst%3DA.%2BM.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMcdermott%26aufirst%3DU.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DPotent%2520Organo-Osmium%2520Compound%2520Shifts%2520Metabolism%2520in%2520Epithelial%2520Ovarian%2520Cancer%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3DE3800%26epage%3D3805%26doi%3D10.1073%2Fpnas.1500925112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Google</span><span class="NLM_x">. Google Scholar. </span><a href="http://scholar.google.com/" class="extLink">http://scholar.google.com/</a> (accessed August 11,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Google.+Google+Scholar.+http%3A%2F%2Fscholar.google.com%2F+%28accessed+August+11%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sancton, T.; Le Quesne, N.</span><span> </span><span class="NLM_article-title">From Despair to Glory</span>.  <span class="citation_source-journal">Time International</span>; July 19,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=T.+Sancton&author=N.+Le+Quesne&title=From+Despair+to+Glory"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSancton%26aufirst%3DT.%26atitle%3DFrom%2520Despair%2520to%2520Glory%26jtitle%3DTime%2520International%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Armstrong, L.</span> <span class="citation_source-book">It’s Not About the Bike: My Journey Back to Life</span>; <span class="NLM_publisher-name">The Berkley Publishing Group</span>: <span class="NLM_publisher-loc">New York, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=L.+Armstrong&title=It%E2%80%99s+Not+About+the+Bike%3A+My+Journey+Back+to+Life"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DL.%26btitle%3DIt%25E2%2580%2599s%2520Not%2520About%2520the%2520Bike%253A%2520My%2520Journey%2520Back%2520to%2520Life%26pub%3DThe%2520Berkley%2520Publishing%2520Group%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Schnell, F. M.</span><span> </span><span class="NLM_article-title">Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span><span class="refDoi"> DOI: 10.1634/theoncologist.8-2-187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1634%2Ftheoncologist.8-2-187" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=187-198&author=F.+M.+Schnell&title=Chemotherapy-Induced+Nausea+and+Vomiting%3A+The+Importance+of+Acute+Antiemetic+Control&doi=10.1634%2Ftheoncologist.8-2-187"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-2-187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-2-187%26sid%3Dliteratum%253Aachs%26aulast%3DSchnell%26aufirst%3DF.%2BM.%26atitle%3DChemotherapy-Induced%2520Nausea%2520and%2520Vomiting%253A%2520The%2520Importance%2520of%2520Acute%2520Antiemetic%2520Control%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26spage%3D187%26epage%3D198%26doi%3D10.1634%2Ftheoncologist.8-2-187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Karasawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyger, P. S.</span><span> </span><span class="NLM_article-title">An Integrated View of Cisplatin-Induced Nephrotoxicity and Ototoxicity</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.toxlet.2015.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.toxlet.2015.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26101797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyiurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2015&pages=219-227&author=T.+Karasawaauthor=P.+S.+Steyger&title=An+Integrated+View+of+Cisplatin-Induced+Nephrotoxicity+and+Ototoxicity&doi=10.1016%2Fj.toxlet.2015.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An integrated view of cisplatin-induced nephrotoxicity and ototoxicity</span></div><div class="casAuthors">Karasawa, Takatoshi; Steyger, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-227</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Cisplatin is one of the most widely-used drugs to treat cancers.  However, its nephrotoxic and ototoxic side-effects remain major clin. limitations.  Recent studies have improved our understanding of the mol. mechanisms of cisplatin-induced nephrotoxicity and ototoxicity.  While cisplatin binding to DNA is the major cytotoxic mechanism in proliferating (cancer) cells, nephrotoxicity and ototoxicity appear to result from toxic levels of reactive oxygen species and protein dysregulation within various cellular compartments.  In this review, we discuss mol. mechanisms of cisplatin-induced nephrotoxicity and ototoxicity.  We also discuss potential clin. strategies to prevent nephrotoxicity and ototoxicity and their current limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYhpFPdWYJwbVg90H21EOLACvtfcHk0lhvb24gsXkduw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyiurbI&md5=73d8dd65d26d256bddcb16e414417d6d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2015.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2015.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DKarasawa%26aufirst%3DT.%26aulast%3DSteyger%26aufirst%3DP.%2BS.%26atitle%3DAn%2520Integrated%2520View%2520of%2520Cisplatin-Induced%2520Nephrotoxicity%2520and%2520Ototoxicity%26jtitle%3DToxicol.%2520Lett.%26date%3D2015%26volume%3D237%26spage%3D219%26epage%3D227%26doi%3D10.1016%2Fj.toxlet.2015.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span> </span><span class="NLM_article-title">The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer</span>. In  <span class="citation_source-book">Wellcome Witnesses to Twentieth Century Medicine Seminars</span>; <span class="NLM_contrib-group">Christie, D. A.; Tansey, E. M.</span>, Eds.; Wellcome Witnesses to Twentieth Century Medicine, Vol. 30; <span class="NLM_publisher-name">The Trustee of the Wellcome Trust</span>: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+A.+Christie&author=E.+M.+Tansey&title=Wellcome+Witnesses+to+Twentieth+Century+Medicine+Seminars"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Discovery%252C%2520Use%2520and%2520Impact%2520of%2520Platinum%2520Salts%2520as%2520Chemotherapy%2520Agents%2520for%2520Cancer%26btitle%3DWellcome%2520Witnesses%2520to%2520Twentieth%2520Century%2520Medicine%2520Seminars%26aulast%3DChristie%26aufirst%3DD.%2BA.%26pub%3DThe%2520Trustee%2520of%2520the%2520Wellcome%2520Trust%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Carter, S. K.; Cleare, M. J.; Connors, T. A.; Conran, P. B.; Dienstbier, Z.; Ellerby, R. A.; Harder, M. C.; Hill, J. M.; Hindy, I.; Krakoff, I.; Roberts, J. J.; Robins, A. B.; Talley, R. W.; Thomson, A. J.; Wallace, H. J.; Williams, R. J.; Wiltshaw, E.</span> <span class="citation_source-book">Platinum Coordination Complexes in Cancer Chemotherapy</span>; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1974</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1974&author=S.+K.+Carter&author=M.+J.+Cleare&author=T.+A.+Connors&author=P.+B.+Conran&author=Z.+Dienstbier&author=R.+A.+Ellerby&author=M.+C.+Harder&author=J.+M.+Hill&author=I.+Hindy&author=I.+Krakoff&author=J.+J.+Roberts&author=A.+B.+Robins&author=R.+W.+Talley&author=A.+J.+Thomson&author=H.+J.+Wallace&author=R.+J.+Williams&author=E.+Wiltshaw&title=Platinum+Coordination+Complexes+in+Cancer+Chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DS.%2BK.%26btitle%3DPlatinum%2520Coordination%2520Complexes%2520in%2520Cancer%2520Chemotherapy%26pub%3DSpringer-Verlag%26date%3D1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hill, J. M.; Loeb, E.; Maclellan, A. S.; Hill, N. O.; Khan, A.; Kogler, J.</span><span> </span><span class="NLM_article-title">Further Clinical Experience with <i>cis</i>-Platinum(II) Diamminedichloride</span>. In  <span class="citation_source-book">Platinum Coordination Complexes in Cancer Chemotherapy</span>; <span class="NLM_contrib-group">Connors, T. A.; Roberts, J. J.</span>, Ed.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1974</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2F978-3-642-49306-5_10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1974&pages=145-152&author=J.+M.+Hill&author=E.+Loeb&author=A.+S.+Maclellan&author=N.+O.+Hill&author=A.+Khan&author=J.+Koglerauthor=T.+A.+Connors&author=J.+J.+Roberts&title=Platinum+Coordination+Complexes+in+Cancer+Chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-49306-5_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-49306-5_10%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DJ.%2BM.%26atitle%3DFurther%2520Clinical%2520Experience%2520with%2520cis-Platinum%2528II%2529%2520Diamminedichloride%26btitle%3DPlatinum%2520Coordination%2520Complexes%2520in%2520Cancer%2520Chemotherapy%26aulast%3DConnors%26aufirst%3DT.%2BA.%26pub%3DSpringer-Verlag%26date%3D1974%26spage%3D145%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harland, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddik, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcelwain, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raju, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiltshaw, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peckham, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrap, K. R.</span><span> </span><span class="NLM_article-title">Early Clinical Studies with <i>cis</i>-Diammine-1,1-Cyclobutane Dicarboxylate Platinum II</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1007/BF00257742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF00257742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=6761010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaL3s7ivFyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1982&pages=140-147&author=A.+H.+Calvertauthor=S.+J.+Harlandauthor=D.+R.+Newellauthor=Z.+H.+Siddikauthor=A.+C.+Jonesauthor=T.+J.+Mcelwainauthor=S.+Rajuauthor=E.+Wiltshawauthor=I.+E.+Smithauthor=J.+M.+Bakerauthor=M.+J.+Peckhamauthor=K.+R.+Harrap&title=Early+Clinical+Studies+with+cis-Diammine-1%2C1-Cyclobutane+Dicarboxylate+Platinum+II&doi=10.1007%2FBF00257742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II</span></div><div class="casAuthors">Calvert A H; Harland S J; Newell D R; Siddik Z H; Jones A C; McElwain T J; Raju S; Wiltshaw E; Smith I E; Baker J M; Peckham M J; Harrap K R</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">140-7</span>
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">cis-Diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8), an analogue of cisplatin showing reduced toxicity in preclinical studies, was evaluated in 60 patients.  Doses were given initially every 3 weeks and escalated from 20 to 520 mg/m2.  Following this, doses were given every 4 weeks and escalated from 300 to 500 mg/m2.  The dose-limiting toxicity, thrombocytopoenia, occurred in four-fifths of patients treated at 520 mg/m2, with the nadir occurring 3 weeks after treatment.  Leucopoenia and anaemia also occurred but were less severe.  Vomiting occurred in all patients receiving over 120 mg/m2 but seldom persisted beyond 24 h.  Serial measurements of 51Cr-EDTA clearances, urinary N-acetylglucosaminidase, urinary leucine aminopeptidase, and beta 2-microglobulin did not reveal significant evidence of nephrotoxicity.  Detriment to the audiogram has not been seen in the first 13 patients studied.  Pharmacological studies showed that most of the dose of platinum was excreted in the urine, and that impairment of renal function may be associated with drug retention and an increased risk of myelosuppression.  The previous therapy and age of the patient also affected the tolerance of the drug.  Clinical responses were seen in patients with ovarian carcinoma receiving greater than 120 mg/m2.  A further dose escalation was performed on a 4-week schedule in patients under 65 with good renal function.  The maximum dose it was possible to administer repeatedly without incurring myelosuppression was in the range 400-500 mg/m2.  JM8 is not significantly nephrotoxic and is less emetic than cisplatin.  It has antitumour activity in man and deserves wider evaluation, along with the other analogues under study in various centres, as an alternative to cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT378_1soZJrUH3Rlp_k91zfW6udTcc2eYqrYsxVWmyVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s7ivFyisg%253D%253D&md5=6c38034782d8df6263c086fa4baeebf6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2FBF00257742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00257742%26sid%3Dliteratum%253Aachs%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DHarland%26aufirst%3DS.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26aulast%3DJones%26aufirst%3DA.%2BC.%26aulast%3DMcelwain%26aufirst%3DT.%2BJ.%26aulast%3DRaju%26aufirst%3DS.%26aulast%3DWiltshaw%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DBaker%26aufirst%3DJ.%2BM.%26aulast%3DPeckham%26aufirst%3DM.%2BJ.%26aulast%3DHarrap%26aufirst%3DK.%2BR.%26atitle%3DEarly%2520Clinical%2520Studies%2520with%2520cis-Diammine-1%252C1-Cyclobutane%2520Dicarboxylate%2520Platinum%2520II%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1982%26volume%3D9%26spage%3D140%26epage%3D147%26doi%3D10.1007%2FBF00257742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Goodfield, J.</span> <span class="citation_source-book">Cancer under Siege</span>; <span class="NLM_publisher-name">Hutchinson</span>: <span class="NLM_publisher-loc">London, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">1975</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1975&author=J.+Goodfield&title=Cancer+under+Siege"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfield%26aufirst%3DJ.%26btitle%3DCancer%2520under%2520Siege%26pub%3DHutchinson%26date%3D1975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span> <span class="citation_source-book">Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug</span>; <span class="NLM_publisher-name">Verlag Helvetica Chimica Aeta and Wiley-VCH</span>: <span class="NLM_publisher-loc">Zürich, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cisplatin%3A+Chemistry+and+Biochemistry+of+a+Leading+Anticancer+Drug%3B+Verlag+Helvetica+Chimica+Aeta+and+Wiley-VCH%3A+Z%C3%BCrich%2C+Switzerland%2C+1999."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DCisplatin%253A%2520Chemistry%2520and%2520Biochemistry%2520of%2520a%2520Leading%2520Anticancer%2520Drug%26pub%3DVerlag%2520Helvetica%2520Chimica%2520Aeta%2520and%2520Wiley-VCH%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span>Twitter. <a href="https://twitter.com/" class="extLink">https://twitter.com/</a> (accessed August 11,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Twitter.+https%3A%2F%2Ftwitter.com%2F+%28accessed+August+11%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Descoeur, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzoccaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francois, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maffre, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couette, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busserolles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courteix, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazdunski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eschalier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Authier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourinet, E.</span><span> </span><span class="NLM_article-title">Oxaliplatin-Induced Cold Hypersensitivity Is Due to Remodelling of Ion Channel Expression in Nociceptors</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">266</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.1002/emmm.201100134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Femmm.201100134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=21438154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmt1yhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=266-278&author=J.+Descoeurauthor=V.+Pereiraauthor=A.+Pizzoccaroauthor=A.+Francoisauthor=B.+Lingauthor=V.+Maffreauthor=B.+Couetteauthor=J.+Busserollesauthor=C.+Courteixauthor=J.+Noelauthor=M.+Lazdunskiauthor=A.+Eschalierauthor=N.+Authierauthor=E.+Bourinet&title=Oxaliplatin-Induced+Cold+Hypersensitivity+Is+Due+to+Remodelling+of+Ion+Channel+Expression+in+Nociceptors&doi=10.1002%2Femmm.201100134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors</span></div><div class="casAuthors">Descoeur, Juliette; Pereira, Vanessa; Pizzoccaro, Anne; Francois, Amaury; Ling, Bing; Maffre, Violette; Couette, Brigitte; Busserolles, Jerome; Courteix, Christine; Noel, Jacques; Lazdunski, Michel; Eschalier, Alain; Authier, Nicolas; Bourinet, Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">266-278</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cold hypersensitivity is the hallmark of oxaliplatin-induced neuropathy, which develops in nearly all patients under this chemotherapy.  To date, pain management strategies have failed to alleviate these symptoms, hence development of adapted analgesics is needed.  Here, we report that oxaliplatin exaggerates cold perception in mice as well as in patients.  These symptoms are mediated by primary afferent sensory neurons expressing the thermoreceptor TRPM8.  Mechanistically, oxaliplatin promotes over-excitability by drastically lowering the expression of distinct potassium channels (TREK1, TRAAK) and by increasing the expression of pro-excitatory channels such as the hyperpolarization-activated channels (HCNs).  These findings are corroborated by the anal. of TREK1-TRAAK null mice and use of the specific HCN inhibitor ivabradine, which abolishes the oxaliplatin-induced cold hypersensibility.  These results suggest that oxaliplatin exacerbates cold perception by modulating the transcription of distinct ionic conductances that together shape sensory neuron responses to cold.  The translational and clin. implication of these findings would be that ivabradine may represent a tailored treatment for oxaliplatin-induced neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLi-ACdibowbVg90H21EOLACvtfcHk0lhss7vnrL_8TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmt1yhsrk%253D&md5=fe6a66edde85115e7a99b05693c94439</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Femmm.201100134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201100134%26sid%3Dliteratum%253Aachs%26aulast%3DDescoeur%26aufirst%3DJ.%26aulast%3DPereira%26aufirst%3DV.%26aulast%3DPizzoccaro%26aufirst%3DA.%26aulast%3DFrancois%26aufirst%3DA.%26aulast%3DLing%26aufirst%3DB.%26aulast%3DMaffre%26aufirst%3DV.%26aulast%3DCouette%26aufirst%3DB.%26aulast%3DBusserolles%26aufirst%3DJ.%26aulast%3DCourteix%26aufirst%3DC.%26aulast%3DNoel%26aufirst%3DJ.%26aulast%3DLazdunski%26aufirst%3DM.%26aulast%3DEschalier%26aufirst%3DA.%26aulast%3DAuthier%26aufirst%3DN.%26aulast%3DBourinet%26aufirst%3DE.%26atitle%3DOxaliplatin-Induced%2520Cold%2520Hypersensitivity%2520Is%2520Due%2520to%2520Remodelling%2520of%2520Ion%2520Channel%2520Expression%2520in%2520Nociceptors%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D266%26epage%3D278%26doi%3D10.1002%2Femmm.201100134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Schierl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohnloser, J.</span><span> </span><span class="NLM_article-title">Long-Term Platinum Excretion in Patients Treated with Cisplatin</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1007/BF00685736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF00685736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=7720180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK2M3js1Gluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=75-78&author=R.+Schierlauthor=B.+Rohrerauthor=J.+Hohnloser&title=Long-Term+Platinum+Excretion+in+Patients+Treated+with+Cisplatin&doi=10.1007%2FBF00685736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term platinum excretion in patients treated with cisplatin</span></div><div class="casAuthors">Schierl R; Rohrer B; Hohnloser J</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-8</span>
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">The purpose of this study was to determine long-term renal platinum excretion after chemotherapy with cisplatin.  We examined urinary platinum concentrations in 23 men at 150-3022 days after anticancer treatment for testicular neoplasm.  Spot urine samples were analyzed by voltammetry.  This new, subtle method with a detection limit of 2 pg platinum allows determination of even the natural background level.  Urinary platinum concentrations in our patients ranged between 0.74 and 77.24 micrograms/g creatinine, depending on the total delivered dose and follow-up period.  Regression analysis of the data showed two phases of long-term renal platinum excretion, one occurring at between 150 and 900 days of follow-up and the other with an onset at 900 days after cisplatin administration (r1(2) = 0.82, r2(2) = 0.88).  Two biological half-lives of 160 and 720 days were calculated.  Our results show that urinary platinum concentrations determined at 8 years after cisplatin therapy are 40 times higher than the background level (up to 0.02 micrograms/g creatinine).  Our findings on the long-term pharmacokinetics of this anticancer agent may facilitate further studies on sites of platinum storage in the human body as well as clinical studies on the late adverse effects of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbaoG3R9PV8Y3yKPtYViAGfW6udTcc2eYLVeUF5QTLL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3js1Gluw%253D%253D&md5=695387ab341736a93877701636255d7c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2FBF00685736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00685736%26sid%3Dliteratum%253Aachs%26aulast%3DSchierl%26aufirst%3DR.%26aulast%3DRohrer%26aufirst%3DB.%26aulast%3DHohnloser%26aufirst%3DJ.%26atitle%3DLong-Term%2520Platinum%2520Excretion%2520in%2520Patients%2520Treated%2520with%2520Cisplatin%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1995%26volume%3D36%26spage%3D75%26epage%3D78%26doi%3D10.1007%2FBF00685736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Theon, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascoe, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krag, D. N.</span><span> </span><span class="NLM_article-title">Intratumoral Chemotherapy with Cisplatin in Oily Emulsion in Horses</span> <span class="citation_source-journal">J. Am. Vet. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">202</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=8428832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK3s7lsV2itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=1993&pages=261-267&author=A.+P.+Theonauthor=J.+R.+Pascoeauthor=G.+P.+Carlsonauthor=D.+N.+Krag&title=Intratumoral+Chemotherapy+with+Cisplatin+in+Oily+Emulsion+in+Horses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumoral chemotherapy with cisplatin in oily emulsion in horses</span></div><div class="casAuthors">Theon A P; Pascoe J R; Carlson G P; Krag D N</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Veterinary Medical Association</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-7</span>
        ISSN:<span class="NLM_cas:issn">0003-1488</span>.
    </div><div class="casAbstract">Twenty horses with 30 lesions were studied to evaluate the effects of intratumoral chemotherapy with cisplatin in sesame oil on equine sarcoids (n = 19), squamous cell carcinomas (n = 7), and squamous cell papillomas (n = 4).  Treatment consisted of 4 sessions of intratumoral cisplatin chemotherapy at 2-week intervals.  A controlled-release formulation of cisplatin in sesame oil was used to limit drug egress from the injection site.  Mean dosage per session was 0.97 (+/- 0.17, SEM) mg of cisplatin/cm3 of tumor tissue treated for tumor volumes ranging from 10 to 20 cm3.  Dosage tended to be slightly higher for smaller tumors and slightly lower for larger tumors.  Tumor regression was observed in all horses.  Complete response was observed in 18 of the sarcoids, 5 of the squamous cell carcinomas, and 4 of the squamous cell papillomas.  The mean relapse-free interval was 21.6 and 14 months in horses with sarcoid and carcinoma/papilloma, respectively.  The 1-year relapse-free rates were 87 and 65% for equine sarcoid and carcinoma/papilloma, respectively.  In horses with relapse, 70% had tumor recurrence outside the treated field.  Cisplatin-related local toxicosis was minimal.  Intratumoral cisplatin chemotherapy was found to be a practical and effective treatment of sarcoid and squamous cell carcinoma/papilloma in horses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKREFwGL5d7zslzEEsg76ufW6udTcc2eYLVeUF5QTLL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s7lsV2itA%253D%253D&md5=f1d8119d94e2e6a29c090baecdb341ac</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTheon%26aufirst%3DA.%2BP.%26aulast%3DPascoe%26aufirst%3DJ.%2BR.%26aulast%3DCarlson%26aufirst%3DG.%2BP.%26aulast%3DKrag%26aufirst%3DD.%2BN.%26atitle%3DIntratumoral%2520Chemotherapy%2520with%2520Cisplatin%2520in%2520Oily%2520Emulsion%2520in%2520Horses%26jtitle%3DJ.%2520Am.%2520Vet.%2520Med.%2520Assoc.%26date%3D1993%26volume%3D202%26spage%3D261%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Theon, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magdesian, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusterla, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galuppo, L. D.</span><span> </span><span class="NLM_article-title">Long-Term Outcome Associated with Intratumoral Chemotherapy with Cisplatin for Cutaneous Tumors in Equidae: 573 Cases (1995–2004)</span> <span class="citation_source-journal">J. Am. Vet. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">230</span><span class="NLM_x">, </span> <span class="NLM_fpage">1506</span><span class="NLM_x">–</span> <span class="NLM_lpage">1513</span><span class="refDoi"> DOI: 10.2460/javma.230.10.1506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2460%2Fjavma.230.10.1506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=17504043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsVGmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=2007&pages=1506-1513&author=A.+P.+Theonauthor=W.+D.+Wilsonauthor=K.+G.+Magdesianauthor=N.+Pusterlaauthor=J.+R.+Snyderauthor=L.+D.+Galuppo&title=Long-Term+Outcome+Associated+with+Intratumoral+Chemotherapy+with+Cisplatin+for+Cutaneous+Tumors+in+Equidae%3A+573+Cases+%281995%E2%80%932004%29&doi=10.2460%2Fjavma.230.10.1506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004)</span></div><div class="casAuthors">Theon, Alain P.; Wilson, W. David; Magdesian, K. Gary; Pusterla, Nicola; Snyder, Jack R.; Galuppo, Larry D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Veterinary Medical Association</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1506-1513</span>CODEN:
                <span class="NLM_cas:coden">JAVMA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-1488</span>.
    
            (<span class="NLM_cas:orgname">American Veterinary Medical Association</span>)
        </div><div class="casAbstract">Objective: To det. outcome assocd. with cutaneous tumors treated via intratumoral chemotherapy with cisplatin and identify risk factors affecting local tumor control and complications in equidae.  Design: Retrospective case series.  Animals: 573 equidae with 630 cutaneous tumors.  Procedures: Medical records of horses, mules, donkeys, and ponies with cutaneous tumors treated via intratumoral chemotherapy with cisplatin were analyzed.  Results: 549 horses, 13 mules, 8 donkeys, and 3 ponies with 630 histol. confirmed cutaneous tumors were included.  Tumors included sarcoids (n = 409), squamous cell carcinomas (151), soft tissue sarcomas (28), cutaneous lymphomas (26), and melanomas (16).  Overall cure rate, defined as local control at 4 years, was 93.3%.  For all tumor stages combined, cure rates after 1 course of treatment were 96.3% for sarcoids, 96% for lymphomas, 88% for squamous cell carcinomas, 85% for soft tissue sarcomas, and 81 % for melanomas.  Treatment protocol, tumor stage, and prior treatment were significant prognostic factors for tumor control.  Treatment efficacy was lower for large tumors, those with gross postoperative residual disease, and those that had been treated previously with other modalities.  Treatment was well tolerated.  Local reactions were more likely to occur and to be more severe after the third and fourth treatment sessions.  Conclusions and Clin. Relevance: Results confirmed the value of intratumoral chemotherapy with cisplatin for treatment of cutaneous tumors in equidae.  The results cannot be extrapolated to other formulations of cisplatin or other protocols that might be used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7YNWHcLKSF7Vg90H21EOLACvtfcHk0lhB5Htb4dE-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsVGmtbs%253D&md5=0e29db20d601e80f756ed07ad0c296ce</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2460%2Fjavma.230.10.1506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2460%252Fjavma.230.10.1506%26sid%3Dliteratum%253Aachs%26aulast%3DTheon%26aufirst%3DA.%2BP.%26aulast%3DWilson%26aufirst%3DW.%2BD.%26aulast%3DMagdesian%26aufirst%3DK.%2BG.%26aulast%3DPusterla%26aufirst%3DN.%26aulast%3DSnyder%26aufirst%3DJ.%2BR.%26aulast%3DGaluppo%26aufirst%3DL.%2BD.%26atitle%3DLong-Term%2520Outcome%2520Associated%2520with%2520Intratumoral%2520Chemotherapy%2520with%2520Cisplatin%2520for%2520Cutaneous%2520Tumors%2520in%2520Equidae%253A%2520573%2520Cases%2520%25281995%25E2%2580%25932004%2529%26jtitle%3DJ.%2520Am.%2520Vet.%2520Med.%2520Assoc.%26date%3D2007%26volume%3D230%26spage%3D1506%26epage%3D1513%26doi%3D10.2460%2Fjavma.230.10.1506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Knapp, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denicola, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blevins, W. E.</span><span> </span><span class="NLM_article-title">Cisplatin Toxicity in Cats</span> <span class="citation_source-journal">J. Vet. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1111/j.1939-1676.1987.tb01983.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1111%2Fj.1939-1676.1987.tb01983.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3506619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL2sXktlaks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1987&pages=29-35&author=D.+W.+Knappauthor=R.+C.+Richardsonauthor=D.+B.+Denicolaauthor=G.+G.+Longauthor=W.+E.+Blevins&title=Cisplatin+Toxicity+in+Cats&doi=10.1111%2Fj.1939-1676.1987.tb01983.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin toxicity in cats</span></div><div class="casAuthors">Knapp, Deborah W.; Richardson, Ralph C.; DeNicola, Dennis B.; Long, Gerald G.; Blevins, William E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Veterinary Internal Medicine</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">JVIMEM</span>;
        ISSN:<span class="NLM_cas:issn">0891-6640</span>.
    </div><div class="casAbstract">Cisplatin (cis-diamminedichloroplatinum; Platinol) was administered to cats, divided into 3 groups.  In group 1, cisplatin was administered at a dose of 60 mg/m2.  In an attempt to avoid renal toxicity, saline diuresis was induced by administering 0.9% saline soln. i.v. at a rate of 20 mL/kg/h for 4 h before and 2 h after cisplatin administration.  All cats became dyspneic and died 48-96 h after cisplatin administration.  Postmortem findings included severe hydrothorax, pulmonary edema, and mediastinal edema.  In group 2, cats entered a trial comparing the effects of saline diuresis and cisplatin (60 mg/m2) with the effects of saline diuresis and placebo (0.9% saline soln.).  The cats in the saline control group remained completely normal, whereas the cats that received cisplatin developed clin. signs and gross postmortem pulmonary changes identical to those in the first group of cats.  Histopathol. examn. showed that the alveolar septa were thickened and congested, and contained macrophages, occasional neutrophils, thrombi, and small foci of necrosis and fibrin.  Microangiopathic changes were seen in the alveolar capillaries.  In the 3rd group, cats were treated with a lower dose of cisplatin.  Two cats that received 40 mg/m2 of cisplatin developed pulmonary changes similar to, but less severe than, those seen in the cats that received the higher dose of cisplatin.  One cat treated with 20 mg/m2 of cisplatin showed no pulmonary changes ante mortem or post mortem.  Apparently, there is species-specific, dose-related, primary pulmonary toxicity of cisplatin in cats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR0hPPllMjqLVg90H21EOLACvtfcHk0lirWxAkMge11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktlaks7g%253D&md5=866d198e4118f3213a8570cfa0a717aa</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fj.1939-1676.1987.tb01983.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1939-1676.1987.tb01983.x%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DD.%2BW.%26aulast%3DRichardson%26aufirst%3DR.%2BC.%26aulast%3DDenicola%26aufirst%3DD.%2BB.%26aulast%3DLong%26aufirst%3DG.%2BG.%26aulast%3DBlevins%26aufirst%3DW.%2BE.%26atitle%3DCisplatin%2520Toxicity%2520in%2520Cats%26jtitle%3DJ.%2520Vet.%2520Intern.%2520Med.%26date%3D1987%26volume%3D1%26spage%3D29%26epage%3D35%26doi%3D10.1111%2Fj.1939-1676.1987.tb01983.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Bell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lage, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spirtos, N. M.</span><span> </span><span class="NLM_article-title">Randomized Phase III Trial of Three Versus Six Cycles of Adjuvant Carboplatin and Paclitaxel in Early Stage Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">432</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/j.ygyno.2006.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.ygyno.2006.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=16860852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1WmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2006&pages=432-439&author=J.+Bellauthor=M.+F.+Bradyauthor=R.+C.+Youngauthor=J.+Lageauthor=J.+L.+Walkerauthor=K.+Y.+Lookauthor=G.+S.+Roseauthor=N.+M.+Spirtos&title=Randomized+Phase+III+Trial+of+Three+Versus+Six+Cycles+of+Adjuvant+Carboplatin+and+Paclitaxel+in+Early+Stage+Epithelial+Ovarian+Carcinoma%3A+A+Gynecologic+Oncology+Group+Study&doi=10.1016%2Fj.ygyno.2006.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study</span></div><div class="casAuthors">Bell, Jeffrey; Brady, Mark F.; Young, Robert C.; Lage, Janice; Walker, Joan L.; Look, Katherine Y.; Rose, G. Scott; Spirtos, Nick M.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">432-439</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Objective: Compared to 3 cycles, to det. if 6 cycles of adjuvant carboplatin (C) and paclitaxel (P) significantly lower the rate of recurrence in surgically staged patients with stage IA grade 3, IB grade 3, clear cell, IC, and completely resected stage II epithelial ovarian cancer (EOC); and to compare toxicities.  Methods: Postoperatively, randomization was to either 3 or 6 cycles of chemotherapy consisting of P (175 mg/m2 over 3 h) and C (7.5 AUC over 30 min) every 21 days.  Recurrence was any clin. or radiol. evidence of new tumor.  Results: Of 457 patients, 427 (93%) were histol. and medically eligible.  While thorough surgical staging was required, it was incomplete or inadequately documented in 29% of otherwise eligible patients.  Median age was 55.5 years; 69% of patients had stage I disease.  Median follow-up is 6.8 years for 344 women alive at last contact.  Grade 3 or 4 neurotoxicity occurred in 4/211 (2%) and 24/212 (11%) treated patients on the 3- and 6-cycle regimens, resp. (p < 0.01); 6 cycles also caused significantly more severe anemia and granulocytopenia.  The recurrence rate for 6 cycles was 24% lower (hazard ratio [HR]: 0.761; 95% confidence interval [CI]: 0.51-1.13, p = 0.18), and the estd. probability of recurrence within 5 years was 20.1% (6 cycles) vs. 25.4% (3 cycles).  The overall death rate was similar for these regimens (HR: 1.02; 95% CI: 0.662-1.57).  Conclusions: Compared to 3 cycles, 6 cycles of C and P do not significantly alter the recurrence rate in high risk early stage EOC but are assocd. with more toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7p5Bzf60wVrVg90H21EOLACvtfcHk0lirWxAkMge11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1WmsLw%253D&md5=1ab153d8d4c2990e1321741b4b6b2cba</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2006.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2006.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DJ.%26aulast%3DBrady%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BC.%26aulast%3DLage%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DJ.%2BL.%26aulast%3DLook%26aufirst%3DK.%2BY.%26aulast%3DRose%26aufirst%3DG.%2BS.%26aulast%3DSpirtos%26aufirst%3DN.%2BM.%26atitle%3DRandomized%2520Phase%2520III%2520Trial%2520of%2520Three%2520Versus%2520Six%2520Cycles%2520of%2520Adjuvant%2520Carboplatin%2520and%2520Paclitaxel%2520in%2520Early%2520Stage%2520Epithelial%2520Ovarian%2520Carcinoma%253A%2520A%2520Gynecologic%2520Oncology%2520Group%2520Study%26jtitle%3DGynecol.%2520Oncol.%26date%3D2006%26volume%3D102%26spage%3D432%26epage%3D439%26doi%3D10.1016%2Fj.ygyno.2006.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Vasey, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabra, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span> </span><span class="NLM_article-title">Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">1682</span><span class="NLM_x">–</span> <span class="NLM_lpage">1691</span><span class="refDoi"> DOI: 10.1093/jnci/djh323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1093%2Fjnci%2Fdjh323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=15547181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVSqsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=1682-1691&author=P.+A.+Vaseyauthor=G.+C.+Jaysonauthor=A.+Gordonauthor=H.+Gabraauthor=R.+Colemanauthor=R.+Atkinsonauthor=D.+Parkinauthor=J.+Paulauthor=A.+Hayauthor=S.+B.+Kaye&title=Phase+III+Randomized+Trial+of+Docetaxel-Carboplatin+Versus+Paclitaxel-Carboplatin+as+First-Line+Chemotherapy+for+Ovarian+Carcinoma&doi=10.1093%2Fjnci%2Fdjh323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma</span></div><div class="casAuthors">Vasey, Paul A.; Jayson, Gordon C.; Gordon, Alan; Gabra, Hani; Coleman, Rob; Atkinson, Ronnie; Parkin, David; Paul, James; Hay, Andrea; Kaye, Stan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1682-1691</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the std. of care for treatment of ovarian carcinoma.  We compared the combination of docetaxel-carboplatin with the combination of paclitaxel-carboplatin as first-line chemotherapy for stage Ic-IV epithelial ovarian or primary peritoneal cancer.  Methods: We randomly assigned 1077 patients to receive docetaxel at 75 mg/m2 of body surface area (1-h i.v. infusion) or paclitaxel at 175 mg/m2 (3-h i.v. infusion).  Both treatments then were followed by carboplatin to an area under the plasma concn.-time curve of 5.  The treatments were repeated every 3 wk for six cycles; in responding patients, an addnl. three cycles of single-agent carboplatin was permitted.  Survival curves were calcd. by the Kaplan-Meier method, and hazard ratios were estd. with the Cox proportional hazards model.  All statistical tests were two-sided.  Results: After a median follow-up of 23 mo, both groups had similar progression-free survival (medians of 15.0 mo for docetaxel-carboplatin and 14.8 mo for paclitaxel-carboplatin; hazard ratio [HR] docetaxel-paclitaxel = 0.97, 95% confidence interval [CI] = 0.83 to 1.13; P = .707), overall survival rates at 2 years (64.2% and 68.9%, resp.; HR = 1.13, 95% CI = 0.92 to 1.39; P = .238), and objective tumor (58.7% and 59.5%, resp.; difference between docetaxel and paclitaxel = -0.8%, 95% CI = -8.6% to 7.1%; P = .868) and CA-125 (75.8% and 76.8%, resp.; difference docetaxel-paclitaxel = -1.0%, 95% CI = -7.2% to 5.1%; P = .794) response rates.  However, docetaxel-carboplatin was assocd. with substantially less overall and grade 2 or higher neurotoxicity than paclitaxel-carboplatin (grade ≥2 neurosensory toxicity in 11% vs. 30%, difference = 19%, 95% CI = 15% to 24%; P<.001; grade ≥2 neuromotor toxicity in 3% vs. 7%, difference = 4%, 95% CI = 1% to 7%; P<.001).  Treatment with docetaxel-carboplatin was assocd. with statistically significantly more grade 3-4 neutropenia (94% vs. 84%, difference = 11%, 95% CI = 7% to 14%; P<.001) and neutropenic complications than treatment with paclitaxel-carboplatin, although myelosuppression did not influence dose delivery or patient safety.  Global quality of life was similar in both arms, but substantive differences in many symptom scores favored docetaxel.  Conclusions: Docetaxel-carboplatin appears to be similar to paclitaxel-carboplatin in terms of progression-free survival and response, although longer follow-up is required for a definitive statement on survival.  Thus, docetaxel-carboplatin represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGF4Oxy6qx57Vg90H21EOLACvtfcHk0lirWxAkMge11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVSqsrzJ&md5=708b4c48bcdd5cac03b014b0ef82ac9a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh323%26sid%3Dliteratum%253Aachs%26aulast%3DVasey%26aufirst%3DP.%2BA.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DGabra%26aufirst%3DH.%26aulast%3DColeman%26aufirst%3DR.%26aulast%3DAtkinson%26aufirst%3DR.%26aulast%3DParkin%26aufirst%3DD.%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DHay%26aufirst%3DA.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DPhase%2520III%2520Randomized%2520Trial%2520of%2520Docetaxel-Carboplatin%2520Versus%2520Paclitaxel-Carboplatin%2520as%2520First-Line%2520Chemotherapy%2520for%2520Ovarian%2520Carcinoma%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26spage%3D1682%26epage%3D1691%26doi%3D10.1093%2Fjnci%2Fdjh323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Holmes, D.</span><span> </span><span class="NLM_article-title">Ovarian Cancer: Beyond Resistance</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">527</span><span class="NLM_x">, </span> <span class="NLM_fpage">S217</span><span class="refDoi"> DOI: 10.1038/527S217a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2F527S217a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=527&publication_year=2015&pages=S217&author=D.+Holmes&title=Ovarian+Cancer%3A+Beyond+Resistance&doi=10.1038%2F527S217a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2F527S217a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F527S217a%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DD.%26atitle%3DOvarian%2520Cancer%253A%2520Beyond%2520Resistance%26jtitle%3DNature%26date%3D2015%26volume%3D527%26spage%3DS217%26doi%3D10.1038%2F527S217a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Holmes, D.</span><span> </span><span class="NLM_article-title">The Problem with Platinum</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">527</span><span class="NLM_x">, </span> <span class="NLM_fpage">S218</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1038/527S218a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2F527S218a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26605762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFagtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=527&publication_year=2015&pages=S218-219&author=D.+Holmes&title=The+Problem+with+Platinum&doi=10.1038%2F527S218a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The problem with platinum</span></div><div class="casAuthors">Holmes, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">527</span>
        (<span class="NLM_cas:issue">7579</span>),
    <span class="NLM_cas:pages">S218-S219</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ovarian cancer is difficult to treat, largely because tumors are often found late and develop resistance to initial treatment: platinum-based therapy.  New approaches promise to break through the platinum barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVjf3jPVtZp7Vg90H21EOLACvtfcHk0lhkeDOJR0syhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFagtbzP&md5=20930f1ce5ec0519d9a7695956c37613</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2F527S218a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F527S218a%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DD.%26atitle%3DThe%2520Problem%2520with%2520Platinum%26jtitle%3DNature%26date%3D2015%26volume%3D527%26spage%3DS218%26epage%3D219%26doi%3D10.1038%2F527S218a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Colvis, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, C. P.</span><span> </span><span class="NLM_article-title">Innovation in Therapeutics Development at the NCATS</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">230</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1038/npp.2013.247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2Fnpp.2013.247" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=230-232&author=C.+M.+Colvisauthor=C.+P.+Austin&title=Innovation+in+Therapeutics+Development+at+the+NCATS&doi=10.1038%2Fnpp.2013.247"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.247%26sid%3Dliteratum%253Aachs%26aulast%3DColvis%26aufirst%3DC.%2BM.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26atitle%3DInnovation%2520in%2520Therapeutics%2520Development%2520at%2520the%2520NCATS%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D230%26epage%3D232%26doi%3D10.1038%2Fnpp.2013.247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telma, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madigan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldlust, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeschele, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">3913</span><span class="NLM_x">–</span> <span class="NLM_lpage">3922</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1158%2F0008-5472.CAN-14-0247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24812268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFCqsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3913-3922&author=M.+D.+Hallauthor=K.+A.+Telmaauthor=K.+E.+Changauthor=T.+D.+Leeauthor=J.+P.+Madiganauthor=J.+R.+Lloydauthor=I.+S.+Goldlustauthor=J.+D.+Hoescheleauthor=M.+M.+Gottesman&title=Say+No+to+DMSO%3A+Dimethylsulfoxide+Inactivates+Cisplatin%2C+Carboplatin%2C+and+Other+Platinum+Complexes&doi=10.1158%2F0008-5472.CAN-14-0247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes</span></div><div class="casAuthors">Hall, Matthew D.; Telma, Katherine A.; Chang, Ki-Eun; Lee, Tobie D.; Madigan, James P.; Lloyd, John R.; Goldlust, Ian S.; Hoeschele, James D.; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3913-3922</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a consequence are extensively studied in the lab. setting.  In this study, we examd. the literature and found a significant no. of studies (11%-34%) in prominent cancer journals utilizing cisplatin dissolved in DMSO.  However, dissolving cisplatin in DMSO for lab.-based studies results in ligand displacement and changes to the structure of the complex.  We examd. the effect of DMSO on platinum complexes, including cisplatin, carboplatin, and oxaliplatin, finding that DMSO reacted with the complexes, inhibited their cytotoxicity and their ability to initiate cell death.  These results render a substantial portion of the literature on cisplatin uninterpretable.  Raising awareness of this significant issue in the cancer biol. community is crit., and we make recommendations on appropriate solvation of platinum drugs for research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobW5pF1M4oWLVg90H21EOLACvtfcHk0lhkeDOJR0syhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFCqsL%252FJ&md5=5597b73f3aa127dcfb1121f6ead387e2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0247%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DTelma%26aufirst%3DK.%2BA.%26aulast%3DChang%26aufirst%3DK.%2BE.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DMadigan%26aufirst%3DJ.%2BP.%26aulast%3DLloyd%26aufirst%3DJ.%2BR.%26aulast%3DGoldlust%26aufirst%3DI.%2BS.%26aulast%3DHoeschele%26aufirst%3DJ.%2BD.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DSay%2520No%2520to%2520DMSO%253A%2520Dimethylsulfoxide%2520Inactivates%2520Cisplatin%252C%2520Carboplatin%252C%2520and%2520Other%2520Platinum%2520Complexes%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3913%26epage%3D3922%26doi%3D10.1158%2F0008-5472.CAN-14-0247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Lowe, D.</span> DMSO Will Ruin Your Platinum Drugs. Take Heed. <a href="http://blogs.sciencemag.org/pipeline/archives/2014/05/12/dmso_will_ruin_your_platinum_drugs_take_heed" class="extLink">http://blogs.sciencemag.org/pipeline/archives/2014/05/12/dmso_will_ruin_your_platinum_drugs_take_heed</a> (accessed July 29,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lowe%2C+D.+DMSO+Will+Ruin+Your+Platinum+Drugs.+Take+Heed.+http%3A%2F%2Fblogs.sciencemag.org%2Fpipeline%2Farchives%2F2014%2F05%2F12%2Fdmso_will_ruin_your_platinum_drugs_take_heed+%28accessed+July+29%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DD.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kerrison, S. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, P. J.</span><span> </span><span class="NLM_article-title">Solvolysis of <i>cis</i>-[Pt(Nh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] in Dimethyl Sulphoxide and Reactions of Glycine with [PtCl<sub>3</sub>(Me<sub>2</sub>SO)]<sup>−</sup> as Probed by <sup>195</sup>Pt Nuclear Magnetic Resonance Shifts and <sup>195</sup>Pt–<sup>15</sup>N Coupling Constants</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">863</span><span class="refDoi"> DOI: 10.1039/C39770000861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC39770000861" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&pages=861-863&author=S.+J.+S.+Kerrisonauthor=P.+J.+Sadler&title=Solvolysis+of+cis-%5BPt%28Nh3%292Cl2%5D+in+Dimethyl+Sulphoxide+and+Reactions+of+Glycine+with+%5BPtCl3%28Me2SO%29%5D%E2%88%92+as+Probed+by+195Pt+Nuclear+Magnetic+Resonance+Shifts+and+195Pt%E2%80%9315N+Coupling+Constants&doi=10.1039%2FC39770000861"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1039%2FC39770000861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC39770000861%26sid%3Dliteratum%253Aachs%26aulast%3DKerrison%26aufirst%3DS.%2BJ.%2BS.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DSolvolysis%2520of%2520cis-%255BPt%2528Nh3%25292Cl2%255D%2520in%2520Dimethyl%2520Sulphoxide%2520and%2520Reactions%2520of%2520Glycine%2520with%2520%255BPtCl3%2528Me2SO%2529%255D%25E2%2588%2592%2520as%2520Probed%2520by%2520195Pt%2520Nuclear%2520Magnetic%2520Resonance%2520Shifts%2520and%2520195Pt%25E2%2580%259315N%2520Coupling%2520Constants%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D1977%26spage%3D861%26epage%3D863%26doi%3D10.1039%2FC39770000861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">De Vries, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Jong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span> </span><span class="NLM_article-title">Molecular Imaging as a Tool for Drug Development and Trial Design</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2585</span><span class="NLM_x">–</span> <span class="NLM_lpage">2587</span><span class="refDoi"> DOI: 10.1200/JCO.2015.61.6425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1200%2FJCO.2015.61.6425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26169612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=2585-2587&author=E.+G.+De+Vriesauthor=S.+De+Jongauthor=J.+A.+Gietema&title=Molecular+Imaging+as+a+Tool+for+Drug+Development+and+Trial+Design&doi=10.1200%2FJCO.2015.61.6425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular imaging as a tool for drug development and trial design</span></div><div class="casAuthors">de Vries, Elisabeth G. E.; de Jong, Steven; Gietema, Jourik A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2585-2587</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review discussing mol. imaging as a tool for drug development and trial design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZOEeBjKjpQbVg90H21EOLACvtfcHk0lj2ESX7LRlaEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVKmtg%253D%253D&md5=79a6f5d1423b527beea7210c5b00aa3e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.61.6425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.61.6425%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVries%26aufirst%3DE.%2BG.%26aulast%3DDe%2BJong%26aufirst%3DS.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520Imaging%2520as%2520a%2520Tool%2520for%2520Drug%2520Development%2520and%2520Trial%2520Design%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D2585%26epage%3D2587%26doi%3D10.1200%2FJCO.2015.61.6425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Kurdziel, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalen, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bear, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccumiskey, J. F.</span><span> </span><span class="NLM_article-title">Imaging Multidrug Resistance with 4-[<sup>18</sup>F]Fluoropaclitaxel</span> <span class="citation_source-journal">Nucl. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">823</span><span class="NLM_x">–</span> <span class="NLM_lpage">831</span><span class="refDoi"> DOI: 10.1016/j.nucmedbio.2007.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.nucmedbio.2007.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=17921033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFeiu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2007&pages=823-831&author=K.+A.+Kurdzielauthor=J.+D.+Kalenauthor=J.+I.+Hirschauthor=J.+D.+Wilsonauthor=R.+Agarwalauthor=D.+Barrettauthor=H.+D.+Bearauthor=J.+F.+Mccumiskey&title=Imaging+Multidrug+Resistance+with+4-%5B18F%5DFluoropaclitaxel&doi=10.1016%2Fj.nucmedbio.2007.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging multidrug resistance with 4-[18F]fluoropaclitaxel</span></div><div class="casAuthors">Kurdziel, Karen A.; Kalen, Joseph D.; Hirsch, Jerry I.; Wilson, John D.; Agarwal, Rakesh; Barrett, Daniel; Bear, Harry D.; McCumiskey, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">823-831</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Multidrug resistance (MDR) is a cause of treatment failure in many cancer patients.  MDR refers to a phenotype whereby a tumor is resistant to a large no. of natural chemotherapeutic drugs.  Having prior knowledge of the presence of such resistance would decrease morbidity from unsuccessful therapy and allow for the selection of individuals who may benefit from the coadministration of MDR-inhibiting drugs.  The Tc-99m-labeled single-photon-emitting radiotracers sestamibi and tetrofosmin have shown some predictive value.  However, positron-emitting radiotracers, which allow for dynamic quant. imaging, hold promise for a more accurate and specific identification of MDRtumors.MDR-expressing tumors are resistant to paclitaxel, which is commonly used as a chemotherapeutic agent. 4-[18F]Fluoropaclitaxel (FPAC) is a PET-radiolabeled analog of paclitaxel.  Preclin. studies have shown the uptake of FPAC to be inversely proportional to tumor MDR expression.  FPAC PET imaging in normal volunteers shows biodistribution to be similar to that in nonhuman primates.  Imaging in a breast cancer patient showed FPAC localization in a primary tumor that responded to chemotherapy, while failure to localize in mediastinal disease corresponded with only partial response.FPAC PET imaging shows promise for the noninvasive pretreatment identification of MDR-expressing tumors.  While much addnl. work is needed, this work represents a step toward image-guided personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXaHmVvKFbKbVg90H21EOLACvtfcHk0lj2ESX7LRlaEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFeiu7%252FN&md5=c02b8dffdcd6f0cd38cc8de142262bd5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2007.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2007.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKurdziel%26aufirst%3DK.%2BA.%26aulast%3DKalen%26aufirst%3DJ.%2BD.%26aulast%3DHirsch%26aufirst%3DJ.%2BI.%26aulast%3DWilson%26aufirst%3DJ.%2BD.%26aulast%3DAgarwal%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DD.%26aulast%3DBear%26aufirst%3DH.%2BD.%26aulast%3DMccumiskey%26aufirst%3DJ.%2BF.%26atitle%3DImaging%2520Multidrug%2520Resistance%2520with%25204-%255B18F%255DFluoropaclitaxel%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2007%26volume%3D34%26spage%3D823%26epage%3D831%26doi%3D10.1016%2Fj.nucmedbio.2007.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalhor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swisher, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba, Ii</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddik, Z. H.</span><span> </span><span class="NLM_article-title">Tissue Platinum Concentration and Tumor Response in Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3345</span><span class="NLM_x">–</span> <span class="NLM_lpage">3352</span><span class="refDoi"> DOI: 10.1200/JCO.2011.40.8120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1200%2FJCO.2011.40.8120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=22891266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3345-3352&author=E.+S.+Kimauthor=J.+J.+Leeauthor=G.+Heauthor=C.+W.+Chowauthor=J.+Fujimotoauthor=N.+Kalhorauthor=S.+G.+Swisherauthor=Ii+Wistubaauthor=D.+J.+Stewartauthor=Z.+H.+Siddik&title=Tissue+Platinum+Concentration+and+Tumor+Response+in+Non-Small-Cell+Lung+Cancer&doi=10.1200%2FJCO.2011.40.8120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue platinum concentration and tumor response in non-small-cell lung cancer</span></div><div class="casAuthors">Kim, Eric S.; Lee, J. Jack; He, Guangan; Chow, Chi-Wan; Fujimoto, Junya; Kalhor, Neda; Swisher, Stephen G.; Wistuba, Ignacio I.; Stewart, David J.; Siddik, Zahid H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3345-3352</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Platinum resistance is a major limitation in the treatment of advanced non-small-cell lung cancer (NSCLC).  Reduced intracellular drug accumulation is one of the most consistently identified features of platinum-resistant cell lines, but clin. data are limited.  We assessed the effects of tissue platinum concns. on response and survival in NSCLC.  Patients and Methods: We measured total platinum concns. by flameless at. absorption spectrophotometry in 44 archived fresh-frozen NSCLC specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy.  Tissue platinum concn. was correlated with percent redn. in tumor size on post- vs. prechemotherapy computed tomog. scans.  The relationship between tissue platinum concn. and survival was assessed by univariate and multicovariate Cox proportional hazards regression model anal. and Kaplan-Meier anal.  Results: Tissue platinum concn. correlated significantly with percent redn. in tumor size (P < .001).  The same correlations were seen with cisplatin, carboplatin, and all histol. subgroups.  Furthermore, there was no significant impact of potential variables such as no. of cycles and time lapse from last chemotherapy on platinum concn.  Patients with higher platinum concn. had longer time to recurrence (P = .034), progression-free survival (P = .018), and overall survival (P = .005) in the multicovariate Cox model anal. after adjusting for no. of cycles.  Conclusion: This clin. study established a relationship between tissue platinum concn. and response in NSCLC.  It suggests that reduced platinum accumulation might be an important mechanism of platinum resistance in the clin. setting.  Further studies investigating factors that modulate intracellular platinum concn. are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFMnMq23__QrVg90H21EOLACvtfcHk0lhO3u9s-h5eiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FE&md5=efa46c60ca5de7a95c029737b95c0dd3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.8120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.8120%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DChow%26aufirst%3DC.%2BW.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DKalhor%26aufirst%3DN.%26aulast%3DSwisher%26aufirst%3DS.%2BG.%26aulast%3DWistuba%26aufirst%3DIi%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26atitle%3DTissue%2520Platinum%2520Concentration%2520and%2520Tumor%2520Response%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3345%26epage%3D3352%26doi%3D10.1200%2FJCO.2011.40.8120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Guancial, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, G.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abu-Farsakh, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span> </span><span class="NLM_article-title">Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0155503</span><span class="refDoi"> DOI: 10.1371/journal.pone.0155503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1371%2Fjournal.pone.0155503" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0155503&author=E.+A.+Guancialauthor=D.+Kilariauthor=G.-Q.+Xiaoauthor=S.+H.+Abu-Farsakhauthor=A.+Baranauthor=E.+M.+Messingauthor=E.+S.+Kim&title=Platinum+Concentration+and+Pathologic+Response+to+Cisplatin-Based+Neoadjuvant+Chemotherapy+in+Muscle-Invasive+Bladder+Cancer&doi=10.1371%2Fjournal.pone.0155503"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0155503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0155503%26sid%3Dliteratum%253Aachs%26aulast%3DGuancial%26aufirst%3DE.%2BA.%26aulast%3DKilari%26aufirst%3DD.%26aulast%3DXiao%26aufirst%3DG.-Q.%26aulast%3DAbu-Farsakh%26aufirst%3DS.%2BH.%26aulast%3DBaran%26aufirst%3DA.%26aulast%3DMessing%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DPlatinum%2520Concentration%2520and%2520Pathologic%2520Response%2520to%2520Cisplatin-Based%2520Neoadjuvant%2520Chemotherapy%2520in%2520Muscle-Invasive%2520Bladder%2520Cancer%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0155503%26doi%3D10.1371%2Fjournal.pone.0155503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Hoeschele, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. A.</span><span> </span><span class="NLM_article-title">Correlations of Physico-Chemical and Biological Properties with in Vivo Biodistribution Data for Platinum-195m-Labeled Chloroammineplatinum(II) Complexes</span> <span class="citation_source-journal">ACS Symp. Ser.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span><span class="refDoi"> DOI: 10.1021/bk-1980-0140.ch011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bk-1980-0140.ch011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=1980&pages=181-208&author=J.+D.+Hoescheleauthor=T.+A.+Butlerauthor=J.+A.+Roberts&title=Correlations+of+Physico-Chemical+and+Biological+Properties+with+in+Vivo+Biodistribution+Data+for+Platinum-195m-Labeled+Chloroammineplatinum%28II%29+Complexes&doi=10.1021%2Fbk-1980-0140.ch011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fbk-1980-0140.ch011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbk-1980-0140.ch011%26sid%3Dliteratum%253Aachs%26aulast%3DHoeschele%26aufirst%3DJ.%2BD.%26aulast%3DButler%26aufirst%3DT.%2BA.%26aulast%3DRoberts%26aufirst%3DJ.%2BA.%26atitle%3DCorrelations%2520of%2520Physico-Chemical%2520and%2520Biological%2520Properties%2520with%2520in%2520Vivo%2520Biodistribution%2520Data%2520for%2520Platinum-195m-Labeled%2520Chloroammineplatinum%2528II%2529%2520Complexes%26jtitle%3DACS%2520Symp.%2520Ser.%26date%3D1980%26volume%3D140%26spage%3D181%26epage%3D208%26doi%3D10.1021%2Fbk-1980-0140.ch011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Shen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawinowicz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Identification of Cytoskeletal [<sup>14</sup>C]Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">789</span><span class="NLM_x">–</span> <span class="NLM_lpage">793</span><span class="refDoi"> DOI: 10.1124/mol.66.4.789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1124%2Fmol.66.4.789" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2004&pages=789-793&author=D.+W.+Shenauthor=X.+J.+Liangauthor=M.+A.+Gawinowiczauthor=M.+M.+Gottesman&title=Identification+of+Cytoskeletal+%5B14C%5DCarboplatin-Binding+Proteins+Reveals+Reduced+Expression+and+Disorganization+of+Actin+and+Filamin+in+Cisplatin-Resistant+Cell+Lines&doi=10.1124%2Fmol.66.4.789"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1124%2Fmol.66.4.789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.66.4.789%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DD.%2BW.%26aulast%3DLiang%26aufirst%3DX.%2BJ.%26aulast%3DGawinowicz%26aufirst%3DM.%2BA.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DIdentification%2520of%2520Cytoskeletal%2520%255B14C%255DCarboplatin-Binding%2520Proteins%2520Reveals%2520Reduced%2520Expression%2520and%2520Disorganization%2520of%2520Actin%2520and%2520Filamin%2520in%2520Cisplatin-Resistant%2520Cell%2520Lines%26jtitle%3DMol.%2520Pharmacol.%26date%3D2004%26volume%3D66%26spage%3D789%26epage%3D793%26doi%3D10.1124%2Fmol.66.4.789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Hah, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stivers, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vere White, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, P. T.</span><span> </span><span class="NLM_article-title">Kinetics of Carboplatin-DNA Binding in Genomic DNA and Bladder Cancer Cells as Determined by Accelerator Mass Spectrometry</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.1021/tx060058c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx060058c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=622-626&author=S.+S.+Hahauthor=K.+M.+Stiversauthor=R.+W.+De+Vere+Whiteauthor=P.+T.+Henderson&title=Kinetics+of+Carboplatin-DNA+Binding+in+Genomic+DNA+and+Bladder+Cancer+Cells+as+Determined+by+Accelerator+Mass+Spectrometry&doi=10.1021%2Ftx060058c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Ftx060058c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx060058c%26sid%3Dliteratum%253Aachs%26aulast%3DHah%26aufirst%3DS.%2BS.%26aulast%3DStivers%26aufirst%3DK.%2BM.%26aulast%3DDe%2BVere%2BWhite%26aufirst%3DR.%2BW.%26aulast%3DHenderson%26aufirst%3DP.%2BT.%26atitle%3DKinetics%2520of%2520Carboplatin-DNA%2520Binding%2520in%2520Genomic%2520DNA%2520and%2520Bladder%2520Cancer%2520Cells%2520as%2520Determined%2520by%2520Accelerator%2520Mass%2520Spectrometry%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D622%26epage%3D626%26doi%3D10.1021%2Ftx060058c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Jong, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mckeage, M. J.</span><span> </span><span class="NLM_article-title">Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span><span class="refDoi"> DOI: 10.1124/jpet.111.181297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1124%2Fjpet.111.181297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=21606177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFemu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=537-547&author=N.+N.+Jongauthor=T.+Nakanishiauthor=J.+J.+Liuauthor=I.+Tamaiauthor=M.+J.+Mckeage&title=Oxaliplatin+Transport+Mediated+by+Organic+Cation%2FCarnitine+Transporters+OCTN1+and+OCTN2+in+Overexpressing+Human+Embryonic+Kidney+293+Cells+and+Rat+Dorsal+Root+Ganglion+Neurons&doi=10.1124%2Fjpet.111.181297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons</span></div><div class="casAuthors">Jong, Nancy N.; Nakanishi, Takeo; Liu, Johnson J.; Tamai, Ikumi; McKeage, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">537-547</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The org. cation/carnitine transporters OCTN1 and OCTN2 are related to other org. cation transporters (OCT1, OCT2, and OCT3) known for transporting oxaliplatin, an anticancer drug with dose-limiting neurotoxicity.  In this study, we sought to det. whether OCTN1 and OCTN2 also transported oxaliplatin and to characterize their functional expression and contributions to its neuronal accumulation and neurotoxicity in dorsal root ganglion (DRG) neurons relative to those of OCTs.  [14C]Oxaliplatin uptake, platinum accumulation, and cytotoxicity were detd. in OCTN-overexpressing human embryonic kidney (HEK) 293 cells and primary cultures of rat DRG neurons.  Levels of mRNA and functional activities of rat (r)Octns and rOcts in rat DRG tissue and primary cultures were characterized using reverse transcription-polymerase chain reaction and uptake of model OCT/OCTN substrates, including [3H]1-methyl-4-phenylpyridinium (MPP+) (OCT1-3), [14C]tetraethylammonium bromide (TEA+) (OCT1-3 and OCTN1/2), [3H]ergothioneine (OCTN1), and [3H]L-carnitine (OCTN2).  HEK293 cells overexpressing rOctn1, rOctn2, human OCTN1, and human OCTN2 showed increased uptake and cytotoxicity of oxaliplatin compared with mock-transfected HEK293 controls; in addn., both uptake and cytotoxicity were inhibited by ergothioneine and L-carnitine.  The uptake of ergothioneine mediated by OCTN1 and of L-carnitine mediated by OCTN2 was decreased during oxaliplatin exposure.  ROctn1 and rOctn2 mRNA was readily detected in rat DRG tissue, and they were functionally active in cultured rat DRG neurons, more so than rOct1, rOct2, or rOct3.  DRG neuronal accumulation of [14C]oxaliplatin and platinum during oxaliplatin exposure depended on time, concn., temp., and sodium and was inhibited by ergothioneine and to a lesser extent by L-carnitine but not by MPP+.  Loss of DRG neuronal viability during oxaliplatin exposure was inhibited by ergothioneine but not by L-carnitine or MPP+.  OCTN1 and OCTN2 both transport oxaliplatin and are functionally expressed by DRG neurons.  OCTN1-mediated transport of oxaliplatin appears to contribute to its neuronal accumulation and treatment-limiting neurotoxicity more so than OCTN2 or OCTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVcdk40NbRYbVg90H21EOLACvtfcHk0lj-8RaQMgLp5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFemu7s%253D&md5=3cbd5069a2276e8d0631859c5288f484</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181297%26sid%3Dliteratum%253Aachs%26aulast%3DJong%26aufirst%3DN.%2BN.%26aulast%3DNakanishi%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DTamai%26aufirst%3DI.%26aulast%3DMckeage%26aufirst%3DM.%2BJ.%26atitle%3DOxaliplatin%2520Transport%2520Mediated%2520by%2520Organic%2520Cation%252FCarnitine%2520Transporters%2520OCTN1%2520and%2520OCTN2%2520in%2520Overexpressing%2520Human%2520Embryonic%2520Kidney%2520293%2520Cells%2520and%2520Rat%2520Dorsal%2520Root%2520Ganglion%2520Neurons%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D537%26epage%3D547%26doi%3D10.1124%2Fjpet.111.181297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Rani, P. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naidu, M. U.</span><span> </span><span class="NLM_article-title">Phase 0 - Microdosing Strategy in Clinical Trials</span> <span class="citation_source-journal">Indian J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.4103/0253-7613.45147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.4103%2F0253-7613.45147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=21279177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC3M7lsFSgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=240-242&author=P.+U.+Raniauthor=M.+U.+Naidu&title=Phase+0+-+Microdosing+Strategy+in+Clinical+Trials&doi=10.4103%2F0253-7613.45147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 0 - Microdosing strategy in clinical trials</span></div><div class="casAuthors">Rani P Usha; Naidu M U R</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">240-2</span>
        ISSN:<span class="NLM_cas:issn">0253-7613</span>.
    </div><div class="casAbstract">Drug development is an activity that is long, complex and expensive.  In 2004, attrition in the drug development paradigm prompted the US Food and Drug Administration (FDA) to introduce its 'Critical Path' document, which highlighted the serious discordance between major scientific advances and limited drug development process.  One issue addressed was that of microdosing.  The concept of microdosing involves the use of extremely low, nonpharmacologically active doses of a drug to define the pharmacokinetic profile of the medication in human subjects.  Microdosing, thus, appears as a new viable concept in the 'toolbox' of the drug development activity.  It appears that microdosing strategy could complement standard animal-to-human scaling, redefining the existing concept of phase I clinical research.  In future, when research methods and technology involved in Phase 0 studies become more sophisticated, human microdosing may be applied to a number of drugs developed subsequently.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNNIg2EbPCTySm0e6ZOaemfW6udTcc2ebqu9BZTPz4Cbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7lsFSgsQ%253D%253D&md5=2b013af26b15e5ec640b212fe0c15acf</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.4103%2F0253-7613.45147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0253-7613.45147%26sid%3Dliteratum%253Aachs%26aulast%3DRani%26aufirst%3DP.%2BU.%26aulast%3DNaidu%26aufirst%3DM.%2BU.%26atitle%3DPhase%25200%2520-%2520Microdosing%2520Strategy%2520in%2520Clinical%2520Trials%26jtitle%3DIndian%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D40%26spage%3D240%26epage%3D242%26doi%3D10.4103%2F0253-7613.45147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Cimino, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, P. T.</span><span> </span><span class="NLM_article-title">Personalized Medicine for Targeted and Platinum-Based Chemotherapy of Lung and Bladder Cancer</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.4155/bio.12.325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.4155%2Fbio.12.325" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=369-391&author=G.+D.+Ciminoauthor=C.+X.+Panauthor=P.+T.+Henderson&title=Personalized+Medicine+for+Targeted+and+Platinum-Based+Chemotherapy+of+Lung+and+Bladder+Cancer&doi=10.4155%2Fbio.12.325"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.4155%2Fbio.12.325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.12.325%26sid%3Dliteratum%253Aachs%26aulast%3DCimino%26aufirst%3DG.%2BD.%26aulast%3DPan%26aufirst%3DC.%2BX.%26aulast%3DHenderson%26aufirst%3DP.%2BT.%26atitle%3DPersonalized%2520Medicine%2520for%2520Targeted%2520and%2520Platinum-Based%2520Chemotherapy%2520of%2520Lung%2520and%2520Bladder%2520Cancer%26jtitle%3DBioanalysis%26date%3D2013%26volume%3D5%26spage%3D369%26epage%3D391%26doi%3D10.4155%2Fbio.12.325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Dowell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sancho, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, W.</span><span> </span><span class="NLM_article-title">Noninvasive Measurements for Studying the Tumoral Pharmacokinetics of Platinum Anticancer Drugs in Solid Tumors</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1016/S0169-409X(99)00059-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0169-409X%2899%2900059-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=111-126&author=J.+A.+Dowellauthor=A.+R.+Sanchoauthor=D.+Anandauthor=W.+Wolf&title=Noninvasive+Measurements+for+Studying+the+Tumoral+Pharmacokinetics+of+Platinum+Anticancer+Drugs+in+Solid+Tumors&doi=10.1016%2FS0169-409X%2899%2900059-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2899%2900059-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252899%252900059-9%26sid%3Dliteratum%253Aachs%26aulast%3DDowell%26aufirst%3DJ.%2BA.%26aulast%3DSancho%26aufirst%3DA.%2BR.%26aulast%3DAnand%26aufirst%3DD.%26aulast%3DWolf%26aufirst%3DW.%26atitle%3DNoninvasive%2520Measurements%2520for%2520Studying%2520the%2520Tumoral%2520Pharmacokinetics%2520of%2520Platinum%2520Anticancer%2520Drugs%2520in%2520Solid%2520Tumors%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2000%26volume%3D41%26spage%3D111%26epage%3D126%26doi%3D10.1016%2FS0169-409X%2899%2900059-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Baer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcauliffe, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. G.</span><span> </span><span class="NLM_article-title">Microscale Syntheses of Anti-Tumour Platinum Compounds Labelled with <sup>191</sup>Pt</span> <span class="citation_source-journal">Int. J. Appl. Radiat. Isot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1016/0020-708X(85)90064-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2F0020-708X%2885%2990064-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3888854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL2MXktlWmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1985&pages=181-184&author=J.+Baerauthor=R.+Harrisonauthor=C.+A.+Mcauliffeauthor=A.+Zakiauthor=H.+L.+Sharmaauthor=A.+G.+Smith&title=Microscale+Syntheses+of+Anti-Tumour+Platinum+Compounds+Labelled+with+191Pt&doi=10.1016%2F0020-708X%2885%2990064-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Microscale syntheses of anti-tumor platinum compounds labeled with platinum-191</span></div><div class="casAuthors">Baer, J.; Harrison, R.; McAuliffe, C. A.; Zaki, A.; Sharma, H. L.; Smith, A. G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-4</span>CODEN:
                <span class="NLM_cas:coden">IJARAY</span>;
        ISSN:<span class="NLM_cas:issn">0020-708X</span>.
    </div><div class="casAbstract">The microscale prepn. of cis-[191PtL2Cl2] (L = NH3, cyclopropylamine), cis, trans-[191PtCl2(OH)2(iso-PrNH2)2] (I), and cis-[191Pt(NH3)2Q] (II; H2Q = 1,1-cyclobutanedicarboxylic acid) was developed.  Generally, Na2[PtCl6]-H2[191PtCl6] are reduced by N2H4 to Na2[191PtCl4] which was converted to Na2[191PtI4] with the addn. of NaI.  Na2[191PtI4] reacted with the various amines to give cis-[191PtL12I2] (L1 = NH3, cyclopropylamine, iso-PrNH2).  cis-[191PtL2I2] were converted to cis-[191PtL2Cl2] via cis-[191PtL2(H2O)2](NO3)2 by treatment with AgNO3 and then NaCl or HCl.  cis-[191Pt(NH2Pr-iso)2Cl2] was obtained similarly and oxidized with H2O2 to give I.  Treatment of cis-[191Pt(NH3)2I2] with aq. AgNO3 and then H2Q gave II.  Thin-layer chromatog. was used to control the purity of the radiolabeled Pt complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDEhlmgcT-kbVg90H21EOLACvtfcHk0ljre8akG0wgTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktlWmtLg%253D&md5=5353775fd032964e48ac668ada0b0eb5</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2F0020-708X%2885%2990064-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0020-708X%252885%252990064-X%26sid%3Dliteratum%253Aachs%26aulast%3DBaer%26aufirst%3DJ.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DMcauliffe%26aufirst%3DC.%2BA.%26aulast%3DZaki%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DH.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BG.%26atitle%3DMicroscale%2520Syntheses%2520of%2520Anti-Tumour%2520Platinum%2520Compounds%2520Labelled%2520with%2520191Pt%26jtitle%3DInt.%2520J.%2520Appl.%2520Radiat.%2520Isot.%26date%3D1985%26volume%3D36%26spage%3D181%26epage%3D184%26doi%3D10.1016%2F0020-708X%2885%2990064-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Lange, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harder, H. C.</span><span> </span><span class="NLM_article-title">The Antitumor Agent <i>cis</i>-Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>: Distribution Studies and Dose Calculations for <sup>193m</sup>Pt and <sup>195m</sup>Pt</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1973&pages=191-195&author=R.+C.+Langeauthor=R.+P.+Spencerauthor=H.+C.+Harder&title=The+Antitumor+Agent+cis-Pt%28NH3%292Cl2%3A+Distribution+Studies+and+Dose+Calculations+for+193mPt+and+195mPt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DR.%2BC.%26aulast%3DSpencer%26aufirst%3DR.%2BP.%26aulast%3DHarder%26aufirst%3DH.%2BC.%26atitle%3DThe%2520Antitumor%2520Agent%2520cis-Pt%2528NH3%25292Cl2%253A%2520Distribution%2520Studies%2520and%2520Dose%2520Calculations%2520for%2520193mPt%2520and%2520195mPt%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1973%26volume%3D14%26spage%3D191%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Areberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wennerberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norrgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattsson, S.</span><span> </span><span class="NLM_article-title">Antitumor Effect of Radioactive Cisplatin (<sup>191</sup>Pt) on Nude Mice</span> <span class="citation_source-journal">Int. J. Radiat. Oncol., Biol., Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1016/S0360-3016(00)01419-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0360-3016%2800%2901419-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11172966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFegtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2001&pages=827-832&author=J.+Arebergauthor=J.+Wennerbergauthor=A.+Johnssonauthor=K.+Norrgrenauthor=S.+Mattsson&title=Antitumor+Effect+of+Radioactive+Cisplatin+%28191Pt%29+on+Nude+Mice&doi=10.1016%2FS0360-3016%2800%2901419-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effect of radioactive cisplatin (191Pt) on nude mice</span></div><div class="casAuthors">Areberg, J.; Wennerberg, J.; Johnsson, A.; Norrgren, K.; Mattsson, S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">827-832</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Purpose: To investigate the effect of 191Pt-cisplatin in vivo in terms of the antitumor effect and general toxicity on tumor-bearing nude mice.  Methods and Materials: Tumor-bearing (human squamous cell carcinoma, AB) nude mice were divided into 4 groups and given, i.p., physiol. saline (controls), cisplatin, 191Pt-cisplatin (80 MBq/mg), or 191Pt-cisplatin (160 MBq/mg), resp.  Mortality and wt. were used as parameters for monitoring the general toxic effect, while specific growth delay (SGD) and the area under the logarithm of the relative tumor size curve (AUC-log[RTS]) were used to evaluate the antitumor effect of the treatments.  Results: Both SGD and AUC-log(RTS) values showed that 191Pt-cisplatin was significantly (P < 0.05) more effective in retarding tumor growth than nonradioactive cisplatin.  No differences in mortality between the different groups could be obsd. and no significant differences in wt. change between the mice treated with cisplatin or 191Pt-cisplatin could be seen.  Conclusion: 191Pt-cisplatin is a more effective drug than nonradioactive cisplatin in retarding tumor growth on nude mice without adding systemic toxic effects.  Apparently, radioactive cisplatin may prove to be an alternative to conventional cisplatin; however, the possible toxic effects on organs at risk have to be thoroughly investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqJMj8-BZeQrVg90H21EOLACvtfcHk0ljre8akG0wgTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFegtrk%253D&md5=1153f2f33fb81ed5c98b65cddf5eaed3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0360-3016%2800%2901419-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0360-3016%252800%252901419-X%26sid%3Dliteratum%253Aachs%26aulast%3DAreberg%26aufirst%3DJ.%26aulast%3DWennerberg%26aufirst%3DJ.%26aulast%3DJohnsson%26aufirst%3DA.%26aulast%3DNorrgren%26aufirst%3DK.%26aulast%3DMattsson%26aufirst%3DS.%26atitle%3DAntitumor%2520Effect%2520of%2520Radioactive%2520Cisplatin%2520%2528191Pt%2529%2520on%2520Nude%2520Mice%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D2001%26volume%3D49%26spage%3D827%26epage%3D832%26doi%3D10.1016%2FS0360-3016%2800%2901419-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Smith, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassidy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bartolo, N.</span><span> </span><span class="NLM_article-title">Rapid and Reliable Synthesis of 195mPt-Cisplatin and 195mPt-Carboplatin for Use in Prognosis of Cancer</span> <span class="citation_source-journal">J. Labelled Compd. Radiopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">S756</span><span class="NLM_x">–</span> <span class="NLM_lpage">S758</span><span class="refDoi"> DOI: 10.1002/jlcr.25804401266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fjlcr.25804401266" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=S756-S758&author=S.+V.+Smithauthor=D.+Cassidyauthor=N.+Di+Bartolo&title=Rapid+and+Reliable+Synthesis+of+195mPt-Cisplatin+and+195mPt-Carboplatin+for+Use+in+Prognosis+of+Cancer&doi=10.1002%2Fjlcr.25804401266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.25804401266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.25804401266%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%2BV.%26aulast%3DCassidy%26aufirst%3DD.%26aulast%3DDi%2BBartolo%26aufirst%3DN.%26atitle%3DRapid%2520and%2520Reliable%2520Synthesis%2520of%2520195mPt-Cisplatin%2520and%2520195mPt-Carboplatin%2520for%2520Use%2520in%2520Prognosis%2520of%2520Cancer%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2001%26volume%3D44%26spage%3DS756%26epage%3DS758%26doi%3D10.1002%2Fjlcr.25804401266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Zeevaart, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagener, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marjanovic-Painter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathekge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. V.</span><span> </span><span class="NLM_article-title">Production of High Specific Activity (195m) Pt-Cisplatinum at South African Nuclear Energy Corporation for Phase 0 Clinical Trials in Healthy Individual Subjects</span> <span class="citation_source-journal">J. Labelled Compd. Radiopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span><span class="refDoi"> DOI: 10.1002/jlcr.3091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fjlcr.3091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24285528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCrs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=495-503&author=J.+R.+Zeevaartauthor=J.+Wagenerauthor=B.+Marjanovic-Painterauthor=M.+Sathekgeauthor=N.+Soniauthor=C.+Zinnauthor=G.+Perkinsauthor=S.+V.+Smith&title=Production+of+High+Specific+Activity+%28195m%29+Pt-Cisplatinum+at+South+African+Nuclear+Energy+Corporation+for+Phase+0+Clinical+Trials+in+Healthy+Individual+Subjects&doi=10.1002%2Fjlcr.3091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Production of high specific activity 195mPt-cisplatinum at South African Nuclear Energy Corporation for Phase 0 clinical trials in healthy individual subjects</span></div><div class="casAuthors">Zeevaart, Jan Rijn; Wagener, Judith; Marjanovic-Painter, Biljana; Sathekge, Mike; Soni, Nischal; Zinn, Christa; Perkins, Gary; Smith, Suzanne V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">495-503</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Platinum agents continue to be the main chemotherapeutic agents used in the first-line and second-line treatments of cancer patients.  It is important to fully understand the biol. profile of these compds. in order to optimize the dose given to each patient.  In a joint project with the Australian Nuclear Science and Technol. Organization and the Nuclear Medicine Department at Steve Biko Academic Hospital, South African Nuclear Energy Corporation synthesized and supplied 195mPt-cisplatinum (commonly referred to as cisplatin) for a clin. pilot study on healthy volunteers.  Enriched 194PtCl2 was prepd. by digestion of enriched 194Pt metal (>95%) followed by thermal decompn. over a 3 h period.  The 194PtCl2 was then placed in a quartz ampoule, was irradiated in SAFARI-1 up to 200 h, then decay cooled for a min. of 34 h prior to synthesis of final product. 195mPt(NH3)2I2, formed with the addn. of KI and NH4OH, was converted to the diaqua species [195mPt(NH3)2(H2O)2]2+ by reaction with AgNO3.  The conversion to 195mPt-cisplatinum was completed by the addn. of concd. HCl.  The final product yield was 51.7% ± 5.2% (n = 5).  The chem. and radionuclidic purity in each case was >95%.  The use of a high flux reactor position affords a higher specific activity product (15.9 ± 2.5 MBq/mg at end of synthesis) than previously found (5 MBq/mg).  Volunteers received between 108 and 126 MBq of radioactivity, which is equiv. to 6.8-10.0 mg of carrier cisplatinum.  Such high specific activities afforded a significant redn. (∼50%) in the chem. dose of a carrier cisplatinum, which represents less than 10% of a typical chemotherapeutic dose given to patients.  A good manufg. practice GMP compliant product was produced and was administered to 10 healthy volunteers as part of an ethically approved Phase 0 clin. trial.  The majority of the injected activity 27.5% ± 5.8% was excreted in the urine within 5 h post injection (p.i.).  Only 8.5% ± 3.1% of cisplatinum remained in blood pools at 5 h, which gradually cleared over the 6-day monitoring period p.i.  At the end of the study (6 days p.i.), a total of 37.4% ± 5.3% of the product had cleared from the blood into urine, and approx. 63% remained in the body.  The significantly lower concn. of carrier cisplatinum used for imaging resulted in a well-tolerated product.  Copyright © 2013 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjVN1R8YfhD7Vg90H21EOLACvtfcHk0lhNgTyu7h1N4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCrs7jO&md5=004bad0893e16b947023a7e392e5a6d6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3091%26sid%3Dliteratum%253Aachs%26aulast%3DZeevaart%26aufirst%3DJ.%2BR.%26aulast%3DWagener%26aufirst%3DJ.%26aulast%3DMarjanovic-Painter%26aufirst%3DB.%26aulast%3DSathekge%26aufirst%3DM.%26aulast%3DSoni%26aufirst%3DN.%26aulast%3DZinn%26aufirst%3DC.%26aulast%3DPerkins%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DS.%2BV.%26atitle%3DProduction%2520of%2520High%2520Specific%2520Activity%2520%2528195m%2529%2520Pt-Cisplatinum%2520at%2520South%2520African%2520Nuclear%2520Energy%2520Corporation%2520for%2520Phase%25200%2520Clinical%2520Trials%2520in%2520Healthy%2520Individual%2520Subjects%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2013%26volume%3D56%26spage%3D495%26epage%3D503%26doi%3D10.1002%2Fjlcr.3091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Anand, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, W.</span><span> </span><span class="NLM_article-title">A New, Semi-Automated System for the Micro-Scale Synthesis of [195mPt]Cisplatin Suitable for Clinical Studies</span> <span class="citation_source-journal">Int. J. Rad. Appl. Instrum. A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">814</span><span class="refDoi"> DOI: 10.1016/0883-2889(92)90247-C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2F0883-2889%2892%2990247-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1319424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK38zgvVWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=809-814&author=D.+Anandauthor=W.+Wolf&title=A+New%2C+Semi-Automated+System+for+the+Micro-Scale+Synthesis+of+%5B195mPt%5DCisplatin+Suitable+for+Clinical+Studies&doi=10.1016%2F0883-2889%2892%2990247-C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A new, semi-automated system for the micro-scale synthesis of [195mPt]cisplatin suitable for clinical studies</span></div><div class="casAuthors">Anand D; Wolf W</div><div class="citationInfo"><span class="NLM_cas:title">International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">809-14</span>
        ISSN:<span class="NLM_cas:issn">0883-2889</span>.
    </div><div class="casAbstract">A new, semi-automated system for the microscale synthesis of [195mPt]cisplatin has been developed.  Radiochemical yields of up to 70% of pure [195mPt]cisplatin can be obtained routinely e.g. 555-629 MBq (15-17 mCi) from 925 MBq (25 mCi) of [195mPt]Pt metal.  Chemical losses during synthesis, and radiation exposure of personnel, have been minimized.  These increased yields are the consequence of the elimination of most transfers, and enhanced yields at most steps: ammination losses decreased from 27 to 7%, and at the diiodo- to di-acquo- conversion, from 34 to 11%.  The versatility of such a system is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfPfP9rchDjdy3lHz94U-GfW6udTcc2ebsnBWbiz4-YLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zgvVWmsw%253D%253D&md5=5aded7bb8637ad7072b754faf60b2378</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0883-2889%2892%2990247-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0883-2889%252892%252990247-C%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DD.%26aulast%3DWolf%26aufirst%3DW.%26atitle%3DA%2520New%252C%2520Semi-Automated%2520System%2520for%2520the%2520Micro-Scale%2520Synthesis%2520of%2520%255B195mPt%255DCisplatin%2520Suitable%2520for%2520Clinical%2520Studies%26jtitle%3DInt.%2520J.%2520Rad.%2520Appl.%2520Instrum.%2520A%26date%3D1992%26volume%3D43%26spage%3D809%26epage%3D814%26doi%3D10.1016%2F0883-2889%2892%2990247-C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Aalbersberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Wit-Van Der Veen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwaagstra, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codee-Van Der Schilden, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vegt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, W.</span><span> </span><span class="NLM_article-title">Preclinical Imaging Characteristics of 195m-Platinum Spect</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1382</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1382&author=E.+Aalbersbergauthor=L.+De+Wit-Van+Der+Veenauthor=O.+Zwaagstraauthor=K.+Codee-Van+Der+Schildenauthor=E.+Vegtauthor=W.+Vogel&title=Preclinical+Imaging+Characteristics+of+195m-Platinum+Spect"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAalbersberg%26aufirst%3DE.%26aulast%3DDe%2BWit-Van%2BDer%2BVeen%26aufirst%3DL.%26aulast%3DZwaagstra%26aufirst%3DO.%26aulast%3DCodee-Van%2BDer%2BSchilden%26aufirst%3DK.%26aulast%3DVegt%26aufirst%3DE.%26aulast%3DVogel%26aufirst%3DW.%26atitle%3DPreclinical%2520Imaging%2520Characteristics%2520of%2520195m-Platinum%2520Spect%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D1382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Buckley, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sharkawi, A. M.</span><span> </span><span class="NLM_article-title">Gamma Camera Scintigraphy of Tumours Using (195m)Pt-Cisplatin</span> <span class="citation_source-journal">Phys. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1325</span><span class="NLM_x">–</span> <span class="NLM_lpage">1332</span><span class="refDoi"> DOI: 10.1088/0031-9155/51/5/020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1088%2F0031-9155%2F51%2F5%2F020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=16481697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD28XivFCltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2006&pages=1325-1332&author=S.+E.+Buckleyauthor=P.+A.+Aliauthor=C.+J.+Evansauthor=A.+M.+El-Sharkawi&title=Gamma+Camera+Scintigraphy+of+Tumours+Using+%28195m%29Pt-Cisplatin&doi=10.1088%2F0031-9155%2F51%2F5%2F020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Gamma camera scintigraphy of tumours using 195mPt-cisplatin</span></div><div class="casAuthors">Buckley, S. E.; Ali, P. A.; Evans, C. J.; El-Sharkawi, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Physics in Medicine & Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1325-1332</span>CODEN:
                <span class="NLM_cas:coden">PHMBA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9155</span>.
    
            (<span class="NLM_cas:orgname">Institute of Physics Publishing</span>)
        </div><div class="casAbstract">Platinum enriched with 194Pt was irradiated for 4 days in NRG's TIRO 1 reactor, to produce 195mPt.  Spectral anal. of the product was performed using a calibrated hyper pure germanium detector and its constituent radioisotopes were identified as 195mPt, 199Au and 192Ir.  Using the detector's intrinsic efficiency calibration, their activities were estd. to be 1049, 133 and 5.8 MBq, resp.  The performance of the gamma camera was tested using quality control procedures recommended by the Institute of Physics and Engineering in Medicine (IPEM) and was found to be satisfactory.  A torso phantom was used to det. the min. detection limit (MDL) of 195mPt in a 2 cm diam. tumor using SPECT acquisitions (32 steps, 60 s per step).  The MDL was found to be 8 ppm assuming an administered patient dose of 50 MBq and a total cisplatin dose of 105 mg.  This work indicates that 195mPt-cisplatin is suitable for clin. scintigraphy and has led to the development of a clin. protocol that has been approved for a pilot study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppYj4VILSZ8rVg90H21EOLACvtfcHk0lhNgTyu7h1N4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivFCltLk%253D&md5=8f9737fa10cf945f99fa24bcc3a8c4ab</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1088%2F0031-9155%2F51%2F5%2F020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F0031-9155%252F51%252F5%252F020%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DS.%2BE.%26aulast%3DAli%26aufirst%3DP.%2BA.%26aulast%3DEvans%26aufirst%3DC.%2BJ.%26aulast%3DEl-Sharkawi%26aufirst%3DA.%2BM.%26atitle%3DGamma%2520Camera%2520Scintigraphy%2520of%2520Tumours%2520Using%2520%2528195m%2529Pt-Cisplatin%26jtitle%3DPhys.%2520Med.%2520Biol.%26date%3D2006%26volume%3D51%26spage%3D1325%26epage%3D1332%26doi%3D10.1088%2F0031-9155%2F51%2F5%2F020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Smith, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D. M.</span><span> </span><span class="NLM_article-title">Distribution and Retention of the Antitumor Agent 195mPt-<i>cis</i>-Dichlorodiammine Platinum (II) in Man</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1974&pages=349-351&author=H.+S.+Smithauthor=D.+M.+Taylor&title=Distribution+and+Retention+of+the+Antitumor+Agent+195mPt-cis-Dichlorodiammine+Platinum+%28II%29+in+Man"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DH.%2BS.%26aulast%3DTaylor%26aufirst%3DD.%2BM.%26atitle%3DDistribution%2520and%2520Retention%2520of%2520the%2520Antitumor%2520Agent%2520195mPt-cis-Dichlorodiammine%2520Platinum%2520%2528II%2529%2520in%2520Man%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1974%26volume%3D15%26spage%3D349%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Owens, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adam, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcauliffe, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowther, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. W.</span><span> </span><span class="NLM_article-title">In Vivo Distribution Studies of Radioactively Labelled Platinum Complexes; <i>cis</i>-Dichlorodiammine Platinum(II), <i>cis</i>-<i>trans</i>-Dichlorodihydroxy-<i>bis</i>-(Isopropylamine) Platinum(IV), <i>cis</i>-Dichloro-<i>bis</i>-Cyclopropylamine Platinum(II), and <i>cis</i>-Diammine 1,1-Cyclobutanedicarboxylate Platinum(II) in Patients with Malignant Disease, Using a Gamma Camera</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.1007/BF00258128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF00258128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3888431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaL2M3gt1Wmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1985&pages=253-257&author=S.+E.+Owensauthor=N.+Thatcherauthor=H.+Sharmaauthor=N.+Adamauthor=R.+Harrisonauthor=A.+Smithauthor=A.+Zakiauthor=J.+C.+Baerauthor=C.+A.+Mcauliffeauthor=D.+Crowtherauthor=B.+W.+Fox&title=In+Vivo+Distribution+Studies+of+Radioactively+Labelled+Platinum+Complexes%3B+cis-Dichlorodiammine+Platinum%28II%29%2C+cis-trans-Dichlorodihydroxy-bis-%28Isopropylamine%29+Platinum%28IV%29%2C+cis-Dichloro-bis-Cyclopropylamine+Platinum%28II%29%2C+and+cis-Diammine+1%2C1-Cyclobutanedicarboxylate+Platinum%28II%29+in+Patients+with+Malignant+Disease%2C+Using+a+Gamma+Camera&doi=10.1007%2FBF00258128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera</span></div><div class="casAuthors">Owens S E; Thatcher N; Sharma H; Adam N; Harrison R; Smith A; Zaki A; Baer J C; McAuliffe C A; Crowther D</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-7</span>
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">The in vivo distribution in man of the four platinum derivatives cis-dichlorodiammine platinum(II) (DDP), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV) (CHIP), cis-dichloro-bis-cyclopropylamine platinum(II) (CP), and cis-diammine 1, 1-cyclobutanedicarboxylate platinum(II) (CBDCA) has been observed.  The availability of these compounds labelled with the radioactive isotope of platinum, platinum-191, has made serial in vivo imaging of their distribution possible.  Injection of 17-35 MBq (5-28 mg) of the labelled compound IV was followed by imaging, using a gamma camera, with particular reference to the kidneys, liver, and tumour site.  Hepatic and renal clearances were observed in all nine patients, but no unequivocal evidence of tumour uptake was found.  The left kidney uptake was estimated at times up to 7 days after injection.  Mathematical analysis of some of the uptake curves failed to show any significant difference between the clearance times observed.  However, the two patients who received CBDCA did show a higher initial renal uptake, falling within the 1st day to levels comparable with those of the other compounds, and the three patients who received DDP showed consistently liver uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ00CmCmNs_b5XHngOXiV_fW6udTcc2eZT1J6z0uVzrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M3gt1Wmuw%253D%253D&md5=e478d34790f17bdfa79d3c0da141922a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2FBF00258128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00258128%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DS.%2BE.%26aulast%3DThatcher%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DH.%26aulast%3DAdam%26aufirst%3DN.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DZaki%26aufirst%3DA.%26aulast%3DBaer%26aufirst%3DJ.%2BC.%26aulast%3DMcauliffe%26aufirst%3DC.%2BA.%26aulast%3DCrowther%26aufirst%3DD.%26aulast%3DFox%26aufirst%3DB.%2BW.%26atitle%3DIn%2520Vivo%2520Distribution%2520Studies%2520of%2520Radioactively%2520Labelled%2520Platinum%2520Complexes%253B%2520cis-Dichlorodiammine%2520Platinum%2528II%2529%252C%2520cis-trans-Dichlorodihydroxy-bis-%2528Isopropylamine%2529%2520Platinum%2528IV%2529%252C%2520cis-Dichloro-bis-Cyclopropylamine%2520Platinum%2528II%2529%252C%2520and%2520cis-Diammine%25201%252C1-Cyclobutanedicarboxylate%2520Platinum%2528II%2529%2520in%2520Patients%2520with%2520Malignant%2520Disease%252C%2520Using%2520a%2520Gamma%2520Camera%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1985%26volume%3D14%26spage%3D253%26epage%3D257%26doi%3D10.1007%2FBF00258128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Shani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertram, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahalan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muggia, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, W.</span><span> </span><span class="NLM_article-title">Noninvasive Monitoring of Drug Biodistribution and Metabolism: Studies with Intraarterial Pt-195m-Cisplatin in Humans</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1877</span><span class="NLM_x">–</span> <span class="NLM_lpage">1881</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1989&pages=1877-1881&author=J.+Shaniauthor=J.+Bertramauthor=C.+Russellauthor=R.+Dahalanauthor=D.+C.+Chenauthor=R.+Partiauthor=J.+Ahmadiauthor=R.+A.+Kempfauthor=T.+K.+Kawadaauthor=F.+M.+Muggiaauthor=W.+Wolf&title=Noninvasive+Monitoring+of+Drug+Biodistribution+and+Metabolism%3A+Studies+with+Intraarterial+Pt-195m-Cisplatin+in+Humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShani%26aufirst%3DJ.%26aulast%3DBertram%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DC.%26aulast%3DDahalan%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DD.%2BC.%26aulast%3DParti%26aufirst%3DR.%26aulast%3DAhmadi%26aufirst%3DJ.%26aulast%3DKempf%26aufirst%3DR.%2BA.%26aulast%3DKawada%26aufirst%3DT.%2BK.%26aulast%3DMuggia%26aufirst%3DF.%2BM.%26aulast%3DWolf%26aufirst%3DW.%26atitle%3DNoninvasive%2520Monitoring%2520of%2520Drug%2520Biodistribution%2520and%2520Metabolism%253A%2520Studies%2520with%2520Intraarterial%2520Pt-195m-Cisplatin%2520in%2520Humans%26jtitle%3DCancer%2520Res.%26date%3D1989%26volume%3D49%26spage%3D1877%26epage%3D1881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Areberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorkman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einarsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundqvist, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattsson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norrgren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheike, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, R.</span><span> </span><span class="NLM_article-title">Gamma Camera Imaging of Platinum in Tumours and Tissues of Patients after Administration of 191Pt-Cisplatin</span> <span class="citation_source-journal">Acta Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1080%2F028418699431654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10227445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK1M3ktF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=221-228&author=J.+Arebergauthor=S.+Bjorkmanauthor=L.+Einarssonauthor=B.+Frankenbergauthor=H.+Lundqvistauthor=S.+Mattssonauthor=K.+Norrgrenauthor=O.+Scheikeauthor=R.+Wallin&title=Gamma+Camera+Imaging+of+Platinum+in+Tumours+and+Tissues+of+Patients+after+Administration+of+191Pt-Cisplatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Gamma camera imaging of platinum in tumours and tissues of patients after administration of 191Pt-cisplatin</span></div><div class="casAuthors">Areberg J; Bjorkman S; Einarsson L; Frankenberg B; Lundqvist H; Mattsson S; Norrgren K; Scheike O; Wallin R</div><div class="citationInfo"><span class="NLM_cas:title">Acta oncologica (Stockholm, Sweden)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-8</span>
        ISSN:<span class="NLM_cas:issn">0284-186X</span>.
    </div><div class="casAbstract">The aim of this study was to visualize non-invasively the uptake of platinum in tumours and tissues after treatment with cisplatin. 191Pt-cisplatin was synthesized from 191PtCl4 with rigorous pharmaceutical quality control.  The uptake of platinum by both tumorous and healthy tissues was studied by gamma camera imaging in 14 patients, 5 of whom showed a clear uptake of platinum in regions corresponding to known tumour sites.  Maximum concentrations of platinum in the tumours were on average 4.9+/-1.0 microg/g, when normalized to an administered amount of 180 mg cisplatin.  In all the patients, the liver was the organ that showed the highest uptake.  Platinum uptake was also seen in the spleen, gall bladder, gastrointestinal tract, bladder, kidneys, ureter, neck and mediastinum and urogenital region.  By using in-house production of 191Pt-cisplatin, it was possible to monitor the uptake of platinum in tumorous tissues and healthy organs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4zzS-26QlET0O18WR3iAofW6udTcc2eZT1J6z0uVzrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3ktF2rtg%253D%253D&md5=e230aebbfe4b97ed283342015ae78f6c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1080%2F028418699431654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F028418699431654%26sid%3Dliteratum%253Aachs%26aulast%3DAreberg%26aufirst%3DJ.%26aulast%3DBjorkman%26aufirst%3DS.%26aulast%3DEinarsson%26aufirst%3DL.%26aulast%3DFrankenberg%26aufirst%3DB.%26aulast%3DLundqvist%26aufirst%3DH.%26aulast%3DMattsson%26aufirst%3DS.%26aulast%3DNorrgren%26aufirst%3DK.%26aulast%3DScheike%26aufirst%3DO.%26aulast%3DWallin%26aufirst%3DR.%26atitle%3DGamma%2520Camera%2520Imaging%2520of%2520Platinum%2520in%2520Tumours%2520and%2520Tissues%2520of%2520Patients%2520after%2520Administration%2520of%2520191Pt-Cisplatin%26jtitle%3DActa%2520Oncol.%26date%3D1999%26volume%3D38%26spage%3D221%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Sathekge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagener, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marjanovic-Painter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van De Wiele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’asseler, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeevaart, J. R.</span><span> </span><span class="NLM_article-title">Biodistribution and Dosimetry of 195mPt-Cisplatin in Normal Volunteers. Imaging Agent for Single Photon Emission Computed Tomography</span> <span class="citation_source-journal">Nuklearmedizin</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.3413/Nukmed-0599-13-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.3413%2FNukmed-0599-13-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24108524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1anurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=222-227&author=M.+Sathekgeauthor=J.+Wagenerauthor=S.+V.+Smithauthor=N.+Soniauthor=B.+Marjanovic-Painterauthor=C.+Zinnauthor=C.+Van+De+Wieleauthor=Y.+D%E2%80%99asselerauthor=G.+Perkinsauthor=J.+R.+Zeevaart&title=Biodistribution+and+Dosimetry+of+195mPt-Cisplatin+in+Normal+Volunteers.+Imaging+Agent+for+Single+Photon+Emission+Computed+Tomography&doi=10.3413%2FNukmed-0599-13-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Imaging agent for single photon emission computed tomography</span></div><div class="casAuthors">Sathekge, M.; Wagener, J.; Smith, S. V.; Soni, N.; Marjanovic-Painter, B.; Zinn, C.; Van de Wiele, C.; D'Asseler, Y.; Perkins, G.; Zeevaart, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Nuklearmedizin</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">222-227</span>CODEN:
                <span class="NLM_cas:coden">NMIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0029-5566</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">195mPt-cisplatin is regarded as a promising imaging agent for optimizing dosage in patients receiving cisplatin chemotherapy.  Methods: We investigated the whole-body distribution and radiation dosimetry of 195mPt-cisplatin in humans.  Whole-body scans were obtained up to 144 h after i.v. injection of 112.4 MBq 195mPt-cisplatin in each of five subjects.  Blood samples were taken at various times up to 144 h after injection.  Urine was collected up to 114 h after injection for calcn. of renal clearance and whole-body clearance.  Time/activity curves were generated by fitting the organ-specific geometric mean counts, obtained from regions of interest, on the resp. images as a function of the time after injection.  OLINDA software package was applied to calc. the adsorbed radiation dose for various organs.  Results: Most of the activity (32 ± 4%) was excreted in the urine during the first 5 h.  The effective clearance half-life derived from extrapolation o the whole-body curve was 40 h (1.7 days).  On av., the highest dose was received by the kidneys (mean dose received 2.68 ± 1.5 mGy/MBq), followed by the spleen (mean dose received 1.6 ± 0.8 mGy/MBq) followed by the liver (mean dose received 1.45 ± 0.38 mGy/MBq).  The estd. mean ED for the adult subject was 0.185 ± 0.034 mSv/MBq.  Conclusion: 195mPt-cisplatin proved a safe radiopharmaceutical with a favorable biodistribution for early and delayed imaging of pathol. above the diaphragm.  The ED obtained was 0.185 ± 0.034 mSv/MBq.  The highest organ dose was received by the kidneys (2.68 ± 1.5 mGy/MBq).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3SbBHnIM0krVg90H21EOLACvtfcHk0liz5Qv0QVnVFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1anurs%253D&md5=a73b3e1e31b75ab73d0ab6ea9e0fb010</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3413%2FNukmed-0599-13-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3413%252FNukmed-0599-13-06%26sid%3Dliteratum%253Aachs%26aulast%3DSathekge%26aufirst%3DM.%26aulast%3DWagener%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%2BV.%26aulast%3DSoni%26aufirst%3DN.%26aulast%3DMarjanovic-Painter%26aufirst%3DB.%26aulast%3DZinn%26aufirst%3DC.%26aulast%3DVan%2BDe%2BWiele%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599asseler%26aufirst%3DY.%26aulast%3DPerkins%26aufirst%3DG.%26aulast%3DZeevaart%26aufirst%3DJ.%2BR.%26atitle%3DBiodistribution%2520and%2520Dosimetry%2520of%2520195mPt-Cisplatin%2520in%2520Normal%2520Volunteers.%2520Imaging%2520Agent%2520for%2520Single%2520Photon%2520Emission%2520Computed%2520Tomography%26jtitle%3DNuklearmedizin%26date%3D2013%26volume%3D52%26spage%3D222%26epage%3D227%26doi%3D10.3413%2FNukmed-0599-13-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Holschbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamkens, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamacher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stöcklin, G.</span><span> </span><span class="NLM_article-title">[13N]Cisplatin: A Fast and Efficient On-Line Synthesis Using a Solid State Support</span> <span class="citation_source-journal">Appl. Radiat. Isot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">744</span><span class="refDoi"> DOI: 10.1016/S0969-8043(96)00323-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0969-8043%2896%2900323-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaK2sXktVems7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1997&pages=739-744&author=M.+Holschbachauthor=W.+Hamkensauthor=A.+Steinbachauthor=K.+Hamacherauthor=G.+St%C3%B6cklin&title=%5B13N%5DCisplatin%3A+A+Fast+and+Efficient+On-Line+Synthesis+Using+a+Solid+State+Support&doi=10.1016%2FS0969-8043%2896%2900323-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">[13N]cisplatin: a fast and efficient online synthesis using a solid state support</span></div><div class="casAuthors">Holschbach, M.; Hamkens, W.; Steinbach, A.; Hamacher, K.; Stocklin, G.</div><div class="citationInfo"><span class="NLM_cas:title">Applied Radiation and Isotopes</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">739-744</span>CODEN:
                <span class="NLM_cas:coden">ARISEF</span>;
        ISSN:<span class="NLM_cas:issn">0969-8043</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A new, convenient and fast on-column method using a strong anion exchange resin as the solid state support was developed for the online synthesis of nitrogen-13 (T1/2 = 9.96 min) labeled cisplatin ([13N]cisplatin).  The whole synthesis, including sterile formulation of the product, is accomplished within 15 min.  Using this method, after optimization of the reaction parameters, carrier-added [13N]cisplatin (1) can be obtained ready for injection in a decay-cor. radiochem. yield of 80% with a specific radioactivity of 30 MBq/μmol and a radiochem. purity of >98%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYfZniiOMm4rVg90H21EOLACvtfcHk0liz5Qv0QVnVFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktVems7Y%253D&md5=1c381d8c584507090a79c4d6ddd4a722</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2FS0969-8043%2896%2900323-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-8043%252896%252900323-5%26sid%3Dliteratum%253Aachs%26aulast%3DHolschbach%26aufirst%3DM.%26aulast%3DHamkens%26aufirst%3DW.%26aulast%3DSteinbach%26aufirst%3DA.%26aulast%3DHamacher%26aufirst%3DK.%26aulast%3DSt%25C3%25B6cklin%26aufirst%3DG.%26atitle%3D%255B13N%255DCisplatin%253A%2520A%2520Fast%2520and%2520Efficient%2520On-Line%2520Synthesis%2520Using%2520a%2520Solid%2520State%2520Support%26jtitle%3DAppl.%2520Radiat.%2520Isot.%26date%3D1997%26volume%3D48%26spage%3D739%26epage%3D744%26doi%3D10.1016%2FS0969-8043%2896%2900323-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">De Spiegeleer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slegers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandecasteele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Den Bossche, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelstraete, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claeys, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Moerloose, P.</span><span> </span><span class="NLM_article-title">Microscale Synthesis of Nitrogen-13-Labeled Cisplatin</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1986&pages=399-403&author=B.+De+Spiegeleerauthor=G.+Slegersauthor=C.+Vandecasteeleauthor=W.+Van+Den+Bosscheauthor=K.+Schelstraeteauthor=A.+Claeysauthor=P.+De+Moerloose&title=Microscale+Synthesis+of+Nitrogen-13-Labeled+Cisplatin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSpiegeleer%26aufirst%3DB.%26aulast%3DSlegers%26aufirst%3DG.%26aulast%3DVandecasteele%26aufirst%3DC.%26aulast%3DVan%2BDen%2BBossche%26aufirst%3DW.%26aulast%3DSchelstraete%26aufirst%3DK.%26aulast%3DClaeys%26aufirst%3DA.%26aulast%3DDe%2BMoerloose%26aufirst%3DP.%26atitle%3DMicroscale%2520Synthesis%2520of%2520Nitrogen-13-Labeled%2520Cisplatin%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1986%26volume%3D27%26spage%3D399%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Haber, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenspire, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginos, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, D. A.</span><span> </span><span class="NLM_article-title">Synthesis of [13N]Cisplatin</span> <span class="citation_source-journal">J. Labelled Compd. Radiopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1002/jlcr.2580220512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fjlcr.2580220512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL2MXltFGlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1985&pages=509-516&author=M.+T.+Haberauthor=A.+J.+L.+Cooperauthor=K.+C.+Rosenspireauthor=J.+Z.+Ginosauthor=D.+A.+Rottenberg&title=Synthesis+of+%5B13N%5DCisplatin&doi=10.1002%2Fjlcr.2580220512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of [13N]cisplatin</span></div><div class="casAuthors">Haber, Martin T.; Cooper, Arthur J. L.; Rosenspire, Karen C.; Ginos, James Z.; Rottenberg, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">509-16</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    </div><div class="casAbstract">A method for the "carrier-added" synthesis of [13N]cisplatin  [98182-38-8] is described.  Yields were ∼1-4 mCi from 20-40 mCi of [13N]ammonia with a total synthesis time of 19-28 min.  The product was ∼96% radiochemically pure as judged by HPLC anal. and had a specific activity of ∼100 mCi/mmole in 1.0 mL of saline.  [13N]Cisplatin was administered i.p. to mice.  Of the tissues investigated, concn. of label was highest in kidneys.  At 10 min, considerable label in the blood, liver and kidney was in a form other than cisplatin.  However, no evidence was obtained that [13N]ammonia was released from [13N]cisplatin in vivo.  [13N]Cisplatin may be used to assess drug delivery to primary and metastatic brain tumors in patients receiving i.v. or intraarterial cisplatin chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHtBOxIHOnP7Vg90H21EOLACvtfcHk0ljUdJJSbtgRww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltFGlsr8%253D&md5=41a84ff68e641b25e3f55bf50b4ef748</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.2580220512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.2580220512%26sid%3Dliteratum%253Aachs%26aulast%3DHaber%26aufirst%3DM.%2BT.%26aulast%3DCooper%26aufirst%3DA.%2BJ.%2BL.%26aulast%3DRosenspire%26aufirst%3DK.%2BC.%26aulast%3DGinos%26aufirst%3DJ.%2BZ.%26aulast%3DRottenberg%26aufirst%3DD.%2BA.%26atitle%3DSynthesis%2520of%2520%255B13N%255DCisplatin%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D1985%26volume%3D22%26spage%3D509%26epage%3D516%26doi%3D10.1002%2Fjlcr.2580220512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Ginos, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhawan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strother, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottenberg, D. A.</span><span> </span><span class="NLM_article-title">[<sup>13</sup>N]Cisplatin PET to Assess Pharmacokinetics of Intra-Arterial Versus Intravenous Chemotherapy for Malignant Brain Tumors</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1844</span><span class="NLM_x">–</span> <span class="NLM_lpage">1852</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1987&pages=1844-1852&author=J.+Z.+Ginosauthor=A.+J.+Cooperauthor=V.+Dhawanauthor=J.+C.+Laiauthor=S.+C.+Strotherauthor=N.+Alcockauthor=D.+A.+Rottenberg&title=%5B13N%5DCisplatin+PET+to+Assess+Pharmacokinetics+of+Intra-Arterial+Versus+Intravenous+Chemotherapy+for+Malignant+Brain+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGinos%26aufirst%3DJ.%2BZ.%26aulast%3DCooper%26aufirst%3DA.%2BJ.%26aulast%3DDhawan%26aufirst%3DV.%26aulast%3DLai%26aufirst%3DJ.%2BC.%26aulast%3DStrother%26aufirst%3DS.%2BC.%26aulast%3DAlcock%26aufirst%3DN.%26aulast%3DRottenberg%26aufirst%3DD.%2BA.%26atitle%3D%255B13N%255DCisplatin%2520PET%2520to%2520Assess%2520Pharmacokinetics%2520of%2520Intra-Arterial%2520Versus%2520Intravenous%2520Chemotherapy%2520for%2520Malignant%2520Brain%2520Tumors%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1987%26volume%3D28%26spage%3D1844%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Graham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhsin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Oxaliplatin</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1038/nrd1287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1038%2Fnrd1287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=11-12&author=J.+Grahamauthor=M.+Muhsinauthor=P.+Kirkpatrick&title=Oxaliplatin&doi=10.1038%2Fnrd1287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnrd1287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1287%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DMuhsin%26aufirst%3DM.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DOxaliplatin%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D11%26epage%3D12%26doi%3D10.1038%2Fnrd1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Wheate, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craig, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oun, R.</span><span> </span><span class="NLM_article-title">The Status of Platinum Anticancer Drugs in the Clinic and in Clinical Trials</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8113</span><span class="NLM_x">–</span> <span class="NLM_lpage">8127</span><span class="refDoi"> DOI: 10.1039/c0dt00292e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2Fc0dt00292e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=20593091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8113-8127&author=N.+J.+Wheateauthor=S.+Walkerauthor=G.+E.+Craigauthor=R.+Oun&title=The+Status+of+Platinum+Anticancer+Drugs+in+the+Clinic+and+in+Clinical+Trials&doi=10.1039%2Fc0dt00292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">The status of platinum anticancer drugs in the clinic and in clinical trials</span></div><div class="casAuthors">Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8113-8127</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma.  Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance.  Over the last 30 years, 23 other platinum-based drugs have entered clin. trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations.  During this time there have been more failures than successes with the development of 14 drugs being halted during clin. trials.  Currently there are four drugs in the various phases of clin. trial (satraplatin, picoplatin, Lipoplatin and ProLindac).  No new small mol. platinum drug has entered clin. trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade.  In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clin. trials and those discontinued during clin. trials, and discuss the results in the context of where we believe the field will develop over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSuqxBzUTjbVg90H21EOLACvtfcHk0ljUdJJSbtgRww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO&md5=bfa2fef3a7c3c4a3122a0fa60e45f804</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1039%2Fc0dt00292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt00292e%26sid%3Dliteratum%253Aachs%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DG.%2BE.%26aulast%3DOun%26aufirst%3DR.%26atitle%3DThe%2520Status%2520of%2520Platinum%2520Anticancer%2520Drugs%2520in%2520the%2520Clinic%2520and%2520in%2520Clinical%2520Trials%26jtitle%3DDalton%2520Trans.%26date%3D2010%26volume%3D39%26spage%3D8113%26epage%3D8127%26doi%3D10.1039%2Fc0dt00292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Bécouarn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agostini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trufflandier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulanger, V.</span><span> </span><span class="NLM_article-title">Oxaliplatin: Available Data in Non-Colorectal Gastrointestinal Malignancies</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span><span class="refDoi"> DOI: 10.1016/S1040-8428(01)00169-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS1040-8428%2801%2900169-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11738949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BD3MnptFClsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=265-272&author=Y.+B%C3%A9couarnauthor=C.+Agostiniauthor=N.+Trufflandierauthor=V.+Boulanger&title=Oxaliplatin%3A+Available+Data+in+Non-Colorectal+Gastrointestinal+Malignancies&doi=10.1016%2FS1040-8428%2801%2900169-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin: available data in non-colorectal gastrointestinal malignancies</span></div><div class="casAuthors">Becouarn Y; Agostini C; Trufflandier N; Boulanger V</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">265-72</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">Oxaliplatin is a third-generation platinum compound which has proven its efficacy alone or in combination with 5-fluorouracil (5-FU) and/or new anticancer drugs in advanced colorectal cancer.  Compared to the amount of available data in this cancer, little is known about the use of oxaliplatin in non-colorectal gastrointestinal malignancies. (1) The preclinical activity of the drug alone or in combination; (2) the phase I studies (oxaliplatin alone or in combination with irinotecan, raltitrexed, gemcitabine, folinic acid and 5-FU); (3) the phase II studies developed in gastric, pancreatic, biliary tract, hepatocellular carcinoma and malignant mesothelioma; and (4) some of the ongoing trials with regard to non-colorectal gastrointestinal malignancies are reviewed in this paper.  To date, oxaliplatin appears as a real candidate for clinical development in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8mY4KUE2d4Ob6AVA-44PTfW6udTcc2eZJBaxxVLQ2Z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnptFClsg%253D%253D&md5=43d603c7fab3dc93270cc631877e8689</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS1040-8428%2801%2900169-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1040-8428%252801%252900169-X%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A9couarn%26aufirst%3DY.%26aulast%3DAgostini%26aufirst%3DC.%26aulast%3DTrufflandier%26aufirst%3DN.%26aulast%3DBoulanger%26aufirst%3DV.%26atitle%3DOxaliplatin%253A%2520Available%2520Data%2520in%2520Non-Colorectal%2520Gastrointestinal%2520Malignancies%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2001%26volume%3D40%26spage%3D265%26epage%3D272%26doi%3D10.1016%2FS1040-8428%2801%2900169-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Boulikas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christofis, P.</span><span> </span><span class="NLM_article-title">Designing Platinum Compounds in Cancer: Structures and Mechanisms</span> <span class="citation_source-journal">Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=537-583&author=T.+Boulikasauthor=A.+Pantosauthor=E.+Bellisauthor=P.+Christofis&title=Designing+Platinum+Compounds+in+Cancer%3A+Structures+and+Mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoulikas%26aufirst%3DT.%26aulast%3DPantos%26aufirst%3DA.%26aulast%3DBellis%26aufirst%3DE.%26aulast%3DChristofis%26aufirst%3DP.%26atitle%3DDesigning%2520Platinum%2520Compounds%2520in%2520Cancer%253A%2520Structures%2520and%2520Mechanisms%26jtitle%3DCancer%2520Ther.%26date%3D2007%26volume%3D5%26spage%3D537%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Clavel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monfardini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gundersen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegenthaler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinedo, H. M.</span><span> </span><span class="NLM_article-title">Phase II Study of Iproplatin (CHIP, JM-9) in Advanced Testicular Cancers Progressing after Prior Chemotherapy</span> <span class="citation_source-journal">Eur. J. Cancer Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1345</span><span class="NLM_x">–</span> <span class="NLM_lpage">1348</span><span class="refDoi"> DOI: 10.1016/0277-5379(88)90226-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2F0277-5379%2888%2990226-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3181255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaL1M%252FjtV2jtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1988&pages=1345-1348&author=M.+Clavelauthor=S.+Monfardiniauthor=S.+Gundersenauthor=S.+Kayeauthor=P.+Siegenthalerauthor=J.+Renardauthor=M.+Van+Glabbekeauthor=H.+M.+Pinedo&title=Phase+II+Study+of+Iproplatin+%28CHIP%2C+JM-9%29+in+Advanced+Testicular+Cancers+Progressing+after+Prior+Chemotherapy&doi=10.1016%2F0277-5379%2888%2990226-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy</span></div><div class="casAuthors">Clavel M; Monfardini S; Gundersen S; Kaye S; Siegenthaler P; Renard J; van Glabbeke M; Pinedo H M</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer & clinical oncology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1345-8</span>
        ISSN:<span class="NLM_cas:issn">0277-5379</span>.
    </div><div class="casAbstract">Twenty-two patients with advanced testicular cancer received iproplatin at a dose of 180-240 mg/m2 every 4 weeks.  All the patients progressed or recurred after chemotherapy including cisplatin.  The most severe toxicity was thrombocytopenia with two toxic deaths after a first cycle of 240 and 180 mg/m2 respectively.  Nausea and vomiting were almost universal but mild in intensity.  One renal failure occurred 6 weeks after the first cycle while the tumor was progressing.  No antitumor activity was observed in this heavily pretreated population of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEQbLT51sM_tK0qsdY6Nc1fW6udTcc2eafjXvKDjzuDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1M%252FjtV2jtg%253D%253D&md5=bc3fe34619ce3efb008c4db44e565bda</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0277-5379%2888%2990226-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0277-5379%252888%252990226-X%26sid%3Dliteratum%253Aachs%26aulast%3DClavel%26aufirst%3DM.%26aulast%3DMonfardini%26aufirst%3DS.%26aulast%3DGundersen%26aufirst%3DS.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DSiegenthaler%26aufirst%3DP.%26aulast%3DRenard%26aufirst%3DJ.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26atitle%3DPhase%2520II%2520Study%2520of%2520Iproplatin%2520%2528CHIP%252C%2520JM-9%2529%2520in%2520Advanced%2520Testicular%2520Cancers%2520Progressing%2520after%2520Prior%2520Chemotherapy%26jtitle%3DEur.%2520J.%2520Cancer%2520Clin.%2520Oncol.%26date%3D1988%26volume%3D24%26spage%3D1345%26epage%3D1348%26doi%3D10.1016%2F0277-5379%2888%2990226-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Bhargava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaishampayan, U. N.</span><span> </span><span class="NLM_article-title">Satraplatin: Leading the New Generation of Oral Platinum Agents</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1787</span><span class="NLM_x">–</span> <span class="NLM_lpage">1797</span><span class="refDoi"> DOI: 10.1517/13543780903362437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1517%2F13543780903362437" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1787-1797&author=A.+Bhargavaauthor=U.+N.+Vaishampayan&title=Satraplatin%3A+Leading+the+New+Generation+of+Oral+Platinum+Agents&doi=10.1517%2F13543780903362437"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1517%2F13543780903362437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780903362437%26sid%3Dliteratum%253Aachs%26aulast%3DBhargava%26aufirst%3DA.%26aulast%3DVaishampayan%26aufirst%3DU.%2BN.%26atitle%3DSatraplatin%253A%2520Leading%2520the%2520New%2520Generation%2520of%2520Oral%2520Platinum%2520Agents%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1787%26epage%3D1797%26doi%3D10.1517%2F13543780903362437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beale, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span> </span><span class="NLM_article-title">Mini-Review: Discovery and Development of Platinum Complexes Designed to Circumvent Cisplatin Resistance</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1016/S0162-0134(99)00141-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0162-0134%2899%2900141-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1999&pages=111-115&author=L.+R.+Kellandauthor=S.+Y.+Sharpauthor=C.+F.+O%E2%80%99Neillauthor=F.+I.+Raynaudauthor=P.+J.+Bealeauthor=I.+R.+Judson&title=Mini-Review%3A+Discovery+and+Development+of+Platinum+Complexes+Designed+to+Circumvent+Cisplatin+Resistance&doi=10.1016%2FS0162-0134%2899%2900141-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2FS0162-0134%2899%2900141-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-0134%252899%252900141-5%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DC.%2BF.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DBeale%26aufirst%3DP.%2BJ.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26atitle%3DMini-Review%253A%2520Discovery%2520and%2520Development%2520of%2520Platinum%2520Complexes%2520Designed%2520to%2520Circumvent%2520Cisplatin%2520Resistance%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D1999%26volume%3D77%26spage%3D111%26epage%3D115%26doi%3D10.1016%2FS0162-0134%2899%2900141-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Manzotti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratesi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Domenico, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalletti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polizzi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span> </span><span class="NLM_article-title">BBR 3464: A Novel Triplatinum Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2626</span><span class="NLM_x">–</span> <span class="NLM_lpage">2634</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10914703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslentrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=2626-2634&author=C.+Manzottiauthor=G.+Pratesiauthor=E.+Mentaauthor=R.+Di+Domenicoauthor=E.+Cavallettiauthor=H.+H.+Fiebigauthor=L.+R.+Kellandauthor=N.+Farrellauthor=D.+Polizziauthor=R.+Supinoauthor=G.+Pezzoniauthor=F.+Zunino&title=BBR+3464%3A+A+Novel+Triplatinum+Complex%2C+Exhibiting+a+Preclinical+Profile+of+Antitumor+Efficacy+Different+from+Cisplatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin</span></div><div class="casAuthors">Manzotti, Carla; Pratesi, Graziella; Menta, Ernesto; Domenico, Roberto Di; Cavalletti, Ennio; Fiebig, Heinz H.; Kelland, Lloyd R.; Farrell, Nicholas; Polizzi, Donatella; Supino, Rosanna; Pezzoni, Gabriella; Zunino, Franco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2626-2634</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The triplatinum complex BBR 3464 was evaluated in a series of human tumor cell lines and tumor xenografts, with special emphasis on tumor types known to be resistant to cisplatin.  In a panel of seven human tumor cell lines naturally resistant to cisplatin (three ovarian tumors and four melanomas), BBR 3464 was extremely potent, with IC50 values at least 20-fold lower than cisplatin.  Against eight human tumor xenografts, including four tumors refractory to cisplatin, BBR 3464 was very active, producing a >80% inhibition of growth in seven of them.  The efficacy of BBR 3464 against cisplatin-resistant tumors was consistent with the ability of the drug to completely overcome resistance in three cell systems characterized by acquired resistance to cisplatin.  Moreover, BBR 3464 caused a more prolonged effect than cisplatin, which was reflected by higher specific growth delay values.  This prolonged effect is likely to be related to a more persistent perturbation of the cell cycle by BBR 3464 than by cisplatin, as shown in one ovarian tumor cell line.  Finally, the profile of sensitivity to BBR 3464 within the 60-cell-line screening panel of the National Cancer Institute, NIH (Bethesda, MD) differed from those of established drugs, thus supporting the hypothesis of a distinct mechanism of cytotoxic activity of BBR 3464.  This novel triplatinum complex, in the light of its innovative antitumor activity profile, has the potential to become a useful clin. agent for the treatment of unresponsive tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopg8SLf4JVV7Vg90H21EOLACvtfcHk0liCAl_lWIgpFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslentrg%253D&md5=23e5bf1975dadbe2c77411ab21b7d969</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManzotti%26aufirst%3DC.%26aulast%3DPratesi%26aufirst%3DG.%26aulast%3DMenta%26aufirst%3DE.%26aulast%3DDi%2BDomenico%26aufirst%3DR.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DFiebig%26aufirst%3DH.%2BH.%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DFarrell%26aufirst%3DN.%26aulast%3DPolizzi%26aufirst%3DD.%26aulast%3DSupino%26aufirst%3DR.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DBBR%25203464%253A%2520A%2520Novel%2520Triplatinum%2520Complex%252C%2520Exhibiting%2520a%2520Preclinical%2520Profile%2520of%2520Antitumor%2520Efficacy%2520Different%2520from%2520Cisplatin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2000%26volume%3D6%26spage%3D2626%26epage%3D2634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Misset, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleiberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekradda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cvitkovic, E.</span><span> </span><span class="NLM_article-title">Oxaliplatin Clinical Activity: A Review</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1016/S1040-8428(00)00070-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS1040-8428%2800%2900070-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10936465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BD3cvmvFSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=75-93&author=J.+L.+Missetauthor=H.+Bleibergauthor=W.+Sutherlandauthor=M.+Bekraddaauthor=E.+Cvitkovic&title=Oxaliplatin+Clinical+Activity%3A+A+Review&doi=10.1016%2FS1040-8428%2800%2900070-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin clinical activity: a review</span></div><div class="casAuthors">Misset J L; Bleiberg H; Sutherland W; Bekradda M; Cvitkovic E</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-93</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">Oxaliplatin (Eloxatin), a recently developed third-generation cisplatin analogue with a 1,2-diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in a wide variety of tumour types.  Synergistic with 5-FU in colorectal cancer (CRC), the combination has proven efficacy in 5-FU-resistant advanced disease and in previously untreated CRC, as demonstrated in controlled phase III trials, while evaluation in the adjuvant setting is ongoing.  Due to its excellent safety profile, its unique mechanism of action and lack of cross-resistance with other active agents in CRC, oxaliplatin has also been combined with CPT-11 and Raltitrexed with promising results.  Trials in pretreated and untreated advanced ovarian cancer (AOC), as a single agent or in combination with cisplatin, cyclophosphamide or paclitaxel, indicate a yet to be defined role in AOC and confirm its lack of cross-resistance with cis/carboplatin.  Clinical investigations of single agent and combination therapies in breast, lung, prostate and germ-cell carcinomas, non-Hodgkin's lymphoma and malignant mesothelioma are being pursued.  While the role of oxaliplatin in medical oncology is yet to be fully defined, it appears to be an important new anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRR6rm3u9EVofh3YQQtAhNufW6udTcc2ea1H_MCEuLoGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvmvFSjsQ%253D%253D&md5=05c3d3fa62e6ee0a8bcd8e4b59303f83</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS1040-8428%2800%2900070-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1040-8428%252800%252900070-6%26sid%3Dliteratum%253Aachs%26aulast%3DMisset%26aufirst%3DJ.%2BL.%26aulast%3DBleiberg%26aufirst%3DH.%26aulast%3DSutherland%26aufirst%3DW.%26aulast%3DBekradda%26aufirst%3DM.%26aulast%3DCvitkovic%26aufirst%3DE.%26atitle%3DOxaliplatin%2520Clinical%2520Activity%253A%2520A%2520Review%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2000%26volume%3D35%26spage%3D75%26epage%3D93%26doi%3D10.1016%2FS1040-8428%2800%2900070-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Tashiro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kidani, Y.</span><span> </span><span class="NLM_article-title">Antitumor Activity of a New Platinum Complex, Oxalato (<i>trans</i>-L-1,2-Diaminocyclohexane)Platinum (II): New Experimental Data</span> <span class="citation_source-journal">Biomed. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">260</span><span class="refDoi"> DOI: 10.1016/0753-3322(89)90004-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2F0753-3322%2889%2990004-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=2790145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL1MXkvV2qsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1989&pages=251-260&author=T.+Tashiroauthor=Y.+Kawadaauthor=Y.+Sakuraiauthor=Y.+Kidani&title=Antitumor+Activity+of+a+New+Platinum+Complex%2C+Oxalato+%28trans-L-1%2C2-Diaminocyclohexane%29Platinum+%28II%29%3A+New+Experimental+Data&doi=10.1016%2F0753-3322%2889%2990004-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum(II):  new experimental data</span></div><div class="casAuthors">Tashiro, T.; Kawada, Y.; Sakurai, Y.; Kidani, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-60</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    </div><div class="casAbstract">The antitumor activity of a new pl complex, oxalato (trans-l-1,2-diaminocyclohexane) platinum(II) (I), was studied.  This water-sol. pt complex had a more prominent life-prolonging effect in mice bearing leukemia L1210 than did cisplatin (DDP).  In addn., a subline of L1210 having a 40-fold resistance to DDP (L1210/DDP) had no cross-resistance to I both in vivo and in vitro.  Esp. in vivo I was more active against L1210/DDP than against the original L1210, and all mice were cured at 6.25 and 3.12 mg/kg.  I was also effective against several mouse tumors such as P38 leukemia, B16 melanoma, Lewis lung carcinoma, colon 26 and colon 38 adenocarcinomas, and M5076 fibrosarcoma, though its antitumor spectrum was somewhat different from that of DDP.  The synthesis of both DNa and RNA in L1210 cells was inhibited by ∼50% with exposure to 10 μM I for 1 h, followed by postincubation in drug-free medium for 6-24 h, while only the inhibition of DNA synthesis was obsd. by DDP in the same expt.  If severe toxicity is nt obsd. in preclin. study, I expected to be a new clin. active Pt complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXWZM8wczamrVg90H21EOLACvtfcHk0lhNyKHvnuGd3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvV2qsbY%253D&md5=3d59bdb675f5fd518f4a1abcf9623bb4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2F0753-3322%2889%2990004-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0753-3322%252889%252990004-8%26sid%3Dliteratum%253Aachs%26aulast%3DTashiro%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DY.%26aulast%3DSakurai%26aufirst%3DY.%26aulast%3DKidani%26aufirst%3DY.%26atitle%3DAntitumor%2520Activity%2520of%2520a%2520New%2520Platinum%2520Complex%252C%2520Oxalato%2520%2528trans-L-1%252C2-Diaminocyclohexane%2529Platinum%2520%2528II%2529%253A%2520New%2520Experimental%2520Data%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D1989%26volume%3D43%26spage%3D251%26epage%3D260%26doi%3D10.1016%2F0753-3322%2889%2990004-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span>National Cancer Institute. Clinical Trials Information for Patients and Caregivers. <a href="http://www.cancer.gov/about-cancer/treatment/clinical-trials" class="extLink">http://www.cancer.gov/about-cancer/treatment/clinical-trials</a> (accessed August 11,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Cancer+Institute.+Clinical+Trials+Information+for+Patients+and+Caregivers.+http%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Ftreatment%2Fclinical-trials+%28accessed+August+11%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Shimada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itamochi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kigawa, J.</span><span> </span><span class="NLM_article-title">Nedaplatin: A Cisplatin Derivative in Cancer Chemotherapy</span> <span class="citation_source-journal">Cancer Manage. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span><span class="refDoi"> DOI: 10.2147/CMAR.S35785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2147%2FCMAR.S35785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=23696716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFCksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=67-76&author=M.+Shimadaauthor=H.+Itamochiauthor=J.+Kigawa&title=Nedaplatin%3A+A+Cisplatin+Derivative+in+Cancer+Chemotherapy&doi=10.2147%2FCMAR.S35785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Nedaplatin: a cisplatin derivative in cancer chemotherapy</span></div><div class="casAuthors">Shimada, Muneaki; Itamochi, Hiroaki; Kigawa, Junzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-76</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Nedaplatin, a cisplatin analog, has been developed to decrease the toxicities induced by cisplatin, such as nephrotoxicity and gastrointestinal toxicity.  The dose of nedaplatin is detd. by body surface area, not by the area under the curve (AUC).  The recommended therapeutic dose is 80-100 mg/m2, although the pharmacokinetic profile of nedaplatin is similar to that of carboplatin.  In our preliminary study, there was a favorable correlation between AUC and creatinine clearance (CL), suggesting that renal function should be considered when nedaplatin is administered.  Ishibashi's formula, i.e., DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance +4.47, would be predictable and useful for estg. the individual dose of nedaplatin.  Several Phase II studies have suggested that nedaplatin might be a useful second analog, esp. for patients with non-small cell lung cancer, esophageal cancer, uterine cervical cancer, head and neck cancer or urothelial cancer.  Further, nedaplatin was reported to be a useful chemotherapeutic agent with radiosensitizing properties; however, there is no Phase III study of nedaplatin, neither with chemotherapy nor with concurrent chemoradiotherapy, because nedaplatin is not commonly used throughout the world.  Further evaluation in a randomized controlled trial is warranted to demonstrate definitively the activity of nedaplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7whQ23DbyirVg90H21EOLACvtfcHk0lhNyKHvnuGd3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFCksr8%253D&md5=fbfa5bc15615267da65b041c30ad60bb</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S35785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S35785%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DM.%26aulast%3DItamochi%26aufirst%3DH.%26aulast%3DKigawa%26aufirst%3DJ.%26atitle%3DNedaplatin%253A%2520A%2520Cisplatin%2520Derivative%2520in%2520Cancer%2520Chemotherapy%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2013%26volume%3D5%26spage%3D67%26epage%3D76%26doi%3D10.2147%2FCMAR.S35785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Totani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aono, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, Y.</span><span> </span><span class="NLM_article-title">Synthesis of (Glycolato-<i>O</i>,<i>O</i>′)Diammineplatinum(II) and Its Related Complexes</span> <span class="citation_source-journal">Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span><span class="refDoi"> DOI: 10.1246/cl.1986.429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1246%2Fcl.1986.429" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1986&pages=429-432&author=T.+Totaniauthor=K.+Aonoauthor=M.+Komuraauthor=Y.+Adachi&title=Synthesis+of+%28Glycolato-O%2CO%E2%80%B2%29Diammineplatinum%28II%29+and+Its+Related+Complexes&doi=10.1246%2Fcl.1986.429"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1246%2Fcl.1986.429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.1986.429%26sid%3Dliteratum%253Aachs%26aulast%3DTotani%26aufirst%3DT.%26aulast%3DAono%26aufirst%3DK.%26aulast%3DKomura%26aufirst%3DM.%26aulast%3DAdachi%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520%2528Glycolato-O%252CO%25E2%2580%25B2%2529Diammineplatinum%2528II%2529%2520and%2520Its%2520Related%2520Complexes%26jtitle%3DChem.%2520Lett.%26date%3D1986%26volume%3D15%26spage%3D429%26epage%3D432%26doi%3D10.1246%2Fcl.1986.429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Shiratori, O.</span><span> </span><span class="NLM_article-title">Anti-Tumor Activity of 254-S, a Platinum Complex, in Rodents</span> <span class="citation_source-journal">Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">636</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL28XmtFynur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1985&pages=635-636&author=O.+Shiratori&title=Anti-Tumor+Activity+of+254-S%2C+a+Platinum+Complex%2C+in+Rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of 254-S, a platinum complex, in rodents</span></div><div class="casAuthors">Shiratori, O.; Kasai, H.; Uchida, N.; Takeda, Y.; Totani, T.; Sato, K.</div><div class="citationInfo"><span class="NLM_cas:title"></span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">Anticancer Sect. 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">635-6</span>CODEN:
                <span class="NLM_cas:coden">55GNAX</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Univ. Tokyo Press</span>)
        </div><div class="casAbstract">(Glycolato-O,O')diammineplatinum (II) (254-S)  [95734-82-0] was tested for antitumor activity in rodents, and the results were compared with those of cisplatin (CDDP).  254-S exhibited high antitumor activity against solid tumors but only a moderate effect on leukemic tumors.  Its antitumor activity was better than that of CDDP.  The nephrotoxicity of 254-S was low when compared with CDDP.  When either drug was given in 5 successive i.v. administrations, the relationships between antitumor activities and toxic properties (gastrointestinal toxicity, nephrotoxicity and myelosuppression) in mice suggested the better selectivity of 254-S than CDDP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNhmZzTtiQtLVg90H21EOLACvtfcHk0lhjQwFHX0aXOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XmtFynur8%253D&md5=6f841bac45ec19050ad59039290c8468</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShiratori%26aufirst%3DO.%26atitle%3DAnti-Tumor%2520Activity%2520of%2520254-S%252C%2520a%2520Platinum%2520Complex%252C%2520in%2520Rodents%26jtitle%3DRecent%2520Adv.%2520Chemother.%252C%2520Proc.%2520Int.%2520Congr.%2520Chemother.%252C%252014th%26date%3D1985%26spage%3D635%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Shukuya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel for Advanced or Relapsed Squamous Cell Carcinoma of the Lung (WJOG5208L): A Randomised, Open-Label, Phase 3 Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1630</span><span class="NLM_x">–</span> <span class="NLM_lpage">1638</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00305-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS1470-2045%2815%2900305-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26522337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslems7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1630-1638&author=T.+Shukuyaauthor=T.+Yamanakaauthor=T.+Setoauthor=H.+Dagaauthor=K.+Gotoauthor=H.+Sakaauthor=S.+Sugawaraauthor=T.+Takahashiauthor=S.+Yokotaauthor=H.+Kanedaauthor=T.+Kawaguchiauthor=S.+Nagaseauthor=T.+Oguriauthor=Y.+Iwamotoauthor=T.+Nishimuraauthor=Y.+Hattoriauthor=K.+Nakagawaauthor=Y.+Nakanishiauthor=N.+Yamamoto&title=Nedaplatin+Plus+Docetaxel+Versus+Cisplatin+Plus+Docetaxel+for+Advanced+or+Relapsed+Squamous+Cell+Carcinoma+of+the+Lung+%28WJOG5208L%29%3A+A+Randomised%2C+Open-Label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2815%2900305-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Shukuya, Takehito; Yamanaka, Takeharu; Seto, Takashi; Daga, Haruko; Goto, Koichi; Saka, Hideo; Sugawara, Shunichi; Takahashi, Toshiaki; Yokota, Soichiro; Kaneda, Hiroyasu; Kawaguchi, Tomoya; Nagase, Seisuke; Oguri, Tetsuya; Iwamoto, Yasuo; Nishimura, Takashi; Hattori, Yoshihiro; Nakagawa, Kazuhiko; Nakanishi, Yoichi; Yamamoto, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1630-1638</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The combination of nedaplatin, a cisplatin deriv., and docetaxel showed promising activity for advanced squamous cell lung carcinoma in a previous phase 1-2 study.  We compared nedaplatin plus docetaxel with cisplatin plus docetaxel in patients with previously untreated advanced or relapsed squamous cell lung carcinoma to det. effects on overall survival.  We did a randomised, open-label, phase 3 study at 53 institutions in Japan.  Eligibility criteria included pathol. proven squamous cell lung cancer with stage IIIB/IV or postoperative recurrence, age 20-74 years, Eastern Cooperative Oncol. Group performance status of 0-1, no previous chemotherapy or recurrence more than a year after previous adjuvant chemotherapy, and adequate organ function.  Patients were randomly assigned (1:1) to 100 mg/m2 nedaplatin and 60 mg/m2 docetaxel i.v., or 80 mg/m2 cisplatin and 60 mg/m2 docetaxel, every 3 wk for four to six cycles (at the treating oncologist's discretion).  Randomisation was done centrally at the West Japan Oncol. Group data center via a computer-generated allocation sequence with dynamic minimisation that balanced stage (IIIB/IV or postoperative recurrent), sex, and institution.  The primary endpoint was overall survival in the modified intention-to-treat population (ie, all patients who were randomly assigned and met the inclusion criteria).  Safety analyses were done in all randomly assigned patients who received at least one dose of the study regimen.  This trial is registered with the UMIN Clin. Trials Registry, no. UMIN000002015, and is closed to new participants.  Between July 6, 2009, and July 26, 2012, 355 patients were randomly assigned. 349 patients were included in the modified intention-to-treat anal. (177 in the nedaplatin group and 172 in the cisplatin group).  Overall survival was significantly longer in the nedaplatin group (median 13·6 mo, 95% CI 11·6-15·6) than in the cisplatin group (11·4 mo,10·2-12·2; hazard ratio 0·81, 95% CI 0·65-1·02; p=0·037, one-sided stratified log-rank test).  Grade 3 or worse nausea (seven of 177 patients in the nedaplatin group and 25 of 175 in the cisplatin group), fatigue (six vs 20), hyponatremia (24 vs 53), and hypokalemia (four vs 15) were more frequent in the cisplatin group than in the nedaplatin group, whereas grade 3 or worse leucopenia (98 vs 77), neutropenia (146 vs 123), and thrombocytopenia (16 vs none) were more frequent in the nedaplatin group than in the cisplatin group.  Treatment-related deaths occurred in four and three patients in nedaplatin and cisplatin groups, resp.  Overall survival was significantly longer with nedaplatin plus docetaxel than with cisplatin plus docetaxel, and the regimens had different safety profiles.  Nedaplatin plus docetaxel could be a new treatment option for advanced or relapsed squamous cell lung cancer.  West Japan Oncol. Group and Sanofi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRMD5nXRBk7Vg90H21EOLACvtfcHk0lhjQwFHX0aXOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslems7zN&md5=8b8768e16f3d6a3ea9f1d4158c7f0042</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900305-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900305-8%26sid%3Dliteratum%253Aachs%26aulast%3DShukuya%26aufirst%3DT.%26aulast%3DYamanaka%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DDaga%26aufirst%3DH.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DSaka%26aufirst%3DH.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DYokota%26aufirst%3DS.%26aulast%3DKaneda%26aufirst%3DH.%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DS.%26aulast%3DOguri%26aufirst%3DT.%26aulast%3DIwamoto%26aufirst%3DY.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DHattori%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DNedaplatin%2520Plus%2520Docetaxel%2520Versus%2520Cisplatin%2520Plus%2520Docetaxel%2520for%2520Advanced%2520or%2520Relapsed%2520Squamous%2520Cell%2520Carcinoma%2520of%2520the%2520Lung%2520%2528WJOG5208L%2529%253A%2520A%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1630%26epage%3D1638%26doi%3D10.1016%2FS1470-2045%2815%2900305-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J.</span><span> </span><span class="NLM_article-title">Nedaplatin: A New Platinum for Squamous Lung Cancer?</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1573</span><span class="NLM_x">–</span> <span class="NLM_lpage">1574</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00400-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS1470-2045%2815%2900400-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26522336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC28znsVCitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1573-1574&author=Y.+Wuauthor=J.+Spicer&title=Nedaplatin%3A+A+New+Platinum+for+Squamous+Lung+Cancer%3F&doi=10.1016%2FS1470-2045%2815%2900400-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Nedaplatin: a new platinum for squamous lung cancer?</span></div><div class="casAuthors">Wu Yin; Spicer James</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1573-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfGmAznCJDLO98rul4nhSdfW6udTcc2ebiTl3WET74wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28znsVCitg%253D%253D&md5=6907a8f513478594cb47f650e860270f</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900400-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900400-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DSpicer%26aufirst%3DJ.%26atitle%3DNedaplatin%253A%2520A%2520New%2520Platinum%2520for%2520Squamous%2520Lung%2520Cancer%253F%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1573%26epage%3D1574%26doi%3D10.1016%2FS1470-2045%2815%2900400-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Kim, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. S.</span><span> </span><span class="NLM_article-title">General Pharmacology of <i>cis</i>-Malonato[4R,5R)-4,5-<i>bis</i>-(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II)</span> <span class="citation_source-journal">Drug Res. (Stuttgart, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1080</span><span class="NLM_x">–</span> <span class="NLM_lpage">1088</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=7986249" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1994&pages=1080-1088&author=D.+K.+Kimauthor=J.+S.+Ahnauthor=G.+Ryuauthor=K.+H.+Kimauthor=C.+W.+Parkauthor=M.+S.+Kimauthor=M.+H.+Chungauthor=S.+G.+Shinauthor=Y.+H.+Suhauthor=Y.+S.+Kim&title=General+Pharmacology+of+cis-Malonato%5B4R%2C5R%29-4%2C5-bis-%28aminomethyl%29-2-isopropyl-1%2C3-dioxolane%5Dplatinum%28II%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DRyu%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DPark%26aufirst%3DC.%2BW.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DChung%26aufirst%3DM.%2BH.%26aulast%3DShin%26aufirst%3DS.%2BG.%26aulast%3DSuh%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DY.%2BS.%26atitle%3DGeneral%2520Pharmacology%2520of%2520cis-Malonato%255B4R%252C5R%2529-4%252C5-bis-%2528aminomethyl%2529-2-isopropyl-1%252C3-dioxolane%255Dplatinum%2528II%2529%26jtitle%3DDrug%2520Res.%2520%2528Stuttgart%252C%2520Ger.%2529%26date%3D1994%26volume%3D44%26spage%3D1080%26epage%3D1088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Kim, D.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.-G.</span><span> </span><span class="NLM_article-title">Synthesis and Antitumor Activity of a Series of [2-Substituted-4,5-<i>bis</i>(Aminomethyl)-1,3-Dioxolane]Platinum(II) Complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1471</span><span class="NLM_x">–</span> <span class="NLM_lpage">1485</span><span class="refDoi"> DOI: 10.1021/jm00036a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00036a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1471-1485&author=D.-K.+Kimauthor=G.+Kimauthor=J.+Gamauthor=Y.-B.+Choauthor=H.-T.+Kimauthor=J.-H.+Taiauthor=K.+H.+Kimauthor=W.-S.+Hongauthor=J.-G.+Park&title=Synthesis+and+Antitumor+Activity+of+a+Series+of+%5B2-Substituted-4%2C5-bis%28Aminomethyl%29-1%2C3-Dioxolane%5DPlatinum%28II%29+Complexes&doi=10.1021%2Fjm00036a013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm00036a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00036a013%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.-K.%26aulast%3DKim%26aufirst%3DG.%26aulast%3DGam%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DY.-B.%26aulast%3DKim%26aufirst%3DH.-T.%26aulast%3DTai%26aufirst%3DJ.-H.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DJ.-G.%26atitle%3DSynthesis%2520and%2520Antitumor%2520Activity%2520of%2520a%2520Series%2520of%2520%255B2-Substituted-4%252C5-bis%2528Aminomethyl%2529-1%252C3-Dioxolane%255DPlatinum%2528II%2529%2520Complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1471%26epage%3D1485%26doi%3D10.1021%2Fjm00036a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Kim, D.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span> </span><span class="NLM_article-title">Antitumor Activity of <i>cis</i>-Malonato[(4R,5R)-4,5-<i>bis</i>(Aminomethy1)-2-Isopropyl-1,3-Dioxolanelplatinum(II), a New Platinum Analogue, as an Anticancer Agent</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span><span class="refDoi"> DOI: 10.1007/s002800050260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2Fs002800050260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=7850928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaK2MXkslGitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1995&pages=441-445&author=D.-K.+Kimauthor=H.-T.+Kimauthor=Y.-B.+Choauthor=J.+H.+Taiauthor=J.+S.+Ahnauthor=T.-S.+Kimauthor=K.+H.+Kimauthor=W.-S.+Hong&title=Antitumor+Activity+of+cis-Malonato%5B%284R%2C5R%29-4%2C5-bis%28Aminomethy1%29-2-Isopropyl-1%2C3-Dioxolanelplatinum%28II%29%2C+a+New+Platinum+Analogue%2C+as+an+Anticancer+Agent&doi=10.1007%2Fs002800050260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analog, as an anticancer agent</span></div><div class="casAuthors">Kim, Dae-Kee; Kim, Hun-Taek; Cho, Yong-Baik; Tai, Joo Ho; Ahn, Jae Suk; Kim, Taek-Soo; Kim, Key H.; Hong, Weon-Seon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-5</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">The in vitro and in vivo antitumor activity of a new antitumor platinum complex, cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) (SKI 2053R, NSC D644591), were evaluated and compared with those of cisplatin (CDDP) and carboplatin (CBDCA) using murine tumors.  SKI 2053R was highly active in vitro against both L1210 murine leukemia and its CDDP-resistant subline, L1210/DDP; the relative resistances were 20.0-, 14.5-, and 2.7-fold for CDDP, CBDCA, and SKI 2053R, resp.  SKI 2053R showed activity comparable with or superior to either CDDP or CBDCA in mice implanted with L1210.  In mice implanted with L1210/DDP, as compared with CBDCA, SKI 2053R showed high values for the percentage of treated survivors relative to controls and for nos. of cured mice, whereas CDDP had virtually no activity.  In mice implanted with P388, all three drugs were highly active, but the intensity of activity was shown to be ranked in the following order: SKI 2053R > CDDP > CBDCA.  The antitumor activity of SKI 2053R against Lewis lung carcinoma was comparable with that of both CDDP and CBDCA.  The antitumor activity of SKI 2053R was further investigated against two human tumor xenografts, KATO III (stomach adenocarcinoma) and WiDr (colon adenocarcinoma), implanted s.c. in nude mice and was compared with that of CDDP.  In SKI 2053R-treated groups, the time required for a mean tumor wt. of 1,000 mg was 33.1 days in KATO III xenografts and 35.0 days in WiDr xenografts as compared with 30.2 and 27.2 days in CDDP-treated groups, resp.  SKI 2053R achieved growth-inhibition rates comparable with those of CDDP against KATO III (65% vs. 59%) and WiDr xenografts (64% vs. 54%) on day 35.  These results indicate that SKI 2053R is an attractive candidate for further development as a clin. useful anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr67-hkqW73drVg90H21EOLACvtfcHk0lgnD6hsqbG1qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkslGitbg%253D&md5=728ebb114ad68695442c1de41ce67902</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1007%2Fs002800050260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800050260%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.-K.%26aulast%3DKim%26aufirst%3DH.-T.%26aulast%3DCho%26aufirst%3DY.-B.%26aulast%3DTai%26aufirst%3DJ.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DT.-S.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DW.-S.%26atitle%3DAntitumor%2520Activity%2520of%2520cis-Malonato%255B%25284R%252C5R%2529-4%252C5-bis%2528Aminomethy1%2529-2-Isopropyl-1%252C3-Dioxolanelplatinum%2528II%2529%252C%2520a%2520New%2520Platinum%2520Analogue%252C%2520as%2520an%2520Anticancer%2520Agent%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1995%26volume%3D35%26spage%3D441%26epage%3D445%26doi%3D10.1007%2Fs002800050260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Min, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H. R.</span><span> </span><span class="NLM_article-title">Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-Line Treatment in Patients with Advanced Gastric Cancer</span> <span class="citation_source-journal">J. Korean Med. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span><span class="refDoi"> DOI: 10.3346/jkms.2004.19.3.369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.3346%2Fjkms.2004.19.3.369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=15201502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Crsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=369-373&author=Y.+J.+Minauthor=S.-J.+Bangauthor=J.+W.+Shinauthor=D.+H.+Kimauthor=J.+H.+Parkauthor=G.+Y.+Kimauthor=B.+K.+Koauthor=D.+H.+Choiauthor=H.+R.+Cho&title=Combination+Chemotherapy+with+5-Fluorouracil+and+Heptaplatin+as+First-Line+Treatment+in+Patients+with+Advanced+Gastric+Cancer&doi=10.3346%2Fjkms.2004.19.3.369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer</span></div><div class="casAuthors">Min, Young Joo; Bang, Sung-Jo; Shin, Jung Woo; Kim, Do Ha; Park, Jae Hoo; Kim, Gyu Yeol; Ko, Byung Kyun; Choi, Dae Hwa; Cho, Hong Rae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Korean Medical Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">369-373</span>CODEN:
                <span class="NLM_cas:coden">JKMSEH</span>;
        ISSN:<span class="NLM_cas:issn">1011-8934</span>.
    
            (<span class="NLM_cas:orgname">Korean Academy of Medical Science</span>)
        </div><div class="casAbstract">Heptaplatin is a recently developed platinum deriv.  This agent has been reported to give a response rate of 17% as a single agent, and tolerable toxicity, in the treatment of advanced gastric cancer.  This study evaluated the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer.  Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited.  5-FU was administered over 120 h by continuous i.v. infusion from day 1 to 5, at a daily dose of 1000 mg/m2 and heptaplatin was administered over 1 h by i.v. infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 wk.  The response rate was 21%; median progression-free survival was 1.9 mo.  Median overall survival was 6.2 mo and the 1-yr survival rate was 29% for all patients.  The most frequent toxicity was proteinuria.  Toxicities were generally mild and reversible.  This study demonstrates that the 5-FU/heptaplatin combination is less active but tolerated in patients with advanced gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgvRLqD41Q77Vg90H21EOLACvtfcHk0lgnD6hsqbG1qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Crsrs%253D&md5=97279e40a4b743b58f465088074d6c22</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3346%2Fjkms.2004.19.3.369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3346%252Fjkms.2004.19.3.369%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DY.%2BJ.%26aulast%3DBang%26aufirst%3DS.-J.%26aulast%3DShin%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DG.%2BY.%26aulast%3DKo%26aufirst%3DB.%2BK.%26aulast%3DChoi%26aufirst%3DD.%2BH.%26aulast%3DCho%26aufirst%3DH.%2BR.%26atitle%3DCombination%2520Chemotherapy%2520with%25205-Fluorouracil%2520and%2520Heptaplatin%2520as%2520First-Line%2520Treatment%2520in%2520Patients%2520with%2520Advanced%2520Gastric%2520Cancer%26jtitle%3DJ.%2520Korean%2520Med.%2520Sci.%26date%3D2004%26volume%3D19%26spage%3D369%26epage%3D373%26doi%3D10.3346%2Fjkms.2004.19.3.369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Mckeage, M. J.</span><span> </span><span class="NLM_article-title">Lobaplatin: A New Antitumour Platinum Drug</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span><span class="refDoi"> DOI: 10.1517/13543784.10.1.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1517%2F13543784.10.1.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11116285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpvFel" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2001&pages=119-128&author=M.+J.+Mckeage&title=Lobaplatin%3A+A+New+Antitumour+Platinum+Drug&doi=10.1517%2F13543784.10.1.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Lobaplatin: a new antitumour platinum drug</span></div><div class="casAuthors">McKeage, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-128</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review with 39 refs.  Lobaplatin (D-19466) is a diastereometric mixt. of platinum(II) complexes contg. a 1,2-bis(aminomethyl)cyclobutane stable ligand and lactic acid as the leaving group.  Its antitumor activity results from the formation of DNA-drug adducts, mainly as GG and AG intra-strand cross-links.  Lobaplatin influences the expression of the c-myc gene, which is involved in oncogenesis, apoptosis and cell proliferation.  Lobaplatin has activity in a wide range of preclin. tumor models and appears to overcome tumor resistance to cisplatin and carboplatin in some of these models.  In the body, lobaplatin remains largely intact until removed by glomerular filtration.  Exposure of the body to lobaplatin (AUC) correlates with dose, creatinine clearance and the degree of thrombocytopenia.  Phase I clin. trials of three quite different administration schedules found the same dose-limiting toxicity (thrombocytopenia) and similar max. tolerated doses (60 mg/m2 per 3 - 4 wk).  In Phase II trials, lobaplatin showed activity in patients with a variety of tumor types.  Many of the patients who responded to lobaplatin may also have responded to cisplatin and carboplatin because they had had no prior chemotherapy or had a prolonged remission after earlier treatment.  In conclusion, lobaplatin is a new platinum drug, which overcomes some forms of cisplatin resistance in preclin. tumor models.  Several potential clin. applications remain unexplored, such as its use in relapsed testicular cancer and in combination with other cancer chemotherapeutic agents and ionizing radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzV7y3v0DRdrVg90H21EOLACvtfcHk0lh8U9jA5K1OWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpvFel&md5=2c5090c19117c004efc82a04ad3c90a2</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1517%2F13543784.10.1.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.10.1.119%26sid%3Dliteratum%253Aachs%26aulast%3DMckeage%26aufirst%3DM.%2BJ.%26atitle%3DLobaplatin%253A%2520A%2520New%2520Antitumour%2520Platinum%2520Drug%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2001%26volume%3D10%26spage%3D119%26epage%3D128%26doi%3D10.1517%2F13543784.10.1.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Schumacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Respondek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">J, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitzel-Zerrahn, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voegeli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgard, P.</span><span> </span><span class="NLM_article-title">Synthesis and Pharmacological Activity of Cyclobutane-Platinum (II) Complexes</span> <span class="citation_source-journal">Eur. Food Res. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1989&pages=163&author=W.+Schumacherauthor=J.+Respondekauthor=E.+Jauthor=F.+Hitzel-Zerrahnauthor=R.+Voegeliauthor=J.+Pohlauthor=P.+Hilgard&title=Synthesis+and+Pharmacological+Activity+of+Cyclobutane-Platinum+%28II%29+Complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DW.%26aulast%3DRespondek%26aufirst%3DJ.%26aulast%3DJ%26aufirst%3DE.%26aulast%3DHitzel-Zerrahn%26aufirst%3DF.%26aulast%3DVoegeli%26aufirst%3DR.%26aulast%3DPohl%26aufirst%3DJ.%26aulast%3DHilgard%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Activity%2520of%2520Cyclobutane-Platinum%2520%2528II%2529%2520Complexes%26jtitle%3DEur.%2520Food%2520Res.%2520Technol.%26date%3D1989%26volume%3D22%26spage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Voegeli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Respondek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgard, P.</span><span> </span><span class="NLM_article-title">D-19466, a New Cyclobutane-Platinum Complex with Antitumor Activity</span> <span class="citation_source-journal">J. Cancer Res. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">442</span><span class="refDoi"> DOI: 10.1007/BF01612990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF01612990" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1990&pages=439-442&author=R.+Voegeliauthor=W.+Schumacherauthor=J.+Engelauthor=J.+Respondekauthor=P.+Hilgard&title=D-19466%2C+a+New+Cyclobutane-Platinum+Complex+with+Antitumor+Activity&doi=10.1007%2FBF01612990"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2FBF01612990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01612990%26sid%3Dliteratum%253Aachs%26aulast%3DVoegeli%26aufirst%3DR.%26aulast%3DSchumacher%26aufirst%3DW.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRespondek%26aufirst%3DJ.%26aulast%3DHilgard%26aufirst%3DP.%26atitle%3DD-19466%252C%2520a%2520New%2520Cyclobutane-Platinum%2520Complex%2520with%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D1990%26volume%3D116%26spage%3D439%26epage%3D442%26doi%3D10.1007%2FBF01612990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><div class="note"><p class="first last">Adis R&D Profile.</p></div><span> </span><span class="NLM_article-title">Lobaplatin: D 19466</span>.  <span class="citation_source-journal">Drugs R&amp;D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span>.<span class="refDoi"> DOI: 10.2165/00126839-200304060-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2165%2F00126839-200304060-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=14584968" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Adis+R%26D+Profile.+Lobaplatin%3A+D+19466.+Drugs+R%26amp%3BD+2003%2C+4%2C+369%E2%80%93372.+10.2165%2F00126839-200304060-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2165%2F00126839-200304060-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00126839-200304060-00008%26sid%3Dliteratum%253Aachs%26atitle%3DLobaplatin%253A%2520D%252019466%26jtitle%3DDrugs%2520R%2526amp%253BD%26date%3D2003%26volume%3D4%26spage%3D369%26epage%3D372%26doi%3D10.2165%2F00126839-200304060-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Chen, M. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, B. H.</span><span> </span><span class="NLM_article-title">The Efficacy and Toxicities of Combined Lobaplatin with Paclitaxel as a First-Line Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma</span> <span class="citation_source-journal">J. Thorac. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1749</span><span class="NLM_x">–</span> <span class="NLM_lpage">1755</span><span class="refDoi"> DOI: 10.3978/j.issn.2072-1439.2015.10.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.3978%2Fj.issn.2072-1439.2015.10.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26623097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC28rgsl2ltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=1749-1755&author=M.+Q.+Chenauthor=C.+Chenauthor=H.+J.+Luauthor=B.+H.+Xu&title=The+Efficacy+and+Toxicities+of+Combined+Lobaplatin+with+Paclitaxel+as+a+First-Line+Chemotherapy+for+Advanced+Esophageal+Squamous+Cell+Carcinoma&doi=10.3978%2Fj.issn.2072-1439.2015.10.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma</span></div><div class="casAuthors">Chen Ming-Qiu; Chen Cheng; Lu Hai-Jie; Xu Ben-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1749-55</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">BACKGROUND:  To assess the efficacy and toxicities of combined lobaplatin with paclitaxel (LP) as a first line chemotherapy in esophageal cancer.  METHODS:  The clinical data of 45 patients with esophageal squamous cell carcinoma treated initially with lobaplatin-paclitaxel chemotherapy were collected and reviewed retrospectively.  The overall response, treatment toxicities and dysphagia relief were analyzed with SPSS software.  RESULTS:  The overall response rate was 42.2%, with 1 patient (2.2%) showing complete remission, 18 patients (40.0%) with partial remission, 19 (42.2%) with stable disease (SD), and 7 (15.6%) with progressive disease, respectively.  The most common hematological toxicity was leucopenia with grade 0, I, II, III and IV in 16 (35.6%), 10 (22.2%), 11 (24.4%), 7 (15.6%), and 1 patient (2.2%), respectively.  Thirty-seven patients (82.2%) experienced grade I-II nausea/vomiting without grade III-IV instances occurring.  Four patients (8.9%) experienced grade I hepatotoxicity.  No nephrotoxicity was observed.  Five in thirteen patients treated with concurrent chemoradiotherapy (CRT) suffered severe radiation pneumonitis.  The dysphagia resolved or improved in 32 patients (71%).  CONCLUSIONS:  Lobaplatin-paclitaxel showed a significant antitumor effect to squamous esophageal cancer with manageable toxicities.  Limitation of the surveillance time and the retrospective nature, the effect that based on these data formal prospective trials appear warranted and are needed prior to routine first line use of this regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhohMhvcF2mEBuFdjgVNKSfW6udTcc2eYPX-D0gZMKeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgsl2ltg%253D%253D&md5=ae3922ee56135bd4c61ce4b0283cd8f1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2072-1439.2015.10.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2072-1439.2015.10.23%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%2BQ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%2BJ.%26aulast%3DXu%26aufirst%3DB.%2BH.%26atitle%3DThe%2520Efficacy%2520and%2520Toxicities%2520of%2520Combined%2520Lobaplatin%2520with%2520Paclitaxel%2520as%2520a%2520First-Line%2520Chemotherapy%2520for%2520Advanced%2520Esophageal%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2015%26volume%3D7%26spage%3D1749%26epage%3D1755%26doi%3D10.3978%2Fj.issn.2072-1439.2015.10.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Tanaka, K.; Kunimatsu, T.; Shimakura, J.; Hanada, M.</span><span> </span><span class="NLM_article-title">Development of Miriplatin, a Novel Antitumor Platinum for Hepatocellular Carcinoma</span>.  <span class="citation_source-journal">Sumitomo Kagaku R&D Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">I1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=I1-12&author=K.+Tanaka&author=T.+Kunimatsu&author=J.+Shimakura&author=M.+Hanada&title=Development+of+Miriplatin%2C+a+Novel+Antitumor+Platinum+for+Hepatocellular+Carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520Miriplatin%252C%2520a%2520Novel%2520Antitumor%2520Platinum%2520for%2520Hepatocellular%2520Carcinoma%26jtitle%3DSumitomo%2520Kagaku%2520R%2526D%2520Rep.%26date%3D2011%26spage%3DI1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Horikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaji, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, Y.</span><span> </span><span class="NLM_article-title">Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review</span> <span class="citation_source-journal">AJR, Am. J. Roentgenol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">205</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">773</span><span class="refDoi"> DOI: 10.2214/AJR.15.14825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2214%2FAJR.15.14825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26397324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC283ltFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2015&pages=764-773&author=M.+Horikawaauthor=S.+Miyayamaauthor=T.+Irieauthor=T.+Kajiauthor=Y.+Arai&title=Development+of+Conventional+Transarterial+Chemoembolization+for+Hepatocellular+Carcinomas+in+Japan%3A+Historical%2C+Strategic%2C+and+Technical+Review&doi=10.2214%2FAJR.15.14825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review</span></div><div class="casAuthors">Horikawa Masahiro; Miyayama Shiro; Irie Toshiyuki; Kaji Tatsumi; Arai Yasuaki</div><div class="citationInfo"><span class="NLM_cas:title">AJR. American journal of roentgenology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">764-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This article reviews the development of transarterial chemoembolization (TACE) in Japan, particularly ethiodized oil-based conventional TACE, from historical, strategic, and technical points of view.  We also present the current status of standardized conventional TACE.  CONCLUSION:  Conventional TACE has been developed toward a more-selective and hemodynamic-conscious method, along with technical innovation and knowledge accumulation.  Standardization of this method is necessary for further scientific evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQyjP-EcgsE8ny-c-E1v-fmfW6udTcc2eYSyaKa_RX0ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ltFyntg%253D%253D&md5=a4ce91986596a8c7fca97385491852a0</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2214%2FAJR.15.14825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2214%252FAJR.15.14825%26sid%3Dliteratum%253Aachs%26aulast%3DHorikawa%26aufirst%3DM.%26aulast%3DMiyayama%26aufirst%3DS.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DKaji%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520Conventional%2520Transarterial%2520Chemoembolization%2520for%2520Hepatocellular%2520Carcinomas%2520in%2520Japan%253A%2520Historical%252C%2520Strategic%252C%2520and%2520Technical%2520Review%26jtitle%3DAJR%252C%2520Am.%2520J.%2520Roentgenol.%26date%3D2015%26volume%3D205%26spage%3D764%26epage%3D773%26doi%3D10.2214%2FAJR.15.14825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Nishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osaki, Y.</span><span> </span><span class="NLM_article-title">Transcatheter Arterial Embolic Therapies for Hepatocellular Carcinoma: A Literature Review</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">6877</span><span class="NLM_x">–</span> <span class="NLM_lpage">6886</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25503113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=6877-6886&author=H.+Nishikawaauthor=R.+Kitaauthor=T.+Kimuraauthor=Y.+Osaki&title=Transcatheter+Arterial+Embolic+Therapies+for+Hepatocellular+Carcinoma%3A+A+Literature+Review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review</span></div><div class="casAuthors">Nishikawa, Hiroki; Kita, Ryuichi; Kimura, Toru; Osaki, Yukio</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6877-6886</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Palliative therapies for hepatocellular carcinoma (HCC) include transcatheter arterial embolic therapies, radiation therapy and systemic chemotherapies such as sorafenib.  Conventional transcatheter arterial chemoembolization (cTACE) is the golden std. for the treatment of intermediate-stage HCC, and involves the administration of chemotherapuetic drugs, with or without lipiodol, by means of a catheter directly to the feeding artery of the targeted tumor followed by administration of embolic agents, while the concept of drug-eluting bead TACE (DEB-TACE) builds on the rationale for cTACE.  DEB-TACE has been demonstrated to substantially improve the pharmacokinetic profile of TACE, providing levels of consistency and repeatability in patients that are not available with cTACE.  On the other hand, the technique of radioembolization therapy for HCC involves the delivery of high-dose radiation via the hepatic artery.  In the present review, we summarize the current status of these transcatheter arterial embolic therapies in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLlmlisB-Fv7Vg90H21EOLACvtfcHk0liNsmxe3KaCHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCjs70%253D&md5=d0b9d6b217c9cea791530ba0df3e24c8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNishikawa%26aufirst%3DH.%26aulast%3DKita%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DOsaki%26aufirst%3DY.%26atitle%3DTranscatheter%2520Arterial%2520Embolic%2520Therapies%2520for%2520Hepatocellular%2520Carcinoma%253A%2520A%2520Literature%2520Review%26jtitle%3DAnticancer%2520Res.%26date%3D2014%26volume%3D34%26spage%3D6877%26epage%3D6886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Maeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span> </span><span class="NLM_article-title">Liposoluble Platinum (II) Complexes with Antitumor Activity</span> <span class="citation_source-journal">Jpn. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">525</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=3015851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADyaL28Xlt1KrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1986&pages=523-525&author=M.+Maedaauthor=N.+A.+Uchidaauthor=T.+Sasaki&title=Liposoluble+Platinum+%28II%29+Complexes+with+Antitumor+Activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Liposoluble platinum(II) complexes with antitumor activity</span></div><div class="casAuthors">Maeda, Mitsuaki; Uchida, Noriko A.; Sasaki, Takuma</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">523-5</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    </div><div class="casAbstract">Lipid-sol. bis(carboxylato)-cyclohexane-1,2-diammineplatinum(II) and bis(carboxylato)-cis-diammineplatinum(II) complexes were synthesized and tested for antitumor activity against leukemia L1210 cells in mice.  The former complexes had excellent antitumor activity without any toxicity to the host at the therapeutic dose when used with lipiodol as a carrier solvent.  The latter complexes had neither antitumor activity nor toxicity in vivo.  The former complexes were gradually released from lipiodol to saline in vitro; the latter were not.  The activity depended on the chain length of the carboxylato residue and also on the mol. shape of the ligand part of the complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6FW8vhmU3l7Vg90H21EOLACvtfcHk0liNsmxe3KaCHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xlt1KrsL8%253D&md5=975e93841fd751ddbd565379991c9efd</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DM.%26aulast%3DUchida%26aufirst%3DN.%2BA.%26aulast%3DSasaki%26aufirst%3DT.%26atitle%3DLiposoluble%2520Platinum%2520%2528II%2529%2520Complexes%2520with%2520Antitumor%2520Activity%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D1986%26volume%3D77%26spage%3D523%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Monneret, C.</span><span> </span><span class="NLM_article-title">Platinum Anticancer Drugs. From Serendipity to Rational Design</span> <span class="citation_source-journal">Ann. Pharm. Fr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/j.pharma.2011.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.pharma.2011.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=22115131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFertb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2011&pages=286-295&author=C.+Monneret&title=Platinum+Anticancer+Drugs.+From+Serendipity+to+Rational+Design&doi=10.1016%2Fj.pharma.2011.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum anticancer drugs. From serendipity to rational design</span></div><div class="casAuthors">Monneret, C.</div><div class="citationInfo"><span class="NLM_cas:title">Annales Pharmaceutiques Francaises</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">286-295</span>CODEN:
                <span class="NLM_cas:coden">APFRAD</span>;
        ISSN:<span class="NLM_cas:issn">0003-4509</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The discovery of cis-platin was serendipitous.  In 1965, Rosenberg was looking into the effects of an elec. field on the growth of Escherichia coli bacteria.  He noticed that bacteria ceased to divide when placed in an elec. field but what Rosenberg also obsd. was a 300-fold increase in the size of the bacteria.  He attributed this to the fact that somehow the platinum-conducting plates were inducing cell growth but inhibiting cell division.  It was later deduced that the platinum species responsible for this was cis-platin.  Rosenberg hypothesized that if cis-platin could inhibit bacterial cell division it could also stop tumor cell growth.  This conjecture has proven correct and has led to the introduction of cis-platin in cancer therapy.  Indeed, in 1978, six years after clin. trials conducted by the NCI and Bristol-Myers-Squibb, the U.S.  Food and Drug Administration (FDA) approved cis-platin under the name of Platinol for treating patients with metastatic testicular or ovarian cancer in combination with other drugs but also for treating bladder cancer.  Bristol-Myers Squibb also licensed carboplatin, a second-generation platinum drug with fewer side effects, in 1979.  Carboplatin entered the U.S. market as Paraplatin in 1989 for initial treatment of advanced ovarian cancer in established combination with other approved chemotherapeutic agents.  Numerous platin derivs. have been further developed with more or less success and the third deriv. to be approved in 1994 was oxaliplatin under the name of Eloxatin.  It was the first platin-based drug to be active against metastatic colorectal cancer in combination with fluorouracil and folinic acid.  The two others platin-based drugs to be approved were nedaplatin (Aqupla) in Japan and lobaplatin in China, resp.  More recently, a strategy to overcome resistance due to interaction with thiol-contg. mols. led to the synthesis of picoplatin in which one of the amines linked to Pt was replaced by a bulky Me substituted pyridine allowing the drug more time to reach its target, DNA.  On the other hand, efforts which were made to find new orally administered analog led to satraplatin bearing to axial acetate groups.  Both drugs are still under clin. trials.  An alternatively route to the discovery of new derivs. turns to the development of improved delivery strategies such as liposomes and polymers.  Liposomal cis-platin or lipoplatin in under a phase III randomized clin. trial for patients suffering from small cell lung cancer whereas polymer-based drug, Prolindac is currently under investigation for pretreated ovarian cancers in up to eight European centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRuS3noNGs2LVg90H21EOLACvtfcHk0lh16GM07f-KHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFertb%252FI&md5=510a97a52d39a9a82d176b5acf6b9d6b</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.pharma.2011.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharma.2011.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DMonneret%26aufirst%3DC.%26atitle%3DPlatinum%2520Anticancer%2520Drugs.%2520From%2520Serendipity%2520to%2520Rational%2520Design%26jtitle%3DAnn.%2520Pharm.%2520Fr.%26date%3D2011%26volume%3D69%26spage%3D286%26epage%3D295%26doi%3D10.1016%2Fj.pharma.2011.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Lee, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuh, H. J.</span><span> </span><span class="NLM_article-title">Anti-Tumor Activity of Heptaplatin in Combination with 5-Fluorouracil or Paclitaxel against Human Head and Neck Cancer Cells in Vitro</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span><span class="refDoi"> DOI: 10.1097/01.cad.0000205033.08838.c7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1097%2F01.cad.0000205033.08838.c7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=377-384&author=J.+W.+Leeauthor=J.+K.+Parkauthor=S.+H.+Leeauthor=S.+Y.+Kimauthor=Y.+B.+Choauthor=H.+J.+Kuh&title=Anti-Tumor+Activity+of+Heptaplatin+in+Combination+with+5-Fluorouracil+or+Paclitaxel+against+Human+Head+and+Neck+Cancer+Cells+in+Vitro&doi=10.1097%2F01.cad.0000205033.08838.c7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1097%2F01.cad.0000205033.08838.c7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cad.0000205033.08838.c7%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DCho%26aufirst%3DY.%2BB.%26aulast%3DKuh%26aufirst%3DH.%2BJ.%26atitle%3DAnti-Tumor%2520Activity%2520of%2520Heptaplatin%2520in%2520Combination%2520with%25205-Fluorouracil%2520or%2520Paclitaxel%2520against%2520Human%2520Head%2520and%2520Neck%2520Cancer%2520Cells%2520in%2520Vitro%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2006%26volume%3D17%26spage%3D377%26epage%3D384%26doi%3D10.1097%2F01.cad.0000205033.08838.c7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Garattini, S.</span><span> </span><span class="NLM_article-title">Are Me-Too Drugs Justified?</span> <span class="citation_source-journal">J. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=9442441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK1c7gsVGhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1997&pages=283-294&author=S.+Garattini&title=Are+Me-Too+Drugs+Justified%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Are me-too drugs justified?</span></div><div class="casAuthors">Garattini S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nephrology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">283-94</span>
        ISSN:<span class="NLM_cas:issn">1121-8428</span>.
    </div><div class="casAbstract">The successful progress of pharmacology in the treatment of several diseases has led to the development of a powerful pharmaceutical industry with an estimated market of over $250 billion.  It is therefore understandable that as drug development and marketing has become a major business it has adopted the rules common to other commercial fields.  This is a potentially dangerous trend because it undermines what should be the main goal of drug development, i.e. to make active medicinal agents available to the patient with precise and reliable information, at the lowest possible cost, particularly when a national health system has to supply the drugs to patients who have too low an income to pay for them.  The huge drug market has also set in motion a competition among pharmaceutical firms.  This has meant that as soon as a prototype drug becomes available several other similarly active compounds immediately follow.  These followers are usually called "me-too drugs".  Me-too drugs can be broadly defined as chemically related to the prototype, or other chemical compounds which have an identical mechanism of action.  This increasing marketing of me-too drugs has been questioned, so pharmaceutical firms are justifying the development of not-so-innovative drugs.  The most common arguments can be summarized as follows: me-too drugs offer an improvement on the efficacy of the prototype; they show a different profile of adverse effects; they are effective in patients resistant to the prototype; they improve compliance in long-term treatment; they are less expensive than the prototype.  It is the purpose of this paper to review the evidence substantiating these statements, giving some figures regarding me-too drugs and presenting a few examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9ikU0p6ekImLFM_lbR1VmfW6udTcc2ebHC5YW_Ea3w7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7gsVGhsQ%253D%253D&md5=f52c1878d906d6c798931083a5cb8a07</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarattini%26aufirst%3DS.%26atitle%3DAre%2520Me-Too%2520Drugs%2520Justified%253F%26jtitle%3DJ.%2520Nephrol.%26date%3D1997%26volume%3D10%26spage%3D283%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Kennedy, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzharris, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colls, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, C. H.</span><span> </span><span class="NLM_article-title">Carboplatin Is Ototoxic</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1007/BF02897206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2FBF02897206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=2192812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADyaK3c3ptFGksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1990&pages=232-234&author=I.+C.+Kennedyauthor=B.+M.+Fitzharrisauthor=B.+M.+Collsauthor=C.+H.+Atkinson&title=Carboplatin+Is+Ototoxic&doi=10.1007%2FBF02897206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Carboplatin is ototoxic</span></div><div class="casAuthors">Kennedy I C; Fitzharris B M; Colls B M; Atkinson C H</div><div class="citationInfo"><span class="NLM_cas:title">Cancer chemotherapy and pharmacology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-4</span>
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    </div><div class="casAbstract">For assessment of the ototoxic potential of carboplatin [cis-diammine-1,1-cyclobutane dicarboxylate platinum(II); CBDCA], pure-tone audiograms were evaluated in 27 patients receiving a total of 119 doses of carboplatin in the range of 300-400 mg/m2.  Pure-tone audiometry (PTA) was done immediately prior to and 4 weeks after the administration of 80 doses (67%).  Defining carboplatin ototoxicity as an increase of greater than or equal to 30 dB in auditory thresholds that was unexplainable by other causes, we identified 5 examples (19%).  Hearing loss tended to be cumulative with increasing dose and was always maximal at 8,000 Hz.  Two patients had an increase in auditory thresholds at 1,000 Hz, but this only amounted to 10 dB in each case.  Patients developing ototoxicity tended to be older.  Sex, the pre-treatment creatinine clearance, the pretreatment audiogram, the number of doses, and the cumulative dose did not emerge as being reliable predictors of subsequent ototoxicity.  We conclude that although carboplatin is ototoxic, clinically significant deafness does not occur with conventional dosing and routine audiometric monitoring is therefore unnecessary.  However, we suggest that caution should be exercised when carboplatin is given either at higher doses or for longer periods when there is concomitant use of other potentially ototoxic agents or when there is significant pre-existing auditory impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3L2hDNQQnD-dfST00W0BcfW6udTcc2ebHC5YW_Ea3w7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c3ptFGksg%253D%253D&md5=baec917338edde5b5799a7f52584b2eb</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2FBF02897206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02897206%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DI.%2BC.%26aulast%3DFitzharris%26aufirst%3DB.%2BM.%26aulast%3DColls%26aufirst%3DB.%2BM.%26aulast%3DAtkinson%26aufirst%3DC.%2BH.%26atitle%3DCarboplatin%2520Is%2520Ototoxic%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D1990%26volume%3D26%26spage%3D232%26epage%3D234%26doi%3D10.1007%2FBF02897206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Chitapanarux, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorvidhaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamnerdsupaphon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumitsawan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tharavichitkul, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukthomya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J.</span><span> </span><span class="NLM_article-title">Chemoradiation Comparing Cisplatin Versus Carboplatin in Locally Advanced Nasopharyngeal Cancer: Randomised, Non-Inferiority, Open Trial</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">–</span> <span class="NLM_lpage">1406</span><span class="refDoi"> DOI: 10.1016/j.ejca.2007.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.ejca.2007.03.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=1399-1406&author=I.+Chitapanaruxauthor=V.+Lorvidhayaauthor=P.+Kamnerdsupaphonauthor=Y.+Sumitsawanauthor=E.+Tharavichitkulauthor=V.+Sukthomyaauthor=J.+Ford&title=Chemoradiation+Comparing+Cisplatin+Versus+Carboplatin+in+Locally+Advanced+Nasopharyngeal+Cancer%3A+Randomised%2C+Non-Inferiority%2C+Open+Trial&doi=10.1016%2Fj.ejca.2007.03.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2007.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2007.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DChitapanarux%26aufirst%3DI.%26aulast%3DLorvidhaya%26aufirst%3DV.%26aulast%3DKamnerdsupaphon%26aufirst%3DP.%26aulast%3DSumitsawan%26aufirst%3DY.%26aulast%3DTharavichitkul%26aufirst%3DE.%26aulast%3DSukthomya%26aufirst%3DV.%26aulast%3DFord%26aufirst%3DJ.%26atitle%3DChemoradiation%2520Comparing%2520Cisplatin%2520Versus%2520Carboplatin%2520in%2520Locally%2520Advanced%2520Nasopharyngeal%2520Cancer%253A%2520Randomised%252C%2520Non-Inferiority%252C%2520Open%2520Trial%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D1399%26epage%3D1406%26doi%3D10.1016%2Fj.ejca.2007.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Minami, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sha, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schacht, J.</span><span> </span><span class="NLM_article-title">Antioxidant Protection in a New Animal Model of Cisplatin-Induced Ototoxicity</span> <span class="citation_source-journal">Hear. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">198</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1016/j.heares.2004.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.heares.2004.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=15567610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVSktrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2004&pages=137-143&author=S.+B.+Minamiauthor=S.+H.+Shaauthor=J.+Schacht&title=Antioxidant+Protection+in+a+New+Animal+Model+of+Cisplatin-Induced+Ototoxicity&doi=10.1016%2Fj.heares.2004.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Antioxidant protection in a new animal model of cisplatin-induced ototoxicity</span></div><div class="casAuthors">Minami, Shujiro B.; Sha, Su-Hua; Schacht, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">Hearing Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">137-143</span>CODEN:
                <span class="NLM_cas:coden">HERED3</span>;
        ISSN:<span class="NLM_cas:issn">0378-5955</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mortality is a major complication in animal models of cisplatin-induced hearing loss due to the systemic toxicity of the drug.  Here we report on a novel two-cycle treatment in rats, each cycle consisting of four days of cisplatin injections (1 mg/kg, i.p., twice daily) sepd. by 10 days of rest.  This regimen, similar to clin. courses of cancer chemotherapy, produced significant hearing loss without mortality.  Auditory brain stem evoked responses were unchanged after the first cycle but were elevated by 40-50 dB at 16 and 20 kHz after the second.  Loss of outer hair cells occurred after the second cycle, predominantly in the base of the cochlea.  Total cochlear antioxidants declined progressively during drug treatment and were reduced to 60% of control values after the second cisplatin cycle.  Co-administration of salicylate (100 mg/kg, s.c., twice daily) during both cycles or during the second cycle restored antioxidant levels and reduced cisplatin-induced threshold shifts.  This model of cisplatin ototoxicity without mortality eliminates potentially confounding factors that may det. the survival of a special cohort of animals.  The results also support the notion that reactive oxygen species are involved in cisplatin ototoxicity and show the potential usefulness of antioxidant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-9hzG3oTsP7Vg90H21EOLACvtfcHk0ljVeqiVsy5VIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVSktrjE&md5=879b7ce0345fa5a1de8d175d086373fd</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.heares.2004.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.heares.2004.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DMinami%26aufirst%3DS.%2BB.%26aulast%3DSha%26aufirst%3DS.%2BH.%26aulast%3DSchacht%26aufirst%3DJ.%26atitle%3DAntioxidant%2520Protection%2520in%2520a%2520New%2520Animal%2520Model%2520of%2520Cisplatin-Induced%2520Ototoxicity%26jtitle%3DHear.%2520Res.%26date%3D2004%26volume%3D198%26spage%3D137%26epage%3D143%26doi%3D10.1016%2Fj.heares.2004.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Jacobs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccully, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balis, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span> </span><span class="NLM_article-title">Extracellular Fluid Concentrations of Cisplatin, Carboplatin, and Oxaliplatin in Brain, Muscle, and Blood Measured Using Microdialysis in Nonhuman Primates</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1007/s00280-009-1085-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2Fs00280-009-1085-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=19662415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Gmtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=817-824&author=S.+Jacobsauthor=C.+L.+Mccullyauthor=R.+F.+Murphyauthor=J.+Bacherauthor=F.+M.+Balisauthor=E.+Fox&title=Extracellular+Fluid+Concentrations+of+Cisplatin%2C+Carboplatin%2C+and+Oxaliplatin+in+Brain%2C+Muscle%2C+and+Blood+Measured+Using+Microdialysis+in+Nonhuman+Primates&doi=10.1007%2Fs00280-009-1085-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates</span></div><div class="casAuthors">Jacobs, Shana; McCully, Cynthia L.; Murphy, Robert F.; Bacher, John; Balis, Frank M.; Fox, Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">817-824</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cisplatin, carboplatin, and oxaliplatin are chem. reactive anticancer drugs with modest activity in brain tumors.  Previously, we have demonstrated that drug exposure in cerebrospinal fluid (CSF) for these platinum analogs is <5% of the plasma ultrafiltrate (UF) drug exposure in nonhuman primates.  Microdialysis is a minimally invasive in vivo method for sampling small mols. in the blood and tissue extracellular fluid (ECF).  The purpose of this study was to est. the penetration of platinum analogs into the brain ECF.  We measured free concns. of cisplatin, carboplatin, and oxaliplatin in ECF of brain, muscle, and blood of nonhuman primates using microdialysis and compared ECF platinum concns. in blood and brain to plasma UF and CSF concns. obtained using conventional sampling methods.  For all three platinum analogs, AUC0-4h for microdialysis sampling from the vein was similar to std. plasma UF sampling.  The median AUC0-4h ratio for vein to plasma UF was 1.1 (range, 0.9-1.4).  The platinum analogs had limited distribution (<5%) to the CSF and brain ECF.  CSF penetration predicts for the limited penetration of the platinum analogs into brain ECF, but concordance between CSF and brain ECF measurements was poor.  CSF oxaliplatin concns. (AUC0-4h, 0.4-0.9 μM h) were substantially lower than brain ECF concns. (AUC0-4h, 2.0-8.6 μM h).  The penetration of platinum analogs into CSF and brain is limited.  The differences in the CNS penetrations among the three platinum analogs are not clin. significant.  For cisplatin and carboplatin, CSF penetration appears to be a surrogate for brain extracellular free drug exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosO_rKJl_zN7Vg90H21EOLACvtfcHk0ljVeqiVsy5VIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Gmtb4%253D&md5=4838b37481df0020afbdf5021486d407</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-1085-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-1085-7%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DS.%26aulast%3DMccully%26aufirst%3DC.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BF.%26aulast%3DBacher%26aufirst%3DJ.%26aulast%3DBalis%26aufirst%3DF.%2BM.%26aulast%3DFox%26aufirst%3DE.%26atitle%3DExtracellular%2520Fluid%2520Concentrations%2520of%2520Cisplatin%252C%2520Carboplatin%252C%2520and%2520Oxaliplatin%2520in%2520Brain%252C%2520Muscle%252C%2520and%2520Blood%2520Measured%2520Using%2520Microdialysis%2520in%2520Nonhuman%2520Primates%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2010%26volume%3D65%26spage%3D817%26epage%3D824%26doi%3D10.1007%2Fs00280-009-1085-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span>Phosplatin therapeutics. <a href="http://phosplatin.com" class="extLink">http://phosplatin.com</a> (accessed July 30,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phosplatin+therapeutics.+http%3A%2F%2Fphosplatin.com+%28accessed+July+30%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span>Phosplatin therapeutics. A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered Pt-112 Injection in Subjects with Advanced Solid Tumors. <a href="https://clinicaltrials.gov/ct2/show/NCT02266745" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02266745</a> (accessed August 1,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phosplatin+therapeutics.+A+Phase+1%2C+Open-Label%2C+Dose-Escalation+Study+Evaluating+the+Safety%2C+Pharmacokinetics%2C+and+Clinical+Effects+of+Intravenously+Administered+Pt-112+Injection+in+Subjects+with+Advanced+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02266745+%28accessed+August+1%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Mishur, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, R. N.</span><span> </span><span class="NLM_article-title">Synthesis, X-Ray Crystallographic, and NMR Characterizations of Platinum(II) and Platinum(IV) Pyrophosphato Complexes</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">7972</span><span class="NLM_x">–</span> <span class="NLM_lpage">7982</span><span class="refDoi"> DOI: 10.1021/ic800237a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic800237a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=7972-7982&author=R.+J.+Mishurauthor=C.+Zhengauthor=T.+M.+Gilbertauthor=R.+N.+Bose&title=Synthesis%2C+X-Ray+Crystallographic%2C+and+NMR+Characterizations+of+Platinum%28II%29+and+Platinum%28IV%29+Pyrophosphato+Complexes&doi=10.1021%2Fic800237a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fic800237a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic800237a%26sid%3Dliteratum%253Aachs%26aulast%3DMishur%26aufirst%3DR.%2BJ.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DT.%2BM.%26aulast%3DBose%26aufirst%3DR.%2BN.%26atitle%3DSynthesis%252C%2520X-Ray%2520Crystallographic%252C%2520and%2520NMR%2520Characterizations%2520of%2520Platinum%2528II%2529%2520and%2520Platinum%2528IV%2529%2520Pyrophosphato%2520Complexes%26jtitle%3DInorg.%2520Chem.%26date%3D2008%26volume%3D47%26spage%3D7972%26epage%3D7982%26doi%3D10.1021%2Fic800237a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Bose, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishur, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grayburn, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstetter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salley, T.</span><span> </span><span class="NLM_article-title">Non-DNA-Binding Platinum Anticancer Agents: Cytotoxic Activities of Platinum–Phosphato Complexes Towards Human Ovarian Cancer Cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">18314</span><span class="NLM_x">–</span> <span class="NLM_lpage">18319</span><span class="refDoi"> DOI: 10.1073/pnas.0803094105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1073%2Fpnas.0803094105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=18314-18319&author=R.+N.+Boseauthor=L.+Maurmannauthor=R.+J.+Mishurauthor=L.+Yasuiauthor=S.+Guptaauthor=W.+S.+Grayburnauthor=H.+Hofstetterauthor=T.+Salley&title=Non-DNA-Binding+Platinum+Anticancer+Agents%3A+Cytotoxic+Activities+of+Platinum%E2%80%93Phosphato+Complexes+Towards+Human+Ovarian+Cancer+Cells&doi=10.1073%2Fpnas.0803094105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803094105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803094105%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DR.%2BN.%26aulast%3DMaurmann%26aufirst%3DL.%26aulast%3DMishur%26aufirst%3DR.%2BJ.%26aulast%3DYasui%26aufirst%3DL.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DGrayburn%26aufirst%3DW.%2BS.%26aulast%3DHofstetter%26aufirst%3DH.%26aulast%3DSalley%26aufirst%3DT.%26atitle%3DNon-DNA-Binding%2520Platinum%2520Anticancer%2520Agents%253A%2520Cytotoxic%2520Activities%2520of%2520Platinum%25E2%2580%2593Phosphato%2520Complexes%2520Towards%2520Human%2520Ovarian%2520Cancer%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D18314%26epage%3D18319%26doi%3D10.1073%2Fpnas.0803094105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Bose, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belkacemi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majmudar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mccall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezvareh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nislow, C.</span><span> </span><span class="NLM_article-title">Absence of Activation of DNA Repair Genes and Excellent Efficacy of Phosphaplatins against Human Ovarian Cancers: Implications to Treat Resistant Cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8387</span><span class="NLM_x">–</span> <span class="NLM_lpage">8401</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00732</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00732" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8387-8401&author=R.+N.+Boseauthor=S.+Moghaddasauthor=L.+Belkacemiauthor=S.+Tripathiauthor=N.+R.+Adamsauthor=P.+Majmudarauthor=K.+Mccallauthor=H.+Dezvarehauthor=C.+Nislow&title=Absence+of+Activation+of+DNA+Repair+Genes+and+Excellent+Efficacy+of+Phosphaplatins+against+Human+Ovarian+Cancers%3A+Implications+to+Treat+Resistant+Cancers&doi=10.1021%2Facs.jmedchem.5b00732"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00732%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DR.%2BN.%26aulast%3DMoghaddas%26aufirst%3DS.%26aulast%3DBelkacemi%26aufirst%3DL.%26aulast%3DTripathi%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DN.%2BR.%26aulast%3DMajmudar%26aufirst%3DP.%26aulast%3DMccall%26aufirst%3DK.%26aulast%3DDezvareh%26aufirst%3DH.%26aulast%3DNislow%26aufirst%3DC.%26atitle%3DAbsence%2520of%2520Activation%2520of%2520DNA%2520Repair%2520Genes%2520and%2520Excellent%2520Efficacy%2520of%2520Phosphaplatins%2520against%2520Human%2520Ovarian%2520Cancers%253A%2520Implications%2520to%2520Treat%2520Resistant%2520Cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8387%26epage%3D8401%26doi%3D10.1021%2Facs.jmedchem.5b00732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Moghaddas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majmudar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezvareh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soans, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, R. N.</span><span> </span><span class="NLM_article-title">Phosphaplatins, Next Generation Platinum Antitumor Agents: A Paradigm Shift in Designing and Defining Molecular Targets</span> <span class="citation_source-journal">Inorg. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">393</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1016/j.ica.2012.05.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.ica.2012.05.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aqtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=2012&pages=173-181&author=S.+Moghaddasauthor=P.+Majmudarauthor=R.+Marinauthor=H.+Dezvarehauthor=C.+Qiauthor=E.+Soansauthor=R.+N.+Bose&title=Phosphaplatins%2C+Next+Generation+Platinum+Antitumor+Agents%3A+A+Paradigm+Shift+in+Designing+and+Defining+Molecular+Targets&doi=10.1016%2Fj.ica.2012.05.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphaplatins, next generation platinum antitumor agents: A paradigm shift in designing and defining molecular targets</span></div><div class="casAuthors">Moghaddas, Shadi; Majmudar, Pooja; Marin, Roberto; Dezvareh, Homa; Qi, Chunyan; Soans, Eroica; Bose, Rathindra N.</div><div class="citationInfo"><span class="NLM_cas:title">Inorganica Chimica Acta</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173-181</span>CODEN:
                <span class="NLM_cas:coden">ICHAA3</span>;
        ISSN:<span class="NLM_cas:issn">0020-1693</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Platinum(II)- and platinum(IV)-pyrophosphato-complexes (phosphaplatins) show excellent antitumor properties against a variety of human ovarian cancers, including cisplatin- and carboplatin-sensitive and resistant human cancers.  To identify the lead compd. of this class of non-DNA binding antitumor agents, stereoisomers of cis- and trans-1,2-cyclohexane-diamine(pyrophosphato)platinum(II) and of cis- and trans-1,2-cyclohexane-trans-dihydroxo-diamine(pyrophosphato)platinum(IV) were synthesized, and their in vitro efficacies were evaluated in a variety of human ovarian cancer cells including cisplatin- and carboplatin-resistant cancer cells.  Some of these compds. exhibited IC50 values as low as 0.40 μM, the lowest ever obsd. for any platinum anticancer drugs under identical conditions.  More importantly, these compds. are highly active against cisplatin- and carboplatin-sensitive and resistant cancers; examples of these cancer cells include cisplatin-sensitive A2780, acquired cisplatin- and carboplatin-resistant A2780/C30, and inherent cisplatin-resistant OVCAR-10 cells.  In vivo efficacy detd. by using human ovarian xenografts indeed confirmed that phosphaplatins are quite effective in treating ovarian cancers.  The superiority of phosphaplatins was obsd. in increased life span and tumor regression.  These non-DNA binding compds. exhibit cytotoxicity in ovarian cancers primarily through apoptosis via cell cycle arrest both at S and G2 phases largely in a dose independent manner.  Platinum(II) compds. showed reduced protein binding compared to either cisplatin or carboplatin.  Furthermore, protein binding by phosphaplatins was largely limited to extracellular and cytosolic compartments.  In vivo expts. revealed that platinum accumulations in kidney of mice were significantly less compared to cisplatin.  The max. tolerated dose was found be >60 mg/kg via i.v. administration.  Furthermore, rats treated with R,R-stereomer of the platinum(II) complex exhibited near normal white blood cell, platelet, and neutrophil counts indicating its non-toxic properties.  Furthermore, the lead compd. also stays in plasma for 24 h giving ample time to reach desired targets.  Taken together, these data indicate that phosphaplatins have the potential to treat resistant ovarian cancers, both acquired and de novo, without exhibiting severe toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWedAHz0XkfrVg90H21EOLACvtfcHk0lhBNHw8106w3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aqtrnM&md5=a0963f7bf7dec1630be346c75529a600</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.ica.2012.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ica.2012.05.040%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddas%26aufirst%3DS.%26aulast%3DMajmudar%26aufirst%3DP.%26aulast%3DMarin%26aufirst%3DR.%26aulast%3DDezvareh%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DC.%26aulast%3DSoans%26aufirst%3DE.%26aulast%3DBose%26aufirst%3DR.%2BN.%26atitle%3DPhosphaplatins%252C%2520Next%2520Generation%2520Platinum%2520Antitumor%2520Agents%253A%2520A%2520Paradigm%2520Shift%2520in%2520Designing%2520and%2520Defining%2520Molecular%2520Targets%26jtitle%3DInorg.%2520Chim.%2520Acta%26date%3D2012%26volume%3D393%26spage%3D173%26epage%3D181%26doi%3D10.1016%2Fj.ica.2012.05.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span>Businesswire. Phosplatin Therapeutics Announces the Execution of Regional Licensing Agreement for Its Novel Therapeutic Agent in Oncology, Pt-112. <a href="http://www.businesswire.com/news/home/20150818005165/en/Phosplatin-Therapeutics-Announces-Execution-Regional-Licensing-Agreement" class="extLink">http://www.businesswire.com/news/home/20150818005165/en/Phosplatin-Therapeutics-Announces-Execution-Regional-Licensing-Agreement</a> (accessed July 30,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Businesswire.+Phosplatin+Therapeutics+Announces+the+Execution+of+Regional+Licensing+Agreement+for+Its+Novel+Therapeutic+Agent+in+Oncology%2C+Pt-112.+http%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20150818005165%2Fen%2FPhosplatin-Therapeutics-Announces-Execution-Regional-Licensing-Agreement+%28accessed+July+30%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span>Placon Therapeutics. Placon Therapeutics Announces Company Launch and Fda Acceptance of IND for Novel Platinum Candidate BTP-114. <a href="http://www.placontx.com/wp-content/uploads/2016/03/FDA-Acceptance-of-IND-for-Novel-Platinum-Candidate-BTP-114_032316.pdf" class="extLink">http://www.placontx.com/wp-content/uploads/2016/03/FDA-Acceptance-of-IND-for-Novel-Platinum-Candidate-BTP-114_032316.pdf</a> (accessed July 29,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Placon+Therapeutics.+Placon+Therapeutics+Announces+Company+Launch+and+Fda+Acceptance+of+IND+for+Novel+Platinum+Candidate+BTP-114.+http%3A%2F%2Fwww.placontx.com%2Fwp-content%2Fuploads%2F2016%2F03%2FFDA-Acceptance-of-IND-for-Novel-Platinum-Candidate-BTP-114_032316.pdf+%28accessed+July+29%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span>Placon Therapeutics. <a href="http://www.placontx.com/" class="extLink">http://www.placontx.com/</a> (accessed July 30,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Placon+Therapeutics.+http%3A%2F%2Fwww.placontx.com%2F+%28accessed+July+30%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span>Thepharmaletter. Placon Therapeutics Spun out as Independent Company. <a href="http://www.thepharmaletter.com/article/placon-therapeutics-spun-out-as-independent-company" class="extLink">http://www.thepharmaletter.com/article/placon-therapeutics-spun-out-as-independent-company</a> (accessed July 29,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Thepharmaletter.+Placon+Therapeutics+Spun+out+as+Independent+Company.+http%3A%2F%2Fwww.thepharmaletter.com%2Farticle%2Fplacon-therapeutics-spun-out-as-independent-company+%28accessed+July+29%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Moreau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alargova, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meetze, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazinet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krawiec, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriksciukaite, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemelin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limsoo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramstack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockwood, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinde, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auyeung, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilodeau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span> </span><span class="NLM_article-title">Abstract 4484: BTP-114: An Albumin Binding Cisplatin Prodrug with Improved and Sustained Tumor Growth Inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">4484</span><span class="NLM_x">–</span> <span class="NLM_lpage">4484</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-4484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1158%2F1538-7445.AM2015-4484" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4484-4484&author=B.+Moreauauthor=R.+Alargovaauthor=A.+Brockmanauthor=K.+Whalenauthor=J.+Quinnauthor=K.+Meetzeauthor=P.+Bazinetauthor=M.+Dupontauthor=B.+Krawiecauthor=K.+Kriksciukaiteauthor=C.+Lemelinauthor=P.+Limsooauthor=H.+Ollerauthor=M.+Ramstackauthor=D.+Rockwoodauthor=R.+Shindeauthor=S.+Singhauthor=B.+Whiteauthor=T.+Auyeungauthor=C.+Dunbarauthor=M.+Bilodeauauthor=R.+Wooster&title=Abstract+4484%3A+BTP-114%3A+An+Albumin+Binding+Cisplatin+Prodrug+with+Improved+and+Sustained+Tumor+Growth+Inhibition&doi=10.1158%2F1538-7445.AM2015-4484"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-4484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-4484%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DB.%26aulast%3DAlargova%26aufirst%3DR.%26aulast%3DBrockman%26aufirst%3DA.%26aulast%3DWhalen%26aufirst%3DK.%26aulast%3DQuinn%26aufirst%3DJ.%26aulast%3DMeetze%26aufirst%3DK.%26aulast%3DBazinet%26aufirst%3DP.%26aulast%3DDupont%26aufirst%3DM.%26aulast%3DKrawiec%26aufirst%3DB.%26aulast%3DKriksciukaite%26aufirst%3DK.%26aulast%3DLemelin%26aufirst%3DC.%26aulast%3DLimsoo%26aufirst%3DP.%26aulast%3DOller%26aufirst%3DH.%26aulast%3DRamstack%26aufirst%3DM.%26aulast%3DRockwood%26aufirst%3DD.%26aulast%3DShinde%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DB.%26aulast%3DAuyeung%26aufirst%3DT.%26aulast%3DDunbar%26aufirst%3DC.%26aulast%3DBilodeau%26aufirst%3DM.%26aulast%3DWooster%26aufirst%3DR.%26atitle%3DAbstract%25204484%253A%2520BTP-114%253A%2520An%2520Albumin%2520Binding%2520Cisplatin%2520Prodrug%2520with%2520Improved%2520and%2520Sustained%2520Tumor%2520Growth%2520Inhibition%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4484%26epage%3D4484%26doi%3D10.1158%2F1538-7445.AM2015-4484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Smith, M. E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspersen, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morais, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, J. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caddick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chudasama, V.</span><span> </span><span class="NLM_article-title">A Platform for Efficient, Thiol-Stable Conjugation to Albumin’s Native Single Accessible Cysteine</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">7946</span><span class="NLM_x">–</span> <span class="NLM_lpage">7949</span><span class="refDoi"> DOI: 10.1039/C5OB01205H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC5OB01205H" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=7946-7949&author=M.+E.+B.+Smithauthor=M.+B.+Caspersenauthor=E.+Robinsonauthor=M.+Moraisauthor=A.+Maruaniauthor=J.+P.+M.+Nunesauthor=K.+Nichollsauthor=M.+J.+Saxtonauthor=S.+Caddickauthor=J.+R.+Bakerauthor=V.+Chudasama&title=A+Platform+for+Efficient%2C+Thiol-Stable+Conjugation+to+Albumin%E2%80%99s+Native+Single+Accessible+Cysteine&doi=10.1039%2FC5OB01205H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1039%2FC5OB01205H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB01205H%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BE.%2BB.%26aulast%3DCaspersen%26aufirst%3DM.%2BB.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DMorais%26aufirst%3DM.%26aulast%3DMaruani%26aufirst%3DA.%26aulast%3DNunes%26aufirst%3DJ.%2BP.%2BM.%26aulast%3DNicholls%26aufirst%3DK.%26aulast%3DSaxton%26aufirst%3DM.%2BJ.%26aulast%3DCaddick%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DChudasama%26aufirst%3DV.%26atitle%3DA%2520Platform%2520for%2520Efficient%252C%2520Thiol-Stable%2520Conjugation%2520to%2520Albumin%25E2%2580%2599s%2520Native%2520Single%2520Accessible%2520Cysteine%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2015%26volume%3D13%26spage%3D7946%26epage%3D7949%26doi%3D10.1039%2FC5OB01205H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Pichler, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffeter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dömötör, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enyedy, É. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groza, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Köllensperger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanksi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowol, C. R.</span><span> </span><span class="NLM_article-title">Maleimide-Functionalised Platinum(IV) Complexes as a Synthetic Platform for Targeted Drug Delivery</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2249</span><span class="NLM_x">–</span> <span class="NLM_lpage">2251</span><span class="refDoi"> DOI: 10.1039/c3cc39258a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2Fc3cc39258a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=23396381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislyisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=2249-2251&author=V.+Pichlerauthor=J.+Mayrauthor=P.+Heffeterauthor=O.+D%C3%B6m%C3%B6t%C3%B6rauthor=%C3%89.+A.+Enyedyauthor=G.+Hermannauthor=D.+Grozaauthor=G.+K%C3%B6llenspergerauthor=M.+Galanksiauthor=W.+Bergerauthor=B.+K.+Kepplerauthor=C.+R.+Kowol&title=Maleimide-Functionalised+Platinum%28IV%29+Complexes+as+a+Synthetic+Platform+for+Targeted+Drug+Delivery&doi=10.1039%2Fc3cc39258a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery</span></div><div class="casAuthors">Pichler, Verena; Mayr, Josef; Heffeter, Petra; Doemoetoer, Orsolya; Enyedy, Eva A.; Hermann, Gerrit; Groza, Diana; Koellensperger, Gunda; Galanksi, Markus; Berger, Walter; Keppler, Bernhard K.; Kowol, Christian R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2249-2251</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Maleimide-functionalized Pt(IV) complexes [(N-N)Y2Pt(OCONHCH2CH2Imd)2] (N-N = trans-1,2-cyclohexanediamine, ethylenediamine; Y = Cl, Y2 = oxalato; Imd = maleimido, succinimido) were prepd. by oxidn. of Pt(II) complexes [(N-N)Y2Pt] and reaction with N-(2-isocyanatoethyl)succinimide or N-(2-isocyanatoethyl)maleimide.  Maleimide-substituted platinum complexes feature highly selective binding properties to thiol groups of thiol-contg. tumor-targeting mols. like human serum albumin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXGfxW_PNYibVg90H21EOLACvtfcHk0ljUvaQ-GOCT2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislyisbg%253D&md5=fb09e326dd09eed355a7dca7293b85fe</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1039%2Fc3cc39258a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc39258a%26sid%3Dliteratum%253Aachs%26aulast%3DPichler%26aufirst%3DV.%26aulast%3DMayr%26aufirst%3DJ.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DD%25C3%25B6m%25C3%25B6t%25C3%25B6r%26aufirst%3DO.%26aulast%3DEnyedy%26aufirst%3D%25C3%2589.%2BA.%26aulast%3DHermann%26aufirst%3DG.%26aulast%3DGroza%26aufirst%3DD.%26aulast%3DK%25C3%25B6llensperger%26aufirst%3DG.%26aulast%3DGalanksi%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26atitle%3DMaleimide-Functionalised%2520Platinum%2528IV%2529%2520Complexes%2520as%2520a%2520Synthetic%2520Platform%2520for%2520Targeted%2520Drug%2520Delivery%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D49%26spage%3D2249%26epage%3D2251%26doi%3D10.1039%2Fc3cc39258a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Zheng, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suntharalingam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">8790</span><span class="NLM_x">–</span> <span class="NLM_lpage">8798</span><span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.+R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+Prodrugs+Designed+to+Bind+Non-Covalently+to+Human+Serum+Albumin+for+Drug+Delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0lh_ns1RoYxsUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520Prodrugs%2520Designed%2520to%2520Bind%2520Non-Covalently%2520to%2520Human%2520Serum%2520Albumin%2520for%2520Drug%2520Delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Kundranda, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, J.</span><span> </span><span class="NLM_article-title">Albumin-Bound Paclitaxel in Solid Tumors: Clinical Development and Future Directions</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3767</span><span class="NLM_x">–</span> <span class="NLM_lpage">3777</span><span class="refDoi"> DOI: 10.2147/DDDT.S88023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2147%2FDDDT.S88023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26244011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=3767-3777&author=M.+N.+Kundrandaauthor=J.+Niu&title=Albumin-Bound+Paclitaxel+in+Solid+Tumors%3A+Clinical+Development+and+Future+Directions&doi=10.2147%2FDDDT.S88023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin-bound paclitaxel in solid tumors: clinical development and future directions</span></div><div class="casAuthors">Kundranda, Madappa N.; Niu, Jiaxin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3767-3777</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities assocd. with the solvents used in the formulation of std. paclitaxel and to potentially improve efficacy.  Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclitaxel to tumors and decrease the incidence of serious toxicities, including severe allergic reactions.  To date, nab-paclitaxel has been indicated for the treat-ment of three solid tumors in the USA.  It was first approved for the treatment of metastatic breast cancer in 2005, followed by locally advanced or metastatic non-small-cell lung cancer in 2012, and most recently for metastatic pancreatic cancer in 2013.  Nab-paclitaxel is also under investigation for the treatment of a no. of other solid tumors.  This review highlights key clin. efficacy and safety outcomes of nab-paclitaxel in the solid tumors for which it is currently indicated, discusses ongoing trials that may provide new data for the expansion of nab-paclitaxel's indications into other solid tumors, and provides a clin. perspective on the use of nab-paclitaxel in practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5bBd89dzHbbVg90H21EOLACvtfcHk0lh_ns1RoYxsUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOisbg%253D&md5=59eb234cc3342ced970e186ae29071a4</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S88023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S88023%26sid%3Dliteratum%253Aachs%26aulast%3DKundranda%26aufirst%3DM.%2BN.%26aulast%3DNiu%26aufirst%3DJ.%26atitle%3DAlbumin-Bound%2520Paclitaxel%2520in%2520Solid%2520Tumors%253A%2520Clinical%2520Development%2520and%2520Future%2520Directions%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D3767%26epage%3D3777%26doi%3D10.2147%2FDDDT.S88023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Manaenko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span> </span><span class="NLM_article-title">Comparison Evans Blue Injection Routes: Intravenous Versus Intraperitoneal, for Measurement of Blood-Brain Barrier in a Mice Hemorrhage Model</span> <span class="citation_source-journal">J. Neurosci. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1016/j.jneumeth.2010.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.jneumeth.2010.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=21168441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC3M7jvV2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2011&pages=206-210&author=A.+Manaenkoauthor=H.+Chenauthor=J.+Kammerauthor=J.+H.+Zhangauthor=J.+Tang&title=Comparison+Evans+Blue+Injection+Routes%3A+Intravenous+Versus+Intraperitoneal%2C+for+Measurement+of+Blood-Brain+Barrier+in+a+Mice+Hemorrhage+Model&doi=10.1016%2Fj.jneumeth.2010.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison Evans Blue injection routes: Intravenous versus intraperitoneal, for measurement of blood-brain barrier in a mice hemorrhage model</span></div><div class="casAuthors">Manaenko Anatol; Chen Hank; Kammer Jerome; Zhang John H; Tang Jiping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroscience methods</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">206-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  Intracerebral hemorrhage is one of the most devastating subtypes of stroke, leaving survivors with severe neurological deficits.  Disruption of the blood brain barrier (BBB) following hemorrhage results in the development of vasogenic brain edema, a most life-threatening event after such events as intracerebral hemorrhage (ICH).  The Evans Blue assay is a popular method for the quantification of BBB disruption.  Although this method is in common use, there are several protocols of the assay in the literature which vary in the route of administration, as well as the circulation time of the stain.  In this study, we compared the amounts of accumulated stain in brain tissue following intraperitoneal versus intravenous injection at 0.5, 3 and 24h of circulation time.  METHODS:  58 CD-1 mice were used.  Animals were divided into ICH (N=42), sham groups (N=6) and naive (N=10).  ICH animals received stereotactic injection of collagenase type VII into the right basal ganglia.  Sham animals received only needle trauma.  Evans Blue stain was injected 24h after collagenase injection or needle trauma.  The consistency of ICH produced was characterized by estimation of hematoma volume via hemoglobin assay and neurological evaluation.  RESULTS:  The produced hematoma and neurological deficits were well comparable between different experimental groups.  There was no statistically significant difference in the results of the Evans Blue assay with regard to administration route.  CONCLUSIONS:  The amount of Evans Blue stain accumulated in the brains of mice after ICH produced by collagenase injection was independent of the stain administration route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwm-8zIl3llcNIRw0GKUoEfW6udTcc2eardqonEhMT_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7jvV2juw%253D%253D&md5=6111a6fc0d6c6263e16c410d9407f2b2</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.jneumeth.2010.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneumeth.2010.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DManaenko%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DKammer%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%2BH.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DComparison%2520Evans%2520Blue%2520Injection%2520Routes%253A%2520Intravenous%2520Versus%2520Intraperitoneal%252C%2520for%2520Measurement%2520of%2520Blood-Brain%2520Barrier%2520in%2520a%2520Mice%2520Hemorrhage%2520Model%26jtitle%3DJ.%2520Neurosci.%2520Methods%26date%3D2011%26volume%3D195%26spage%3D206%26epage%3D210%26doi%3D10.1016%2Fj.jneumeth.2010.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Mcdonald, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baluk, P.</span><span> </span><span class="NLM_article-title">Significance of Blood Vessel Leakiness in Cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5381</span><span class="NLM_x">–</span> <span class="NLM_lpage">5385</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5381-5385&author=D.+M.+Mcdonaldauthor=P.+Baluk&title=Significance+of+Blood+Vessel+Leakiness+in+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcdonald%26aufirst%3DD.%2BM.%26aulast%3DBaluk%26aufirst%3DP.%26atitle%3DSignificance%2520of%2520Blood%2520Vessel%2520Leakiness%2520in%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5381%26epage%3D5385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Yu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remick, S. C.</span><span> </span><span class="NLM_article-title">Dicycloplatin, a Novel Platinum Analog in Chemotherapy: Synthesis of Chinese Pre-Clinical and Clinical Profile and Emerging Mechanistic Studies</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24403501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktV2isLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=455-463&author=J.+J.+Yuauthor=X.+Yangauthor=Q.+Songauthor=M.+D.+Muellerauthor=S.+C.+Remick&title=Dicycloplatin%2C+a+Novel+Platinum+Analog+in+Chemotherapy%3A+Synthesis+of+Chinese+Pre-Clinical+and+Clinical+Profile+and+Emerging+Mechanistic+Studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of Chinese pre-clinical and clinical profile and emerging mechanistic studies</span></div><div class="casAuthors">Yu, Jing Jie; Yang, Xuqing; Song, Qinhua; Mueller, Michael D.; Remick, Scot C.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1B</span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">A review.  Dicycloplatin (DCP) has better soly. and stability than both cisplatin and carboplatin.  Pre-clin. and phase I studies demonstrated significant antitumor activity and fewer adverse events than carboplatin.  Phase II clin. trials in advanced non-small cell lung cancer found efficacy and safety of DCP-plus-paclitaxel comparable to carboplatin-plus-paclitaxel but better tolerability.  This article summarizes and reviews pre-clin. and clin. data for dicycloplatin from the Chinese medical literature.  We also report on new mechanistic findings in our lab. in West Virginia, USA.  Patient blood samples were collected for DCP-prototype detn. by liq. chromatog. mass spectrometry (LC-MS/MS).  Mol. studies of ovarian cancer celts treated with DCP or cisplatin were carried out for gene-signature profiling using immunoblotting.  Pharmacokinetic mass-spectrometry showed different spectrum profiles of DCP and carboplatin in plasma.  Plasma concn. of DCP prototype was 17.1 μg/mL 2h after administration, with a peak concn. of 26.9 μg/mL at 0.5 h.  Immunoblotting showed DCP-induced activation of DNA damage pathways, including double-phosphorylated checkpoint kinase 2 (CHK2) and breast cancer 1 (BRCA1) and triple-phosphorylated p53, compared to controls.  Cisplatin produced a similar profile, with increased p53 protein.  DCP and cisplatin activate DNA-damage response through similar pathways.  DCP may be more sol. and stable, and better-tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH1uuOD4c2VbVg90H21EOLACvtfcHk0liBqUHPrdo1cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktV2isLY%253D&md5=205f6779a4061021bb18c1eee25aec60</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DM.%2BD.%26aulast%3DRemick%26aufirst%3DS.%2BC.%26atitle%3DDicycloplatin%252C%2520a%2520Novel%2520Platinum%2520Analog%2520in%2520Chemotherapy%253A%2520Synthesis%2520of%2520Chinese%2520Pre-Clinical%2520and%2520Clinical%2520Profile%2520and%2520Emerging%2520Mechanistic%2520Studies%26jtitle%3DAnticancer%2520Res.%26date%3D2014%26volume%3D34%26spage%3D455%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Li, G.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.-W.</span><span> </span><span class="NLM_article-title">Effect of Dicycloplatin, a Novel Platinum Chemotherapeutical Drug, on Inhibiting Cell Growth and Inducing Cell Apoptosis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e48994</span><span class="refDoi"> DOI: 10.1371/journal.pone.0048994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1371%2Fjournal.pone.0048994" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e48994&author=G.-Q.+Liauthor=X.-G.+Chenauthor=X.-P.+Wuauthor=J.-D.+Xieauthor=Y.-J.+Liangauthor=X.-Q.+Zhaoauthor=W.-Q.+Chenauthor=L.-W.+Fu&title=Effect+of+Dicycloplatin%2C+a+Novel+Platinum+Chemotherapeutical+Drug%2C+on+Inhibiting+Cell+Growth+and+Inducing+Cell+Apoptosis&doi=10.1371%2Fjournal.pone.0048994"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0048994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0048994%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DG.-Q.%26aulast%3DChen%26aufirst%3DX.-G.%26aulast%3DWu%26aufirst%3DX.-P.%26aulast%3DXie%26aufirst%3DJ.-D.%26aulast%3DLiang%26aufirst%3DY.-J.%26aulast%3DZhao%26aufirst%3DX.-Q.%26aulast%3DChen%26aufirst%3DW.-Q.%26aulast%3DFu%26aufirst%3DL.-W.%26atitle%3DEffect%2520of%2520Dicycloplatin%252C%2520a%2520Novel%2520Platinum%2520Chemotherapeutical%2520Drug%252C%2520on%2520Inhibiting%2520Cell%2520Growth%2520and%2520Inducing%2520Cell%2520Apoptosis%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De48994%26doi%3D10.1371%2Fjournal.pone.0048994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Liu, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, Z. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, Q. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. Y.</span><span> </span><span class="NLM_article-title">A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel as First-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancers</span> <span class="citation_source-journal">Arch. Med. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">724</span><span class="refDoi"> DOI: 10.5114/aoms.2014.44862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.5114%2Faoms.2014.44862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25276156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ggt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=717-724&author=K.+J.+Liuauthor=Z.+Z.+Guanauthor=Y.+Liangauthor=X.+Q.+Yangauthor=J.+Pengauthor=H.+Huangauthor=Q.+X.+Shaoauthor=M.+Z.+Wangauthor=Y.+Z.+Zhuauthor=C.+P.+Wuauthor=S.+B.+Wangauthor=J.+P.+Xiongauthor=Y.+X.+Baiauthor=S.+Y.+Yuauthor=Y.+Zhangauthor=X.+H.+Huauthor=J.+F.+Fengauthor=S.+X.+Wuauthor=S.+C.+Jiaoauthor=C.+C.+Zhouauthor=J.+Wangauthor=H.+Y.+Wu&title=A+Double-Blind%2C+Randomized+Phase+II+Study+of+Dicycloplatin+Plus+Paclitaxel+Versus+Carboplatin+Plus+Paclitaxel+as+First-Line+Therapy+for+Patients+with+Advanced+Non-Small-Cell+Lung+Cancers&doi=10.5114%2Faoms.2014.44862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers</span></div><div class="casAuthors">Liu, Ke-Jun; Guan, Zhong-Zhen; Liang, Ying; Yang, Xu-Qing; Peng, Jin; Huang, He; Shao, Qing-Xiang; Wang, Meng-Zhao; Zhu, Yun-Zhong; Wu, Chang-Ping; Wang, Shao-Bin; Xiong, Jian-Ping; Bai, Yu-Xian; Yu, Shi-Ying; Zhang, Yang; Hu, Xiao-Hua; Feng, Ji-Feng; Wu, Shi-Xiu; Jiao, Shun-Chang; Zhou, Cai-Cun; Wang, Jie; Wu, Hai-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Medical Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-724</span>CODEN:
                <span class="NLM_cas:coden">AMSRDQ</span>;
        ISSN:<span class="NLM_cas:issn">1734-1922</span>.
    
            (<span class="NLM_cas:orgname">Termedia Publishing House</span>)
        </div><div class="casAbstract">Introduction: The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as firstline treatment for patients with advanced non-small-cell lung cancer (NSCLC).  Material and methods: In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1 : 1) to receive dicycloplatin 450 mg/m2 or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m2 (D + P or C + P) every 3 wk for up to 4 to 6 cycles.  The primary endpoint was response rate.  Secondary endpoints included progression- free survival (PFS), overall survival (OS) and adverse events.  Results: The response rates for the D + P and C + P arm were 36.44% and 30.51%, resp. (p = 0.33).  The median PFS was 5.6 mo in the D + P arm and 4.7 mo in the C + P arm (p = 0.31).  The median OS was 14.9 mo for D + P and 12.9 mo for C + P (p = 0.37).  Adverse events in the two arms were well balanced.  The most common grade 3/4 adverse event was hematol. toxicity.  Conclusions: Patients treated with D + P had similar response and survival rates to those treated with C + P, and toxicities of both treatments were generally tolerable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph9Zf2cMstcbVg90H21EOLACvtfcHk0liBqUHPrdo1cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ggt7jO&md5=528336ed9d7dfabc17ad868c252de29a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.5114%2Faoms.2014.44862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Faoms.2014.44862%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BJ.%26aulast%3DGuan%26aufirst%3DZ.%2BZ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%2BQ.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DShao%26aufirst%3DQ.%2BX.%26aulast%3DWang%26aufirst%3DM.%2BZ.%26aulast%3DZhu%26aufirst%3DY.%2BZ.%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DS.%2BB.%26aulast%3DXiong%26aufirst%3DJ.%2BP.%26aulast%3DBai%26aufirst%3DY.%2BX.%26aulast%3DYu%26aufirst%3DS.%2BY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%2BH.%26aulast%3DFeng%26aufirst%3DJ.%2BF.%26aulast%3DWu%26aufirst%3DS.%2BX.%26aulast%3DJiao%26aufirst%3DS.%2BC.%26aulast%3DZhou%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%2BY.%26atitle%3DA%2520Double-Blind%252C%2520Randomized%2520Phase%2520II%2520Study%2520of%2520Dicycloplatin%2520Plus%2520Paclitaxel%2520Versus%2520Carboplatin%2520Plus%2520Paclitaxel%2520as%2520First-Line%2520Therapy%2520for%2520Patients%2520with%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancers%26jtitle%3DArch.%2520Med.%2520Sci.%26date%3D2014%26volume%3D10%26spage%3D717%26epage%3D724%26doi%3D10.5114%2Faoms.2014.44862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, H.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, X.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, R.-G.</span><span> </span><span class="NLM_article-title">Advances in Drug Delivery System for Platinum Agents Based Combination Therapy</span> <span class="citation_source-journal">Cancer Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.7497/j.issn.2095-3941.2015.0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.7497%2Fj.issn.2095-3941.2015.0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26779373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=362-374&author=X.+Kangauthor=H.-H.+Xiaoauthor=H.-Q.+Songauthor=X.-B.+Jingauthor=L.-S.+Yanauthor=R.-G.+Qi&title=Advances+in+Drug+Delivery+System+for+Platinum+Agents+Based+Combination+Therapy&doi=10.7497%2Fj.issn.2095-3941.2015.0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in drug delivery system for platinum agents based combination therapy</span></div><div class="casAuthors">Kang, Xiang; Xiao, Hai-Hua; Song, Hai-Qin; Jing, Xia-Bin; Yan, Le-San; Qi, Ruo-Gu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4Spec.Iss.</span>),
    <span class="NLM_cas:pages">362-374</span>CODEN:
                <span class="NLM_cas:coden">CBMADQ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Tianjin Medical University Cancer Institute and Hospital</span>)
        </div><div class="casAbstract">Platinum-based anticancer agents are widely used as first-line drugs in cancer chemotherapy for various solid tumors.  However, great side effects and occurrence of resistance remain as the major drawbacks for almost all the platinum drugs developed.  To conquer these problems, new strategies should be adopted for platinum drug based chemotherapy.  Modern nanotechnol. has been widely employed in the delivery of various therapeutics and diagnostic.  It provides the possibility of targeted delivery of a certain anticancer drug to the tumor site, which could minimize toxicity and optimize the drug efficacy.  Here, in this review, we focused on the recent progress in polymer based drug delivery systems for platinum-based combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6c7l6YI7qmbVg90H21EOLACvtfcHk0liBqUHPrdo1cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVaqs7g%253D&md5=086ed651b447b0d2563c81c555c26702</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.7497%2Fj.issn.2095-3941.2015.0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7497%252Fj.issn.2095-3941.2015.0063%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DH.-H.%26aulast%3DSong%26aufirst%3DH.-Q.%26aulast%3DJing%26aufirst%3DX.-B.%26aulast%3DYan%26aufirst%3DL.-S.%26aulast%3DQi%26aufirst%3DR.-G.%26atitle%3DAdvances%2520in%2520Drug%2520Delivery%2520System%2520for%2520Platinum%2520Agents%2520Based%2520Combination%2520Therapy%26jtitle%3DCancer%2520Biol.%2520Med.%26date%3D2015%26volume%3D12%26spage%3D362%26epage%3D374%26doi%3D10.7497%2Fj.issn.2095-3941.2015.0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Xue, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X. J.</span><span> </span><span class="NLM_article-title">Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">10452</span><span class="NLM_x">–</span> <span class="NLM_lpage">10464</span><span class="refDoi"> DOI: 10.1021/nn405004f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn405004f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOmsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=10452-10464&author=X.+Xueauthor=M.+D.+Hallauthor=Q.+Zhangauthor=P.+C.+Wangauthor=M.+M.+Gottesmanauthor=X.+J.+Liang&title=Nanoscale+Drug+Delivery+Platforms+Overcome+Platinum-Based+Resistance+in+Cancer+Cells+Due+to+Abnormal+Membrane+Protein+Trafficking&doi=10.1021%2Fnn405004f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking</span></div><div class="casAuthors">Xue, Xue; Hall, Matthew D.; Zhang, Qiang; Wang, Paul C.; Gottesman, Michael M.; Liang, Xing-Jie</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">10452-10464</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of cellular resistance to platinum-based chemotherapies is often assocd. with reduced intracellular platinum concns.  In some models, this redn. is due to abnormal membrane protein trafficking, resulting in reduced uptake by transporters at the cell surface.  Given the central role of platinum drugs in the clinic, it is crit. to overcome cisplatin resistance by bypassing the plasma membrane barrier to significantly increase the intracellular cisplatin concn. enough to inhibit the proliferation of cisplatin-resistant cells.  Therefore, rational design of appropriate nanoscale drug delivery platforms (nDDPs) loaded with cisplatin or other platinum analogs as payloads is a possible strategy to solve this problem.  This review will focus on the known mechanism of membrane trafficking in cisplatin-resistant cells and the development and employment of nDDPs to improve cell uptake of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY72iH-5DvhrVg90H21EOLACvtfcHk0liHWe6iBkYIqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOmsLzK&md5=cf4f50585f7ab097c93fd8ae516ff37c</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fnn405004f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn405004f%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DX.%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DP.%2BC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DLiang%26aufirst%3DX.%2BJ.%26atitle%3DNanoscale%2520Drug%2520Delivery%2520Platforms%2520Overcome%2520Platinum-Based%2520Resistance%2520in%2520Cancer%2520Cells%2520Due%2520to%2520Abnormal%2520Membrane%2520Protein%2520Trafficking%26jtitle%3DACS%2520Nano%26date%3D2013%26volume%3D7%26spage%3D10452%26epage%3D10464%26doi%3D10.1021%2Fnn405004f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Duggan, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, G. M.</span><span> </span><span class="NLM_article-title">Pegylated Liposomal Doxorubicin</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">2531</span><span class="NLM_x">–</span> <span class="NLM_lpage">2558</span><span class="refDoi"> DOI: 10.2165/11207510-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2165%2F11207510-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=22141391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1aqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2531-2558&author=S.+T.+Dugganauthor=G.+M.+Keating&title=Pegylated+Liposomal+Doxorubicin&doi=10.2165%2F11207510-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma</span></div><div class="casAuthors">Duggan, Sean T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2531-2558</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Pegylated liposomal doxorubicin (Caelyx, Doxil) represents an improved formulation of conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic profile.  This article reviews the efficacy and tolerability of pegylated liposomal doxorubicin in metastatic breast cancer, progressive ovarian cancer, relapsed or refractory multiple myeloma and AIDS-related Kaposi's sarcoma, as well as summarizing its pharmacol. properties.  In three randomized, open-label, multicentre trials, monotherapy with pegylated liposomal doxorubicin was as effective as doxorubicin or capecitabine in the first-line treatment of metastatic breast cancer, and as effective as vinorelbine or combination mitomycin plus vinblastine in taxane-refractory metastatic breast cancer.  Pegylated liposomal doxorubicin alone was as effective as topotecan or gemcitabine alone in patients with progressive ovarian cancer resistant or refractory to platinum- or paclitaxel-based therapy, according to the results of three randomized multicentre trials.  In addn., in patients with progressive ovarian cancer who had received prior platinum-based therapy, progression-free survival was significantly longer with pegylated liposomal doxorubicin plus carboplatin than with paclitaxel plus carboplatin, according to the results of a randomized, open-label multicentre trial.  Combination therapy with pegylated liposomal doxorubicin plus bortezomib was more effective than bortezomib alone in patients with relapsed or refractory multiple myeloma, according to the results of a randomized, open-label, multinational trial.  Randomized multinational trials also demonstrated the efficacy of pegylated liposomal doxorubicin in patients with advanced AIDS-related Kaposi's sarcoma.  Pegylated liposomal doxorubicin exhibited a relatively favorable safety profile compared with conventional doxorubicin and other available chemotherapy agents.  The most common treatment-related adverse events included myelosuppression, palmar-plantar erythrodysesthesia and stomatitis, although these are manageable with appropriate supportive measures.  To conclude, pegylated liposomal doxorubicin is a useful option in the treatment of various malignancies, including metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBGBjVK3YlF7Vg90H21EOLACvtfcHk0liHWe6iBkYIqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1aqtro%253D&md5=3ef7823018be550e9f487cd861efc5ae</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.2165%2F11207510-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11207510-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%2BT.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DPegylated%2520Liposomal%2520Doxorubicin%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D2531%26epage%3D2558%26doi%3D10.2165%2F11207510-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span> </span><span class="NLM_article-title">Application of Liposomal Technologies for Delivery of Platinum Analogs in Oncology</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3309</span><span class="NLM_x">–</span> <span class="NLM_lpage">3319</span><span class="refDoi"> DOI: 10.2147/IJN.S38354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.2147%2FIJN.S38354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24023517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FosF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=3309-3319&author=D.+Liuauthor=C.+Heauthor=A.+Z.+Wangauthor=W.+Lin&title=Application+of+Liposomal+Technologies+for+Delivery+of+Platinum+Analogs+in+Oncology&doi=10.2147%2FIJN.S38354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Application of liposomal technologies for delivery of platinum analogs in oncology</span></div><div class="casAuthors">Liu Demin; He Chunbai; Wang Andrew Z; Lin Wenbin</div><div class="citationInfo"><span class="NLM_cas:title">International journal of nanomedicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3309-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics.  While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties.  Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further.  Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin.  Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin®), SPI-77, Lipoplatin®, Lipoxal®, and LiPlaCis®.  Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery.  In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles.  We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9qo79Plh9RWGmni0r9GoKfW6udTcc2eYH0JeXYau0Xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FosF2jtA%253D%253D&md5=8f8281ea8e2b4bffc63d948c7b960fba</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.2147%2FIJN.S38354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S38354%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DA.%2BZ.%26aulast%3DLin%26aufirst%3DW.%26atitle%3DApplication%2520of%2520Liposomal%2520Technologies%2520for%2520Delivery%2520of%2520Platinum%2520Analogs%2520in%2520Oncology%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2013%26volume%3D8%26spage%3D3309%26epage%3D3319%26doi%3D10.2147%2FIJN.S38354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">European Medicines Agency</span><span class="NLM_x">. Public Summary of Positive Opinionfor Orphan Designation of Cisplatin (Liposomal) for the Treatmentof Pancreatic Cancer. </span> <span class="citation_source-book">Pre-Authorization Evaluation of Medicines for Human Use</span>; <span class="NLM_publisher-name">Committee for Orphan Medicinal Products</span>: <span class="NLM_publisher-loc">London</span>, November 30,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=European+Medicines+Agency&title=Pre-Authorization+Evaluation+of+Medicines+for+Human+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DPre-Authorization%2520Evaluation%2520of%2520Medicines%2520for%2520Human%2520Use%26pub%3DCommittee%2520for%2520Orphan%2520Medicinal%2520Products%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Han, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Z.</span><span> </span><span class="NLM_article-title">Recent Advances in Platinum (Iv) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1268</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span><span class="refDoi"> DOI: 10.1002/med.21360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fmed.21360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26280923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1KjsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1268-1299&author=X.+Hanauthor=J.+Sunauthor=Y.+Wangauthor=Z.+He&title=Recent+Advances+in+Platinum+%28Iv%29+Complex-Based+Delivery+Systems+to+Improve+Platinum+%28II%29+Anticancer+Therapy&doi=10.1002%2Fmed.21360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy</span></div><div class="casAuthors">Han, Xiaopeng; Sun, Jin; Wang, Yongjun; He, Zhonggui</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1268-1299</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Cisplatin and its platinum (Pt) (II) derivs. play a key role in the fight against various human cancers such as testicular, ovarian, head and neck, lung tumors.  However, their application in clinic is limited due to dose- dependent toxicities and acquired drug resistances, which have prompted extensive research effort toward the development of more effective Pt (II) delivery strategies.  The synthesis of Pt (IV) complex is one such an area of intense research fields, which involves their in vivo conversion into active Pt (II) mols. under the reducing intracellular environment, and has demonstrated encouraging preclin. and clin. outcomes.  Compared with Pt (II) complexes, Pt (IV) complexes not only exhibit an increased stability and reduced side effects, but also facilitate the i.v.-to-oral switch in cancer chemotherapy.  The overview briefly analyzes statuses of Pt (II) complex that are in clin. use, and then focuses on the development of Pt (IV) complexes.  Finally, recent advances in Pt (IV) complexes in combination with nanocarriers are highlighted, addressing the shortcomings of Pt (IV) complexes, such as their instability in blood and irreversibly binding to plasma proteins and nonspecific distribution, and taking advantage of passive and active targeting effect to improve Pt (II) anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoorUB6a37jSbVg90H21EOLACvtfcHk0ljlxq7c8iXkFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1KjsLrI&md5=7c99c1bbe8eb959b26ae3c3fa649ba1d</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2Fmed.21360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21360%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DZ.%26atitle%3DRecent%2520Advances%2520in%2520Platinum%2520%2528Iv%2529%2520Complex-Based%2520Delivery%2520Systems%2520to%2520Improve%2520Platinum%2520%2528II%2529%2520Anticancer%2520Therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D1268%26epage%3D1299%26doi%3D10.1002%2Fmed.21360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Martin, R. B.</span><span> </span><span class="NLM_article-title">Platinum Complexes: Hydrolysis and Binding to N(7) and N(1) of Purines</span>. In  <span class="citation_source-book">Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug</span>; <span class="NLM_contrib-group">Lippart, B.</span>, Ed.; <span class="NLM_publisher-name">Verlag Helvetica Chimica Acta</span>: <span class="NLM_publisher-loc">Zürich, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2F9783906390420.ch7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=181-205&author=R.+B.+Martinauthor=B.+Lippart&title=Cisplatin%3A+Chemistry+and+Biochemistry+of+a+Leading+Anticancer+Drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1002%2F9783906390420.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783906390420.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BB.%26atitle%3DPlatinum%2520Complexes%253A%2520Hydrolysis%2520and%2520Binding%2520to%2520N%25287%2529%2520and%2520N%25281%2529%2520of%2520Purines%26btitle%3DCisplatin%253A%2520Chemistry%2520and%2520Biochemistry%2520of%2520a%2520Leading%2520Anticancer%2520Drug%26aulast%3DLippart%26aufirst%3DB.%26pub%3DVerlag%2520Helvetica%2520Chimica%2520Acta%26date%3D2006%26spage%3D181%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Kataoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, Y.</span><span> </span><span class="NLM_article-title">Block Copolymer Micelles for Drug Delivery: Design, Characterization and Biological Significance</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span><span class="refDoi"> DOI: 10.1016/S0169-409X(00)00124-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2FS0169-409X%2800%2900124-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11251249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvVajs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2001&pages=113-131&author=K.+Kataokaauthor=A.+Haradaauthor=Y.+Nagasaki&title=Block+Copolymer+Micelles+for+Drug+Delivery%3A+Design%2C+Characterization+and+Biological+Significance&doi=10.1016%2FS0169-409X%2800%2900124-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Block copolymer micelles for drug delivery: design, characterization and biological significance</span></div><div class="casAuthors">Kataoka, K.; Harada, A.; Nagasaki, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-131</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 94 refs.  Recently, colloidal carrier systems have been receiving much attention in the field of drug targeting because of their high loading capacity for drugs as well as their unique disposition characteristics in the body.  This paper highlights the utility of polymeric micelles formed through the multimol. assembly of block copolymers as novel core-shell typed colloidal carriers for drug and gene targeting.  The process of micellization in aq. milieu is described in detail based on differences in the driving force of core segregation, including hydrophobic interaction, electrostatic interaction, metal complexation, and hydrogen bonding of constituent block copolymers.  The segregated core embedded in the hydrophilic palisade is shown to function as a reservoir for genes, enzymes, and a variety of drugs with diverse characteristics.  Functionalization of the outer surface of the polymeric micelle to modify its physicochem. and biol. properties is reviewed from the standpoint of designing micellar carrier systems for receptor-mediated drug delivery.  Further, the distribution of polymeric micelles is described to demonstrate their long-circulating characteristics and significant tumor accumulation, emphasizing their promising utility in tumor-targeting therapy.  As an important perspective on carrier systems based on polymeric micelles, their feasibility as non-viral gene vectors is also summarized in this review article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUrMDCJxgepbVg90H21EOLACvtfcHk0ljlxq7c8iXkFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvVajs78%253D&md5=00f04e4f6e4071c41db0403f8232d170</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900124-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900124-1%26sid%3Dliteratum%253Aachs%26aulast%3DKataoka%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DA.%26aulast%3DNagasaki%26aufirst%3DY.%26atitle%3DBlock%2520Copolymer%2520Micelles%2520for%2520Drug%2520Delivery%253A%2520Design%252C%2520Characterization%2520and%2520Biological%2520Significance%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D47%26spage%3D113%26epage%3D131%26doi%3D10.1016%2FS0169-409X%2800%2900124-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span>M.D. Anderson Cancer Center, NanoCarrier Co., Ltd. A Phase 1 Dose-Escalation and Pharmacokinetic Study of Nc-4016 in Patients with Advanced Solid Tumors or Lymphoma. <a href="https://clinicaltrials.gov/ct2/show/NCT01999491" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01999491</a> (accessed August 01,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=M.D.+Anderson+Cancer+Center%2C+NanoCarrier+Co.%2C+Ltd.+A+Phase+1+Dose-Escalation+and+Pharmacokinetic+Study+of+Nc-4016+in+Patients+with+Advanced+Solid+Tumors+or+Lymphoma.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01999491+%28accessed+August+01%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span>Nanocarrier. Research and Development Pipeline. <a href="http://www.nanocarrier.co.jp/en/research/pipeline/index.html" class="extLink">http://www.nanocarrier.co.jp/en/research/pipeline/index.html</a> (accessed July 30,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Nanocarrier.+Research+and+Development+Pipeline.+http%3A%2F%2Fwww.nanocarrier.co.jp%2Fen%2Fresearch%2Fpipeline%2Findex.html+%28accessed+July+30%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Nowotnik, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cvitkovic, E.</span><span> </span><span class="NLM_article-title">Prolindac (Ap5346): A Review of the Development of an HPMA DACH Platinum Polymer Therapeutic</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1214</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span><span class="refDoi"> DOI: 10.1016/j.addr.2009.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.addr.2009.06.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1214-1219&author=D.+P.+Nowotnikauthor=E.+Cvitkovic&title=Prolindac+%28Ap5346%29%3A+A+Review+of+the+Development+of+an+HPMA+DACH+Platinum+Polymer+Therapeutic&doi=10.1016%2Fj.addr.2009.06.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2009.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2009.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DNowotnik%26aufirst%3DD.%2BP.%26aulast%3DCvitkovic%26aufirst%3DE.%26atitle%3DProlindac%2520%2528Ap5346%2529%253A%2520A%2520Review%2520of%2520the%2520Development%2520of%2520an%2520HPMA%2520DACH%2520Platinum%2520Polymer%2520Therapeutic%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2009%26volume%3D61%26spage%3D1214%26epage%3D1219%26doi%3D10.1016%2Fj.addr.2009.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Duncan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicent, M. J.</span><span> </span><span class="NLM_article-title">Do Hpma Copolymer Conjugates Have a Future as Clinically Useful Nanomedicines? A Critical Overview of Current Status and Future Opportunities</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span><span class="refDoi"> DOI: 10.1016/j.addr.2009.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.addr.2009.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=272-282&author=R.+Duncanauthor=M.+J.+Vicent&title=Do+Hpma+Copolymer+Conjugates+Have+a+Future+as+Clinically+Useful+Nanomedicines%3F+A+Critical+Overview+of+Current+Status+and+Future+Opportunities&doi=10.1016%2Fj.addr.2009.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2009.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2009.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DDuncan%26aufirst%3DR.%26aulast%3DVicent%26aufirst%3DM.%2BJ.%26atitle%3DDo%2520Hpma%2520Copolymer%2520Conjugates%2520Have%2520a%2520Future%2520as%2520Clinically%2520Useful%2520Nanomedicines%253F%2520A%2520Critical%2520Overview%2520of%2520Current%2520Status%2520and%2520Future%2520Opportunities%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D272%26epage%3D282%26doi%3D10.1016%2Fj.addr.2009.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Carter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Antibody-Drug Conjugates for Cancer Therapy</span> <span class="citation_source-journal">Cancer J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1097/PPO.0b013e318172d704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1097%2FPPO.0b013e318172d704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=18536555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlWlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=154-169&author=P.+J.+Carterauthor=P.+D.+Senter&title=Antibody-Drug+Conjugates+for+Cancer+Therapy&doi=10.1097%2FPPO.0b013e318172d704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Carter, Paul J.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-169</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The antibody-drug conjugate (ADC) concept is to use an antibody to deliver a cytotoxic drug selectively to a target such as a tumor-assocd. antigen.  Such conjugates represent a broadly applicable approach to enhance the antitumor activity of antibodies and improve the tumor-to-normal tissue selectivity of chemotherapy.  Crit. parameters for ADC development include target antigen selection, conjugate internalization by tumor cells, drug potency and stability of the linker between drug and antibody.  Other important considerations include the conjugation methods, drug-to-antibody ratio, and the effects of drug conjugation on antibody properties.  Highly potent drugs with more stable linkers have been attached to a new generation of antibodies to create conjugates with pronounced antitumor activities in preclin. studies and encouraging results in early stage clin. trials.  This review details these advances, discusses some of the remaining challenges, and overviews ADCs currently in clin. trials for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXcG9SMjwzf7Vg90H21EOLACvtfcHk0lhldONUqzcHmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlWlsLo%253D&md5=457f161e8dda16b17f74a269af4a17dd</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1097%2FPPO.0b013e318172d704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0b013e318172d704%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DP.%2BJ.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody-Drug%2520Conjugates%2520for%2520Cancer%2520Therapy%26jtitle%3DCancer%2520J.%26date%3D2008%26volume%3D14%26spage%3D154%26epage%3D169%26doi%3D10.1097%2FPPO.0b013e318172d704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">Ado-Trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for Her2-Positive Breast Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6949</span><span class="NLM_x">–</span> <span class="NLM_lpage">6964</span><span class="refDoi"> DOI: 10.1021/jm500766w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500766w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6949-6964&author=J.+M.+Lambertauthor=R.+V.+Chari&title=Ado-Trastuzumab+Emtansine+%28T-DM1%29%3A+An+Antibody-Drug+Conjugate+%28ADC%29+for+Her2-Positive+Breast+Cancer&doi=10.1021%2Fjm500766w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer</span></div><div class="casAuthors">Lambert, John M.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6949-6964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor receptor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent, joined by a stable linker.  Upon binding to HER2, the conjugate is internalized via receptor-mediated endocytosis, and an active deriv. of DM1 is subsequently released by proteolytic degrdn. of the antibody moiety within the lysosome.  Initial clin. evaluation led to a phase III trial in advanced HER2-pos. breast cancer patients who had relapsed after prior treatment with trastuzumab and a taxane, which showed that T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine.  In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-pos. metastatic breast cancer who had previously received trastuzumab and a taxane, sep. or in combination, the first ADC to receive full approval based on a randomized study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAu4MvRWFwLVg90H21EOLACvtfcHk0lhldONUqzcHmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7rE&md5=3ddee50cc227097126dd47e7683a6ac7</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm500766w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500766w%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DAdo-Trastuzumab%2520Emtansine%2520%2528T-DM1%2529%253A%2520An%2520Antibody-Drug%2520Conjugate%2520%2528ADC%2529%2520for%2520Her2-Positive%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6949%26epage%3D6964%26doi%3D10.1021%2Fjm500766w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Mehmood, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qasem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeeshan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jehangir, E.</span><span> </span><span class="NLM_article-title">Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibody Treatments</span> <span class="citation_source-journal">Oncol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.4081/oncol.2014.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.4081%2Foncol.2014.256" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=97-108&author=R.+K.+Mehmoodauthor=J.+Parkerauthor=S.+Ahmedauthor=E.+Qasemauthor=A.+A.+Mohammedauthor=M.+Zeeshanauthor=E.+Jehangir&title=Review+of+Cisplatin+and+Oxaliplatin+in+Current+Immunogenic+and+Monoclonal+Antibody+Treatments&doi=10.4081%2Foncol.2014.256"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.4081%2Foncol.2014.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4081%252Foncol.2014.256%26sid%3Dliteratum%253Aachs%26aulast%3DMehmood%26aufirst%3DR.%2BK.%26aulast%3DParker%26aufirst%3DJ.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DQasem%26aufirst%3DE.%26aulast%3DMohammed%26aufirst%3DA.%2BA.%26aulast%3DZeeshan%26aufirst%3DM.%26aulast%3DJehangir%26aufirst%3DE.%26atitle%3DReview%2520of%2520Cisplatin%2520and%2520Oxaliplatin%2520in%2520Current%2520Immunogenic%2520and%2520Monoclonal%2520Antibody%2520Treatments%26jtitle%3DOncol.%2520Rev.%26date%3D2014%26volume%3D8%26spage%3D97%26epage%3D108%26doi%3D10.4081%2Foncol.2014.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Huang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span> </span><span class="NLM_article-title">Biological Evaluation of a Novel Herceptin-Platinum (II) Conjugate for Efficient and Cancer Cell Specific Delivery</span> <span class="citation_source-journal">Biomed. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1016/j.biopha.2015.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1016%2Fj.biopha.2015.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26211591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVeksL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2015&pages=116-122&author=R.+Huangauthor=Y.+Sunauthor=X.+Y.+Zhangauthor=B.+W.+Sunauthor=Q.+C.+Wangauthor=J.+Zhu&title=Biological+Evaluation+of+a+Novel+Herceptin-Platinum+%28II%29+Conjugate+for+Efficient+and+Cancer+Cell+Specific+Delivery&doi=10.1016%2Fj.biopha.2015.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery</span></div><div class="casAuthors">Huang, Rong; Sun, Yu; Zhang, Xiang-yang; Sun, Bai-wang; Wang, Qiu-cui; Zhu, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-122</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Platinum-based drugs have been widely used for the treatment of malignant tumors.  However, their applications are limited by severe side effects for their lack of selectivity for cancer cells.  The development of antibody drug conjugates (ADCs) have provided a platform to reduce drug toxicity and improve drug efficacy.  Here we describe a nover conjugate comprising of Herceptin (an anti-HER2 antibody) and platinum drug via a cathepsin B cleavable dipetide for enhancing drug accumulation and HER2-pos. cancer cell specific delivery.  This conjugate is believed to be cleaved by cathepsin B, leading to a 1,6-elimination reaction and activation of drug release.  Herceptin-Pt(II) is evaluated to have approx. loaded with 6.4 mol platinum drugs per mol of antibody.  We demonstrate that Herceptin-Pt(II) retain high and selective binding affinity for HER2 protein and HER2-pos. SK-BR-3 cancer cells.  The in vitro cytotoxicity tests indicate that Herceptin-Pt(II) exhibits much higher cytotoxicity than oxaliplatin against SK-BR-3 cells.  More importantly, Herceptin-Pt(II) shows no obvious inhibition against the growth of both MCF-7 and MDA-MB-231 cells, which express lower levels of HER2.  Furthermore, compared with free oxaliplatin, Herceptin significantly improved the cellular uptake of platinum drugs in SK-BR-3 cells.  In summary, Herceptin-platinum (II) conjugate is a remarkable and potent platform for efficient and cancer cell specific delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp4caYAhtmNbVg90H21EOLACvtfcHk0lgVZ3CS8vrsyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVeksL%252FO&md5=78c38ba2afa07c50ec7c9bb38a6b4c9e</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2015.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2015.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BY.%26aulast%3DSun%26aufirst%3DB.%2BW.%26aulast%3DWang%26aufirst%3DQ.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DBiological%2520Evaluation%2520of%2520a%2520Novel%2520Herceptin-Platinum%2520%2528II%2529%2520Conjugate%2520for%2520Efficient%2520and%2520Cancer%2520Cell%2520Specific%2520Delivery%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2015%26volume%3D73%26spage%3D116%26epage%3D122%26doi%3D10.1016%2Fj.biopha.2015.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Lasorsa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Losacco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobazzi, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzariti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natile, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnesano, F.</span><span> </span><span class="NLM_article-title">Probing the Interaction between Cisplatin and the Therapeutic Monoclonal Antibody Trastuzumab</span> <span class="citation_source-journal">RSC Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">29229</span><span class="NLM_x">–</span> <span class="NLM_lpage">29236</span><span class="refDoi"> DOI: 10.1039/C6RA04337B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC6RA04337B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVOntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=29229-29236&author=A.+Lasorsaauthor=M.+Losaccoauthor=R.+M.+Iacobazziauthor=L.+Porcelliauthor=A.+Azzaritiauthor=G.+Natileauthor=F.+Arnesano&title=Probing+the+Interaction+between+Cisplatin+and+the+Therapeutic+Monoclonal+Antibody+Trastuzumab&doi=10.1039%2FC6RA04337B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab</span></div><div class="casAuthors">Lasorsa, Alessia; Losacco, Maurizio; Iacobazzi, Rosa Maria; Porcelli, Letizia; Azzariti, Amalia; Natile, Giovanni; Arnesano, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">29229-29236</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Trastuzumab (Herceptin) is a fully humanized monoclonal Ig γ-1 (IgG1) antibody directed against the HER2/neu receptor, which is up-regulated in about 20-25% of gastric and breast cancer patients.  The combination of trastuzumab with cisplatin results in a favorable toxicity profile in the case of advanced HER2-pos. gastric and gastroesophageal cancers, gaining the approval by the U.  S. FDA in 2010. However, the current literature reveals no at. details about platinum drug-trastuzumab interactions, probably because of size limitations.  Our research aim has been to probe the interaction between the monoclonal antibody trastuzumab and cisplatin by means of electrospray mass spectrometry anal. within the "divide and conquer" approach and 1H, 15N-HSQC NMR spectroscopy (using 15N-labeled cisplatin).  We demonstrate that trastuzumab is able to bind platinum and that there is no involvement of the residues belonging to the antigen-binding region so that the receptor recognition is not affected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzZyw236U9YrVg90H21EOLACvtfcHk0lgVZ3CS8vrsyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVOntr0%253D&md5=acafafadd64cfdf6917a026172fa576e</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1039%2FC6RA04337B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6RA04337B%26sid%3Dliteratum%253Aachs%26aulast%3DLasorsa%26aufirst%3DA.%26aulast%3DLosacco%26aufirst%3DM.%26aulast%3DIacobazzi%26aufirst%3DR.%2BM.%26aulast%3DPorcelli%26aufirst%3DL.%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DNatile%26aufirst%3DG.%26aulast%3DArnesano%26aufirst%3DF.%26atitle%3DProbing%2520the%2520Interaction%2520between%2520Cisplatin%2520and%2520the%2520Therapeutic%2520Monoclonal%2520Antibody%2520Trastuzumab%26jtitle%3DRSC%2520Adv.%26date%3D2016%26volume%3D6%26spage%3D29229%26epage%3D29236%26doi%3D10.1039%2FC6RA04337B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Mei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maecker, H. T.</span><span> </span><span class="NLM_article-title">Platinum-Conjugated Antibodies for Application in Mass Cytometry</span> <span class="citation_source-journal">Cytometry, Part A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1002/cyto.a.22778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fcyto.a.22778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26355391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28Xksl2qsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=292-300&author=H.+E.+Meiauthor=M.+D.+Leipoldauthor=H.+T.+Maecker&title=Platinum-Conjugated+Antibodies+for+Application+in+Mass+Cytometry&doi=10.1002%2Fcyto.a.22778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum-conjugated antibodies for application in mass cytometry</span></div><div class="casAuthors">Mei, Henrik E.; Leipold, Michael D.; Maecker, Holden T.</div><div class="citationInfo"><span class="NLM_cas:title">Cytometry, Part A</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-300</span>CODEN:
                <span class="NLM_cas:coden">CPAYAV</span>;
        ISSN:<span class="NLM_cas:issn">1552-4922</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mass cytometry has overcome limitations of fluorescent single cell cytometry by allowing for the measurement of up to currently ∼40 different parameters on a single cell level.  However, the cellular proteome comprises many more potential analytes, and current mass cytometry instrumentation allows for theor. up to 121 different mass detection channels.  The labeling of specific probes with appropriate metal ions is a significant hurdle for exploiting more of mass cytometry's anal. capacity.  To this end, we here describe the labeling of antibody with natural abundance or isotopically purified platinum as formulated in cisplatin and circumventing the use of chelator-loaded polymers.  We confirm the utility of cisplatin-antibody-conjugates for surface, intracellular, and phosphoepitope-specific immunophenotyping, as well as for application in cell surface CD45-based barcoding.  Cisplatin-labeling of antibody increases the anal. capacity of the CyTOF platform by two channels based on available reagents, and has the potential to add a total of six channels for detection of specific probes, thus helping to better extend the anal. mass range of mass cytometers. © 2015 International Society for Advancement of Cytometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorrsgfqkQvM7Vg90H21EOLACvtfcHk0lgVZ3CS8vrsyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xksl2qsbc%253D&md5=237ede329da694217c65d93b1fa1005a</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fcyto.a.22778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcyto.a.22778%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DH.%2BE.%26aulast%3DLeipold%26aufirst%3DM.%2BD.%26aulast%3DMaecker%26aufirst%3DH.%2BT.%26atitle%3DPlatinum-Conjugated%2520Antibodies%2520for%2520Application%2520in%2520Mass%2520Cytometry%26jtitle%3DCytometry%252C%2520Part%2520A%26date%3D2016%26volume%3D89%26spage%3D292%26epage%3D300%26doi%3D10.1002%2Fcyto.a.22778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Waalboer, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muns, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sijbrandi, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schasfoort, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haselberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somsen, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houthoff, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dongen, G. A.</span><span> </span><span class="NLM_article-title">Platinum(II) as Bifunctional Linker in Antibody-Drug Conjugate Formation: Coupling of a 4-Nitrobenzo-2-Oxa-1,3-Diazole Fluorophore to Trastuzumab as a Model</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1002/cmdc.201402496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fcmdc.201402496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25809281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFWlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=797-803&author=D.+C.+Waalboerauthor=J.+A.+Munsauthor=N.+J.+Sijbrandiauthor=R.+B.+Schasfoortauthor=R.+Haselbergauthor=G.+W.+Somsenauthor=H.+J.+Houthoffauthor=G.+A.+Van+Dongen&title=Platinum%28II%29+as+Bifunctional+Linker+in+Antibody-Drug+Conjugate+Formation%3A+Coupling+of+a+4-Nitrobenzo-2-Oxa-1%2C3-Diazole+Fluorophore+to+Trastuzumab+as+a+Model&doi=10.1002%2Fcmdc.201402496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(II) as bifunctional linker in antibody-drug conjugate formation: Coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model</span></div><div class="casAuthors">Waalboer, Dennis C. J.; Muns, Joey A.; Sijbrandi, Niels J.; Schasfoort, Richard B. M.; Haselberg, Rob; Somsen, Govert W.; Houthoff, Hendrik-Jan; van Dongen, Guus A. M. S.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">797-803</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The potential of platinum(II) as a bifunctional linker in the coordination of small mols., such as imaging agents or (cytotoxic) drugs, to monoclonal antibodies (mAbs) was investigated with a 4-nitrobenzo-2-oxa-1,3-diazole (NBD) fluorophore and trastuzumab (Herceptin®) as a model antibody.  The effect of ligand and reaction conditions on conjugation efficiency was explored for [Pt(en)(L-NBD)Cl](NO3) (en=ethylenediamine), with L=N-heteroarom., N-alkyl amine, or thioether.  Conjugation proceeded most efficiently at pH 8.0 in the presence of NaClO4 or Na2SO4 in tricine or HEPES buffer.  Reaction of N-coordinated complexes (20 equiv) with trastuzumab at 37 °C for 2 h, followed by removal of weakly bound complexes with excess thiourea, afforded conjugates with an NBD/mAb ratio of 1.5-2.9 that were stable in phosphate-buffered saline at room temp. for at least 48 h.  In contrast, thioether-coordinated complexes afforded unstable conjugates.  Finally, surface plasmon resonance anal. showed no loss in binding affinity of trastuzumab after conjugation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn2KJu_pLNwLVg90H21EOLACvtfcHk0lg4095UL7uW_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFWlu7k%253D&md5=d25d03ee976ad98150a6c3e7dd299570</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402496%26sid%3Dliteratum%253Aachs%26aulast%3DWaalboer%26aufirst%3DD.%2BC.%26aulast%3DMuns%26aufirst%3DJ.%2BA.%26aulast%3DSijbrandi%26aufirst%3DN.%2BJ.%26aulast%3DSchasfoort%26aufirst%3DR.%2BB.%26aulast%3DHaselberg%26aufirst%3DR.%26aulast%3DSomsen%26aufirst%3DG.%2BW.%26aulast%3DHouthoff%26aufirst%3DH.%2BJ.%26aulast%3DVan%2BDongen%26aufirst%3DG.%2BA.%26atitle%3DPlatinum%2528II%2529%2520as%2520Bifunctional%2520Linker%2520in%2520Antibody-Drug%2520Conjugate%2520Formation%253A%2520Coupling%2520of%2520a%25204-Nitrobenzo-2-Oxa-1%252C3-Diazole%2520Fluorophore%2520to%2520Trastuzumab%2520as%2520a%2520Model%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D797%26epage%3D803%26doi%3D10.1002%2Fcmdc.201402496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Johnstone, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suntharalingam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span> <span class="citation_source-journal">Chem. Rev. (Washington, DC, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">3436</span><span class="NLM_x">–</span> <span class="NLM_lpage">3486</span><span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=3436-3486&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=The+Next+Generation+of+Platinum+Drugs%3A+Targeted+Pt%28II%29+Agents%2C+Nanoparticle+Delivery%2C+and+Pt%28IV%29+Prodrugs&doi=10.1021%2Facs.chemrev.5b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span></div><div class="casAuthors">Johnstone, Timothy C.; Suntharalingam, Kogularamanan; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3436-3486</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic.  Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs.  The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs.  In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs.  The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished.  We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compds., platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes.  Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles.  Addnl. nanoformulations, including supramol. self-assembled structures, proteins, peptides, metal-org. frameworks, and coordination polymers, will then be described.  Finally, the significant clin. progress made by nanoparticle formulations of platinum(II) agents will be reviewed.  We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKCOwDrVtJrVg90H21EOLACvtfcHk0lg4095UL7uW_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D&md5=d7adf3279441d8e56bddf501f06cda6e</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00597%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Next%2520Generation%2520of%2520Platinum%2520Drugs%253A%2520Targeted%2520Pt%2528II%2529%2520Agents%252C%2520Nanoparticle%2520Delivery%252C%2520and%2520Pt%2528IV%2529%2520Prodrugs%26jtitle%3DChem.%2520Rev.%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2016%26volume%3D116%26spage%3D3436%26epage%3D3486%26doi%3D10.1021%2Facs.chemrev.5b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Mukhopadhyay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haskel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1021/bc070031k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc070031k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWhtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=39-49&author=S.+Mukhopadhyayauthor=C.+M.+Barnesauthor=A.+Haskelauthor=S.+M.+Shortauthor=K.+R.+Barnesauthor=S.+J.+Lippard&title=Conjugated+Platinum%28IV%29-Peptide+Complexes+for+Targeting+Angiogenic+Tumor+Vasculature&doi=10.1021%2Fbc070031k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature</span></div><div class="casAuthors">Mukhopadhyay, Sumitra; Barnes, Carmen M.; Haskel, Ariel; Short, Sarah M.; Barnes, Katie R.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-49</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The integrins αvβ3 and αvβ5 and the membrane-spanning surface protein aminopeptidase N (APN) are highly expressed in tumor-induced angiogenesis, making them attractive targets for therapeutic intervention.  Both integrins and APN recognize a broad range of peptides contg. RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) motifs, resp.  Here, we describe the design, synthesis, and characterization of a series of mono- and difunctionalized platinum(IV) complexes in which a conjugated peptide motif, contg. RGD, (CRGDC)c, (RGDfK)c, or NGR, is appended as a "tumor-homing device" to target tumor endothelial cells selectively over healthy cells. Platinum(IV)-peptide complexes with nonspecific amino acids or peptide moieties were prepd. as controls.  Concn.-response curves of these compds. were evaluated against primary proliferating endothelial cells and tumor cell lines and compared to those of cisplatin, a well-described platinum-based chemotherapeutic agent.  The Pt(IV)-RGD conjugates were highly and specifically cytotoxic to cell lines contg. αvβ3 and αvβ5, approaching the activity of cisplatin.  The Pt(IV)-NGR complexes were less active than Pt(IV)-RGD-contg. compds. but more active than nonspecific Pt-peptide controls.  Integrin αvβ3 mediated, at least in part, the anti-proliferative effect of a Pt(IV)-RGD conjugate, as demonstrated by a decreased inhibitory response when endothelial cells were either (1) incubated with an excess of αvβ3/αvβ5-specific RGD pentapeptides or (2) transfected with RNAi for β3, but not β1, integrins.  These results suggest a rational approach to improved chemotherapy with Pt(IV)-peptide conjugates by selective drug delivery to the tumor compartment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl92LLNxja-rVg90H21EOLACvtfcHk0lg4095UL7uW_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWhtbzJ&md5=d12897f15d2582321ee037868e81c87c</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fbc070031k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc070031k%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DS.%26aulast%3DBarnes%26aufirst%3DC.%2BM.%26aulast%3DHaskel%26aufirst%3DA.%26aulast%3DShort%26aufirst%3DS.%2BM.%26aulast%3DBarnes%26aufirst%3DK.%2BR.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DConjugated%2520Platinum%2528IV%2529-Peptide%2520Complexes%2520for%2520Targeting%2520Angiogenic%2520Tumor%2520Vasculature%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D39%26epage%3D49%26doi%3D10.1021%2Fbc070031k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Massaguer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Canto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escribano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrabes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artigas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchan, V.</span><span> </span><span class="NLM_article-title">Integrin-Targeted Delivery into Cancer Cells of a Pt(IV) Pro-Drug through Conjugation to Rgd-Containing Peptides</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1039/C4DT02710H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC4DT02710H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25369773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGisr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=202-212&author=A.+Massaguerauthor=A.+Gonzalez-Cantoauthor=E.+Escribanoauthor=S.+Barrabesauthor=G.+Artigasauthor=V.+Morenoauthor=V.+Marchan&title=Integrin-Targeted+Delivery+into+Cancer+Cells+of+a+Pt%28IV%29+Pro-Drug+through+Conjugation+to+Rgd-Containing+Peptides&doi=10.1039%2FC4DT02710H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides</span></div><div class="casAuthors">Massaguer, Anna; Gonzalez-Canto, Alejandro; Escribano, Esther; Barrabes, Silvia; Artigas, Gerard; Moreno, Virtudes; Marchan, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">202-212</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Conjugates of a Pt(IV) deriv. of picoplatin with monomeric (Pt-c(RGDfK)), (5) and tetrameric (Pt-RAFT-{c(RGDfK)}4), (6) RGD-contg. peptides were synthesized with the aim of exploiting their selectivity and high affinity for αVβ3 and αVβ5 integrins for targeted delivery of this anticancer metallodrug to tumor cells overexpressing these receptors.  Solid- and soln.-phase approaches in combination with click chem. were used for the prepn. of the conjugates, which were characterized by high resoln. ESI MS and NMR.  αVβ3 And αVβ5 integrin expression was evaluated in a broad panel of human cancer and non-malignant cells.  SK-MEL-28 melanoma cells were selected based on the high expression levels of both integrins, while CAPAN-1 pancreatic cancer cells and 1BR3G fibroblasts were selected as the neg. control.  Internalization expts. revealed a good correlation between integrin expression and the cellular uptake of the corresponding fluorescein-labeled peptides and that the internalization capacity of the tetrameric RGD-contg. peptide was considerably higher than that of the monomeric one.  Cytotoxic expts. indicated that the antitumor activity of picoplatin in melanoma cells was increased by 2.6-fold when its Pt(IV) deriv. was conjugated to c(RGDfK) (IC50 = 12.8 ± 2.1 μM) and by 20-fold when conjugated to RAFT-{c(RGDfK)}4 (IC50 = 1.7 ± 0.6 μM).  In contrast, the cytotoxicity of the conjugates was inhibited in control cells lacking αVβ3 and αVβ5 integrin expression.  Finally, cellular uptake studies by ICP-MS confirmed a good correlation between the levels of expression of integrins, intracellular platinum accumulation and antitumor activity.  Indeed, accumulation and cytotoxicity were much higher in SK-MEL-28 cells than in CAPAN-1, being particularly higher in the case of the tetrameric conjugate.  The overall results highlight that the great ability of RAFT-{c(RGDfK)}4 to bind to and to be internalized by integrins overexpressed in SK-MEL-28 cells results in higher accumulation of the Pt(IV) complex, leading to a high antitumor activity.  These studies provide new insights into the potential of targeting αVβ3 and αVβ5 integrins with Pt(IV) anticancer pro-drugs conjugated to tumor-targeting devices based on RGD-contg. peptides, particularly on how multivalency can improve both the selectivity and potency of such metallodrugs by increasing cellular accumulation in tumor tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIlGCFXdzfPbVg90H21EOLACvtfcHk0ljBLvga8bxWuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGisr3F&md5=9df742389cee81f670e03c5aafb7282b</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1039%2FC4DT02710H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4DT02710H%26sid%3Dliteratum%253Aachs%26aulast%3DMassaguer%26aufirst%3DA.%26aulast%3DGonzalez-Canto%26aufirst%3DA.%26aulast%3DEscribano%26aufirst%3DE.%26aulast%3DBarrabes%26aufirst%3DS.%26aulast%3DArtigas%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DMarchan%26aufirst%3DV.%26atitle%3DIntegrin-Targeted%2520Delivery%2520into%2520Cancer%2520Cells%2520of%2520a%2520Pt%2528IV%2529%2520Pro-Drug%2520through%2520Conjugation%2520to%2520Rgd-Containing%2520Peptides%26jtitle%3DDalton%2520Trans.%26date%3D2015%26volume%3D44%26spage%3D202%26epage%3D212%26doi%3D10.1039%2FC4DT02710H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Gibson, D.</span><span> </span><span class="NLM_article-title">The Mechanism of Action of Platinum Anticancer Agents--What Do We Really Know About It?</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">10681</span><span class="NLM_x">–</span> <span class="NLM_lpage">10689</span><span class="refDoi"> DOI: 10.1039/b918871c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2Fb918871c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=10681-10689&author=D.+Gibson&title=The+Mechanism+of+Action+of+Platinum+Anticancer+Agents%2D%2DWhat+Do+We+Really+Know+About+It%3F&doi=10.1039%2Fb918871c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1039%2Fb918871c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb918871c%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DThe%2520Mechanism%2520of%2520Action%2520of%2520Platinum%2520Anticancer%2520Agents--What%2520Do%2520We%2520Really%2520Know%2520About%2520It%253F%26jtitle%3DDalton%2520Trans.%26date%3D2009%26volume%3D48%26spage%3D10681%26epage%3D10689%26doi%3D10.1039%2Fb918871c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Klein, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Platinum Drug Distribution in Cancer Cells and Tumors</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">4911</span><span class="NLM_x">–</span> <span class="NLM_lpage">4920</span><span class="refDoi"> DOI: 10.1021/cr9001066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9001066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGktbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=4911-4920&author=A.+V.+Kleinauthor=T.+W.+Hambley&title=Platinum+Drug+Distribution+in+Cancer+Cells+and+Tumors&doi=10.1021%2Fcr9001066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum Drug Distribution in Cancer Cells and Tumors</span></div><div class="casAuthors">Klein, Alice V.; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4911-4920</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the recent advances made in the understanding of how the platinum drug enter and exit cells, their intracellular behavior and distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorm8HZ2Ow8obVg90H21EOLACvtfcHk0ljBLvga8bxWuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGktbrK&md5=52e875daab0f8922c581179d988b094c</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fcr9001066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9001066%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DA.%2BV.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DPlatinum%2520Drug%2520Distribution%2520in%2520Cancer%2520Cells%2520and%2520Tumors%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26spage%3D4911%26epage%3D4920%26doi%3D10.1021%2Fcr9001066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Molenaar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teuben, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heetebrij, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reedijk, J.</span><span> </span><span class="NLM_article-title">New Insights in the Cellular Processing of Platinum Antitumor Compounds, Using Fluorophore-Labeled Platinum Complexes and Digital Fluorescence Microscopy</span> <span class="citation_source-journal">JBIC, J. Biol. Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1007/s007750000153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2Fs007750000153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=11085656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2000&pages=655-665&author=C.+Molenaarauthor=J.+M.+Teubenauthor=R.+J.+Heetebrijauthor=H.+J.+Tankeauthor=J.+Reedijk&title=New+Insights+in+the+Cellular+Processing+of+Platinum+Antitumor+Compounds%2C+Using+Fluorophore-Labeled+Platinum+Complexes+and+Digital+Fluorescence+Microscopy&doi=10.1007%2Fs007750000153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy</span></div><div class="casAuthors">Molenaar, Chris; Teuben, Jan-Maarten; Heetebrij, Robert J.; Tanke, Hans J.; Reedijk, Jan</div><div class="citationInfo"><span class="NLM_cas:title">JBIC, Journal of Biological Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-665</span>CODEN:
                <span class="NLM_cas:coden">JJBCFA</span>;
        ISSN:<span class="NLM_cas:issn">0949-8257</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The cellular distribution and processing pathways of two platinum compds., modeling the antitumor drug cisplatin (cDDP) in human osteosarcoma (U2-OS) cells is reported.  A [Pt(en)Cl2] entity has been covalently linked to a carboxyfluorescein diacetate (CFDA) moiety and to a dinitrophenyl (DNP) moiety.  The two different constructs were administered to living cell cultures that were analyzed using digital fluorescence microscopy.  The non-fluorescent CFDA construct becomes fluorescent after cellular uptake and subsequent acetate hydrolysis by esterases, and is therefore suitable to monitor platinum in living cells; the DNP construct can be visualized by immunocytochem. and consequently serves as a control.  Both complexes were readily internalized by the cells, and localized throughout the whole cell.  After 2-3 h the complex accumulated in the nucleus, but 6-8 h after incubation a punctuate staining of a cytoplasmic region was obsd., that persisted and became more pronounced after 24 h.  The overall fluorescence in the cell decreased over time, implying a secretion of the platinum complex.  Surprisingly, the accumulation remained visible after 72 h.  Co-localization expts. with a Golgi app.-selective stain indicate the involvement of Golgi vesicles in intracellular processing of cisplatin-derived complexes.  Immunocytochem. studies, using the DNP deriv., resulted in very similar images as obtained with the CFDA construct.  CFDA-boc (a non-platinum-contg. fluorescein deriv.) was used as control: a faint staining throughout the whole cell was obsd.  Cisplatin-resistant U2-OS/Pt cells showed staining patterns very similar to the U2-OS cells using both platinum constructs.  This study illustrates that only a very small portion of the platinum complex eventually remains bound to DNA, as after 24 h no significant fluorescence could be obsd. in the nucleus.  Cisplatin-derived complexes with fluorescent tags afford a new insight into the cellular processing of these complexes and therefore may contribute to further unraveling of the mechanism of platinum antitumor complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1jhTmbtSu_bVg90H21EOLACvtfcHk0ljBLvga8bxWuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1Gkurg%253D&md5=d2ccdb9612fed820d117245012efa594</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1007%2Fs007750000153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs007750000153%26sid%3Dliteratum%253Aachs%26aulast%3DMolenaar%26aufirst%3DC.%26aulast%3DTeuben%26aufirst%3DJ.%2BM.%26aulast%3DHeetebrij%26aufirst%3DR.%2BJ.%26aulast%3DTanke%26aufirst%3DH.%2BJ.%26aulast%3DReedijk%26aufirst%3DJ.%26atitle%3DNew%2520Insights%2520in%2520the%2520Cellular%2520Processing%2520of%2520Platinum%2520Antitumor%2520Compounds%252C%2520Using%2520Fluorophore-Labeled%2520Platinum%2520Complexes%2520and%2520Digital%2520Fluorescence%2520Microscopy%26jtitle%3DJBIC%252C%2520J.%2520Biol.%2520Inorg.%2520Chem.%26date%3D2000%26volume%3D5%26spage%3D655%26epage%3D665%26doi%3D10.1007%2Fs007750000153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Benedetti, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabolizadeh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipping, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, N. P.</span><span> </span><span class="NLM_article-title">Effects of Noncovalent Platinum Drug–Protein Interactions on Drug Efficacy: Use of Fluorescent Conjugates as Probes for Drug Metabolism</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">–</span> <span class="NLM_lpage">948</span><span class="refDoi"> DOI: 10.1021/mp2000583</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2000583" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVCntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=940-948&author=B.+T.+Benedettiauthor=E.+J.+Petersonauthor=P.+Kabolizadehauthor=A.+Mart%C3%ADnezauthor=R.+Kippingauthor=N.+P.+Farrell&title=Effects+of+Noncovalent+Platinum+Drug%E2%80%93Protein+Interactions+on+Drug+Efficacy%3A+Use+of+Fluorescent+Conjugates+as+Probes+for+Drug+Metabolism&doi=10.1021%2Fmp2000583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Noncovalent Platinum Drug-Protein Interactions on Drug Efficacy: Use of Fluorescent Conjugates as Probes for Drug Metabolism</span></div><div class="casAuthors">Benedetti, Brad T.; Peterson, Erica J.; Kabolizadeh, Peyman; Martinez, Alberto; Kipping, Ralph; Farrell, Nicholas P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">940-948</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The overall efficacy of Pt based drugs is limited by metabolic deactivation through covalent drug-protein binding.  In this study the factors affecting cytotoxicity in the presence of glutathione, human serum albumin (HSA) and whole serum binding with cisplatin, BBR3464, and TriplatinNC, a "noncovalent" deriv. of BBR3464, were investigated.  Upon treatment with buthionine sulfoximine (BSO), to reduce cellular glutathione levels, cisplatin and BBR3464-induced apoptosis was augmented whereas TriplatinNC-induced cytotoxicity was unaltered.  Treatment of A2780 ovarian carcinoma cells with HSA-bound cisplatin (cisplatin/HSA) and cisplatin preincubated with whole serum showed dramatic decreases in cytotoxicity, cellular accumulation, and DNA adduct formation compared to treatment with cisplatin alone.  Similar effects are seen with BBR3464.  In contrast, TriplatinNC, the HSA-bound deriv. (TriplatinNC/HSA), and TriplatinNC pretreated with whole serum retained identical cytotoxic profiles and equal levels of cellular accumulation at all time points.  Confocal microscopy of both TriplatinNC-NBD, a fluorescent deriv. of TriplatinNC, and TriplatinNC-NBD/HSA showed nuclear/nucleolar localization patterns, distinctly different from the lysosomal localization pattern seen with HSA.  Cisplatin-NBD, a fluorescent deriv. of cisplatin, was shown to accumulate in the nucleus and throughout the cytoplasm while the localization of cisplatin-NBD/HSA was limited to lysosomal regions of the cytoplasm.  The results suggest that TriplatinNC can avoid high levels of metabolic deactivation currently seen with clin. Pt chemotherapeutics, and therefore retain a unique cytotoxic profile after cellular administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxV4dRhBw_NLVg90H21EOLACvtfcHk0lgQtxdB3Qm-Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVCntb4%253D&md5=a8f72f2d13d66440db7a189a5e544d5f</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fmp2000583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2000583%26sid%3Dliteratum%253Aachs%26aulast%3DBenedetti%26aufirst%3DB.%2BT.%26aulast%3DPeterson%26aufirst%3DE.%2BJ.%26aulast%3DKabolizadeh%26aufirst%3DP.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DKipping%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DN.%2BP.%26atitle%3DEffects%2520of%2520Noncovalent%2520Platinum%2520Drug%25E2%2580%2593Protein%2520Interactions%2520on%2520Drug%2520Efficacy%253A%2520Use%2520of%2520Fluorescent%2520Conjugates%2520as%2520Probes%2520for%2520Drug%2520Metabolism%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2011%26volume%3D8%26spage%3D940%26epage%3D948%26doi%3D10.1021%2Fmp2000583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Miller, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Askevold, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span> </span><span class="NLM_article-title">Platinum Compounds for High-Resolution in Vivo Cancer Imaging</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1131</span><span class="NLM_x">–</span> <span class="NLM_lpage">1135</span><span class="refDoi"> DOI: 10.1002/cmdc.201300502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fcmdc.201300502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=24504646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVekt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1131-1135&author=M.+A.+Millerauthor=B.+Askevoldauthor=K.+S.+Yangauthor=R.+H.+Kohlerauthor=R.+Weissleder&title=Platinum+Compounds+for+High-Resolution+in+Vivo+Cancer+Imaging&doi=10.1002%2Fcmdc.201300502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum Compounds for High-Resolution In Vivo Cancer Imaging</span></div><div class="casAuthors">Miller, Miles A.; Askevold, Bjorn; Yang, Katherine S.; Kohler, Rainer H.; Weissleder, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1131-1135</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Platinum(II) compds., principally cisplatin and carboplatin, are commonly used front-line cancer therapeutics.  Despite their widespread use and continued interest in the development of new derivs., including nanoformulations with improved properties, it has been difficult to visualize platinum compds. in live subjects, in real time, and with subcellular resoln.  Here, we present four novel cisplatin- and carboplatin-derived fluorescent imaging compds. for quant. intravital cancer imaging.  We conjugated 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-daiza-s-indacene (BODIPY) to PtII complexes to generate derivs. with robust in vivo fluorescence and retained DNA-damaging and cytotoxic properties.  We successfully applied these compds. to image pharmacokinetics and tumor uptake in a xenograft cancer mouse model.  By using a genetic reporter of single-cell DNA damage for in vivo imaging, Pt drug accumulation and resultant DNA damage could be monitored in individual tumor cells, at subcellular resoln., and in real time in a live animal model of cancer.  These derivs. represent promising imaging tools that will be useful in understanding further the distribution and interactions of platinum within tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvplifjSYPt7Vg90H21EOLACvtfcHk0lgQtxdB3Qm-Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVekt7k%253D&md5=7ff23d3297f04be571c770a0b14f6a16</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300502%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BA.%26aulast%3DAskevold%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DK.%2BS.%26aulast%3DKohler%26aufirst%3DR.%2BH.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DPlatinum%2520Compounds%2520for%2520High-Resolution%2520in%2520Vivo%2520Cancer%2520Imaging%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1131%26epage%3D1135%26doi%3D10.1002%2Fcmdc.201300502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Jagodinsky, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulima, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poprawski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. D.</span><span> </span><span class="NLM_article-title">Evaluation of Fluorophore-Tethered Platinum Complexes to Monitor the Fate of Cisplatin Analogs</span> <span class="citation_source-journal">JBIC, J. Biol. Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1081</span><span class="NLM_x">–</span> <span class="NLM_lpage">1095</span><span class="refDoi"> DOI: 10.1007/s00775-015-1290-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1007%2Fs00775-015-1290-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=26323351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVaisLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1081-1095&author=J.+C.+Jagodinskyauthor=A.+Sulimaauthor=Y.+Caoauthor=J.+E.+Poprawskiauthor=B.+N.+Blackmanauthor=J.+R.+Lloydauthor=R.+E.+Swensonauthor=M.+M.+Gottesmanauthor=M.+D.+Hall&title=Evaluation+of+Fluorophore-Tethered+Platinum+Complexes+to+Monitor+the+Fate+of+Cisplatin+Analogs&doi=10.1007%2Fs00775-015-1290-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs</span></div><div class="casAuthors">Jagodinsky, Justin C.; Sulima, Agnieszka; Cao, Yiqi; Poprawski, Joanna E.; Blackman, Burchelle N.; Lloyd, John R.; Swenson, Rolf E.; Gottesman, Michael M.; Hall, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">JBIC, Journal of Biological Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1081-1095</span>CODEN:
                <span class="NLM_cas:coden">JJBCFA</span>;
        ISSN:<span class="NLM_cas:issn">0949-8257</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a consequence have been extensively studied in the lab. setting, sometimes by generating fluorophore-tagged analogs.  Here, we synthesized two Pt(II) complexes contg. ethane-1,2-diamine ligands linked to a BODIPY fluorophore, and compared their biol. activity with previously reported Pt(II) complexes conjugated to carboxyfluorescein and carboxyfluorescein diacetate.  The cytotoxicity and DNA damage capacity of Pt-fluorophore complexes was compared to cisplatin, and the Pt-BODIPY complexes were found to be more cytotoxic with reduced cytotoxicity in cisplatin-resistant cells.  Microscopy revealed a predominately cytosolic localization, with nuclear distribution at higher concns.  Spheroids grown from parent and resistant cells revealed penetration of Pt-BODIPY into spheroids, and retention of the cisplatin-resistant spheroid phenotype.  While most activity profiles were retained for the Pt-BODIPY complexes, accumulation in resistant cells was only slightly affected, suggesting that some aspects of Pt-fluorophore cellular pharmacol. deviate from cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0bql22wYtrVg90H21EOLACvtfcHk0lgQtxdB3Qm-Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVaisLfO&md5=33269481f79d3d8e81007a0fa0952e26</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1007%2Fs00775-015-1290-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00775-015-1290-2%26sid%3Dliteratum%253Aachs%26aulast%3DJagodinsky%26aufirst%3DJ.%2BC.%26aulast%3DSulima%26aufirst%3DA.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DPoprawski%26aufirst%3DJ.%2BE.%26aulast%3DBlackman%26aufirst%3DB.%2BN.%26aulast%3DLloyd%26aufirst%3DJ.%2BR.%26aulast%3DSwenson%26aufirst%3DR.%2BE.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DEvaluation%2520of%2520Fluorophore-Tethered%2520Platinum%2520Complexes%2520to%2520Monitor%2520the%2520Fate%2520of%2520Cisplatin%2520Analogs%26jtitle%3DJBIC%252C%2520J.%2520Biol.%2520Inorg.%2520Chem.%26date%3D2015%26volume%3D20%26spage%3D1081%26epage%3D1095%26doi%3D10.1007%2Fs00775-015-1290-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Shen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, B. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charles, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, E. J.</span><span> </span><span class="NLM_article-title">Fluorescent Sensing of Monofunctional Platinum Species</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6312</span><span class="NLM_x">–</span> <span class="NLM_lpage">6314</span><span class="refDoi"> DOI: 10.1039/C4CC08077G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC4CC08077G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=25760940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1OmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=6312-6314&author=C.+Shenauthor=B.+D.+W.+Harrisauthor=L.+J.+Dawsonauthor=K.+A.+Charlesauthor=T.+W.+Hambleyauthor=E.+J.+New&title=Fluorescent+Sensing+of+Monofunctional+Platinum+Species&doi=10.1039%2FC4CC08077G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent sensing of monofunctional platinum species</span></div><div class="casAuthors">Shen, Clara; Harris, Benjamin D. W.; Dawson, Lucy J.; Charles, Kellie A.; Hambley, Trevor W.; New, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">6312-6314</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We report here FDCPt1, a novel selective fluorescent sensor for monofunctional platinum species.  In the presence of such species, FDCPt1 exhibits a 70-fold increase in fluorescence emission, and can be used to monitor the metab. of Pt(II)-based complexes in colorectal cancer cells.  This probe is therefore expected to be valuable in studying changes in Pt coordination and distribution during chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_LtQgEYE1MLVg90H21EOLACvtfcHk0lhaJ_VjbD-Z-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1OmtLc%253D&md5=7a5d1712a6d27ef4ca0ba5e0d3f4d2ac</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1039%2FC4CC08077G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC08077G%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DB.%2BD.%2BW.%26aulast%3DDawson%26aufirst%3DL.%2BJ.%26aulast%3DCharles%26aufirst%3DK.%2BA.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26aulast%3DNew%26aufirst%3DE.%2BJ.%26atitle%3DFluorescent%2520Sensing%2520of%2520Monofunctional%2520Platinum%2520Species%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26spage%3D6312%26epage%3D6314%26doi%3D10.1039%2FC4CC08077G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Ding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suryadi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrs, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucera, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bierbach, U.</span><span> </span><span class="NLM_article-title">Using Fluorescent Post-Labeling to Probe the Subcellular Localization of DNA-Targeted Platinum</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3350</span><span class="NLM_x">–</span> <span class="NLM_lpage">3354</span><span class="refDoi"> DOI: 10.1002/anie.201210079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1002%2Fanie.201210079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=3350-3354&author=S.+Dingauthor=X.+Qiaoauthor=J.+Suryadiauthor=G.+S.+Marrsauthor=G.+L.+Kuceraauthor=U.+Bierbach&title=Using+Fluorescent+Post-Labeling+to+Probe+the+Subcellular+Localization+of+DNA-Targeted+Platinum&doi=10.1002%2Fanie.201210079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1002%2Fanie.201210079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201210079%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DS.%26aulast%3DQiao%26aufirst%3DX.%26aulast%3DSuryadi%26aufirst%3DJ.%26aulast%3DMarrs%26aufirst%3DG.%2BS.%26aulast%3DKucera%26aufirst%3DG.%2BL.%26aulast%3DBierbach%26aufirst%3DU.%26atitle%3DUsing%2520Fluorescent%2520Post-Labeling%2520to%2520Probe%2520the%2520Subcellular%2520Localization%2520of%2520DNA-Targeted%2520Platinum%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D3350%26epage%3D3354%26doi%3D10.1002%2Fanie.201210079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Multifunctional Pt(II) Reagents: Covalent Modifications of Pt Complexes Enable Diverse Structural Variation and in-Cell Detection</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span><span class="refDoi"> DOI: 10.1021/acs.accounts.5b00322</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.5b00322" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=56-66&author=J.+D.+Whiteauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Multifunctional+Pt%28II%29+Reagents%3A+Covalent+Modifications+of+Pt+Complexes+Enable+Diverse+Structural+Variation+and+in-Cell+Detection&doi=10.1021%2Facs.accounts.5b00322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional Pt(II) Reagents: Covalent Modifications of Pt Complexes Enable Diverse Structural Variation and In-Cell Detection</span></div><div class="casAuthors">White, Jonathan D.; Haley, Michael M.; DeRose, Victoria J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-66</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To enhance the functionality of Pt-based reagents, several strategies have been developed that utilize Pt compds. modified with small, reactive handles.  This Account encapsulates work done by us and other groups regarding the use of Pt(II) compds. with reactive handles for subsequent elaboration with fluorophores or other functional moieties.  Described strategies include the incorporation of substituents for well-known condensation or nucleophilic displacement-type reactions and their use, for example, to tether spectroscopic handles to Pt reagents for in vivo investigation.  Other chief uses of displacement-type reactions have included tethering various small mols. exhibiting pharmacol. activity directly to Pt, thus adding synergistic effects.  Click chem.-based ligation techniques have also been applied, primarily with azide- and alkyne-appended Pt complexes.  Orthogonally reactive click chem. reactions have proven invaluable when more traditional nucleophilic displacement reactions induce side-reactivity with the Pt center or when systematic functionalization of a larger no. of Pt complexes is desired.  Addnl., a diverse assortment of Pt-fluorophore conjugates have been tethered via click chem. conjugation.In addn. to providing a convenient synthetic path for diversifying Pt compds., the use of click-capable Pt complexes has proved a powerful strategy for postbinding covalent modification and detection with fluorescent probes.  This strategy bypasses undesirable influences of the fluorophore camouflaged as reactivity due to Pt that may be present when detecting preattached Pt-fluorophore conjugates.  Using postbinding strategies, Pt reagent distributions in HeLa and lung carcinoma (NCI-H460) cell cultures were obsd. with two different azide-modified Pt compds., a monofunctional Pt(II)-acridine type and a difunctional Pt(II)-neutral complex.  In addn., cellular distribution was obsd. with an alkyne-appended difunctional Pt(II)-neutral complex analogous in structure to the aforementioned difunctional azide-Pt(II) reagent.  In all cases, significant accumulation of Pt in the nucleolus of cells was obsd., in addn. to broader localization in the nucleus and cytoplasm of the cell.  Using the same strategy of postbinding click modification with fluorescent probes, Pt adducts were detected and roughly quantified on rRNA and tRNA from Pt-treated Saccharomyces cerevisiae; rRNA adducts were found to be relatively long-lived and not targeted for immediate degrdn.  Finally, the utility and feasibility of the alkyne-appended Pt(II) compd. has been further demonstrated with a turn-on fluorophore, dansyl azide, in fluorescent detection of DNA in vitro.  In all, these modifications utilizing reactive handles have allowed for the diversification of new Pt reagents, as well as providing cellular localization information on the modified Pt compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGjFtBGJz6bVg90H21EOLACvtfcHk0lhaJ_VjbD-Z-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVKjtA%253D%253D&md5=970ee8014f7d331730938aec5cc3255a</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.5b00322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.5b00322%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DMultifunctional%2520Pt%2528II%2529%2520Reagents%253A%2520Covalent%2520Modifications%2520of%2520Pt%2520Complexes%2520Enable%2520Diverse%2520Structural%2520Variation%2520and%2520in-Cell%2520Detection%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2016%26volume%3D49%26spage%3D56%26epage%3D66%26doi%3D10.1021%2Facs.accounts.5b00322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborn, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Picazoplatin, an Azide-Containing Platinum(II) Derivative for Target Analysis by Click Chemistry</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x">, </span> <span class="NLM_fpage">11680</span><span class="NLM_x">–</span> <span class="NLM_lpage">11683</span><span class="refDoi"> DOI: 10.1021/ja402453k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja402453k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=11680-11683&author=J.+D.+Whiteauthor=M.+F.+Osbornauthor=A.+D.+Moghaddamauthor=L.+E.+Guzmanauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Picazoplatin%2C+an+Azide-Containing+Platinum%28II%29+Derivative+for+Target+Analysis+by+Click+Chemistry&doi=10.1021%2Fja402453k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Picazoplatin, an Azide-Containing Platinum(II) Derivative for Target Analysis by Click Chemistry</span></div><div class="casAuthors">White, Jonathan D.; Osborn, Maire F.; Moghaddam, Alan D.; Guzman, Lindsay E.; Haley, Michael M.; DeRose, Victoria J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">11680-11683</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the broad use of platinum-based chemotherapeutics, identification of their full range of cellular targets remains a significant challenge.  In order to identify, visualize, and isolate cellular targets of Pt(II) complexes, we have modified the chemotherapeutic drug picoplatin with an azide moiety for subsequent click reactivity.  The new compd. picazoplatin readily binds DNA and RNA oligonucleotides and undergoes facile post-labeling click reactions to alkyne-fluorophore conjugates.  Pt-fluorophore click reactions in rRNA purified from drug-treated Saccharomyces cerevisiae demonstrate its potential for future in vivo efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobeJ8Hr79T4rVg90H21EOLACvtfcHk0lhaJ_VjbD-Z-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgur3F&md5=b973d9c9d069af55729033bbd6e361e7</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fja402453k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja402453k%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DOsborn%26aufirst%3DM.%2BF.%26aulast%3DMoghaddam%26aufirst%3DA.%2BD.%26aulast%3DGuzman%26aufirst%3DL.%2BE.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DPicazoplatin%252C%2520an%2520Azide-Containing%2520Platinum%2528II%2529%2520Derivative%2520for%2520Target%2520Analysis%2520by%2520Click%2520Chemistry%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D11680%26epage%3D11683%26doi%3D10.1021%2Fja402453k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Osborn, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Platinum-Rna Modifications Following Drug Treatment in <i>S. Cerevisiae</i> Identified by Click Chemistry and Enzymatic Mapping</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2404</span><span class="NLM_x">–</span> <span class="NLM_lpage">2411</span><span class="refDoi"> DOI: 10.1021/cb500395z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500395z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2404-2411&author=M.+F.+Osbornauthor=J.+D.+Whiteauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Platinum-Rna+Modifications+Following+Drug+Treatment+in+S.+Cerevisiae+Identified+by+Click+Chemistry+and+Enzymatic+Mapping&doi=10.1021%2Fcb500395z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fcb500395z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500395z%26sid%3Dliteratum%253Aachs%26aulast%3DOsborn%26aufirst%3DM.%2BF.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DPlatinum-Rna%2520Modifications%2520Following%2520Drug%2520Treatment%2520in%2520S.%2520Cerevisiae%2520Identified%2520by%2520Click%2520Chemistry%2520and%2520Enzymatic%2520Mapping%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D2404%26epage%3D2411%26doi%3D10.1021%2Fcb500395z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Moghaddam, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loes, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Convenient Detection of Metal-DNA, Metal-RNA, and Metal-Protein Adducts with a Click-Modified Pt(II) Complex</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3536</span><span class="NLM_x">–</span> <span class="NLM_lpage">3539</span><span class="refDoi"> DOI: 10.1039/C4DT02649G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=10.1039%2FC4DT02649G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=3536-3539&author=A.+D.+Moghaddamauthor=J.+D.+Whiteauthor=R.+M.+Cunninghamauthor=A.+N.+Loesauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Convenient+Detection+of+Metal-DNA%2C+Metal-RNA%2C+and+Metal-Protein+Adducts+with+a+Click-Modified+Pt%28II%29+Complex&doi=10.1039%2FC4DT02649G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1039%2FC4DT02649G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4DT02649G%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DA.%2BD.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DCunningham%26aufirst%3DR.%2BM.%26aulast%3DLoes%26aufirst%3DA.%2BN.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DConvenient%2520Detection%2520of%2520Metal-DNA%252C%2520Metal-RNA%252C%2520and%2520Metal-Protein%2520Adducts%2520with%2520a%2520Click-Modified%2520Pt%2528II%2529%2520Complex%26jtitle%3DDalton%2520Trans.%26date%3D2015%26volume%3D44%26spage%3D3536%26epage%3D3539%26doi%3D10.1039%2FC4DT02649G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Wirth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moghaddam, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginzburg, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakharov, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derose, V. J.</span><span> </span><span class="NLM_article-title">Azide Vs Alkyne Functionalization in Pt(II) Complexes for Post-Treatment Click Modification: Solid-State Structure, Fluorescent Labeling, and Cellular Fate</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">15169</span><span class="NLM_x">–</span> <span class="NLM_lpage">15175</span><span class="refDoi"> DOI: 10.1021/jacs.5b09108</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b09108" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=15169-15175&author=R.+Wirthauthor=J.+D.+Whiteauthor=A.+D.+Moghaddamauthor=A.+L.+Ginzburgauthor=L.+N.+Zakharovauthor=M.+M.+Haleyauthor=V.+J.+Derose&title=Azide+Vs+Alkyne+Functionalization+in+Pt%28II%29+Complexes+for+Post-Treatment+Click+Modification%3A+Solid-State+Structure%2C+Fluorescent+Labeling%2C+and+Cellular+Fate&doi=10.1021%2Fjacs.5b09108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Azide vs Alkyne Functionalization in Pt(II) Complexes for Post-treatment Click Modification: Solid-State Structure, Fluorescent Labeling, and Cellular Fate</span></div><div class="casAuthors">Wirth, Regina; White, Jonathan D.; Moghaddam, Alan D.; Ginzburg, Aurora L.; Zakharov, Lev N.; Haley, Michael M.; DeRose, Victoria J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">15169-15175</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tracking of Pt(II) complexes is of crucial importance toward understanding Pt interactions with cellular biomols.  Post-treatment fluorescent labeling of functionalized Pt(II)-based agents using the bioorthogonal Cu(I)-catalyzed azide-alkyne cycloaddn. (CuAAC) reaction has recently been reported as a promising approach.  Here we describe an azide-functionalized Pt(II) complex, cis-[Pt(2-azidobutyl)amido-1,3-propanediamine)Cl2] (1), contg. the cis geometry and difunctional reactivity of cisplatin, and present a comparative study with its previously described alkyne-functionalized congener.  Single-crystal X-ray diffraction reveals a dramatic change in the solid-state arrangement with exchange of the alkyne for an azide moiety wherein 1 is dominated by a pseudo-chain of Pt-Pt dimers and antiparallel alignment of the azide substituents, in comparison with a circular arrangement supported by CH/π(C≡C) interactions in the alkyne version.  In vitro studies indicate similar DNA binding and click reactivity of both congeners obsd. by fluorescent labeling.  Interestingly, complex 1 shows in vitro enhanced click reactivity in comparison to a previously reported azide-appended Pt(II) complex.  Despite their similar behavior in vitro, preliminary in cellulo HeLa studies indicate a superior imaging potential of azide-functionalized 1.  Post-treatment fluorescent labeling of 1 obsd. by confocal fluorescence microscopy shows nuclear and intense nucleolar localization.  These results demonstrate the potential of 1 in different cell line localization studies and for future isolation and purifn. of Pt-bound targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfj_swPULuT7Vg90H21EOLACvtfcHk0lgExjne8_E8Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjur%252FO&md5=2b636ad1f0177c0be0c880b54ab49edf</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b09108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b09108%26sid%3Dliteratum%253Aachs%26aulast%3DWirth%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DJ.%2BD.%26aulast%3DMoghaddam%26aufirst%3DA.%2BD.%26aulast%3DGinzburg%26aufirst%3DA.%2BL.%26aulast%3DZakharov%26aufirst%3DL.%2BN.%26aulast%3DHaley%26aufirst%3DM.%2BM.%26aulast%3DDerose%26aufirst%3DV.%2BJ.%26atitle%3DAzide%2520Vs%2520Alkyne%2520Functionalization%2520in%2520Pt%2528II%2529%2520Complexes%2520for%2520Post-Treatment%2520Click%2520Modification%253A%2520Solid-State%2520Structure%252C%2520Fluorescent%2520Labeling%252C%2520and%2520Cellular%2520Fate%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D15169%26epage%3D15175%26doi%3D10.1021%2Fjacs.5b09108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01351&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-11%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01351" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01351" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992f48ee1d3c10","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
